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Major depression is a heterogeneous neuropsychiatric disorder with a significant genetic-
stress interaction.  The Wistar-Kyoto (WKY) rat displays hypersensitivity to stress and 
depression-like behaviour and is used as a genetic model of major depression.  However, 
the depression- and anxiety-like behaviour of WKY has not yet been compared between 
the WKY/NCrl and WKY/NHsd substrains when characterizing WKY as a rat model of 
depression.  WKY rats respond to noradrenergic and dopaminergic drugs but not to 
selective serotonin reuptake inhibitors (SSRIs) and are therefore suggested to model 
treatment resistant depression.   The early life stress of maternal separation (MS) has been 
used to produce a rodent model of depression in Sprague-Dawley (SD) rats but results 
have been variable. It was therefore considered that WKY subjected to MS might produce 
a more robust model of depression than either WKY or MS alone. The widely used MS 
SD rat model of depression, as well as MS SD rats subjected to restraint stress in adult 
life, were evaluated as appropriate comparator models of depression.  Furthermore, 
changes in the biochemistry in relevant brain areas of MS SD rats exposed to restraint 
stress in adulthood is still elusive and was further explored.  The glutamate N-methyl-D-
aspartate (NMDA) receptor antagonist, ketamine, has been found to be clinically useful.  
The acute effects of ketamine have not been previously tested in male WKY or MS SD 
rats and it was therefore decided to study the behavioural effects of ketamine in these rat 
models of depression.  
The aim of the first study was to characterize the WKY rat model of depression and to 
select the appropriate substrain of WKY best suited as a model of depression.  The 
WKY/NCrl and WKY/NHsd substrains of WKY were tested for optimal depression-
/anxiety-like behaviour in the forced swim test (FST), open field test (OFT) and elevated 
plus maze (EPM) and compared to the Wistar reference strain.   Both WKY/NCrl and 
WKY/NHsd were less active than Wistar rats in the OFT and FST and WKY/NCrl were 
less active than WKY/ NHsd.  Therefore, the initial study identified WKY/NCrl as the 
appropriate substrain of WKY to model depression.  The WKY/NCrl rats were further 
characterized in terms of their response to an optimal dose of the antidepressant drug, 
desipramine in the FST.   Desipramine has been shown to be effective in reducing the 
depression-like behaviour of WKY and was therefore chosen as the antidepressant drug 
for this study.  A dose of 15 mg/kg desipramine attenuated the depression-like behaviour 
as evidenced by decreased immobility in the FST and was therefore used for subsequent 




MOR and KOR, respectively), and tyrosine hydroxylase in the nucleus accumbens (NAc) 
or prefrontal cortex (PFC) of WKY rats.   
Since MS is a well-accepted animal model of depression, the aim of the second study was 
to create a more robust model of depression by subjecting WKY rats to MS and 
determining their depression-like behaviour, as well as its reversal with chronic 
desipramine treatment and the accompanying neurochemical changes following treatment.  
Depression-like behaviour was recorded in the OFT, FST, and isolation-induced 
ultrasonic vocalizations (USVs), in WKY/NCrl and MS (removal of the pups from the 
dam for 3 h per day from P2 to P14) WKY/NCrl rats.  Wistar rats served as the reference 
strain.  The normally reared WKY/NCrl, MS WKY/NCrl and Wistar rats were injected 
intraperitoneally with either saline or desipramine (15 mg/kg/day) for 15 days and their 
behaviour recorded.   Similar to the first study, WKY/NCrl and MS WKY/NCrl rats 
displayed increased immobility and decreased active swimming and struggling behaviours 
in the FST, and decreased activity in the OFT compared to Wistar rats.  In addition, MS 
WKY/NCrl spent more time in the closed arms of the EPM than normally reared 
WKY/NCrl, and WKY rats emitted more USVs than Wistar rats in response to removal of 
cage mate(s).  Desipramine treatment decreased immobility and increased active 
swimming and struggling behaviour of WKY/NCrl in the FST and also decreased their 
USVs in response to removal of cage mate(s).  Furthermore, MS WKY/NCrl responded to 
the anxiolytic effects of desipramine as evidenced by the increased amount of time spent 
in the open arms of the EPM.   Therefore, MS WKY/NCrl rats displayed depression- and 
anxiety-like behaviour that responded to the antidepressant and anxiolytic effect of 
desipramine in the FST and EPM.  This therefore implied that MS WKY/NCrl rats 
provided a more robust model of depression and anxiety.  The increased number of USVs 
emitted by WKY/ NCrl compared to Wistar rats and decreased number of USVs after 
desipramine treatment, suggest that USVs occurred in response to an aversive situation 
(social isolation) that, in accordance with its communication function, may represent 
social signalling to re-establish social contact with the cage mate(s).  In this study, USVs 
served as a useful marker of depression-/anxiety-like behaviour, with the rats responding 
to antidepressant treatment.     
To determine the effect of chronic desipramine treatment on the neurochemistry in the 
brain of MS WKY rats, changes in dopamine, serotonin (determined by enzyme-linked 
immunosorbent assay (ELISA)), opioid receptor density (MOR and KOR), 
phosphorylated extracellular signal-regulated kinase (p-ERK) and phosphorylated 
glycogen synthase kinase 3β (p-GSK3β) (determined by polyacrylamide gel 




reared WKY/NCrl rats.  Desipramine treatment increased the density of p-GSK3β in the 
PFC of normally reared WKY/NCrl rats but did not affect MS WKY/NCrl rats.  This 
study provides novel evidence for the mechanism of action of desipramine and the 
possible role of p-GSK3β in mediating the reduction of depression-/anxiety-like behaviour 
of WKY/NCrl rats.  However, desipramine had no effect on serotonin and p-ERK levels 
in the PFC or dopamine and opioid receptors in the NAc.     
The aim of the third study was to determine if stress during adulthood can exaggerate the 
depression-/anxiety-like behaviour in the widely used MS SD rat model.  Furthermore, to 
determine changes in brain-derived neurotrophic factor (BDNF) levels in the ventral 
hippocampus and protein profile in the PFC of MS SD rats subjected to stress in 
adulthood.  Depression-like behaviour was measured in the EPM, OFT and FST in the MS 
SD rats exposed to chronic restraint stress (4 h per day for 5 days) in adulthood.  Changes 
in BDNF concentration (measured with an ELISA) was measured in the ventral 
hippocampus in SD rats subjected to MS and restraint stress followed by proteomic 
analysis of the PFC.  As expected, MS increased immobility of SD rats in the FST but 
restraint stress did not enhance the effect of MS on SD rats.  MS on its own induced 
depression-like behaviour but restraint stress was unable to further potentiate the 
depression-like behaviour.  It is suggested that since MS during early development causes 
a disruption in the hypothalamic‐pituitary‐adrenal axis (HPA axis) and long-term changes 
in the response to subsequent stress, it may have prevented restraint stress from exerting 
its depression-like behavioural effect.  Furthermore, MS and restraint stress had no effect 
on BDNF levels in the ventral hippocampus but proteomic analysis of the PFC in SD rats 
revealed a decrease in actin-related proteins in MS rats and non-separated rats subjected to 
restraint stress as well as a general decrease in mitochondrial energy-related proteins in 
MS rats with or without subsequent exposure to restraint stress and non-separated rats 
subjected to restraint stress.  Furthermore, a decrease in proteins involved in protein 
synthesis and an increase in proteins involved in protein degradation were found in rats 
subjected to both MS and restraint stress. 
The aim of the final study was to determine whether the depression-like behaviour of the 
rodent models of depression could also be reversed by acute treatment with ketamine.   
The WKY/NCrl and Wistar rats as well as non-separated SD and MS SD rats were 
injected intraperitoneally with a single dose of either saline or ketamine (5, 10 or 15 
mg/kg).  Isolation-induced USVs (4 days before and 5 h and 29 h after injection of 
ketamine/saline) were recorded as well as their behaviour in the OFT (22 h and 46 h after 
injection of ketamine/saline) and FST (2 h, 48 h and 72 h after injection of 




immobility and decreased swimming behaviour of WKY/NCrl in the FST but did not 
affect Wistar or MS SD rats.  It is suggested that the ketamine-induced immobility in 
WKY/NCrl rats may be related to their reduced NMDA receptor density previously found 
in WKY rats.  
In conclusion, this study is consistent with the use of the WKY/NCrl rat as a model of 
depression.  MS increased the anxiety-like behaviour of the WKY/NCrl, thus providing a 
more robust model to study depression- and anxiety-related behaviour.  WKY/NCrl rats 
responded to chronic desipramine treatment by normalizing their depression-/anxiety-like 
behaviour, decreasing their USVs and increasing p-GSK3β; an effect that was blocked by 
MS.  The USVs emitted appeared to reflect signalling in an attempt to re-establish social 
contact with cage mate(s) that had been removed from the home cage.  The MS SD rats 
showed depression-like behaviour in the FST that was unaffected by additional restraint 
stress.  However, the decrease in structural proteins and proteins related to energy 
metabolism as well as the decrease in proteins related to protein synthesis and increase in 
proteins related to protein degradation in MS rats with or without subsequent restraint 
stress may not be related to their depression-like behaviour.  Consistent with their 
selective response to antidepressant drug treatment, WKY/NCrl rats did not respond to the 
antidepressant effect of a single dose of ketamine which may be related to the dysfunction 
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ERK  extracellular signal-regulated kinase 
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Chapter 1  
Introduction 
 
1.1 Neurobiology of depression 
1.1.1 Major depression 
According to the Diagnostic and Statistical Manual of Mental Disorders V (DSM V), 
depressive disorders feature the presence of sad, empty or irritable mood accompanied by 
somatic and cognitive changes that significantly affect the individual‟s capacity to 
function (American Psychiatric Association 2013).  Depressive disorders can be divided 
into groups according to duration, timing or presumed etiology.  These include disruptive 
mood dysregulation disorder, major depressive disorder, persistent depressive disorder 
(dysthymia), premenstrual dysphoric disorder, substance/medication-induced depressive 
disorder, depressive disorder due to another medical condition, other specified depressive 
disorder and unspecified depressive disorder (American Psychiatric Association 2013).  
Major depressive disorder (unipolar) represents the characteristic condition in this group 
of disorders and will be the focus of the current study. 
Major depression is a multifaceted and heterogeneous disorder that is highly prevalent and 
activated by a complex interaction between genetic, developmental and environmental 
factors (Millan 2006).  The most characteristic symptoms are depressed mood (sadness) 
and the inability to experience pleasure (anhedonia) as discussed below (section 1.1.2). 
1.1.2 Symptoms and diagnosis 
People diagnosed with depression usually experience a combination of symptoms that can 
be divided into core symptoms, subsidiary symptoms and co-morbid symptoms/conditions 
(Fig 1.1).  For major depression to be recognized according to the DSM V (2013), five (or 
more) of the symptoms in figure 1.1 (core symptoms and subsidiary symptoms) should be 
present during the same 2-week period and a change from previous functioning.  At least 
one of the symptoms should reflect depressed mood or the loss of interest in pleasure 
(anhedonia) (American Psychiatric Association 2013).  The rest of the symptoms should 
consist of subsidiary symptoms ranging from the inability to think or concentrate, 




to recurrent thoughts of death.  Despite the diagnostic symptoms, patients often present 
with non-diagnostic symptoms and conditions that further complicate diagnosis (see fig 
1.1).  In addition, to further complicate diagnosis, individual patients may experience 
different subsets of symptoms which may change over time (Millan 2006).   
The various symptoms of depression therefore emphasize the multifaceted and 
heterogeneous nature of depression.  This is further exemplified by the co-morbidity with 
other disorders such as anxiety (Brunello et al. 2000; Thaipisuttikul et al. 2014), psychotic 
disorder (Thaipisuttikul et al. 2014) and Parkinson‟s disease (Shen et al. 2013) that share 
certain symptoms of major depression.  The co-morbid conditions are not only 
psychiatrically related but may also include diabetes mellitus, cardiovascular disease, 
osteoporosis, hepatitis and chronic pain (Millan 2006). 
To differentiate between various mood disorders that require different treatment, the DSM 
V further divided major depression into nine subgroups according to different subsets of 
symptoms experienced (American Psychiatric Association 2013): 
1 Anxious distress:  Feeling keyed up or tense, unusually restless, difficulty 
concentrating because of worry, fear that something awful may happen and feeling 
that the individual might lose control of himself/herself. 
2 Mixed features:  Elevated mood, inflated self-esteem, more talkative, increased 
energy, increased or excessive involvement in activities that have a high potential 
for painful consequences, decreased need for sleep and flight of ideas or subjective 
experience. 
3 Melancholic:  The loss of pleasure in nearly all activities, unchanging emotional 
expression, feelings of excessive guilt, waking too early in the morning (terminal 
insomnia) and significant anorexia or weight loss. 
4 Atypical features:  Characterized by elevated mood in reaction to positive events 
and rejection sensitivity.  These reactions lead to overreaction to criticism or 
rejection.  Hypersomnia and increased appetite and consequently weight gain can 
also be present. 
5 Psychotic features:  Delusions and/or hallucinations are present. 
6 Catatonia:  Characterized by severe psychomotor retardation or excessive activity 
(agitation) 




7 Peripartum onset:  If onset of mood symptoms occurs during pregnancy or in the 
first 4 weeks following delivery of the baby 
















Figure 1.1:  Classification of symptoms/conditions of major depression.  Major depression is 
diagnosed by at least one core symptom and any four (or three if both core symptoms are present) 
subsidiary symptoms.  The major symptoms of major depression are almost never present on their own 
and accompanied by additional non-diagnostic symptoms and underlying conditions.  Adapted from 
American Psychiatric Association (2013) and Millan (2006). 
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1.1.3 Epidemiology and etiology 
Major depression is the second leading cause of years of life lived with disability (YLD) 
and the eleventh leading cause of global burden of disability-adjusted life years (DALYs) 
according to the findings from the Global Burden of Disease study in 2010 (Ferrari et al. 
2013; Murray et al. 2013).  Moreover, it is projected to be the second leading cause of 
DALYs in the year 2030 (Mathers and Loncar 2006; Pike et al. 2013).  According to an 
assessment of the National Comorbidity Survey Replication (Kessler and Merikangas 
2004), major depression is highly prevalent with a lifetime prevalence of approximately 
17 % and related to high morbidity and mortality (Kessler et al. 2005).  The lifetime 
prevalence of major depression in high-income and low- to middle-income countries was 
estimated to be 6.6 % - 21 % and 6.5 % - 18.4 %, respectively (Kessler and Bromet 2013).     
Major depression is also more prevalent in younger people since the prevalence in 18 – 29 
year old individuals was threefold higher than the prevalence in individuals over 60 years 
of age (American Psychiatric Association 2013; Kessler et al. 2003).  Furthermore, women 
have an approximately twofold increased risk of major depression compared to men, but 
only during their child-bearing years (Kessler and Bromet 2013; Setse et al. 2009; Van de 
Velde et al. 2010). 
Major depressive disorder may first appear at any age as a function of genetic and 
developmental predisposition as well as adverse life-events (Kessler et al. 2003; Kinyanda 
et al. 2013; Richards and Salamanca Sanabria 2014).  An epidemiological study showed a 
37 % genetic risk to develop depression (Bienvenu et al. 2011; Sullivan et al. 2000) which 
makes depression a highly heritable disorder.  In addition, stressful life events such as job 
loss, marital difficulties, major health problems and loss of close personal relationships 
has been associated with the development of depression (Berchick et al. 2012; Fava and 
Kendler 2000; Galatzer-Levy and Bonanno 2012; Kessler 1997; Symoens et al. 2014; 
Tseng et al. 2014; Waaktaar et al. 2004).  Furthermore, developmental stress such as 
adverse childhood experiences that include physical and sexual abuse, poor parent-child 
relationships and parental discord and divorce all increase the risk for development of 
depression in adulthood (Chapman et al. 2004; Fava and Kendler 2000; Larson and 
Halfon 2013; Lindert et al. 2014; Raudino et al. 2013).  The genetic and early 
environmental risk factors are also mediated by personality of neuroticism and high levels 
have been shown to directly influence anxiety and depression by increasing the risk for 
development of depressive episodes in response to stressful experiences (Kendler and 
Gardner 2011).     
Major depression is not limited to adult and elderly people since depression is often 
diagnosed in adolescents and children (Keith 2013; Klein et al. 1999a; Vogel 2012; 




Weissman et al. 1999; Yorbik et al. 2004).  Early-onset depression is a serious concern.  It 
is associated with a longer duration of the major depressive episode, increased severity of 
symptoms, higher rates of recurrent depressive episodes, co-morbid psychiatric disorders 
and lifetime substance use disorders (Klein et al. 1999a; Klein et al. 1999b; Korten et al. 
2012; Park et al. 2014; Sihvola et al. 2008; Zisook et al. 2007).  Recovery is strongly 
dependent on the duration of the current depressive episode.  Individuals who have been 
depressed for a short period of time can recover spontaneously (American Psychiatric 
Association 2013).  This emphasizes the need for early treatment since remission is 
difficult for individuals who have a longer duration of untreated episodes or multiple 
recurrent depressive episodes (Fekadu et al. 2009; Ghio et al. 2014; Kurdyak and Cairney 
2011).  Other features associated with reduced recovery in patients with depression 
include symptom severity (Riedel et al. 2011; Riihimäki et al. 2014; Swindle, Jr. et al. 
1998) and the co-morbid conditions (as described in section 1.1.2) such as psychotic 
features (Buoli et al. 2013), anxiety (Agosti 2014; Szádóczky et al. 2004) and personality 
disorders (Agosti et al. 2009; Agosti 2014; Holma et al. 2008).   
1.1.4 Neuroanatomy 
The heterogeneous nature of depression validates the proposal that the symptoms of 
depression are mediated by neural networks involving several brain regions.  Indeed, 
neuroimaging data implicated a key role of the prefrontal cortex (PFC) and its connections 
to the amygdala, hippocampus, and ventral striatum, sites in the diencephalon such as the 
hypothalamus and brainstem in the pathophysiology of depression (Furman et al. 2011; 
Ongür and Price 2000; Salerian and Altar 2012). 
The nucleus accumbens (NAc), as part of the ventral striatum, is associated with 
motivation, reward, motor activity and learning (Day and Carelli 2007; Shirayama and 
Chaki 2006).  As illustrated in figure 1.2, the NAc receives afferent connections from 
various cortical and limbic structures such as the PFC (Brog et al. 1993) and amygdala 
(Brog et al. 1993; Wright et al. 1996), hippocampus (Brog et al. 1993; Groenewegen et al. 
1987) and the ventral tegmental area of the midbrain (Zahm and Brog 1992).  The ventral 
tegmental area sends dopamine projections to the NAc and other limbic areas such as the 
amygdala and hippocampus as well as the PFC (Kahn and Shohamy 2013; Pierce and 
Kumaresan 2006; Yetnikoff et al. 2014).  These dopamine projections form the 
mesocorticolimbic pathway and are implicated in the pathogenesis and treatment of 
depression (Yadid and Friedman 2008).  The NAc also receives noradrenergic and 
serotonergic input from the locus coeruleus and dorsal raphe nuclei, respectively (Ferrucci 
et al. 2013; Moret and Briley 2011; Shirayama and Chaki 2006; Tao and Ma 2012).  The 
locus coeruleus neurons project from the brain stem to the thalamus, dorsal hypothalamus, 




hippocampus, amygdala, cerebellum and cerebral cortex (Leonard 2003; Moret and Briley 
2011).  These brain areas are involved in emotion, cognition, as well as other functions 
affected in depression such as appetite, response to pain, levels of pleasure, sexual 
function and aggressive behaviour (Moret and Briley 2011).  The serotonergic neurons in 
the dorsal raphe nuclei project to limbic structures such as the ventral hippocampus, 
amygdala, lateral septum and the striatum and cerebral cortex (Fukuyama et al. 2013; 
Lanzenberger et al. 2012).  On the other hand, the median raphe nuclei project preferably 
to the temporal cortex, mammillary bodies, dorsal hippocampus and medial septum 
(Lanzenberger et al. 2012).  Furthermore, the NAc receives glutamatergic afferents from 












Figure 1.2:  Connectivity of the NAc with other limbic brain areas associated with the 
pathophysiology of depression.  Adapted from Shirayama and Chaki (2006). 
 
The NAc contains two primary subregions, the central core and peripheral shell, with 
different anatomic organization and functional properties (Sturm et al. 2003).  The NAc 
core (NAcC) is associated with extrapyramidal motor function and the NAc shell (NAcS) 
with the limbic system that has been associated with the pathophysiology of depression 
(Abosch and Cosgrove 2008; Sturm et al. 2003).  The NAcC and NAcS receive different 





















relating to their different functional properties.  The prelimbic area of the PFC projects 
throughout the NAcC and NAcS but is associated more with the NAcC whereas the 
infralimbic area projects selectively to the NAcS (Berendse et al. 1992; Chiba et al. 2001; 
Hayen et al. 2014; Vertes 2004).  Furthermore, the NAcC receives afferent projections 
from the dorsal hippocampus whereas the NAcS receives afferent projections from the 
ventral hippocampus (Behrendt 2011) (Figure 1.3).  Likewise, the efferent projections 
from the NAc core and shell are different.  The NAcC projects to the pre-motor cortical 
areas through the motor thalamus whereas the NAcS projects to subcortical limbic regions 
such as the lateral hypothalamus, ventral pallidum and ventral tegmental area 
(Groenewegen and Trimble 2007; Zahm 1999).  Also, direct connections between the 
NAcC and NAcS have been established indicating that these regions do not function 
completely separate from each other (Day and Carelli 2007; van Dongen et al. 2006).  
Therefore, both the NAcC and NAcS play a central role in connectivity between various 











Figure 1.3:  Connections between the NAcC and NAcS and subregions of the hippocampus and 
PFC.  Adapted from Shirayama and Shigeyuki (2006). 
 
Neuroimaging studies measuring blood flow and metabolism in patients with depression 
showed abnormalities in several brain areas such as the cortex and limbic regions 
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and paralimbic areas and showed reduced blood flow and glucose metabolism in these 
areas of patients with depression (Fujimoto et al. 2008; Gonul et al. 2004; Kimbrell et al. 
2002; Kohn et al. 2007; Martinot et al. 2011; Mayberg et al. 1994; Oda et al. 2003; Ota et 
al. 2014; Wang et al. 2014).   
Further analysis was able to correlate the hypo-function of the PFC to the symptoms of 
depression as evidenced by studies showing that psychomotor impairment is associated 
with reduced blood flow in the PFC (Bennabi et al. 2013; Dolan et al. 1993; Narita et al. 
2004; Videbech et al. 2002; Walther et al. 2012).  Furthermore, treatment response to 
repetitive transcranial magnetic stimulation (rTMS) correlated with cerebral blood flow 
and may be a potential predictor of treatment response (Kito et al. 2012).  However, 
studies showing evidence of abnormalities in limbic regions were less common.  These 
studies showed increased metabolism or blood flow in the amygdala (Drevets et al. 2002; 
Martinot et al. 2011), basal ganglia and hippocampus (Monkul et al. 2012; Videbech et al. 
2002) demonstrating that limbic and cortical brain function are differentially regulated.    
Patients with depression also manifest structural abnormalities in brain areas, mostly in 
the hippocampus and PFC.  Numerous studies have shown a decrease in volume of the 
hippocampus and PFC in patients with depression (Campbell et al. 2004; Frodl et al. 
2002; Frodl et al. 2010; Kumar et al. 1998; Ming-Hong Hsieh et al. 2002; Ozalay et al. 
2013; Sawyer et al. 2012; Shah et al. 1998; Sheline et al. 1996; Taylor et al. 2014).  
Furthermore, the duration or severity of depression correlated with the hippocampal 
volume loss (Sheline et al. 1996; Stratmann et al. 2014; Taylor et al. 2014), which 
appeared reversible following antidepressant drug treatment (Malykhin et al. 2010; 
Sheline et al. 2003).   It is widely recognized that stress associated with the development 
of depression is implicated in the reduced structure of these brain areas.  This was 
evidenced by clinical studies showing that childhood maltreatment, which contributed in 
the development of depression, decreased hippocampal and PFC volume (Frodl et al. 
2010; van Harmelen et al. 2010). 
Animal studies have similarly shown that prolonged stress and increased levels of 
glucocorticoids result in neuronal atrophy and decreased hippocampal neurogenesis 
(reviewed in Duman 2004; Duman 2014).  Evidence for neuronal atrophy or decreased 
neurogenesis has been previously reported in rats exposed to various stressors such as 
exposure to a predator or its odor (Alani et al. 2013; Falconer and Galea 2003; Tanapat et 
al. 2001), chronic restraint stress (Grillo et al. 2014; Pham et al. 2003; Sliwowska et al. 
2010), footshock stress (Kim and Seo 2013; Malberg and Duman 2003), chronic mild 
stress (Jayatissa et al. 2010; Jiang et al. 2014) and the stress of maternal separation (MS) 




in early life (Baek et al. 2012; Hulshof et al. 2011).  The stress response is regulated by 
the hypothalamic‐pituitary‐adrenal (HPA) axis that seeks to maintain homeostasis and 
therefore minimize the impact of threat on the brain (Herman 2013; McEwen 2007).  
Administration of adrenal glucocorticoids as well as excitatory neurotransmitters such as 
glutamate in rats decreased neurogenesis in the hippocampus, thereby mimicking the 
effects of stress and implicating the HPA axis functionality in depression (Cameron et al. 
1998; Gould and Cameron 1996; McEwen 1999; Popoli et al. 2012).  NMDA receptor 
blockade is also effective in preventing stress-induced dendritic atrophy in the PFC (Li et 
al. 2011; Martin and Wellman 2011).  
Therefore, the role of the cortico-limbic brain areas together with their neurocircuitry is 
well recognized in the pathophysiology of depression although the precise role and 
interaction of these structures in depression is not well defined.  The next section will 
focus on the neurochemistry in these brain areas related to depression.   
1.1.5 Neurochemistry 
1.1.5.1 Evidence that led to the monoamine hypothesis of depression 
The monoamines noradrenaline, dopamine and serotonin are neurotransmitters that have 
been widely recognized to be involved in the pathophysiology of depression.  The 
monoamine theory of depression was developed according to the known mechanisms of 
antidepressant drug action.  Most of the antidepressant drugs available (e.g. tricyclic and 
selective serotonin reuptake inhibitors; section 1.4.1) block the reuptake of certain 
monoamines, thereby increasing the concentration of neurotransmitter at the synapse.  On 
the other hand, drugs such as reserpine, that cause a depletion of brain monoamines, may 
induce depression (Elhwuegi 2004; Goodwin and Bunney 1971).  The mechanism of 
action of reserpine and antidepressant drugs led to the monoamine hypothesis that simply 
states that depression is due to a deficiency of synaptic monoamines and is treated with 
antidepressant drugs that increase the monoamine activity (Baumeister et al. 2003; 
Schildkraut 1967).  However, antidepressant drugs are expected to be effective in 
alleviating symptoms of depression after 2-4 weeks (Wells et al. 2003), suggesting that 
their effects are more complex than initially thought. 
The noradrenergic system is involved in drive, motivation, reward and in rapid eye 
movement (REM) sleep (Leonard 2003) which are all aspects affected in depression.    
Various clinical studies have shown abnormalities in the noradrenergic system in 
postmortem tissue of patients that had depression.  Previous studies indicate increased β-
adrenergic receptor density in the temporal cortex and PFC of suicide victims that had 




suffered from depression (Arango et al. 1990; Biegon and Israeli 1988; Mann et al. 1986; 
Rivero et al. 2014).  In addition, postmortem and functional imaging studies of suicide 
victims showed increased density and expression of α2-adrenoceptors in the locus 
coeruleus and PFC (Escribá et al. 2004; Furczyk et al. 2013; Ordway et al. 2003; Rivero et 
al. 2014).  Further support for a role for these noradrenergic receptors in the 
pathophysiology and treatment of depression, came from previous studies that showed 
that antidepressant drug treatment decreased the levels of α2-adrenoceptors in the 
occipital cortex and hippocampus of patients that had depression (De Paermentier et al. 
1997) as well as blood platelets of patients with depression (García-Sevilla et al. 2004).  
Furthermore, a decrease in noradrenaline transporter binding (Klimek et al. 1997) and 
elevated levels of tyrosine hydroxylase (TH) (Ordway et al. 1994; Zhu et al. 1999) have 
been reported in the locus coeruleus of postmortem brain tissue. 
Similarly, dopamine plays an important role in the pathophysiology of depression and is 
associated with motivation, psychomotor control, concentration and the ability to 
experience pleasure (Dunlop and Nemeroff 2007).  The majority of clinical studies 
measuring the concentration of homovanillic acid, a dopamine metabolite, reports lower 
cerebrospinal fluid (CSF) and plasma concentrations in patients with depression compared 
with the controls (Engström et al. 1999; Mitani et al. 2006a; Reddy et al. 1992;Roy et al. 
1989) therefore indicating reduced dopamine function.  However, other studies failed to 
achieve similar results (Aklillu et al. 2009; Sullivan et al. 2006; Vestergaard et al. 1978).  
Additionally, pharmacological depletion or blocking synthesis of monoamines such 
dopamine can induce symptoms of depression in patients in remission or in healthy 
individuals with a family history of depression (Hasler et al. 2008; Pizzagalli 2014; Ruhé 
et al. 2007).  
Serotonin (5-HT) modulates a variety of behavioural and neuropsychological processes 
such as mood, perception, reward, aggression, appetite, sleep, memory, sexuality and 
attention (Berger et al. 2009; Mück-Seler and Pivac 2011).  Serotonergic activity is 
usually measured as the serotonin concentration and its metabolite 5-hydroxyindole acetic 
acid (5-HIAA) in CSF and blood samples of patients with depression.  Regardless of the 
monoamine hypothesis of depression, results are rather conflicting (Mück-Seler and Pivac 
2011) indicating increased serotonin and 5-HIAA levels in the plasma (Barton et al. 2008; 
Mitani et al. 2006a) and decreased (Mann et al. 1996; Träskman-Bendz et al. 1984; Zhang 
et al. 2014) or no difference of 5-HIAA in the CSF or plasma of patients with depression 
(De Bellis et al. 1993; Engström et al. 1999).  In addition, the 5-HT1A and 5-HT2 serotonin 
receptors have also been found to be disrupted in patients with depression.  However, 
previous studies have also revealed contradictory results in both these receptors in blood 




samples or postmortem brain tissue such as the PFC, hippocampus and amygdala of 
patients with depression (Arora and Meltzer 1989; Cheetham et al. 1988; Cheetham et al. 
1990; Lowther et al. 1997; Matsubara et al. 1991; Stockmeier et al. 1997; Yates et al. 
1990; Zhang et al. 2014).  The reason for variability between clinical studies that may 
complicate comparison of serotonin activity may include methodological variability such 
as differences in region (brain tissue, plasma, CSF), severity of depression (e.g. suicide 
attempters vs. non-attempters), medication history of the patients (medicated vs. drug-free 
patients) as well as the diagnostic criteria used to diagnose depression.  For example, the 
diagnoses in some studies that measured serotonin activity included patients with co-
morbid conditions such as anxiety and schizoaffective disorders (Barton et al. 2008; Mann 
et al. 1996) and serotonin activity may therefore be affected by the subtype of depression 
(Mück-Seler et al. 1991).  However, despite these variations between studies, the 
monoamine hypothesis is widely accepted. It has received support from studies that 
suggest hypo-activity of monoamines (Wainwright and Galea 2013; Yadid et al. 2000) 
and lowered mood in patients in remission following serotonin depletion (tryptophan 
depletion) (Hasler 2010; Ruhé et al. 2007). Furthermore, the development of 
antidepressant drugs has been based on their ability to increase monoamine 
neurotransmission. 
However, the monoamine hypothesis has limitations: (1) not all patients with depression 
respond equally to the same antidepressant drug and (2) changes in the monoamine levels 
take place within hours following treatment with antidepressant drugs, but the therapeutic 
response requires repeated administration of the these drugs for weeks (Elhwuegi 2004).  
These limitations led to the more recent monoamine theory of depression which suggests 
that the acute increase in the levels of monoamines may only be an early step in a 
complex cascade of events that leads to a therapeutic effect (Pineyro and Blier 1999).  For 
example, a recent study by Gaska et al. (2012) showed time-dependent changes in gene 
expression following administration of antidepressant drugs.  Therefore, the monoamines 
are not the only role players in the pathophysiology of depression and the monoamine 
theory only partially explains the pathophysiology and the effects of antidepressant drugs 





















Figure 1.4:  Pathways for the synthesis and metabolism of (a) dopamine and noradrenaline (in 
bold) and (b) serotonin (in bold). Noradrenaline is synthesized from the rate-limiting enzyme, tyrosine 
hydroxylase (TH), dopa decarboxylase (DDC) and dopamine beta-hydroxylase (DBH) and metabolized 
to DHPG (3,4-dihydroxyphenyl glycol) and MHPG (3-hydroxy-4-methoxyphenyl glycol) by the 
enzymes monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT), respectively. 
Dopamine is synthesized from tyrosine by the enzyme TH and DDC and metabolized by MAO, AD 
(aldehyde dehydrogenase) and COMT to DOPAC (3,4-dihydroxyphenylacetic acid) and homovanillic 
acid (HVA).  Serotonin is synthesized from the essential amino acid tryptophan by TPH (tryptophan 
hydroxylase) and DDC and metabolized to 5-HIAA (5-hydroxyindole acetic acid).  DOPA = 3,4-
dihydroxyphenylalanine; 5-HTP = 5-hydroxytryptophan.  Adapted from Leonard (2003).    
 
1.1.5.2 The role of glutamate in depression 
According to neurophysiological studies, amino acids have been classified into two 
classes:  (1) excitatory amino acids (glutamate and aspartate) which serve as 
neurotransmitters of excitatory synapses in the central nervous system, and (2) inhibitory 
amino acids (GABA and glycine) which serve as inhibitory neurotransmitters  (Dickenson 
et al. 1997; Petroff 2002). 
Glutamate is the main excitatory neurotransmitter in the central nervous system.  In 
response to neuronal activity, the vesicles containing glutamate fuse with the synaptic 
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(EAAT) regulate the transport of glutamate at the synapse (Mitchell and Baker 2010).  









Figure 1.5:  Metabolism of glutamate.  Adapted from Mitchell and Baker (2010).  Glutamate is derived 
from glucose and α-ketoglutarate and a small amount created from glutamine (Mitchell and Baker 2010).  
It is then taken up into secretory vesicles by the vesicular glutamate transporters (VGLUTs). (Takamori 
2006). GABA = γ-Aminobutyric acid. 
 
Glutamate functions by binding to its ionotropic or metabotropic receptors.  There are 
three major classes of ionotropic receptors based on pharmacological, structural and 
functional criteria:  N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid (AMPA) and kainate (KA) receptors (Niciu et al. 2014).  NMDA 
receptors have the highest affinity for glutamate and three families of NMDA receptor 
subunits exist: (1) NR1, (2) NR2A-D and (3) NR3A-B (Niciu et al. 2014).  AMPA 
receptor subunits are GluR1-4 (Niciu et al. 2014).  AMPA/kainate receptor activation 
mediates the fast excitatory synaptic current (Na+ influx) while NMDA receptor activation 
produces a delayed and prolonged current (Na+ and Ca2+ influx) (Niciu et al. 2014).  
Calcium influx through the NMDA receptor regulates a number of intracellular kinases 
and phosphatases, thereby altering the characteristics of the synapse (Churn et al. 1995; 
Mitchell and Baker 2010; Zhou et al. 2013) and mediating important functions such as 
learning, memory and neural development (Shanmuga Sundaram et al. 2012; Vander et al. 
1998).  However, neuronal cell death results from excess influx of calcium through the 
NMDA receptor (Ankarcrona et al. 1995; Zhou et al. 2013).  Therefore, glutamatergic 
signalling plays a role in both neuroplasticity and excitotoxicity if present in excess 
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of depression, glutamate also contributes to the pathophysiology of depression (Niciu et 
al. 2014; Mitchell and Baker 2010). 
Clinical studies reported abnormal levels of glutamate and its metabolites in depression 
(reviewed in Mitchell and Baker 2010).  A variety of studies reported elevated glutamate 
levels in the plasma of patients with depression (Altamura et al. 1993; Küçükibrahimoglu 
et al. 2009; Mitani et al. 2006b). Using proton magnetic resonance spectroscopy it was 
shown that the occipital cortex, medial PFC and cingulate cortex had high glutamate 
levels (Grimm et al. 2012; McEwen et al. 2012; Sanacora et al. 2004). Postmortem studies 
of patients with depression showed that frontal cortex brain tissue had high levels of 
glutamate (Hashimoto et al. 2007).  Furthermore, plasma glutamate levels correlated 
positively with the severity of depression (Mitani et al. 2006b).  These studies were 
further supported by evidence showing decreased plasma glutamate levels in patients with 
depression following antidepressant treatment (Küçükibrahimoglu et al. 2009; Maes et al. 
1998).  However, other studies were unable to replicate these findings of increased 
glutamate in the plasma, cortex and cortical subareas in patients with depression 
(Altamura et al. 1995; Francis et al. 1989; Yüksel and Ongür 2010).  Therefore, the above 
evidence indicates altered glutamate levels in depression but its correlation with 
symptoms of depression needs further elucidation.     
In addition, NMDA receptor abnormalities have been observed in the PFC, amygdala and 
hippocampus in postmortem studies of patients with major depression.  Reduced 
expression of the NR1, NR2A or NR2B subunit and NMDA receptor binding was found 
in the PFC of patients with major depression (Beneyto and Meador-Woodruff 2008; 
Feyissa et al. 2009).  In other brain areas, NR2A and NR2C subunit expression was 
increased in the amygdala and locus coeruleus respectively (Karolewicz et al. 2005; 
Karolewicz et al. 2009) and NMDA receptor binding increased in the hippocampus of 
patients with major depression (Beneyto et al. 2007).  Furthermore, several studies 
indicate the therapeutic role of NMDA receptor antagonists in depression (Javitt 2004; 
Lauterbach 2011; Niciu et al. 2014; Sultan et al. 2014).  In addition, evidence from 
preclinical studies showed that chronic monoaminergic antidepressant drug treatment 
modulated the NMDA receptor and thereby affected monoamine turnover (Mayer et al. 
2009; Popik et al. 2000; Skolnick 1999).  The inhibitory effect of chronic treatment with 
various antidepressants disrupted the coupling between glycine and glutamate at the 
NMDA receptor binding site (Skolnick 1999).  Therefore, adaptive changes to the NMDA 
receptor produced by monoaminergic antidepressants would be functionally equivalent to 
the effects produced by NMDA antagonists (Poleszak et al. 2011; Popik et al. 2000) and 
therefore supportive for a role of NMDA receptors in depression. 




Glutamate neurotransmission has also been studied in animal models of stress/depression 
showing that glutamate injected into the NAc of rats decreased swimming in the forced 
swim test (FST) which is indicative of depression-like behaviour (Rada et al. 2003).  
Furthermore, the stress of swimming in the FST increased extracellular glutamate in the 
NAc as measured by microdialysis (Rada et al. 2003).  In another study, rats bred to 
express learned helplessness behaviour, showed an increased glutamate/GABA ratio in 
the PFC and hippocampus as measured by magnetic resonance spectroscopy, an effect 
that was reversed by monoamine drug treatment and electroconvulsive shock therapy 
(Sartorius et al. 2007).  Mice bred with reduced VGLUTs expression displayed increased 
depression- and anxiety-like behaviour in the FST, sucrose consumption test and light-
dark exploration test (Garcia-Garcia et al. 2009; Tordera et al. 2007).  Furthermore, 
knockout mice deficient of the NMDA receptor NR2A subunit displayed reduced 
depression- (FST and tail suspension test) and anxiety-like behaviour (EPM, light-dark 
exploration test and novel open field test) (Boyce-Rusta and Holmes 2006).  A previous 
study by Ryan et al. (2009) showed that the NR1 subunit of the NMDA receptor is 
differentially modulated by factors that contribute to the development of depression-like 
behaviour.  This was indicated by lower expression of the NR1 subunit at baseline in the 
genetically predisposed  flinders sensitive line (FSL) rats whereas developmental stress 
such as  MS of FSL rats increased the expression of the NR1 subunit compared to non-
maternally separated FSL rats (Ryan et al. 2009). 
1.1.5.3 The role of opioids in depression 
The discovery of the function of endogenous opioids and their receptors came from the 
early use of opium in both medicinal and recreational practices (Dhawan et al. 1996; Lutz 
and Kieffer 2013).  The opioid system is composed of three receptors: (1) κ-opioid 
receptor (KOR), (2) μ-opioid receptor (MOR) and (3) δ-opioid receptor (DOR)  which 
interact with a family of endogenous opioid peptides known as β-endorphin, enkephalins, 
and dynorphins (Dhawan et al. 1996).  The opioid receptors are expressed throughout the 
brain with the highest KOR densities observed in the NAc, claustrum, dorsal endopiriform 
nucleus and interpeduncular nucleus of rats (Dhawan et al. 1996).  The highest density of 
MOR was observed in the caudate putamen, neocortex, thalamus, NAc, hippocampus and 
amygdala of rats (Dhawan et al. 1996).  The opioid system has been implicated in a 
variety of biological functions such as drug dependence, pain sensitivity, learning and 
memory, immune function, thermoregulation, gastrointestinal motility, cardiovascular and 
respiratory function as well as endocrine function (Bodnar 2014).  In addition, opioids are 
widely believed to play a role in depression. 




Most clinical evidence indicated dysregulation of the receptors of the μ-opioid system in 
depression.  One such study, using positron emission tomography, reported a reduction in 
MOR binding potential compared to healthy individuals in the posterior thalamus during 
neutral emotional states (Kennedy et al. 2006).  Furthermore, a sustained sadness 
condition was associated with a decrease in MOR binding potential in the left inferior 
temporal cortex, anterior cingulate, rostral anterior cingulate, ventral pallidum and 
amygdala of patients with MDD (Kennedy et al. 2006; Zubieta et al. 2003).  On the other 
hand, MOR agonists and KOR antagonists were effective in the treatment of refractory 
depression (Bodkin et al. 1995; Machado-Vieira and Zarate 2011; Nyhuis et al. 2008).  In 
postmortem brains of depressed suicides, MOR density was found to be increased in the 
frontal cortex and caudate (Escribá et al. 2004; Gabilondo et al. 1995). 
In preclinical studies, most evidence indicating an involvement of MOR and KOR in 
depression-like behaviour, came from studies measuring the behavioural effects of agonist 
and antagonists on these receptors.  It was previously reported that administration of MOR 
agonists decreased depression- and anxiety-like behaviour in the learned helplessness 
paradigm, tail suspension test and FST in mice or rat models of depression (Berrocoso et 
al. 2013; Besson et al. 1996; Fichna et al. 2007; Tejedor-Real et al. 1995).  These effects 
were blocked by various MOR antagonists (Berrocoso et al. 2013; Besson et al. 1996; 
Fichna et al. 2007; Ovsyukova et al. 2013; Tejedor-Real et al. 1995).  Furthermore, the 
atypical antidepressant drug, tianeptine, has been reported to have agonist activity at the 
MOR (Gassaway et al. 2014).  On the other hand, KOR activation mediates depression- 
and anxiety-like behaviour whereas KOR inhibition is a potential target of antidepressant 
drug treatment (Lutz and Kieffer 2013; Mague et al. 2003).  This was evidenced by 
studies showing that various KOR antagonists caused increased time spent in the open 
arms of the elevated plus maze (EPM), decreased latency to enter the inner zone in the 
open field test (OFT), decreased immobility in the FST and decreased escape deficit in the 
learned helplessness paradigm indicative of anxiety- and depression-like behaviour in rat 
models of depression (Beardsley et al. 2005; Chartoff et al. 2012; Knoll et al. 2007; 
Mague et al. 2003; Rogala et al. 2012; Shirayama et al. 2004).  
The opioid receptors have also been shown to be involved in the effect of stress induced 
by MS.  Specifically, opioid receptors play a role in depression-like behavior in adult rats 
exposed to early developmental stress as evidenced by decreased MOR levels in the NAc 
(Dimatelis et al. 2012b).  Evidence of opioid involvement in the effect of stress, induced 
by MS, is further strengthened by studies indicating that emotional distress-induced 
ultrasonic vocalizations (USVs) during MS were reduced by MOR agonists and reversed 
by MOR antagonism (Carden and Hofer 1990) whereas KOR stimulation provoked 




calling during MS (Kehoe and Boylan 1994).  Furthermore, activation of the MOR has 
been shown to be involved in infant attachment behaviour as evidenced by mice lacking 
the MOR gene showing a deficit in attachment behaviour (Moles et al. 2004).  These data 
showed that MOR function is necessary for pups to develop normal attachment to the dam 
as shown by fewer distress vocalizations elicited upon MS (Moles et al. 2004).  These 
results were also supported in a recent study, which showed that mice lacking the MOR 
gene and mice treated with a MOR antagonist displayed reduced interest in other mice and 
reduced approach behaviour towards their mother/nest bedding (Cinque et al. 2012).  
Previous studies measuring endogenous opioid peptides such as dynorphins  and 
enkephalins have indicated their involvement in stress-induced behaviours related to 
depression and anxiety (Bruchas et al. 2010; Dziedzicka-Wasylewska and Papp 1996; 
Shirayama et al. 2004).  Different stress paradigms including immobilization, chronic 
mild stress, forced swim stress or learned helplessness increased dynorphin and decreased 
met-enkephalin levels in the hippocampus and NAc (Dziedzicka-Wasylewska and Papp 
1996; Shirayama et al. 2004).  Furthermore, it has been reported that chronic treatment 
with antidepressants increased enkephalin levels in the NAc and striatum (De Felipe et al. 
1985).   Therefore the role of the opioid system in depression is likely to be mediated by 
their endogenous proteins as well as their receptors. 
1.1.5.4 Other neuropeptides associated with the intracellular signalling pathway  
The delayed therapeutic onset of mood upliftment by currently available antidepressant 
treatment suggests that other mediators of depression are involved in the pathophysiology 
of depression.  Other proteins involved in signal transduction pathways have been shown 
to play a role.   
Brain-derived Neurotrophic Factor (BDNF) 
BDNF, a member of the nerve growth factor (NGF) family, is densely expressed in the 
hippocampus (Yan et al. 1997) and suggested to be involved in the etiopathology of 
depression (Castrén and Rantamäki 2010; Duman and Monteggia 2006).  In animals, 
BDNF is decreased in hippocampal tissue of rat models of depression (Elfving et al. 2010; 
Gersner et al. 2014; Roceri et al. 2002).  Furthermore, it has been reported that chronic 
stress as a model of depression, decreased BDNF levels in the hippocampus and PFC of 
rodents (Ray et al. 2011; Xu et al. 2004; Xu et al. 2006) although several inconsistencies 
have been reported with some studies that showed an increase (Adlard et al. 2004; Larsen 
et al. 2010; Naert et al. 2011) or no effect on BDNF (Kuroda and McEwen 1998; 
Rosenbrock et al. 2005). 




Glycogen synthase kinase (GSK) 
GSK-3 plays a central role in many converging intracellular signalling pathways and is 
suggested to be involved in both neuroprotection and psychiatric disorders (Hunsberger et 
al. 2009; Rowe et al. 2007).  GSK is generally pro-apoptotic as opposed to anti-apoptosis 
elicited through inhibition of GSK (Beurel and Jope 2006) and impairments in its 
regulation can have harmful effects on cell function, structure and survival leading to 
various psychiatric disorders (Jope and Johnson 2004).  GSK3α and GSK3β are the two 
active GSK3 isoforms, with GSK3β the most extensively studied isoform mostly 
regulated by inhibitory control (Doble and Woodgett 2003).  GSK3β inhibition can result 
from phosphorylation of the serine 9 at the N-terminal by several protein kinases such as 
protein kinase A (Fang et al. 2000), Akt (Cross et al. 1995) and protein kinase C (Goode 
et al. 1992).  Besides phosphorylation, GSK3β can also be regulated by forming protein 
complexes through the Wingless (Wnt) signalling pathway (Kikuchi et al. 2007) or be 
directly/indirectly controlled by psychotropic drugs (Chen et al. 1999; Klein and Melton 
1996; Roh et al. 2007).  Direct inhibition of GSK3β by the mood-stabilizing drug, lithium, 
provided the first indication of the involvement of GSK3β in mood disorders including 
depression (Klein and Melton 1996; Stambolic et al. 1996).  Since then, different 
neuromodulators involved in depression such as serotonin, dopamine and BDNF were 
found to regulate GSK3β via different downstream mechanisms (Foulstone et al. 1999; Li 
et al. 2004; Sutton and Rushlow 2011). 
Clinical studies showed an increase in GSK3β enzyme activity and a decrease in phospho-
GSK3β (p-GSK3β) (inactive form) in the postmortem PFC of patients that had depression 
and therefore implicating an increase in GSK3β function in depression (Karege et al. 
2007; Karege et al. 2012).  In further support, a previous study showed that a lower 
concentration of p- GSK3β in plasma of patients with depression was associated with a 
higher severity of depression (Pláteník et al. 2014). 
Animal studies reported a decrease in p-GSK3β in the hippocampus and PFC of rats 
exposed to chronic stress-induced depression-like behaviour (14 days of FST stress) that 
was normalized following chronic antidepressant drug treatment (Chen et al. 2012; Liu et 
al. 2012).  Furthermore, inhibition of GSK3β decreased depression-like behaviour in the 
FST in rats and mice (Liu et al. 2013a; Rosa et al. 2008).  These studies therefore support 
a role for GSK3β in the pathophysiology of depression and highlight an important focus 
of research in understanding the mechanism of action of antidepressant drugs.    
Mitogen Activated Protein Kinase (MAPK)/extracellular signal-regulated kinase 
(ERK) 




The MAPK/ERK pathway is important for synaptic plasticity (Thomas and Huganir 2004) 
and has been shown to play a crucial role in depression and the action of antidepressant 
drugs (Fumagalli et al. 2005; Musazzi et al. 2010; Qi et al. 2009).  Furthermore, ERK can 
be considered an integrator of neuroprotective pathways (Almeida et al. 2005; Bravo et al. 
2009; Colucci-D'Amato et al. 2003).  For example, it has been shown that GSK3β is 
regulated by activation of ERK1/2 which decreased GSK3β activity thereby mediating the 
neuroprotective effects of BDNF (Hetman et al. 2002).  In turn, inhibition of GSK3 results 
in increased phosphorylation of ERK1/2 in cell lines (Wang et al. 2006).   
1.2 Animal models of depression 
Animal models are important tools to investigate the etiology and neurobiology of 
neuropsychiatric disorders as well as the mechanism of action of antidepressant drugs to 
screen for novel treatment options.  However, animal models have some limitations as the 
model cannot fully exhibit the entire human condition.  For example, feelings of 
worthlessness, guilt and suicidal ideation made by subjective self-report, are limited to 
patients with depression and can not easily be measured in animals (Nestler and Hyman 
2010) .  Although the animal model is not able to mimic the entire condition, previous 
criteria has been set out of which an animal model should comply (Willner 1984) and that 
can be used to improve current animal models or introduce new models that more closely 
mimic the human condition.  However, since the neurobiology of neuropsychiatric 
disorders is largely unknown, these validation criteria are established on what is currently 
known about the etiology and neurobiology of depression and will be further discussed in 
detail for animal models of depression-like behaviour relevant to this study.  
1.2.1 Validity 
Willner (1984) proposed three different types of validity:  face validity, construct validity 
and predictive validity to which an animal model should comply. 
1.2.1.1 Face validity 
Face validity refers to how well the behaviour of the animal resembles the symptoms of 
depression.  An animal model that mimics multiple symptoms of depression is considered 
a valuable model of depression. 
1.2.1.2 Construct validity 
Construct validity is to assess the theoretical rationale in which the pathophysiological 
changes in patients with depression also manifest in the animal model.  However, the 
pathophysiology of depression is not fully known and currently relies on our 




understanding of the mechanism of antidepressants.  Consensus on what a model is 
supposed to measure is also constantly changing as the theoretical understanding of 
depression evolves.  Construct validity should also take into account principles of the 
etiology of a disorder (Pawlak et al. 2012).  The models of depression link the 
pathophysiology of depression mostly with stress and/or genetic factors whereas the 
development of human depression can be caused by a combination of various 
psychological (adverse life events, adverse childhood experience and personality traits) 
and biological factors (genetic influences, illnesses and medication) (Fava and Kendler 
2000; Saveanu and Nemeroff 2012).  There is also a lack in understanding of how these 
etiological factors influence the theoretical basis underlining depression.  
1.2.1.3 Predictive validity 
Predictive validity is determined by the response of animal models of depression to 
antidepressants, at or near clinical doses, that is also effective in human depression.  A 
valid model should be sensitive and specific in responding to effective antidepressants 
(true positive effects) and should be unresponsive to ineffective antidepressants (true 
negative effects) (Willner and Mitchell 2002).     
1.2.2 Comparison of rat models of depression 
 
Table 1.1:  Comparison of rat models of depression in terms of validity.  + positive results, - negative 
results, 0 no results 









    
Stress in adulthood     
  Learned helplessness + + + Reviewed in Vollmayr (2001) 
and Abelaira et al. (2013) 
 Chronic mild stress + + + Reviewed in Willner (1997) 
 Chronic Restraint stress + + + Reviewed in Buynitsky and 





 Social stress e.g. social 
 defeat stress 
+ / - + / - + / - Reviewed in Yan et al. (2010) 
Early life stress 
  Maternal separation (MS) 
 
+ / - 
 
+ / - 
 
+ / - 
 
Reviewed in Vetulani (2013) 
Lesions     
Olfactory bulbectomy + + + Reviewed in Kelly et al. (1997) 
and Yuan and Slotnick (2014) 
Pharmacological     
Reserpine 0 0 + Reviewed in O‟Neil and Moore 
(2003) 
Tryptophan 0 0 + Reviewed in O‟Neil and Moore 
(2003) 
Genetic     
Selective breeding 
  Wistar-Kyoto (WKY) 
 




+ / - 
 
Reviewed in Crowley and Lucki 
(2005) 
   FSL + / - +  + Reviewed in Overstreet (1993) 
  High DPAT sensitivity 
animals 
+ / - +  + / - Reviewed in Overstreet and 
Steiner (1998) 
  Congenitally learned 
helplessness animals 
+ + + / - Reviewed in Willner and 
Mitchell (2002) and Henn and 
Vollmayr (2005) 




  Swim Low-Active animals + 0  + / - (Weiss et al. 1998; West and 
Weiss 1998) 
Transgenic 








(Calabrese et al. 2015; Olivier et 
al. 2008; van der Marel et al. 
2013) 
  Gene over-expression 
  /under-expression  
+ + + (Coelho et al. 2014; Kangussu 
et al. 2013) 
 
There is no animal model yet available that can replicate the overall symptomology of 
depression.  This could be due to the fact that depression is modeled on what is currently 
known of the theoretical basis of depression and also the complex classification of 
symptoms of depression that is unique for each patient and difficult to model in animals.  
The animal models of depression all differ in depression-related behaviour, 
neuropathology related to depression and treatment response to antidepressant drugs and 
although some models may be more valid than others in terms of the diversity of 
symptoms modeled, it may not necessarily be a useful model.  For example, models based 
on adult stress-induced depression-like behaviour (learned helplessness, chronic mild 
stress, restraint stress, changing photoperiod) may have good face, construct and 
predictive validity but their usefulness as a model of depression is limited by the fact that 
depression-like behaviour develops over a long-term period.  It was suggested that rather 
than creating an animal model that mimic the entire spectrum of disorders, it may be more 
useful to develop an animal model for a specific behavioural spectrum in order to identify 
specific neurobiological systems associated with these behavioural symptoms (Frazer and 
Morilak 2005).  However, there is still a need to improve on the validity of current models 
of depression as our understanding of the neuropathology and etiology of depression 
evolves.  For the purpose of this study, animals models listed in table 1.1 will be briefly 
referred to and only animal models of relevance will be further discussed in terms of face 
validity, predictive validity and construct validity. 




1.2.3 Models of depression based on stress, lesions and pharmacological 
manipulations in adulthood 
Some of the most important factors that induce depressive episodes are stressful life 
events (Kendler et al. 1999; Kessler 1997; Liu and Alloy 2010).  During acute stress, 
systemic alterations strengthen the ability of an organism to maintain homeostasis and to 
minimize the impact of stress (Maccari and Morley-Fletcher 2007).  However, when the 
stress is excessive, the adaptive responses to regulate the stress are lost.  This could induce 
long lasting changes in neurotransmitter, neuroendocrine and hormonal systems that give 
rise to psychiatric disorders such as depression (Chrousos 1995; Tsigos and Chrousos 
2002; Zhu et al. 2014).  The activation of the hypothalamic-pituitary-adrenal (HPA) axis 
and the resulting release of glucocorticoids form the primary neuroendocrine response to 
stress and the basis on which most animal models of depression were and are still 
developed.     
The stress hypothesis of mood disorders has led to the development of various animal 
models of depression (Table 1.1).  The learned helplessness, chronic mild stress and 
restraint stress are the most widely used and best established animal models of stress in 
adulthood leading to depression-like behaviour in rodents.  The learned helplessness was 
developed to model helplessness behavior that result from chronic or acute uncontrollable 
stress (Seligman and Beagley 1975).  However, the usefulness of this model to mimic 
depression has been questioned as a measure that could also indicate learning to become 
inactive than helplessness per se.  Furthermore, the learned helplessness rat model has a 
high predictive validity with response in their escape deficit to a variety of clinical 
effective antidepressants although some false positives (clinically ineffective 
antidepressant that is effective in learned helplessness) have been reported (Bourin et al. 
2001a; Sherman et al. 1982; Yamada et al. 2014).  However, several attempts have been 
made to increase the validity of the model that included selective breeding for learned 
helplessness (congenitally learned helplessness animals) (Henn and Vollmayr 2005; 
Vollmayr and Henn 2001).  The chronic mild stress was developed to model depression-
like behaviour such as anhedonia and considered to have good face validity, construct 
validity and predictive validity (Willner 1997).  The usefulness of the model to mimic the 
depression state that develops over time is enhance by a chronic and more naturalistic 
unpredictable stress compared to the learned helplessness model (Yan et al. 2010).  
Restraint stress (see Stepanichev 2014) is considered a mild stressor with good validity 
and has been widely used to induce stress related behavioural, biochemical and 
physiological changes to study the neurobiology and treatment of depression (Dagnino-
Subiabre et al. 2006; Lapmanee et al. 2013; Naert et al. 2011; O'Mahony et al. 2011).     




Other adulthood stress related models of depression that have been frequently used is the 
resident-intruder test and the more recent photoperiod changing stress model.  It has been 
suggested that models of social stress are more relevant to stress-induced neuropathology 
of depression in humans than environmental models, since they involve a social form of 
stress (Venzala et al. 2012).  By introducing the male intruder to the territory of the 
resident animal, the intruders are attacked and defeated by the resident resulting in 
behavioural, physiological and neurobiological changes that can be reversed by chronic 
antidepressant treatment (Yan et al. 2010).  However, due to the complex variety of 
behaviours induced by social defeat and the different actions of antidepressant drugs on 
behaviours such as anhedonia and social interaction this model could not be described as 
an animal model specific to depression (Chaouloff 2013; Venzala et al. 2012).   
The olfactory bulbectomized model of depression has been extensively reviewed and 
established as a chronic rat model that meet most of the criteria of a valid model of 
depression (Kelly et al. 1997; Yuan and Slotnick 2014).  The model is based on the lesion 
of the olfactory bulb, which disrupts the limbic-hypothalamic axis.  However, the 
olfactory bulbectomized animal is characterized by an agitated type of depression which 
responded to chronic treatment with most antidepressants (Kelly et al. 1997; Lumia et al. 
1992).   
Pharmacological models of depression such as the reserpine and tryptophan models are 
used as tests to screen for antidepressant drugs with a particular pharmacological 
mechanism (O'Neil and Moore 2003).  Reserpine treatment depletes the monoamines 
dopamine, serotonin and noradrenaline and induces a syndrome of reduced locomotor 
activity and body temperature.  A similar method is used for identifying antidepressant 
drugs that selectively increase serotonin concentration by potentiating the serotonin 
syndrome induced by the administration of 5-hydroxytryptophan (5-HTP), the metabolic 
precursor of serotonin (Grahame-Smith 1971).  The tryptophan model is therefore 
selective to antidepressant drugs that affect serotonin and antidepressant drugs active in 
reversal of reserpine-induced effects will not necessarily show an effect in this model 
(O'Neil and Moore 2003).  However, these pharmacological models do not model the 
neurobiology of depression but rather are tests to screen for antidepressant drugs (O'Neil 
and Moore 2003).       
1.2.4 Models of predisposition to depression 
Most models of depression are described according to stress exposure in adulthood as a 
leading factor of depression.  Although stress is a common risk factor for depression, not 
all stress responses are maladaptive since most people do not become depressed after 




serious stressful events whereas some people become depressed after stressful events that 
are considered to be less stressful (Nestler et al. 2002).  Therefore, to accurately model 
depression in animals, the inclusion of factors shaping an individual‟s response to stress to 
be more vulnerable to depression, is essential. 
1.2.4.1 Genetic predisposition 
Despite the role of stress in depression, previous studies showed a genetic predisposition 
to develop depression.  Twin studies have estimated the heritability of depression to be in 
the range of 31 % - 42 % but suggested to be even higher for a reliable diagnosis or for 
subtypes of depression such as recurrent major depression (Bienvenu et al. 2011; Sullivan 
et al. 2000).  Various genetic animals have been developed and provide the opportunity to 
study both the genetic determinants of depression and to more closely meet the clinical 
development of depression (Deussing 2007). 
Low activity in the FST have been proposed to represent depression-like behaviour.  This 
has led to the selective breeding of rats for high (swim high-active rats) and low 
immobility in the FST (swim low-active rats) in that such rats will prove useful in the 
study of depression (Weiss et al. 1998).  These strains do not differ in general activity but 
display differences in activity in acute behavioural tests  (FST, OFT and novel home cage) 
(Crowley and Lucki 2005; Weiss et al. 1998).  However, their face validity is limited 
specifically to the reduced activity in the behavioural tests.  Chronic antidepressant drugs 
were effective by increasing the activity in the FST but also revealed false negative 
(selective serotonin reuptake inhibitors were ineffective) and false positive results for a 
few antidepressant drugs (West and Weiss 1998).  Evidence for the involvement of 
neurotransmitters is limited in this model (Overstreet and Wegener 2013).  Therefore, the 
swim low-active rat model is mostly used as a screening model for antidepressant drugs.   
Other rats were selectively bred according to altered cholinergic and serotonergic 
function.   For example, the Flinders Sensitive Line (FSL) rats were developed according 
to their sensitivity to the anticholinesterase diisopropyl fluorophosphates (DFP) 
(Overstreet and Janowsky 1991). They showed a higher sensitivity to cholinergic agonists 
(Overstreet and Russell 1982) and increased muscarinic receptor density in the striatum 
and hippocampus compared to the Flinders Resistant Line (FRL) rats (Pepe et al. 1988).  
Furthermore, FSL rats showed more sensitivity to the hypothermic effects of the 
serotonergic agonist, 8-OH-DPAT and the hypothermic effects was correlated with their 
exaggerated immobility in the FST.  Additionally, the FSL displayed other depression-like 
behaviours such as elevated REM sleep and reduced social interaction (Overstreet and 
Wegener 2013).  Despite these similarities to depression, the FSL rats did not share all the 




behaviours of depressed humans such as anhedonia (measured as reduced sucrose 
consumption).  The FSL model of depression showed excellent predictive validity since 
all antidepressant drugs tested showed antidepressant-like effects on behaviour in the FST.  
Furthermore, the FSL rats were unresponsive to the effects of antidepressant drugs that 
were not expected to have these effects in the FST (Overstreet and Wegener 2013).   
The High DPAT sensitive (HDS) model is another pharmacologically selected rat model 
of depression that is based on the high serotonin sensitivity of the FSL.  This was 
achieved by selective breeding for high (High DPAT sensitive) and low (Low DPAT 
sensitive) sensitivity to the serotonin agonist, 8-OH-DPAT (Overstreet and Steiner 1998).  
The construct validity is still limited of this rat model since the cholinergic system has 
been the only system explored to date (Overstreet et al. 1994) and therefore not being able 
to make direct comparisons to patients with depression.  The HDS rats were very similar 
to the FSL rats for almost all of the behaviours that have been studied (Overstreet and 
Steiner 1998) in addition to displaying a lack in anhedonia (increased sucrose 
consumption) showed in these rats compared to the Low DPAT sensitive rats (Overstreet 
et al. 1996).  HDS rats responded to the antidepressant effect 8-OH-DPAT and 
desipramine as evidenced by a reduction in response rate and increased reinforcement rate 
in the differential reinforcement of low rate (DRL) 72-s operant schedule (Cousins et al. 
2000).  The DRL was proposed as a measurement to define an antidepressant-like effect 
(Cousins et al. 2000).  However, fluoxetine was without effect in the DRL schedule 
(Cousins et al. 2000).  Therefore, in comparison with FSL rats, behavioural and 
neurochemical comparison as well as response to a wider range of antidepressant drugs is 
incomplete for the HDS rats to be considered a valid model for depression.  
Transgenic animal models have been developed to better understand the underlying 
neurochemical mechanisms leading to psychiatric disorders such as depression and to 
screen for antidepressant drugs (reviewed in Gardier et al. 2009).  Although mutagenesis 
have been conducted mostly in mice, recent studies have also began to focus on rats 
(Calabrese et al. 2015; Coelho et al. 2014; Homberg et al. 2007; Kangussu et al. 2013; 
Olivier et al. 2008).  As an example, genetic manipulation of the serotonergic system 
provided opportunities to study the role of 5-HT in the pathophysiology of depression.  
Knockout of the serotonin transporter gene in rats (SERT-/-) affects serotonin homeostasis 
as evidenced by increased extracellular levels of 5-HT in the ventral hippocampus 
measured by microdialysis and consequently a reduction in several brain areas measured 
by high-performance liquid chromatography (HPLC)(Homberg et al. 2007; Neumann et 
al. 2011).  Behavioural tests revealed that SERT-/- rats displayed depression-like 
behaviour as evidenced by increased immobility in the FST and reduced sucrose 




consumption compared with SERT+/+  rats (Olivier et al. 2008).  Furthermore, they spent 
less time in the center part of the open field as well as on the open arm of the EPM, 
indicating enhanced anxiety-like behaviour (Olivier et al. 2008).  However, the 
behavioural phenotype of SERT-/- mice is complex and dependent on genetic background 
(Domínguez-López et al. 2012; Haenisch and Bönisch 2011; Kalueff et al. 2006; Perona 
et al. 2008). 
More recently, investigators have used transgenic rat models to explore other mechanisms 
involved in the pathophysiology of depression.  For example, transgenic rats that 
expresses an anti-sense RNA against angiotensinogen to suppress its production in 
astrocytes (Kangussu et al. 2013) and over-expression of adenosine A2A receptors in the 
brain (Coelho et al. 2014) were studied to measure their role in depression-/anxiety-like 
behaviour.  Similar to SERT-/- rats, these rats showed depression- and anxiety-like 
behaviour in the FST, sucrose preference test and EPM, respectively (Coelho et al. 2014; 
Kangussu et al. 2013).  Furthermore, administration of the selective serotonin reuptake 
inhibitor, fluoxetine, or angiotensin -(1-7), reversed the anxiety- and depression-like 
behaviour of transgenic rats with low brain angiotensinogen and implicating the role of 
angiotensin and serotonin in depression and anxiety (Kangussu et al. 2013). 
Therefore, the ability to target specific genes of interest through knockout, under-
expression or over-expression allows researchers to examine specific mechanisms 
associated with depression-/anxiety-like behaviour. 
Wistar-Kyoto rat model 
The inbred WKY rat strain was originally bred from the Wistar rat as a normotensive 
control strain for the spontaneously hypertensive rat (Okamoto and Aoki 1963).  Although 
the WKY line was selected from Wistar rats with normal systolic blood pressure 
(Okamoto and Aoki 1963) several neuroendocrine, behavioural and neurochemical 
abnormalities have been reported (Lahmame and Armario 1996; Lahmame et al. 1997; 
Paré 2000; Solberg et al. 2001).  This led to the suggestion of the WKY rat as a model of 
depression.  
The large body of evidence indicated depression- and anxiety-like behaviour in WKY rats 
(Braw et al. 2006; Ivarsson et al. 2005; Jeannotte et al. 2009; Lahmame and Armario 
1996; Lahmame et al. 1997; Lopez-Rubalcava and Lucki 2000; Malkesman et al. 2005; 
Malkesman et al. 2009; Nam et al. 2014; Paré 1992; Paré 2000; Tejani-Butt et al. 2003; 
Zafar et al. 1997).  Depression-like behaviour was evidenced by increased immobility in 
the FST in WKY compared to Sprague-Dawley (SD), Wistar and Fischer-344 control rats 




(“despair” or learned helplessness) (Jeannotte et al. 2009; Lahmame and Armario 1996; 
Lopez-Rubalcava and Lucki 2000; Paré 1992).  A previous study by Nam et al. (2014) 
showed that WKY rats were the only strain that spent more time immobile in the test 
swim of the FST compared to the pretest-swim and therefore an indication of learned 
helplessness.  Similarly, a previous study also showed that WKY rats rapidly acquired the 
learned helplessness following exposure to inescapable shock (Paré 1994).  Furthermore, 
WKY rats displayed a lack in general activity in the OFT and EPM (Malkesman et al. 
2005; Nam et al. 2014; Tejani-Butt et al. 2003).  Therefore, the WKY rats were less active 
in behavioural tests indicating psychomotor retardation.  This was supported by evidence 
indicating that WKY rats did not exhibit motoric retardation since their number of wheel 
turning responses to avoid tail-shock were similar than Wistar and Fisher-344 control rats 
(Paré 1992).  Anhedonic-like behaviour in the WKY rats was less consistent.   Sucrose 
consumption (measure of anhedonia) was reduced in adolescent WKY rats but only 
during night time (Malkesman et al. 2005) whereas other studies found an increase (Nam 
et al. 2014) or no difference (Yamada et al. 2013) in sucrose consumption in adult WKY 
compared to SD and Wistar rats respectively.  On the other hand, WKY rats showed less 
exploratory behaviour towards a conspecific rat (measure of anhedonia) (Nam et al. 2014; 
Pardon et al. 2002; Paré 2000).  Another measure of depression-like behaviour is the time 
spent in the center zone of the EPM which indicates indecisiveness (Nosek et al. 2008).  A 
previous study showed that the WKY rats spent more time spent in the center zone of the 
EPM (Nam et al. 2014) therefore displaying indecision in entering the arms of the EPM. 
In addition, WKY rats showed anxiety-like behaviour in some of the behavioural tests as 
evidenced by increased freezing in the OFT in adolescent WKY rats (Braw et al. 
2006;Malkesman et al. 2005) as well as a longer latency to feed in the novelty-suppressed 
feeding test in adult WKY rats compared to Wistar rats (Yamada et al. 2013).  
Furthermore, Carr and Lucki (2010) showed that WKY rats demonstrated decreased 
latency to begin burying and increased duration of burying in the conditioned defensive 
burying test.  However, adolescent and adult WKY rats showed no anxiety-like behaviour 
in the EPM (Braw et al. 2006;Getachew et al. 2008; Nam et al. 2014; Pardon et al. 2002).   
WKY rats also showed a heightened stress response that was revealed by measurement of 
their depression-like behaviour and susceptibility to stress-induced gastric ulcers.  
Previous studies showed that WKY rats that were exposed to chronic stress displayed a 
reduction in activity and longer response latencies to leave the start area in the OFT 
(Nosek et al. 2008; Zafar et al. 1997) as well as a reduction in investigatory behaviour 
towards a conspecific female rat (Paré 2000).  Furthermore, WKY rats that were exposed 




to water restraint stress showed a higher number and length of gastric ulcers compared to 
SD and Wistar rats (Paré 1992; Tejani-Butt et al. 2003).   
The heightened stress response was further supported physiologically by elevated plasma 
levels of adrenocorticotropic hormone (ACTH) and corticosterone (De La Garza and 
Mahoney, III 2004; Pardon et al. 2002; Rittenhouse et al. 2002; Solberg et al. 2001).  
WKY rats showed prolonged diurnal plasma ACTH and corticosterone levels (Solberg et 
al. 2001) and elevated levels following stress that remained significant for an extended 
period after termination of the stress (Pardon et al. 2002; Rittenhouse et al. 2002; Solberg 
et al. 2001).  Therefore, the WKY rats represent a useful model to assess the 
neurochemical basis of their depression-like behaviour in stressful environments. 
Clinical depression has been associated with abnormal levels of central monoamines 
norepinephrine, serotonin and dopamine (Bonhomme and Esposito 1998; Delgado 2000).  
Similarly, WKY rats showed a dysfunction in monoaminergic neurotransmission 
compared to SD and Wistar rats (De La Garza and Mahoney, III 2004; Jeannotte et al. 
2009; Novick et al. 2008; Pardon et al. 2002; Scholl et al. 2010; Yaroslavsky and Tejani-
Butt 2010).  A previous study indicated that basal levels of noradrenaline were reduced in 
several brain areas in the WKY rats that were dependent on the control strain being used 
since different noradrenaline levels were detected in SD and Wistar control rats (Scholl et 
al. 2010).  This involved reduced noradrenaline levels in the ventral hippocampus, NAcS 
and dorsal raphe nuclei in WKY compared to SD rats and reduced noradrenaline in the 
lateral hypothalamus, NAcC and locus coeruleus compared to Wistar rats (Scholl et al. 
2010).  Furthermore, WKY rats showed reduced noradrenergic reactivity to acute stress as 
evidenced by reduced TH mRNA levels and noradrenaline release that was suggested to 
be the cause of their inability to cope with stressful situations (Pardon et al. 2002).  In 
support of the noradrenaline deficiency, WKY rats have a higher density of noradrenaline 
transporter sites in limbic regions compared to control strains (Tejani-Butt et al. 1994). 
In further support of the monoamine hypothesis, it was previously shown that WKY rats 
had lower serotonin levels and a higher serotonin turnover ratio (5-HIAA / 5-HT) in 
various brain areas such as the amygdala, hypothalamus, NAc, dorsal raphe nuclei, 
substantia nigra and locus coeruleus compared to either or both SD and Wistar rats (Scholl 
et al. 2010; Yamada et al. 2013).  Similar to noradrenaline in WKY rats, strain differences 
in serotonin were dependent on the choice of control strain for comparison since SD and 
Wistar rats also revealed differences in serotonin levels (Scholl et al. 2010).  
Given the role of dopamine in reward and drug addiction (Salamone et al. 2003) as well as 
evidence of dopamine in depression and antidepressant drug action (Bonhomme and 




Esposito 1998), it is expected that dopamine may also play a role in the depression- and 
anxiety-like behaviour in WKY rats.  Indeed, several lines of evidence showed a 
dysfunction in dopamine neurotransmission in WKY rats.  These studies showed changes 
in levels of dopamine as well as its receptors (D1, D2, D3) and dopamine transporter 
(DAT) sites (Jiao et al. 2003; Novick et al. 2008; Scholl et al. 2010; Yaroslavsky et al. 
2006).  However, dopamine neurotransmission between strains were shown to be 
differentially regulated as evidenced by a decreased DAT binding in WKY rats in the 
NAc, amygdala and cell body areas (ventral tegmental area and substantia nigra) and 
increased DAT binding in the hypothalamus and hippocampus compared to either or both 
SD and Wistar rats (Jiao et al. 2003).  The DAT differences across brain areas may 
possibly be due to compensatory mechanisms and may therefore affect the clearance of 
dopamine and resulting changes in dopamine receptor activity.  In support of the 
monoamine hypothesis, WKY rats revealed lower levels of dopamine and its metabolite, 
DOPAC, in the PFC at baseline and in response to stress compared to Wistar and SD rats 
(De La Garza and Mahoney, III 2004).  In addition, dopamine turnover was increased at 
baseline in WKY rats in the NAcS and striatum and decreased in the PFC and NAcS in 
response to acute stress compared to Wistar rats (De La Garza and Mahoney, III 2004).  
Another study was able to confirm lower DOPAC levels in the PFC and higher dopamine 
turnover in the NAcS in WKY rats compared to Wistar rats (Scholl et al. 2010).  The 
increased dopamine turnover in the NAcS of WKY rats was suggested to be the results of 
lower dopamine transporter sites in this area, since reduced reuptake could increase 
extracellular dopamine and therefore dopamine turnover (Scholl et al. 2010).  The 
dopamine deficiency was further supported by evidence of reduced post-synaptic D1 
receptor binding at baseline in WKY rats in the striatum and NAcC compared to Wistar 
rats (Novick et al. 2008).  The increased D2 receptor density in the ventral tegmental area 
and NAcS and increased D3 receptor density in the NAcS, NAcC and striatum was 
explained in term of the dopamine deficiency that resulted in compensatory up-regulation 
of these receptors (Yaroslavsky et al. 2006).  However, the same argument could not be 
applied to other brain areas such as the NAcC, striatum and hypothalamus, which showed 
decreased D2 receptor binding in WKY compared to Wistar rats.  Since dopamine 
transporter sites were reduced in the hypothalamus, it was suggested that the reduced D2 
in WKY rats may be due to elevated levels of DA in this area.  WKY rats had deficient 
dopamine transmission at basal levels as well as in response to stress and may provide an 
important animal model to study the neuropathology of depression.  However, the 
dopamine deficiency hypothesis for previous studies was only consistent in some brain 
areas such as the NAcS and PFC and therefore indicates that dopamine is differently 
regulated in different brain areas that are associated with depression.  However, the 




overall activity of dopamine in WKY rats is complicated by studies that measured DAT in 
different brain areas than studies that measured levels of dopamine metabolites or 
dopamine receptors.  Furthermore, different control strains were used for comparison with 
WKY rats. 
Glutamate and GABA neurotransmitters have been shown to be involved in the pathology 
of depression and mechanism of antidepressant drugs (Luscher et al. 2011; Sanacora et al. 
2012).  Similarly, previous studies reported a dysfunction in glutamate and GABA 
receptor densities in WKY compared to Wistar rats (Lei and Tejani-Butt 2010; Lei et al. 
2009; Tizabi et al. 2012).  This was evidenced by a lower density of NMDA receptor in 
the substantia nigra, striatum, NAc, hippocampus (CA1 region) and cingulate cortex and a 
higher density of GABAA receptor in the substantia nigra, striatum, amygdala, 
hippocampus (CA2, CA3 and dentate gyrus regions) and in the periaqueductal grey area 
of WKY rats compared to Wistar rats (Lei et al. 2009).  Another study was able to 
confirm a lower density of NMDA receptor at basal levels in the striatum, NAc, 
hippocampus and PFC of WKY rats compared to Wistar rats (Lei and Tejani-Butt 2010).   
It was suggested that the lower density of NMDA receptors reflected a deficiency in the 
NMDA receptor complex or a higher level of glutamate neurotransmission whereas the 
higher GABAA receptor density reflected a lower level of GABA neurotransmission (Lei 
and Tejani-Butt 2010; Lei et al. 2009).  Furthermore, chronic stress was able to increase 
NMDA receptor density in the PFC, striatum and NAcC of WKY rats but not in Wistar 
rats (Lei and Tejani-Butt 2010).  However, no difference has been shown previously in 
NMDA receptor density in the hippocampus in female WKY compared to Wistar rats 
(Tizabi et al. 2012).      
The FST is widely used as a screening test for antidepressant drugs (Slattery and Cryan 
2012).  It has previously been shown that WKY rats displayed a selective antidepressant 
drug response in the FST.  For example, immobility behaviour in WKY rats in the FST 
were reduced by chronic (7 days and 12 days) or sub-chronic (3 injections) treatment of 
tricyclic antidepressant drugs (desipramine, imipramine) and noradrenaline and dopamine 
uptake blockers (nomifensine) but unaffected by serotonin uptake blockers and agonists 
(fluoxetine, paroxetine and 8-OH-DPAT) (Lahmame and Armario 1996; Lahmame et al. 
1997; Lopez-Rubalcava and Lucki 2000; Paré 1992; Tejani-Butt et al. 2003).  
Furthermore, differences in experimental protocols between studies had an influence on 
drug response in the WKY rats.  For example, desipramine, the most widely tested 
antidepressant drug in WKY rats has been shown previously to have no effect on 
immobility in a single FST session at a sub-chronic dose (5 mg/kg – 15 mg/kg) but 
decreased immobility in the FST at a higher dose of 25 mg/kg (Lahmame and Armario 




1996).  However, when WKY rats were chronically treated, the immobility levels of 
WKY rats in a single FST were reduced with a lower dose of desipramine (10 mg/kg and 
20mg/kg) (Paré 1992).  On the other hand, sub-chronic and chronic treatment with 
desipramine was effective in reversing the immobility in the FST in WKY rats that were 
previously habituated to a pretest-swim in the FST at a dose of 5 mg/kg - 20 mg/kg 
(Lopez-Rubalcava and Lucki 2000; Tejani-Butt et al. 2003).  Therefore, the response to 
antidepressant drug treatment seemed to be dependent on the experimental protocol such 
as the dose of the antidepressant drug, chronic or sub-chronic treatment as well as the 
inclusion of a pretest or both a pretest and test swim session in FST.   
Since WKY rats have been suggested to be a unique model of treatment-resistant 
depression, they have provided an opportunity to study novel drug targets to improve on 
the shortfalls of currently available antidepressant drugs.  The NMDA receptor antagonist, 
ketamine, has proven to be such an antidepressant drug and could provide better insight in 
studying the neuropathology of depression.  It has previously been shown that acute (2.5 
mg/kg or 5 mg/kg) and chronic treatment (0.5 mg/kg or 2.5 mg/kg for 10 days) of 
ketamine in female WKY and chronic ketamine treatment (0.5 mg/kg for 10 days) in male 
WKY rats reduced their immobility in the FST, indicative of an antidepressant-like effect 
(Tizabi et al. 2012).  Furthermore, the lasting effect of an acute dose of ketamine was 
evidenced by a decreased immobility in the FST at 1 week after the injection in female 
WKY rats (Tizabi et al. 2012).  Molecular targets for ketamine treatment may therefore 
have clinical relevance and by studying the neurobiology in animals could reveal 
important mechanisms involved in treatment-resistant depression. 
In summary, WKY rats displayed face validity, construct validity and predictive validity 
although some behavioural inconsistencies have been reported, especially the sucrose 
consumption test as measure of anhedonia.  In addition, results for anxiety-like behaviour 
in the WKY are inconsistent with positive results obtained only in some of the tests 
whereas no anxiety-like behaviour was reported in the EPM.   The WKY rats were hyper-
responsive to stressful situations that affected the neuroendocrine system as well as 
leading to neurochemical changes. The neurochemistry in particular seemed to be distinct 
in WKY rats and could be partly explained according to the monoamine theory of 
depression at least in some limbic areas of the brain.  However, since differences were 
reported in noradrenaline, serotonin and dopamine neurotransmission between the control 
Wistar and SD rats, studies comparing WKY with different controls will reveal 
inconsistent results.  WKY rats were selective in their response to antidepressant drugs 
which may be due to their unique neurochemistry.         




1.2.4.2 Developmental stress 
Early life adversities (e.g. childhood physical, emotional, sexual abuse and parental loss) 
have been associated with the development of various neuropsychiatric disorders in 
adulthood such as depression and anxiety (Heim and Nemeroff 2001; Lindert et al. 2014; 
Otowa et al. 2014; Slavich et al. 2011; Springer et al. 2007).  Furthermore, the type of 
aversive experience in early life was specific to the clinical spectrum of depression (e.g. 
depression with co-morbid conditions) affected in later life (Gibb et al. 2007; Harkness 
and Wildes 2002).  For example, Gibb et al. (2007) reported that sexual abuse and 
emotional abuse were more associated with co-morbid anxiety whereas physical abuse 
was associated with co-morbid dysthymia. 
Clinical evidence indicated that early adverse experiences that contributed to 
neuropsychiatric disorders later in life, were associated with alterations in the 
neuroendocrine system (Carvalho Fernando et al. 2012; Ehlert et al. 2001).  Heim et al. 
(2008) reported that plasma adrenocorticotropin hormone (ACTH) and cortisol were 
elevated in response to psychosocial stress in humans with depression and a history of 
childhood abuse (Heim et al. 2000; Heim et al. 2008).  This was further supported by the 
correlation of childhood abuse with morphological changes in the hippocampus that 
resulted in a smaller hippocampal volume than depressed individuals without a history of 
childhood abuse (Heim et al. 2008; Vythilingam et al. 2002).  However, such research 
fails to establish a relationship between the type of trauma at different developmental 
stages and development of depression, which can be clearly manipulated in an animal 
experiment.   
Several animal models of manipulation of the early environment have been used to study 
the predisposing factors contributing in the development of depression such as prenatal 
stress, postnatal handling and MS.  These early life stressors cause changes in the 
behaviour and neuroendocrine system that persist into adulthood making them more 
sensitive to subsequent stress (Sánchez et al. 2001; Uchida et al. 2010; Zhang et al. 2013).  
Most of the recent animal models of depression are based on early life environmental 
manipulation that is considered a better model of predisposition of depression than the 
depression models based on a precipitating event (Willner and Mitchell 2002).  
Maternal separation  
MS is a well-established and widely accepted model for predisposition to depression.  
Typically, pups are separated from the dam during the first 2 weeks after birth which is a 
critical stage of brain development (Rice 2000).  This period is characterized as the stress 
hyporesponsive period (SHRP) and protects the brain from high levels of glucocorticoids 




during neuronal development in stress sensitive brain regions (Sapolsky and Meaney 
1986). 
However, early MS activates the HPA axis during the SHRP in MS rat pups that remained 
apparent into adulthood.  This was evidenced by studies showing that repeated MS in 
early life leads to elevated ACTH and/or corticosterone levels during and after MS 
(Daniels et al. 2009; Jahng et al. 2010; McCormick et al. 1998) that persisted into 
adulthood (Daniels et al. 2004; Nishi et al. 2014) and potentiates the corticosterone and 
ACTH response to mild stressors (Francis et al. 2002; Lippmann et al. 2007; Roque et al. 
2014).    The above evidence therefore indicated that MS had immediate effects as well as 
effects in adulthood and suggested that early life stress alters the HPA system throughout 
life in rats.  However, inconsistencies have also been reported with no change in basal 
levels of corticosterone following acute stress during 2 weeks of MS (Lajud et al. 2012) or 
in response to mild stressors in adulthood of previously MS rats (Hulshof et al. 2011; 
Lariviere et al. 2006).  
Several studies reported that MS induced behavioural changes resembling depression and 
anxiety in humans (Daniels et al. 2004; Dimatelis et al. 2012b; Lambás-Señas et al. 2009; 
Lee et al. 2007; Li et al. 2013; Makena et al. 2012; Ryu et al. 2009).  These studies 
showed increased depression-like behaviour as evidenced by increased immobility in the 
FST (Dimatelis et al. 2012b; Lambás-Señas et al. 2009; Lee et al. 2007; Ryu et al. 2009), 
reduced sucrose consumption (Aisa et al. 2007; Huot et al. 2001), reduced ambulatory 
activity (Lee et al. 2007), and cognitive deficits (Aisa et al. 2007; Couto et al. 2012).  In 
addition, anxiety-like behaviours were measured in the EPM and showed that MS rats 
spent decreased time in the open arms and/or increased time in the closed arms indicative 
of anxiety-like behaviour (Daniels et al. 2004; Huot et al. 2001; Li et al. 2013; Ryu et al. 
2009).  Inconsistencies have also been reported with no change in sucrose consumption 
(Matthews et al. 1996; Shalev and Kafkafi 2002) and increased (Lambás-Señas et al. 
2009) or no activity in the OFT (Shalev and Kafkafi 2002).  Body weight was also less 
consistent with reduced (Huot et al. 2001) or increased (Lee et al. 2007; Ryu et al. 2009) 
measured body weight in MS rats.  Although, most studies reported that MS increased 
immobility in the FST it was also previously reported that early life MS in SD rats at 3 
h/day for 2 weeks, only increased immobility with exposure to an additional stressor such 
as chronic restraint stress (Marais et al. 2008).  Previous studies also found disrupted 
prepulse inhibition in adolescent and adult rats that had been exposed to MS in early life 
after a single 24 h exposure (P3, P6, P9 and not P13) or repeated MS (P1 - P21) 
(Ellenbroek et al. 1998; Ellenbroek and Cools 2002; Li et al. 2013).  Since anxiety-like 
behaviour was found in MS rats as well as disruption in prepulse inhibition and cognition, 




other psychiatric disorders such as schizophrenia and diseases such as Alzheimer‟s disease 
were also studied (Garner et al. 2007; Klug and van den Buuse 2012; Li et al. 2013; 
Martisova et al. 2013).  It was therefore concluded that MS is a valid rat model for 
psychiatric disorders (Li et al. 2013) and therefore not limited specifically to depression.     
Early MS in rats also has distinct neurochemical consequences in adulthood.  For 
instance, basal dopamine levels were increased in the striatum and dopamine turnover 
were reduced in the limbic areas such as the medial PFC of adult male rats previously 
exposed to MS (Matthews et al. 2001).  Furthermore, dopamine-2 receptor expression was 
reduced in the hippocampus and NAc of MS adolescent rats (Li et al. 2013).   In support 
of the dopamine hypothesis of depression, a previous study showed evidence of stress-
induced increase in dopamine levels in the NAc, ventral tegmental area and substantia 
nigra only in non-maternally separated rats (Jahng et al. 2010).  This provided evidence of 
a blunted dopamine response to the stress of MS (Jahng et al. 2010).   Furthermore, 
reduced dopamine transporter densities were found in the NAcC and striatum of rats 
previously exposed to MS (P1 – P14 for 3h/day) (Brake et al. 2004).     
Several studies have been conducted on the long-term effect of MS on serotonin 
neurotransmission.  In support of the serotonin hypothesis of depression, serotonin levels 
were reduced in the hippocampus, medial PFC, raphe nucleus and NAc of adult MS rats 
(Jahng et al. 2010; Lee et al. 2007; Matthews et al. 2001).  Furthermore, 5HT1A serotonin 
receptors are involved in the pathophysiology of depression and mechanism of 
antidepressant drugs (Drevets et al. 1999; Haddjeri et al. 1998) and was shown to be 
altered in MS rats.  For example, it has been reported that MS decreased 5-HT1A 
expression in the hippocampus and medial PFC of adolescent rats (Leventopoulos et al. 
2009; Li et al. 2013).   However, other studies were unable to find differences in 5-HT1A 
expression or serotonin transporter expression in various brain areas studied in MS rats 
(Arborelius et al. 2004; Vicentic et al. 2006).  
Other pathways relevant to the pathophysiology of depression include the opioid system 
and were previously found to be regulated by MS (Dimatelis et al. 2012b; Michaels and 
Holtzman 2008).  The stress of MS reduced the MOR density in the NAc in adult rats 
(Dimatelis et al. 2012b) which indicated a depression phenotype since activation of MOR 
leads to antidepression-like behaviour in the FST and learned helplessness rat model 
(Fichna et al. 2007; Rojas-Corrales et al. 2002).  Also, it was reported that MS rats had a 
greater place preference for a MOR agonist and a greater aversion to a KOR agonist 
compared to non-maternally separated rats (Michaels and Holtzman 2008).  This indicated 
that MS stress influence the rewarding or aversive effect of MOR and KOR agonists 




(Michaels and Holtzman 2008).  Further supporting evidence of the importance of the 
opioid system in mother-pup interaction, is studies showing a deficit in attachment 
behaviour in mice lacking the MOR gene (Moles et al. 2004; Wöhr et al. 2011).  
Furthermore, USVs in separated rat pups as an indication of mother-pup interaction 
(Portfors 2007), were reduced by MOR and delta opioid receptor agonists whereas a KOR 
agonist had the opposite effect (Carden et al. 1991).  However, evidence for the long-term 
effects of early MS on opioid receptors is still limited. 
MS may also affect brain function by affecting proliferation and apoptosis (Chocyk et al. 
2011; Irles et al. 2014; Lee et al. 2001).  BDNF has a neuroprotective role through the 
MAPK/ERK pathway (Peng et al. 2008). A decrease in BDNF has been suggested to be 
involved in mediating depression-like behaviour (reviewed in Duman and Monteggia 
2006) and previously shown to be altered by the stress of MS in selected brain areas 
(Lippmann et al. 2007; Pinheiro et al. 2014; Roceri et al. 2002; Xue et al. 2013).  This was 
evidenced by studies that showed reduced BDNF levels in the hippocampus and striatum, 
but an increase in the ventral tegmental area in the adult rats previously exposed to 3 h of 
daily MS (P1 - P14) (Lippmann et al. 2007; Pinheiro et al. 2014).  Furthermore, intra-
ventral tegmental infusions of BDNF resulted in a decreased latency to immobility in the 
FST in rats indicating depression-like behaviour following enhanced signalling of BDNF 
(Eisch et al. 2003).  Furthermore, inhibition of the BDNF pathway in rats through intra-
NAc injections of a virus expressing the truncated BDNF receptor, TrkB-T1, increased the 
latency to immobility in the FST suggesting antidepressant-like behaviour (Eisch et al. 
2003).  It therefore appeared that BDNF in brain areas associated with depression are 
differently regulated by stress.  However, findings in brain areas such as the hippocampus 
did not always reveal consistent results, since previous studies also showed an increase 
(Greisen et al. 2005) or no change (Roceri et al. 2004) in BDNF in adult rats exposed to 
early-life MS for 3 h daily (P2 - P14). 
MS rats also responded to antidepressant drugs such as tricyclic antidepressants 
(tianeptine), serotonin-norepinephrine reuptake inhibitors (venlafaxine) and selective 
serotonin reuptake inhibitors (fluoxetine, paroxetine and escitalopram) that attenuated the 
depression- and anxiety-like behaviours and enhanced HPA axis activity (Couto et al. 
2012; El Khoury et al. 2006; Huot et al. 2001; Leventopoulos et al. 2009; Martisova et al. 
2012; Trujillo et al. 2009).  Studies showed that the antidepressant drugs reduced the 
elevated ACTH and corticosterone levels (Huot et al. 2001; Martisova et al. 2012), 
reduced immobility in the FST (Couto et al. 2012; El Khoury et al. 2006; Martisova et al. 
2012), restored preference for sucrose in the sucrose consumption test (Huot et al. 2001; 
Leventopoulos et al. 2009) and improved memory deficits as measured by increased time 




spent in the platform quadrant in the Morris Water Maze test (Couto et al. 2012).  In 
contrast, a previous study found no effect of the selective serotonin reuptake inhibitor, 
escitalopram, on the depression-like behaviour of MS rats (Dimatelis et al. 2012b).  
Furthermore, the tricyclic antidepressant and selective serotonin reuptake inhibitors 
showed anxiolytic effects in MS rats as evidenced by increased time spent in the open 
arms of the EPM (Huot et al. 2001; Trujillo et al. 2009). In the MS rat model, the selective 
serotonin reuptake inhibitor is the most common antidepressant drug studied and further 
screening of a wider variety of effective antidepressant drugs is required to further 
establish the model‟s predictive validity. 
Therefore, according to the evidence, the MS model of depression showed face validity, 
construct validity and predictive validity in a variety of  behavioral, neurochemical and 
neuroendocrine changes induced by early life stress of MS that is associated with 
depression-/anxiety-like behaviour (Pryce et al. 2005).   However, several behavioural and 
neurobiological inconsistencies have been reported, whereas the neuroendocrine changes 
seemed to be more consistent between studies.  It should be noted that patients with 
depression my exhibit psychomotor retardation or agitation and weight loss or weight gain 
(American Psychiatric Association 2013) and are therefore not a reliable measure to 
model in animal models of depression .  The reason for the inconsistencies between 
studies is often associated with different experimental protocols such as single or litter-
wise separations, difference in frequency and timing of separation, gender differences and 
choice of control (Vetulani 2013).  The use of single or litter-wise separation and male or 
female rats has considerable effects on brain function.  For example, only female rats that 
were MS in a group for 6 h from P1 to P21 had a higher expression of 5HT3 receptor gene 
in the brain stem compared to female rats which were isolated from each other during MS 
(Oreland et al. 2009).  Furthermore, the activity of the HPA axis and emotional behaviour 
is dependent on the gender of the rats (Renard et al. 2007).  Lastly, behavioural, 
neuroendocrine and neurobiological comparison between MS and different controls 
(exposed or without environmental manipulations) may have contributed to the variability 
between studies.  For example, studies often compare MS rats against controls that have 
been briefly handled, non-handled or alternatively, pups are kept under animal rearing 
facility conditions with their cages and bedding changed twice or three times per week.  
However, previous studies showed behavioural and neurochemical differences between 
these controls (Brake et al. 2004; Oreland et al. 2009).  According to the aforementioned 
variability, it is evident that a more robust model of early developmental stress is needed.       




1.2.4.3 Genetic predisposition and developmental stress 
Various studies have shown that exposure to early life stress increased the risk for 
depression and that the experience of stressful events interacts with genetic risk factors 
(Aslund et al. 2009; Caspi et al. 2003; Kaufman et al. 2006; Myers et al. 2014).  For 
example, patients with depression with a polymorphic change in the serotonin transporter 
gene (carriers of the S-allele) or oxytocin receptor gene had a higher risk to develop 
symptoms of depression during stressful events and childhood trauma (Caspi et al. 2003; 
Myers et al. 2014).         
Therefore, instead of focusing on stress or genetic factors in contributing to a depression 
phenotype in rats, the focus has shifted in recent years to the combination of these factors 
in animal models of depression in order to further enhance construct validity (El Khoury 
et al. 2006; Musazzi et al. 2010; Nam et al. 2014; Neumann et al. 2005; Petersén et al. 
2008; Ryan et al. 2009; Wörtwein et al. 2006).  These studies aimed to determine how the 
genetic predisposition modifies the behaviour and neurochemical effects of early life 
trauma (stress of MS) and if early treatment affected the outcome.  However, most of 
these studies studied the effect of MS on the FSL rat model of depression possibly 
because of its well characterized neurobiology.  It has been shown previously that MS had 
marked effects on the swimming duration in the FST in FSL rats but was without effect in 
the FRL control rats (El Khoury et al. 2006; Petersén et al. 2008).  Furthermore, only the 
FSL rats responded to the selective serotonin reuptake inhibitor, escitalopram, by 
increasing their swimming behaviour in the FSL (El Khoury et al. 2006; Petersén et al. 
2008).  Those studies also showed that the effect was only produced or more pronounced 
in the MS FSL compared to the non-maternally separated FSL rats (El Khoury et al. 2006; 
Petersén et al. 2008) .  However, another study was unable to replicate these findings in 
MS FSL rats in the FST possibly because they measured immobility instead of swimming 
behaviour (Musazzi et al. 2010).  In contrast to the former studies, Musazzi et al. (2010) 
found that MS had an effect only in the FRL control rats by increasing the immobility in 
the FST.  Furthermore, although escitalopram treatment similarly decreased the 
immobility only in the FSL rats, the effect in the non-maternally separated FSL was more 
pronounced than in the MS FSL rats (Musazzi et al. 2010).  Since the studies by El 
Khoury et al. (2006), Petersén et al. (2008) and Musazzi et al. (2010) used the same MS 
and treatment protocol in FSL and FRL rats, it therefore appeared that MS affected the 
immobility in the FST in FSL and FRL rats differently than the swimming behaviour.  It 
has also been previously shown that anxiety-like behavioural effects of MS were highly 
dependent on the genetic background (Neumann et al. 2005).  More specifically, rats that 
were bred for high anxiety-like behaviour (decreased time spent in the open arms of the 




EPM, HAB rats), showed signs of reduced anxiety in the modified holeboard test 
following repeated MS (Neumann et al. 2005).  In contrast, rats that were bred for reduced 
anxiety-like behaviour (increased time spent in the open arms of the EPM, LAB rats), 
showed signs of increased anxiety in the EPM following MS (Neumann et al. 2005).  As a 
result of MS, the anxiety-like behaviour in the modified holeboard test did not differ 
between HAB and LAB rats (Neumann et al. 2005).  Therefore, according to above 
studies, the neurobiological outcome and ultimately the psychopathology of 
developmental stress will depend on the genetic vulnerability of the animal/individual. 
Only a few studies measured the anxiety-/depression-like behavioural effects of MS in 
WKY rats (Nam et al. 2014; Sterley et al. 2011; Womersley et al. 2011).  In adolescent 
and adult WKY rats, MS had no overall effect on anxiety-like behaviour and depression-
like behaviour as evidenced by the time spent in the open arms of the EPM and 
immobility in the FST, respectively (Nam et al. 2014; Sterley et al. 2011; Womersley et 
al. 2011).  However, evidence showed that adolescent MS WKY rats spent more time in 
the closed arms of the EPM during the first minute of testing indicative of some anxiety-
like behaviour (Womersley et al. 2011).  Furthermore, when measuring anhedonia 
behaviour, MS WKY rats spent the same amount of time as non-maternally separated 
WKY rats in the avoidance zone in response to the stimulus of a female and male rat 
(Nam et al. 2014).  It was previously suggested that that lack of environmental influences 
may be due to the strong influence of their genetic profile in shaping their depression-like 
behaviour (Nam et al. 2014).  However, this requires further investigation and the need to 
study the effects of early life stress on the antidepressant response in WKY rats.    
 1.3 Tests for depression 
In contrast to an animal model of depression, tests for depression provides a behavioural 
or physiological endpoint measure and are designed to assess the effect of a genetic, 
pharmacological or environmental manipulation (Yan et al. 2010).  Behavioural tests will 








Table 1.2:  Classification of some of the behavioural assays used to measure depression- and 
anxiety-related behaviour in rodents.  Adapted from supplementary information (Nestler and Hyman 
2010). 
Symptom Cluster Assay Validity 
Treatment-based screens 




Tests of anhedonia:  sucrose 
preference, investigatory 
behaviour, sexual behaviour 
Intracranial self-stimulation 
Face 
 USV ? ? 
Neurovegatative (or homeostatic) 









1.3.1 Treatment-based screens 
1.3.1.1 Forced swim test 
The FST, also known as the behavioural despair test or the Porsolt test was developed by 
Porsolt and colleagues in rats (Porsolt et al. 1977; Porsolt et al. 1978).  The FST is the 
most widely used tool for assessing antidepressant-like behaviour.  It is based on the 
observation that rats, following initial escape-orientated activities such as swimming and 
struggling, developed immobility when placed in an inescapable cylinder of water (Cryan 
et al. 2002).  On return in the cylinder of water 24 h later, they resumed to be immobile 
more rapidly (Cryan et al. 2002).  The original view by Porsolt is that since the rat was 
more immobile in the second immersion; it indicated a state of “despair” because the rat 
had learn that escape is impossible (learned helplessness) (Porsolt et al. 1977).  However, 
describing activity in the FST as depression-related has been previously questioned 
(Borsini and Meli 1988) and therefore believed to rather reflect learned immobility (Parra 
et al. 1999) or described as the development of passive behaviour that disengages the rat 




from active behaviour of coping with stress (Cryan et al. 2002).  Nonetheless, the FST has 
received considerable recognition as a screening tool for antidepressant drugs with strong 
predictive validity (Cryan et al. 2005; Detke et al. 1997).   
The FST is sensitive to a variety of antidepressant drugs including all of the major classes 
of tricyclic antidepressants, selective serotonin reuptake inhibitors, monoamine oxidase 
inhibitors, atypical antidepressants and electroconvulsive shock treatment (Borsini and 
Meli 1988).  Treatment with antidepressant drugs (typically 3 injections) between the 
pretest-swim and test swim reduced the amount of time spent immobile and increased the 
time spent in active behaviours (swimming and climbing) during the test swim session 
(Detke et al. 1995; Slattery and Cryan 2012).  However, stimulants, sedatives or motor-
impairing compounds showed false positive results in the test (Borsini and Meli 1988).  
Therefore, it is necessary to determine if the tested drug alters locomotor activity (see 
OFT in section 1.3.2.3 below).  For example, a stimulant may decrease immobility in the 
FST but may also increase locomotor activity, thereby confounding the FST results.  
Furthermore, the FST is unique in distinguishing between serotonergic and noradrenergic 
antidepressant drugs based on different active behaviours (Detke et al. 1995; Detke and 
Lucki 1995).  For example, in addition to decreasing the immobility, the selective 
noradrenaline reuptake inhibitors (desipramine, maprotiline) selectively enhanced 
climbing behaviour and selective serotonin reuptake inhibitors (paroxetine, sertraline, 
fluoxetine) selectively enhanced swimming behaviour in the FST (Detke et al. 1995).  The 
major drawback of the FST is that short-term antidepressant treatment reduced immobility 
in the FST whereas in patients it can take weeks for a therapeutic effect.  However, it has 
been demonstrated that doses of antidepressant drugs that were inactive acutely, reduced 
the immobility when administered chronically which further validates the FST (Detke et 
al. 1997). 
The FST has also been used to establish that greater immobility is produced following 
exposure to chronic stress (Chiba et al. 2012; Liu et al. 2013b; Morley-Fletcher et al. 
2003) or other conditions that provoked depression-like behaviour such as acute drug 
withdrawal (Cryan et al. 2003), developmental stress of MS (Lambás-Señas et al. 2009; 
Sung et al. 2010) or selective breeding (Overstreet 1993; Tejani-Butt et al. 2003; Weiss et 
al. 1998).  The FST procedure has been adapted for rats selectively bred for depression-
like behaviour (Lahmame et al. 1997; Malkesman et al. 2009; Overstreet 2002).  It has 
been suggested that since these rats are characteristically more immobile in the FST, no 
pretest-swim was necessary (Overstreet et al. 2005).  However, this adapted FST protocol 
has not been performed consistently since other studies using established genetic rat 




models of depression included both a pretest-swim and test swim in the FST (Lopez-
Rubalcava and Lucki 2000; Nam et al. 2014; Tejani-Butt et al. 2003).   
Therefore, the fact that the FST gives bi-directional results (pro-depression- and 
antidepressant-like effects) to common manipulations gives the test high predictive 
validity and behavioural dimension that is relevant to depression (Cryan et al. 2005; 
Slattery and Cryan 2012). 
1.3.2 Mood / anxiety 
1.3.2.1 Ultrasonic vocalizations 
Rodents produce and perceive calls in the ultrasonic range, referred to as USVs.  An 
affective hypothesis and social signalling hypothesis was proposed  (Knutson et al. 2002) 
based on evidence that USVs have a communicative function (to direct specific 
behaviour) (Farrell and Alberts 2002; Takahashi et al. 1983) as well as providing 
information on the emotional state (Knutson et al. 2002; Seyfarth and Cheney 2003).  
However, the emotional and communicational functions of USVs are not necessarily 
separable (Brudzynski and Pniak 2002).   
Three types of USVs can be distinguished in rats that are dependent on the stage of 
development, affective state and social context.  For example, infant rats emit isolation-
induced 40-kHz USVs when separated from their mother and littermates indicating 
anxiety-like behaviour (Treit et al. 2010).  Adolescent and adult rats are able to emit two 
primary types of USVs:  22-kHz and 50-kHz (Knutson et al. 2002; Natusch and 
Schwarting 2010; Portfors 2007). The 22-kHz calls are emitted in various aversive 
situations such as exposure to predators (Blanchard et al. 1991), inescapable footshock 
(Sánchez 2003; Wöhr et al. 2005) and inter-male aggression (Thomas et al. 1983) and 
therefore indicating a negative emotional state.  The affective hypothesis of 22-kHz USVs 
is further supported by evidence showing that rats that displayed high levels of anxiety-
like behaviour in the EPM (decreased time spent in open arms of EPM) and freezing 
behaviour, vocalized more than the rats that displayed low levels of anxiety-like 
behaviour and freezing behaviour (Borta et al. 2006).  Therefore, not only the 
aversiveness of the context but also the individual disposition affects the 22-kHz USVs.  
Consistent with the social signalling hypothesis, 22-kHz USVs may also serve as alarm 
cries.  It has been previously shown that 22-kHz USVs in response to a predator (cat) is 
dependent on the presence of other rats since 22-kHz USVs were absent when a rat was 
exposed to a cat without the presence of other rats (Blanchard et al. 1991; Wöhr and 
Schwarting 2010).  This was further supported by studies showing that playback of 22-




kHz calls induce long-lasting behavioural inhibition as measured by general activity 
(Brudzynski and Chiu 1995; Wöhr and Schwarting 2007).  
On the other hand, 50-kHz vocalizations are normally emitted in appetitive situations such 
as play (rough-and-tumble play and tickling), mating, anticipation of food reward, 
electrical brain stimulation and administration of drugs of abuse such as amphetamine  
(Burgdorf et al. 2000; Burgdorf et al. 2008; Knutson et al. 1998; Panksepp and Burgdorf 
2000; Thompson et al. 2006) therefore indicating a positive emotional state.  This was 
further supported by evidence showing that aversive stimuli such as cat odor or bright 
light reduced the emission of playful tickling-induced 50-kHz USV (Panksepp and 
Burfdorf 1999).  Furthermore, rats selected with lower positive affect at an early age, 
indicated by lower 50-kHz response to tickling, elicited increased levels of 22-kHz USVs 
and depression-like behaviour in adulthood such as lower sucrose intake and preference, 
higher levels of immobility in the FST and spending less time in contact with other rats 
(Burgdorf et al. 2009; Mällo et al. 2009).  This suggests that rats with low positive 
emotional state indicated by reduced 50-kHz USVs are predisposed to affective disorders 
such as depression-like behaviour (Mällo et al. 2009).  In addition, hippocampal cell 
proliferation, that has been associated with depression, positively correlated with 50-kHz 
USV and negatively correlated with 22-kHz USVs during tickling (Wöhr et al. 2009).  
Furthermore, rats that experienced tickling as appetitive, as indicated by high number of 
50-kHz USV, had increased hippocampal cell proliferation levels as compared to non-
tickled control rats (Wöhr et al. 2009).     
However, 50-kHz calls have not always been found in situations generally seen as 
rewarding.  For example, 50-kHz USVs occurred in response to separation from 
conspecifics (Wohr et al. 2008).  It was shown that the rat that remained alone in the home 
cage following separation from the cage mates produced a high number of 50-kHz USVs 
(Wohr et al. 2008).  This was suggested to indicate the need for social contact and 
therefore function as social contact calls (Wohr et al. 2008).  In further support of their 
communicative function, playback of 50-kHz USVs induced social exploratory behaviour 
directed towards the sound source (Wöhr and Schwarting 2007).  This was evidenced by 
the increased entries of recipient rats in the three proximal arms of a radial maze in front 
of a loudspeaker compared to fewer entries in the distal arms (Wöhr and Schwarting 
2007).  Other situations seen as non-rewarding showed 50-kHz calls during morphine 
withdrawal (Vivian and Miczek 1991) and aggressive encounters with resident-intruder 
tests that were reduced by anxiolytic drugs (Miczek et al. 1995; Tornatzky and Miczek 
1995). 




The 50-kHz vocalizations have been further characterized according to the affective and 
social signalling hypothesis into flat and frequency modulated (FM) calls.  The flat 50-
kHz calls are emitted during anticipation of social contact, as opposed to FM calls which 
are indicative of the emotional state (Brudzynski and Pniak 2002; Wohr et al. 2008).  For 
example, Burdorf and Panksepp (2006) divided 50-kHz of tickled responders and tickled 
non-responders into flat and FM calls and showed that tickle responder rats exhibited 
more of the FM calls indicative of positive emotion (Burgdorf and Panksepp 2006).  This 
was further supported by evidence showing positive correlation between FM 50-kHz USV 
and appetitive behaviour such as rough-and-tumble-play behaviour and mating (Burgdorf 
et al. 2008).  On the other hand, a high number of flat USV calls occurred in the rat that 
remained alone in the home cage following separation from the cage mate indicating its 
relevance in a social-coordinating function (Wohr et al. 2008).    
1.3.2.2 Elevated plus maze 
The EPM has become one of the most important behavioural tests to evaluate anxiety-like 
behaviour in rodents and the effect of anxiolytic and anxiogenic drugs (Braun et al. 2011; 
Hui et al. 2014; Nosek et al. 2008; Pellow and File 1986).  The EPM is a plus-shaped 
maze composed of two open arms and two closed arms that is connected by a central area. 
The test is based on the fact that rats under normal conditions show preference for closed 
alleys (closed arms) compared to open alleys (open arms).  Open arm avoidance is 
exaggerated by drugs with anxiogenic effects and reversed by treatment with standard 
anxiolytics (Pellow and File 1986).  Furthermore, the EPM is sensitive in showing 
anxiety-like behaviour in rat models predisposed to depression-/anxiety- like behaviour 
(Braw et al. 2006; Daniels et al. 2004; Landgraf and Wigger 2002).  Another behaviour 
infrequently measured, is the time spent in the center of the EPM and suggested to 
indicate indecision or ambivalence that may be related to approach/avoid conflict (Bourin 
et al. 2001b; Nosek et al. 2008; Rodgers and Johnson 1995).  Therefore, the EPM has 
been suggested to have good face and predictive validity (Pawlak et al. 2012; Walf and 
Frye 2007).    
1.3.2.3 Open field test 
The OFT is another test commonly used to assess activity and anxiety-like behaviour in 
rodents (reviewed in Prut and Belzung 2003).  The test is performed by placing the animal 
close to the walls or center of the apparatus and the following behaviour recorded: 
horizontal locomotion, frequency of rearing or leaning and grooming.  When exposed to 
an open field, rodents spontaneously prefer to stay close to the walls of the apparatus and 
spent less time in the central part of the open field.  Increased time spent in the central part 




or a decrease latency to enter the central part of the open field is an indication of reduced 
anxiety-like behaviour that is induced by anxiolytic drugs.  Anxiety-like behaviour in the 
OFT is triggered by two factors:  individual testing (separated from social group) and 
agoraphobia (size of the arena relative to the animal‟s natural environment) (Prut and 
Belzung 2003).  Therefore, anxiolytic treatments may not affect exploration of the animal, 
but the effects on the reaction of the animal to a stressful event (Prut and Belzung 2003).  
In addition, the OFT has been more routinely used in combination with the FST to assess 
locomotor activity in rats following antidepressant drug treatment (Akinfiresoye and 
Tizabi 2013; Overstreet and Griebel 2004; Tejani-Butt et al. 2003; Tizabi et al. 2012).  
Since the FST is a result of an activity measure it has been suggested that the results 
obtained in the FST should be confirmed by additional testing in a locomotor paradigm 
such as the OFT (Slattery and Cryan 2012).  
1.4 Treatment   
1.4.1 Monoaminergic antidepressant drugs 
Since its introduction, nearly 50 years ago, the monoamine hypothesis (as discussed in 
section 1.1.5.1) provided the only neurobiological explanation according to the 
mechanism of antidepressant action.  Antidepressants, currently available, are effective in 
many patients (Morilak and Frazer 2004).  However, the antidepressants have a few 
shortcomings such as undesirable side effects, treatment resistance and the delayed onset 
of action.  Remission is not often achieved and only 60% - 70% of patients with 
depression respond to antidepressant drug treatment while 10% - 30% of those patients 
remain resistant to treatment (Al-Harbi 2012).  Furthermore, depression symptoms can 
even return over the course of chronic treatment (Solomon et al. 2005).  A serious 
drawback of all antidepressants is the requirement of long-term treatment for 2-4 weeks 
before a therapeutic effect is achieved (Wells et al. 2003) because of the the long-term 
adaptive changes required for a change in mood/behaviour.  Environmental factors and 
antidepressant drugs are able to modify the expression of genes (epigenetics) by altering 
DNA methylation and chromatin activation (Dalton et al. 2014).  For example, 
overexpression of histone deacetylase 5 (HDAC5), an enzyme that decreases gene 
expression by decreasing histone acetylation prevented the antidepressant effects of 
imipramine in stressed animals (Tsankova et al. 2006). 
The monoamine oxidase inhibitors and tricyclic antidepressants were the first 
antidepressant discovered (Baldessarini 2001).  The discovery initiated the first 
investigations of the involvement of neurochemistry in depression.  The acute 
mechanisms of these antidepressants were identified as: 




1) Monoamine oxidase inhibitors (e.g. iproniazid, phenelzine, tranylcypromine):  
Inhibition of monoamine oxidase 
2) Tricyclic antidepressants (e.g. imipramine, amitriptyline, desipramine):  inhibition 
of serotonin or noradrenaline reuptake transporters   
This led to the second generation of antidepressant drugs that were more selective for the 
monoamine neurotransmitters and therefore had fewer adverse effects.  These 
antidepressants are widely used and include: selective serotonin reuptake inhibitors 
(SSRIs; e.g. fluoxetine, paroxetine), norepinephrine reuptake inhibitors (NRIs; e.g. 
atomoxetine), serotonin-norepinephrine reuptake inhibitors (SNRI; e.g. venlafaxine) 
noradrenergic and specific serotonergic antidepressants (NaSSAs; e.g. mirtazapine), 
serotonin antagonist and reuptake inhibitors (SARIs; e.g. trazodone) and norepinephrine-
dopamine reuptake inhibitors (NDRIs; e.g. bupropion). 
Despite the drawbacks of available antidepressants, they still provide tools to validate 
behavioural tests to study depression-like behaviour in animal models.  Most importantly, 
they also provide tools to study brain function in depression in order to identify specific 
neurochemical abnormalities as well as to study novel targets for antidepressant drug 
treatment.  Therefore, alternative drug targets for depression are being investigated to 
improve efficiency and onset of antidepressant drugs with fewer side effects.  
1.4.2 Ketamine 
Although the development of novel antidepressant drugs has proven to be extremely 
difficult because of the heterogeneous symptoms of depression, recent studies have found 
that previously known psychotropic drugs are capable of producing a rapid antidepressant 
response.  The NMDA receptor antagonist ketamine has recently been used for the 
treatment of depression.  When administered in subanaesthetic doses, ketamine has rapid 
and long lasting antidepressant effects in patients with major depression (Berman et al. 
2000; Larkin and Beautrais 2011), bipolar disorder (Zarate et al. 2012) and treatment-
resistant depression (Zarate et al. 2006). 
In various rodent models of depression, ketamine showed rapid antidepressant-like effects 
on behaviour in the FST, learned helplessness paradigm and tail suspension test (Garcia et 
al. 2008; Koike et al. 2011; Li et al. 2010; Maeng et al. 2008; Tizabi et al. 2012).  
Ketamine treatment of mice exposed to chronic mild stress at a dose of 3 mg/kg, 
decreased duration of immobility in the FST, latency to feed in the OFT (measure of 
anxiety) and increased sucrose consumption (measure of anhedonia) (Autry et al. 2011).  
Ketamine treatment of rats at a dose of 10 mg/kg and 15 mg/kg has been shown to reduce 




the duration of immobility in the FST induced by the 15-min pretest-swim, at 60 min after 
treatment (Garcia et al. 2008).  Furthermore, ketamine treatment at a dose of 10 mg/kg has 
been shown to reduce the number of escape failures in the learned helplessness paradigm, 
increased sucrose consumption and reduced latency to feed in rats that have been exposed 
to chronic unpredictable stressors (Koike et al. 2011; Li et al. 2011).  However, previous 
studies showed that at higher doses (80 mg/kg or 160 mg/kg), ketamine had no sustained 
antidepressant effect in the FST in rats at 24 h or 1 week after acute treatment (Li et al. 
2010; Popik et al. 2008).  Furthermore, repeated treatment (3 days, 7 days or 3 injections 
at 24, 5 and 1 h before test swim) of ketamine at a dose of 25 mg/kg had no immediate 
effect on immobility in the FST at 1 h after treatment in rats (Fraga et al. 2013; Gigliucci 
et al. 2013).  The long-lasting behavioural effects of ketamine may lead to more insight 
into the molecular mechanisms that needs to be fully understood in order to develop more 
effective antidepressant drugs. 
A previous study by Li et al. (2010) suggests that the immediate and long-lasting effects 
of ketamine are mediated by changes in the signalling pathway of the mammalian target 
of rapamycin (mTOR).  Ketamine administration rapidly (30 min after injection) 
increased phosphorylated and activated levels of mTOR, eukaryotic initiation factor 4E 
and p70S6 kinase in synaptoneurosomes (Li et al. 2010).  Furthermore, the levels of these 
phosphorylated factors returned to baseline after 2 h.  On the other hand, PSD95, GluR1 
and synapsin are upregulated at 2 h after ketamine administration and remained elevated 
for up to 72 h (Li et al. 2010).  Activation of the mTOR pathway by ketamine increased 
BDNF levels in the hippocampus which was suggested to mediate the rapid 
antidepressant-like effects of ketamine (Autry et al. 2011; Garcia et al. 2008). 
1.5 Conclusion 
Major depression is a serious, heterogeneous disorder that is highly prevalent and 
activated by a complex interaction of genetic and environmental factors (Millan 2006).  
Accordingly, depression is associated with disability, increased medical co-morbidities 
and mortality that results in a significant social and economic burden (Lépine and Briley 
2011).  Despite the serious consequences of depression, there is still no diagnostically 
useful biological test to diagnose despression (Saveanu and Nemeroff 2012).  This may be 
because the neurobiology underlying depression remains to be poorly understood.  
Clinical and preclinical evidence show abnormal monoamine neurotransmission of 
serotonin, noradrenaline and dopamine in relevant brain areas associated with depression 
or depression-like behaviour although several inconsistencies have been reported.  These 
inconsistencies may be related to different methodology between studies as well as 




differences in diagnostic features between patients.   Furthermore, the mechanism of 
action of most antidepressant drugs, effective in many people, increases these monoamine 
neurotransmitters at the synapse.  However, the currently available antidepressant drugs 
have several unmet clinical needs ranging from efficacy in treatment resistant patients, 
faster onset of action and decreased side effect profile, emphasizing the need for improved 
drug therapy targeting other neurochemical pathways.  During the past decade, 
converging lines of evidence have led beyond the monoamine hypothesis of depression to 
improve antidepressant drug therapy.  NMDA, opioid receptors and intracellular 
signalling pathways mediating neuroprotection via BDNF, ERK and GSK3β, have been 
shown to be involved in the pathophysiology of depression.  However, evidence 
indicating how different risk factors of depression interact with these signalling pathways 
as well as the mechanism of action of monoaminergic antidepressant drugs on these 
pathways seems to be unresolved.  There is no doubt that various neurotransmitter 
pathways are associated with the pathology of depression and likewise, several brain areas 
such as the limbic and PFC are associated with these pathways.  Advances in brain 
imaging has allowed the identification of these brain regions and associated circuits in the 
pathophysiology of depression, more specifically, reduced activity in the frontal cortical 
areas and hyperactivity in the hippocampus and other limbic brain areas.  Furthermore, the 
NAc plays a central role in the limbic system of the brain and regulates goal-directed 
behaviours by integrating information from limbic structures and the PFC (Goto and 
Grace 2008).  
Animal models of depression provide important tools to unravel the neurobiological 
underpinnings of depression as well as providing development of novel therapeutic 
strategies.  Various studies in the past have focused on animal models with a genetic 
predisposition or stress in adulthood.  However, although these animal models 
demonstrated to have good validity, some are less reliable and useful considering that 
depression develops over a long-term period with multiple risk factors.   In addition, few 
studies provided evidence for depression-/anxiety-like behaviour from the combination of 
these factors.  The genetic WKY rat model of depression showed variability in results 
between studies in anxiety-like behaviour and depression-like behaviour such as measures 
of anhedonia as well as variability in response to antidepressant drug treatment.  Also, 
previous studies reported several behavioural and neurobiological inconsistencies in the 
widely accepted MS model of depression. 
Therefore, it is considered that MS will enhance the validity of WKY rats by 
superimposing the developmental stress of MS onto the genetic WKY model.  As an 
alternative, it is considered that MS subjected to additional stress in adulthood will 




enhance depression-/anxiety-like behaviour and provide novel insight in the molecular 
mechanisms involved in their depression-/anxiety-like behaviour.  Therefore, by 
establishing models that will provide greater predictive validity and higher reliability, the 
rate at which novel drug therapies are developed can be increased. 
1.6 Aims and Objectives 
Study aims: 
▪ To characterize the WKY rat model of depression-/anxiety-like behaviour. 
▪ To establish a more robust WKY model of depression by subjecting WKY to MS. 
▪ To measure depression-/anxiety-like behaviour and associated changes in relevant 
brain areas in the MS SD rat model that will be subjected to stress in adulthood and 
serve as a comparator model of depression.  
▪ To determine the effect of ketamine in WKY and MS SD models of depression in 
order to provide further evidence for their predictive validity. 
Study objectives: 
▪ The WKY rat model will be characterized and appropriate substrain of WKY 
(WKY/NCrl and WKY/NHsd) selected based on its optimal depression- and 
anxiety-like behaviour in the FST, OFT and EPM compared to the Wistar control 
strain.  This will also include the measurement of antidepressant response to 
desipramine in the FST to establish the optimal dose of desipramine and whether a 
pretest-swim is required.  Furthermore, changes in opioid receptors and TH in 
response to desipramine treatment will be measured. 
▪ Following selection of the appropriate substrain of WKY, depression- and anxiety-
like behaviour and antidepressant response to desipramine will be measured in MS 
WKY rats in the FST, OFT, EPM and USVs recorded in order to establish a more 
robust model of depression.  The function of USVs in WKY rats will be further 
explored in order to determine its usefulness as a marker of depression and provide 
further evidence for their depression phenotype.  Furthermore, the effect of 
desipramine treatment on serotonin levels as well as p-GSK3β and p-ERK will be 
measured in the PFC and dopamine levels and opioid receptors in the NAc.   
▪ The widely used MS SD rat model, as a comparator model, will be subjected to an 
additional stress in adulthood (restraint stress) to determine if restraint stress 
exaggerates the depression-/anxiety-like behaviour of MS SD rats.  Furthermore, 




the effect of MS and restraint stress on BDNF levels in the ventral hippocampus 
and protein profile in the PFC of SD rats, will be measured.   
▪ The rapid and sustained antidepressant effects of ketamine on WKY and MS SD rat 
models of depression will be measured in the FST as well as in their response in 
USVs to removal of cage mate(s) as a marker for depression-like behaviour. 
1.7 Study layout 
The thesis comprises four studies that directly relate to the above aims and objectives and 
each will be presented sequentially as follow: 
▪ Chapter 2 (WKY/NCrl, WKY/NHsd and Wistar rats) contains three experiments 
aimed at characterizing the WKY as a valid model of depression.  This will include 
selecting the appropriate substrain of WKY (experiment 1), measuring the response 
to the optimal dose of desipramine (experiment 2) and the effect of desipramine on 
the neurochemistry of WKY rats (experiment 3). 
▪ Chapter 3 will further proceed to study the depression-/anxiety-like behaviour, 
antidepressant effect of chronic treatment with desipramine on depression-/anxiety-
like behaviour and the effect of desipramine treatment on the neurochemistry of the 
appropriate substrain of WKY that will be subjected to MS (WKY/NCrl, MS 
WKY/NCrl and Wistar control).  
▪ As an alternative, the study in Chapter 4 (non-maternally separated SD, MS SD and 
MS SD subjected to restraint stress) will study depression-/anxiety-like behaviour 
and neurochemistry in the MS SD rats subjected to restraint stress.  
▪ Chapter 5 (WKY/NCrl and Wistar; non-maternally separated SD and MS SD rats) 
contains three experiments aimed at determining the sustained (experiment 1) and 
rapid effects (experiment 2) of acute ketamine treatment at different subanaesthetic 
doses in WKY/NCrl rats.  In addition, experiment 3 will determine the sustained 





Chapter 2  
Strain differences in depression-/anxiety-like 
behaviour and antidepressant response 
 
2.1 Introduction 
The WKY rat was developed from the outbred Wistar rat as a control strain for the 
spontaneous hypertensive rat (Okamoto and Aoki 1963) and has also been described as a 
genetic animal model of depression with hyper-responsiveness to stress (Paré 1992; Paré 
2000; Tejani-Butt et al. 2003).  The WKY‟s selective response to antidepressant drugs in 
the FST provides a unique model to study the neurochemical dysfunction responsible for 
the underlying depression-like behaviour.   
The association of the opioid system with depression is well recognized (Chen and 
Lawrence 2004; Lutz and Kieffer 2013; Vilpoux et al. 2002).  Recently, it has been shown 
that opioid receptors are altered in WKY rats (Carr et al. 2010).  This was evidenced by 
higher KOR and dynorphine protein levels in the cortex and NAc as well as 
antidepressant-like behaviour to a KOR antagonist in the FST (Carr et al. 2010).  
However, the effect of antidepressant drugs such as desipramine, which reverses 
depression-like behaviour of WKY rats, on opioid receptors is unknown.  The KOR as 
well as MOR are both expressed on dopamine terminals in the NAc where it has been 
shown to regulate neurotransmission such as dopamine release (Ebner et al. 2010; 
Mansour et al. 1995).   
Previous studies found behavioural differences between WKY obtained from different 
vendors (Browne et al. 2015; Paré and Kluczynski 1997; Sagvolden et al. 2008) and 
therefore the first aim of this study was to compare the depression-/anxiety-like behaviour 
of inbred WKY rats obtained from Charles River Laboratories (WKY/NCrl) to WKY rats 
from Harlan (WKY/NHsd) and outbred Wistar rats in order to establish a robust animal 
model of depression.  Following selection of the appropriate substrain of WKY to use as a 
model of depression, the response to different doses of the antidepressant drug, 
desipramine (8 mg/kg and 15 mg/kg) at the shortest treatment period, as well as the effect 
of a FST pretest-swim on the antidepressant response, was tested.  The effect of the 
pretest-swim was tested by comparing a single FST session with the FST that comprised 
of a pretest-






swim and test swim since both FST protocols have been used previously on the WKY 
animal model of depression (Lahmame et al. 1997; Lopez-Rubalcava and Lucki 2000; 
Malkesman et al. 2009; Paré 1992; Tejani-Butt et al. 2003).  To determine if the 
antidepressant response in the WKY is related to changes in opioid and dopamine 
neurotransmission, we measured the density of MOR, KOR and TH using polyacrylamide 
gel electrophoresis and western blotting. 
2.2 Materials and Methods 
2.2.1 Animals 
A total number of 82 animals (52 WKY/NCrl rats from Charles River Laboratories 
(USA); 15 WKY/NHsd from Harlan (UK); 15 outbred Wistar rats from Charles River 
Laboratories (USA)) bred in the University of Cape Town Animal Unit, were used for this 
study.  Rats were housed in plexiglass cages with woodchip bedding in a temperature-
controlled room (23±1 °C) with food and water available ad libitum. The housing facility 
was maintained on a 12 h light/12 h dark cycle (lights on from 06h00 to 18h00).   
The study was conducted in accordance with the guidelines of the South African National 
Standard: The care and use of animals for scientific purposes (2008) and approved by the 
University of Cape Town Faculty of Health Sciences Animal Ethics Committee 
(#010/036).   
This study consisted of 3 behavioural groups for experiment 1: WKY/NHsd (n = 15), 
WKY/NCrl (n = 15) and Wistar (n = 15) rats.  At approximately postnatal day 60 (P60), 
WKY/NHsd, WKY/NCrl and Wistar rats were tested in the EPM and immediately 
thereafter in the OFT.  One day after the EPM and OFT (P61), rats were allowed to swim 
for 15 min (pretest-swim).  After 24 h, rats were exposed to a second 5-min test swim 
session. 
Experiment 2 and experiment 3 consisted of different groups of WKY/NCrl rats that were 
randomly divided into treatment groups for each experiment.  Experiment 2 consisted of 
the following treatment groups:  (a) WKY/NCrl treated with Saline (WKY Sal) for 4 days 
(n = 3), 9 days (n=4) or 14 days (n = 4) and (b) WKY/NCrl treated with 8 mg/kg 
desipramine (WKY DMI-8) for 4 days (n = 4), 9 days (n = 4) or 14 days (n = 8).  Starting 
on P60, different groups of WKY/NCrl rats were treated for 4 days, 9 days or 14 days 
with 8 mg/kg desipramine or saline.  At 19 h after the last desipramine/saline injection, a 
single 15-min FST was performed on P64 (for rats treated for 4 days), P69 (for rats treated 
for 9 days) and P74 (for rats treated for 14 days). 






Experiment 3 consisted of the following treatment groups:  (a) WKY/NCrl treated with 
Saline (WKY Sal, n = 5) and (b) WKY/NCrl treated with 15 mg/kg desipramine (WKY 
DMI-15, n = 5).  Starting on P60, WKY/NCrl rats were treated for 26 days with 15 mg/kg 
desipramine or saline.  At 19 h after the last desipramine/saline injection (P85), a pretest 
15-min swim was performed.   After 24 h, rats were exposed to a 5-min test swim session. 
On P87, rats were decapitated and brain areas rapidly dissected, snap frozen in liquid 
nitrogen and stored at -80°C until later analysis of the density of MOR, KOR and TH by 
polyacrylamide gel electrophoresis and western blotting.  The same 5 rats/group used for 
measuring FST behaviour, were also selected for biochemical analysis.  
2.2.2 Behaviour  
Behavioural tests were chosen according to the aims of the study with minimal stress to 
the animals.  Behavioural tests were conducted in the light phase (06h00-09h00).  Adult 
male rats were transferred to the behavioural room on the morning of behavioural testing 
and allowed to habituate for 1 h to the behavioural room conditions. 
2.2.2.1 Elevated plus maze (Experiment 1) 
The EPM test is an established measure of anxiety-like behaviour in rodents (Walf and 
Frye 2007). The EPM consist of two opposing open arms 50×10 cm and two opposing 
closed arms with 40 cm high walls and elevated 50 cm above the floor. The arms are 
connected by a central 10×10 cm square.  The EPM test was performed in experiment 1.  
At approximately postnatal day 60 (P60), the rat was placed in the central square facing 
the open arm and allowed to freely explore the open and closed arms of the EPM for 5 
min.  Between recordings, the arena was cleaned with 70% ethanol to prevent the scent of 
the previous rat in apparatus to influence other animals‟ behaviour.  An aerial view of 
time spent in the open arms, closed arms and central square was recorded with a Sony 
Handycam, DCR-SX83E video camera for subsequent scoring with Noldus ethovision XT 
version 7 software (Noldus, Wageningen, Netherlands).  Center-point detection was used 
by Noldus ethovision to track the movement of the rat in order to determine time spent in 
the arms and center zone of the EPM.  The lighting in the room was 80 lux. 
2.2.2.2 Open field test (Experiment 1) 
The OFT was performed immediately after the EPM in the same room, with lighting at 80 
lux. The open field (OF) consists of a 100×100 cm black arena with 50 cm high walls. 
The arena was cleaned with 70 % ethanol after each behavioural recording.  The OFT was 
performed by placing the rat in one of the corners of the OF facing the open arena. The rat 
was allowed to explore the arena for 5 min. Behaviours was recorded with a video camera 






(Sony Handycam, DCR-SX83E, Japan) and subsequently analyzed using Ethovision 
software (Noldus, Wageningen, Netherlands).  Locomotor activity (total distance 
travelled) and anxiety-like behaviour (entries into the inner zone and time spent in the 
inner zone) was scored. 
2.2.2.3 Forced swim test (Experiment 1-3) 
The FST was carried out according to Porsolt et al. (1977) as modified by Detke and 
Lucki (1995).  Rats in experiment 1 (1 day after the EPM and OFT at P61), rats in 
experiment 2 (P64, P69, P74) and rats in experiment 3 (P85) were placed in individual 
transparent cylinders (40×19 cm) containing 30 cm of water (23–25 °C) without their tails 
touching the bottom of the cylinder.  Each rat was allowed to swim for 15 min, which 
facilitates development of immobility 24 h later in the 5-min test swim as well as being a 
requirement to differentiate between vehicle-treated and drug-treated rats in the test swim 
(Borsini et al. 1989; Slattery and Cryan 2012).  The water was changed after each rat‟s 
swim session, to avoid the influence of alarm substances left behind by the previous rat 
(Abel and Bilitzke 1990).  After 24 h, the rats in experiment 1 and experiment 3 were 
exposed to a second 5-min test swim session (19 h after desipramine/saline injection).  
Experiment 2 was performed with a single 15-min FST (19 h after desipramine/saline 
injection) with immobility measured in the first 5 min because a similar result for 
immobility was obtained for the 15-min pretest and 5-min test swims in experiment 1 and 
behavioural differences between WKY and Wistar rats were already apparent within the 
first 5 min of the 15 min pre-test swim.  Similarly, previous studies also showed 
antidepressant effects in genetic rat models of depression in a single 5-min FST session 
(Lahmame et al. 1997; Malkesman and Weller 2009; Overstreet 1993; Yadid et al. 2000).  
The FST behaviour was recorded for both the 15-min pretest-swim and 5-min test swim 
on a video camera for later analysis. Total time immobile (making only movements 
necessary to keep its head above the water), swimming (when the rat moved around the 
tank in a non-vigorous manner) and struggling (diving, jumping, climbing or strongly 
moving all four limbs) was tracked by Ethovision. 
2.2.3 Drug Treatment (Experiments 2-3) 
Starting on P60, rats in experiment 2 and experiment 3 were either injected with 8 mg/kg 
desipramine hydrochloride (Sigma-Aldrich, St Louis, MO, USA), 15 mg/kg desipramine 
hydrochloride or an equivalent volume of 0.9 % sterile saline (n=5) between 11h00 and 
12h00.  Desipramine/saline was administered for 4 days, 9 days or 14 days in experiment 
2 (and 26 days in experiment 3).  The dose 8 mg/kg and 15 mg/kg was based on previous 






studies (Armario et al. 1988; Zhao et al. 2008) and the treatment period for experiment 2 
was selected according to the range from previous studies (Deupree et al. 2007; Paré 
1992; Tejani-Butt et al. 2003).  Desipramine and saline were administered 
intraperitoneally in a volume equivalent to 2.5 ml/kg.  Desipramine was freshly prepared 
each morning by dissolving it first in deionized H2O to enhance solubility and then 
making it up to the required volume with 0.9 % sterile saline (50 % v/v; H2O/saline).  On 
P87 for experiment 3, rats were decapitated and brain areas rapidly dissected, snap frozen 
in liquid nitrogen and stored at -80°C until later biochemical analysis. 
2.2.4 Biochemistry (Experiment 3) 
2.2.4.1 Western blotting with chromogenic detection 
The NAcC, NAcS and PFC brain tissue samples were sonicated for 25 s each in 
radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 1 % Triton X-100, 0.1 % 
sodium dodecyl sulfate, 20 mM Tris base (pH 7.5), 1 % deoxycholate) and protease 
inhibitor cocktail (2 µl/1ml).  Chemicals were supplied by Merck (NaCl, TritonX-100, 
Tris base), Sigma-Aldrich (deoxycholate) and Thermo Scientific (protease inhibitor 
cocktail).  Following sonication, the samples were mixed on a vortex mixer and 
centrifuged at 17200 x g for 30 min at 4 °C.  The supernatants were collected and protein 
concentrations determined with the Pierce BCA Protein Assay kit (Thermo Scientific, 
Rockford, USA).  Samples were read at 562 nm on a Kayto RT-2100C microplate reader.  
After the protein determination, samples were boiled at 95°C for 4 min containing added 
10 mM dithiothreitol (DTT) and 6x loading dye (4 % sodium dodecyl sulfate, 20 % 
glycerol, 10% 2-mercaptoethanol, 0.125 M Tris base (pH 6.8), 0.03 % bromophenol blue).  
Twenty micrograms of total protein was loaded onto 12% SDS-polyacrylamide gels and 
electrophoresed at 150 V for 1.25 h.  Electrophoresed proteins were transferred onto 
nitrocellulose membranes (Amersham Hybond-ECL, GE Healthcare, USA) at 100 V for 1 
h.  The membranes were blocked with 5 % bovine serum albumin (BSA) in phosphate-
buffered saline (PBS) containing 1 % Tween (PBS-Tween) solution for 1 h and then 
immunolabeled with rabbit polyclonal primary antibody against the μ-opioid receptor-1 
(MOR-1, C-20, sc-7488-R; Santa Cruz Biotechnology, Santa Cruz, CA, USA) (1:1000) or 
blocked with 5 %  powdered milk (Clover SA, Roodepoort, South Africa) in PBS-Tween 
buffer for 1 h and then immunolabeled with rabbit polyclonal antibody against the κ-
opioid receptor (KOR-1, H70, sc-9112; Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
(1:2000) or mouse monoclonal antibody against TH (TH-16, T2928; Sigma-Aldrich, St. 
Louis, MO, USA) (1:8000).  Membranes were incubated with their respective antibodies 
overnight at 4 °C.  This was followed by incubation with the appropriate secondary HRP-






conjugated antibodies for 2 h.  Blots were developed using a metal intensified 3,3‟-
Diaminobenzidine (DAB) protocol based on Adams (1981) and optimized for western 
blot detection.  Following secondary antibody incubation, the membranes were washed 
with PBS buffer and developing medium added.  The developing medium consisted of 5 
mg/ml DAB, 10% NiNH4SO4 and 30% CoCl2 which was filtered and 50% H2O2 added 
before addition to the membrane.  The membrane was left to develop between 1-5 min 
and the reaction was stopped by rinsing the membrane in PBS when the bands appeared.  
Blots were reprobed with rabbit polyclonal antibody against p38 MAP kinase (P38, 
Sigma-Aldrich, St. Louis, MO, USA) to confirm equal loading of protein.  Densitometric 
analysis was performed using Un-Scan-It gel analysis software (Silk Scientific, Inc, 
USA).  The density of each band was determined and expressed as a percentage of the 
mean density of all the bands that represented that specific protein on the gel.   
2.2.5 Statistical Analysis 
Data were normally distributed (Shapiro-Wilk test).  Data for experiment 1 were analyzed 
by means of analysis of variance (ANOVA), followed by Tukey‟s post-hoc test with 
correction for multiple comparisons.  Data for experiment 2 and experiment 3 were 
analyzed by using the unpaired t-test.  Data are presented as mean ± SEM. 
2.3 Results    
2.3.1 Behaviour 
2.3.1.1 Experiment 1:  Strain difference in depression-/anxiety-like behaviour 
Elevated plus maze 
One-way ANOVA showed a significant effect of rat strain on time spent in the center area 
of the EPM (F(2, 42) = 8.11, p < 0.01) with no effect on the amount of time spent in the 
open arms (Fig. 2.1a) or closed arms (Fig. 2.1b).  Post-hoc comparisons showed that the 
WKY/NCrl and WKY/NHsd rats spent significantly more time in the center area of the 
EPM than Wistar rats (p < 0.01; Fig. 2.1c). 
Open field test 
One-way ANOVA revealed a significant effect of strain on distance travelled (F(2, 42) = 
39.52, p < 0.001), entries into the inner zone (F(2, 42) = 19.73, p < 0.001) and time spent in 
the inner zone (F(2, 42) = 6.84, p < 0.01) of the OFT.  Post-hoc comparisons revealed that 
both WKY/NHsd and WKY/NCrl rats travelled a shorter distance than Wistar rats (p < 






0.001; Fig. 2.2). WKY/NCrl rats travelled a significantly shorter distance than 
WKY/NHsd rats (p < 0.05).  WKY/NHsd and WKY/NCrl entered the inner zone less 
frequently than Wistar rats (p < 0.001).  Furthermore, WKY/NHsd (p < 0.05) and 
WKY/NCrl (p < 0.01) spent less time in the inner zone than Wistar rats. 
Forced swim test 
One-way ANOVA revealed a significant effect of strain on immobility (F(2, 42) = 22.05, p 
< 0.001), swimming (F(2, 42) = 14.19, p < 0.001) and struggling (F(2, 42) = 22.97, p < 0.001) 
in the FST.  Post-hoc comparisons showed that WKY/NCrl (p < 0.001) and WKY/NHsd 
(p < 0.01) spent significantly more time immobile than Wistar rats (Fig. 2.3a).  
WKY/NCrl spent significantly more time immobile than WKY/NHsd rats (p < 0.01). The 
WKY/NCrl spent less time actively swimming than WKY/NHsd (p < 0.01) and Wistar 
rats (p < 0.001; Fig. 2.3b). The WKY/NHsd and WKY/NCrl spent significantly less time 
struggling than Wistar rats (p < 0.001; Fig. 2.3c). WKY/NCrl spent significantly less time 
struggling than WKY/NHsd (p < 0.05). 







Figure 2.1:  Time spent in the open arms, closed arms and center area by WKY/NHsd, WKY/NCrl 
and Wistar rats in the EPM. The EPM revealed no difference between WKY/NHsd, WKY/NCrl and 
Wistar rats in time spent in the open arms (a) and closed arms (b). The WKY/ NHsd and WKY/NCrl rats 
spent more time in the center zone (c) than Wistar rats. * Wistar significantly different from WKY/NHsd 











Figure 2.2:  Distance travelled, entries into the inner zone and time spent in the inner zone by 
WKY/NHsd, WKY/NCrl and Wistar rats in the OFT.  The WKY/NCrl were less active than 
WKY/NHsd rats in the OFT (a)  Both WKY/NCrl and WKY/NHsd travelled a shorter distance than 
Wistar rats in the OFT.  The WKY/NCrl and WKY/NHsd entered the inner zone less frequently (b) and 
spent less time in the inner zone (c) than Wistar rats. *WKY/NHsd significantly different from 
WKY/NCrl, p < 0.05; ** Wistar significantly different from WKY/NHsd and WKY/NCrl rats, p < 0.001; 
Tukey‟s post-hoc test (n = 15/group). Data presented as mean ± SEM. 
 







Figure 2.3:  Immobility, swimming and struggling behaviours of WKY/NHsd, WKY/NCrl and 
Wistar rats in the FST.  The WKY/NCrl displayed more immobility (a) and less active swimming (b) 
and struggling (c) behaviours than WKY/NHsd rats and both displayed less activity than Wistar rats in 
the FST. * WKY/NHsd significantly different from WKY/NCrl, p < 0.05; ** Wistar significantly 
different from WKY/NCrl andWKY/NHsd rats, p < 0.01; Tukey‟s post-hoc test (n = 15/group).  Data 












2.3.1.2 Experiment 2:  Effect of 8 mg/kg desipramine treatment on a single 
forced swim test session of WKY/NCrl 
Forced swim test 
Unpaired t-test indicated no significant difference between WKY DMI-8 and WKY Sal 
rats in immobility (Fig. 2.4a), swimming (Fig. 2.4b) and struggling (Fig. 2.4c) behaviours 
in the FST after 4 days, 9 days or 14 days of treatment. 
2.3.1.3 Experiment 3:  Effect of 15 mg/kg desipramine on WKY/NCrl in the 
pretest-swim and test swim session 
Forced swim test 
Unpaired t-test revealed no significant difference between WKY Sal and WKY DMI-15 
rats in immobility in the pretest-swim of the FST (Fig. 2.5).  Unpaired t-test indicated that 
WKY Sal rats spent more time immobile than WKY DMI-15 rats (t(8) = 3, p < 0.05; Fig. 
2.6a) and WKY DMI-15 rats spent more time struggling than WKY Sal rats (t(8) = 4.28, p 
< 0.01; Fig 2.6c) with no significant effect on swimming in the 5-min test session of the 
FST (Fig. 2.6b).  
2.3.2 Biochemistry 
2.3.2.1 Experiment 3:  Density of tyrosine hydroxylase and opioid receptor 
protein in the nucleus accumbens and prefrontal cortex 
Unpaired t test revealed no significant difference between WKY Sal and WKY DMI-15 
rats in density of KOR in the PFC (Fig. 2.7a), NAcC (Fig. 2.8a) and NAcS (Fig. 2.9a), 
MOR in the PFC (Fig. 2.7b), NAcC (Fig. 2.8b) and NAcS (Fig. 2.9b) and TH in the 
NAcC (Fig. 2.8c) and NAcS (Fig. 2.9c). 







Figure 2.4:  Immobility, swimming and struggling behaviours of WKY/NCrl rats in the FST 
following treatment with saline or 8 mg/kg desipramine.  The FST revealed no significant difference 
between WKY DMI-8 and WKY Sal on day 5, day 10 and day 15 in immobility (a), swimming (b) and 
struggling (c) behaviours (n = 3-8/group).  Data presented as mean ± SEM. 
 
 







Figure 2.5:  Immobility of WKY/NCrl rats in the FST (pretest-swim) following treatment with 
saline or 15 mg/kg desipramine.  The FST revealed no significant difference between WKY Sal and 
WKY DMI-15 rat groups in the first 5 min of a pretest-swim session following 15 mg/kg desipramine or 
saline treatment (n = 5/group).  Data presented as mean ± SEM. 








Figure 2.6:  Immobility, swimming and struggling behaviours of WKY/NCrl rats in the FST (test 
swim) following treatment with saline or 15 mg/kg desipramine.  The WKY DMI-15 displayed less 
immobility (a) and more active struggling (c) behaviour than WKY Sal rats. * WKY DMI-15 




















Figure 2.7:  KOR and MOR density in the PFC of WKY/NCrl rats, determined by Western blot 
analysis.  Western blots revealed no significant difference in KOR (a) and MOR (b) density between 






















DMI-15 WKY Sal 
P38 















Figure 2.8:  KOR, MOR and TH density in the NAcC of WKY/NCrl rats, determined by Western 
blot analysis.  Western blots revealed no significant difference in KOR (a), MOR (b) and TH (c) density 
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Figure 2.9:  KOR, MOR and TH density in the NAcS of WKY/NCrl rats, determined by Western 
blot analysis.  Western blots revealed no significant difference in KOR (a), MOR (b) and TH (c) density 
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This study is consistent with the use of WKY/NCrl as a model of depression: (1) 
WKY/NCrl rats were less active in the OFT and FST than WKY/NHsd and Wistar rats 
and (2) desipramine treatment decreased depression-like behaviour in the FST. 
In experiment 1, the WKY rats displayed various behavioural characteristics generally 
found in depression namely a lack in general activity (psychomotor retardation) and spent 
less time in the inner zone (anxiety-like behaviour) of the OFT, a significant amount of 
time in the center zone of the EPM (indecisiveness) and a significant amount of time 
immobile in the FST (“despair”) compared to the Wistar rats.  Furthermore, the 
WKY/NCrl displayed less activity in the OFT and FST than the WKY/NHsd substrain.  
The current study is in agreement with various studies that have measured depression-like 
behaviour specifically in WKY from Charles River Laboratories (Lopez-Rubalcava and 
Lucki 2000; Pardon et al. 2002; Paré 2000; Tejani-Butt et al. 2003).  Time spent in the 
center zone of the EPM is in frequently measured but provides an indication of 
indecisiveness (Nosek et al. 2008).  The current study is in agreement with previous 
studies comparing the amount of time the WKY rats spent in the center zone relative to 
other rat strains (Nam et al. 2014; Nosek et al. 2008).  Previous studies also found 
behavioural differences in activity in the OFT, FST and a visual discrimination task 
between substrains of WKY obtained from different suppliers (Browne et al. 2015; Paré 
and Kluczynski 1997; Sagvolden et al. 2008) which they attributed to differences in 
inbreeding programs and the fact that WKY were not fully inbred prior to distribution 
(Kurtz et al. 1989; Paré and Kluczynski 1997; Sagvolden et al. 2009).  However, the study 
by Browne et al. (2015) showed that WKY rats from Taconic (WKY/NTac) displayed 
decreased immobility in the FST compared to WKY/NCrl and WKY/NHsd.  In contrast to 
the present study, no significant difference was found in immobility between WKY/NCrl 
and WKY/NHsd (Browne et al. 2015).  It is therefore important when reporting results 
and making comparisons between studies to indicate the source of WKY rats (Sagvolden 
et al. 2009).  
In experiment 2, 8 mg/kg desipramine had no significant effect after 4 days, 9 days or 14 
days of treatment in the first 5 min of a single 15-min FST session.  Therefore, 8 mg/kg 
desipramine was not sufficient to cause an antidepressant effect or it is also possible that a 
pretest-swim is required for an antidepressant effect to be detected more easily (Borsini et 
al. 1989; Slattery and Cryan 2012).  Previously either the inclusion of a pretest-swim 
(Lopez-Rubalcava and Lucki 2000; Tejani-Butt et al. 2003) or a single swim session 
(Lahmame et al. 1997; Paré 1992) revealed antidepressant activity in WKY rats.  






However, it was also found that a single 5-min FST in prepubertal rats treated chronically 
with 8 mg/kg desipramine had no antidepressant effects (Malkesman et al. 2009).  This 
was investigated in experiment 3 which included a pretest-swim and a higher desipramine 
dosage of 15mg/kg. 
In experiment 3, 15 mg/kg desipramine decreased immobility and increased active 
struggling behaviour of WKY/NCrl rats in the 5-min test session of the FST.   Similar to 
experiment 2, desipramine treatment had no effect on the pretest-swim behavior of the 
rats. The results are therefore in agreement with previous studies in which desipramine 
similarly decreased immobility in WKY/NCrl rats but in some cases, struggling rather 
than swimming behaviour was increased (Lopez-Rubalcava and Lucki 2000; Tejani-Butt 
et al. 2003).  Similar to studies with SD rats (Detke and Lucki 1995; Lucki 1997), the 
noradrenaline uptake inhibitor also showed a selective increase in struggling behaviour in 
WKY/NCrl rats.  The results therefore revealed the necessity of a pretest-swim to detect 
significant differences between treatment groups since neither 8 mg/kg or 15 mg/kg 
affected immobility behavior in a single swim session of the FST. 
Western blot analysis revealed no significant difference in opioid receptor (KOR and 
MOR) and TH densities in the PFC, NAcC and NAcS between WKY rats treated with 
saline and WKY rats treated with desipramine.  It is therefore possible that these 
neurotransmitter systems in the NAc and PFC brain areas are unrelated to the response to 
desipramine treatment (Berrocoso and Mico 2009; Plaznik et al. 1985; Scuvée-Moreau and 
Svensson 1982).  Another reason for the non-significant effect of desipramine on KOR, 
MOR and TH, may originate from the methodology. The increased sensitivity of the DAB 
detection was suggested to enhance sensitivity by adding metal salts of cobalt and nickel 
to the reaction (Adams 1981).  This colorimetric detection method have several 
advantages over other detection methods such as an easier methodology with less trial and 
error, more cost-effectiveness as well as a signal that does not fade over time.  However, 
this method is limited to proteins of high abundance such as MOR, KOR and TH and 
therefore sensitivity is inferior to detection methods such as chemiluminescence when 
detecting low abundance proteins.     
In conclusion, the WKY/NCrl were found to be a robust animal model of depression 
evidenced by high immobility levels in the FST compared to other strains as well as a 





Chapter 3  
Behavioural changes during antidepressant 
treatment of the maternally separated Wistar-
Kyoto rat model of depression 
 
3.1 Introduction 
Stress experienced during the early stages of life can impact negatively on the affective 
state of the individual in adulthood, especially individuals who are genetically predisposed 
in developing depression (Kim et al. 2007; Taylor et al. 2004).  Rodent models of early 
life stress have been used in an effort to better understand the impact of early life 
adversity on behaviour and biochemistry of the brain.  MS of pups from the dam for 3 h 
per day in the early stages of their development, when pups are completely dependent on 
their mother, is considered stressful and a well-established animal model of early 
developmental stress that results in depression-/anxiety-like behaviour later in life 
(Daniels et al. 2004; Dimatelis et al. 2012b; Kalinichev et al. 2002; Lee et al. 2007; 
Sánchez et al. 2001).  However, the response to developmental stress is highly dependent 
on the genetic predisposition (Neumann et al. 2005) but the exact interaction remains 
unknown.  
USVs in animals, as with human speech, provide information on social status (to direct 
specific behaviour) (Farrell and Alberts 2002; Takahashi et al. 1983) as well as emotional 
state (Knutson et al. 2002; Seyfarth and Cheney 2003). However, the emotional and 
communicational functions of USVs are not necessarilyseparate from each other 
(Brudzynski and Pniak 2002). Adolescent and adult rats are able to emit 50-kHz 
vocalizations in appetitive situations such as play, mating, anticipation of food reward and 
electrical brain stimulation (Burgdorf et al. 2000; Burgdorf et al. 2008; Knutson et al. 
1998; Panksepp and Burgdorf 2000). The 50-kHz vocalizations have been further 
characterized into flat and FM calls.  The flat 50-kHz calls are emitted during anticipation 
of social contact, as opposed to FM calls which are indicative of the emotional state 
(Brudzynski and Pniak 2002; Wohr et al. 2008).
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The delayed onset of currently available antidepressant drugs suggests that their 
therapeutic effects are mediated by changes that occur beyond their immediate effects on 
the noradrenergic and serotonergic systems.  Glycogen synthase kinase-3 (GSK3) plays a 
central role in many converging intracellular signalling pathways and is suggested to be 
involved in both neuroprotection and psychiatric disorders (Hunsberger et al. 2009; Rowe 
et al. 2007).  The MAPK/ERK pathway is important for synaptic plasticity (Thomas and 
Huganir 2004) and has been shown to play a crucial role in depression and the action of 
antidepressants (Fumagalli et al. 2005; Musazzi et al. 2010; Qi et al. 2009).  Furthermore, 
ERK can be considered an integrator of neuroprotective pathways (Almeida et al. 2005; 
Bravo et al. 2009; Colucci-D'Amato et al. 2003) and inhibition of GSK3 results in 
increased phosphorylation of ERK1/2 in cell lines (Wang et al. 2006).  Opioid receptors 
are well recognized to play a role in depression. Specifically, opioid receptors play a role 
in depression-like behavior in adult rats as a results of early developmental stress 
(Dimatelis et al. 2012b).   Recent evidence also reported the role of opioid receptors 
having a neuroprotective effect through GSK3-induced apoptosis (Olianas et al. 2011; 
Polakiewicz et al. 1998).    
Despite the involvement of both genetic and environmental factors in depression, only a 
few studies determined depression-/anxiety-like behaviour and antidepressant response in 
genetic rat models of depression exposed to early developmental stress (El Khoury et al. 
2006; Musazzi et al. 2010; Neumann et al. 2005; Petersén et al. 2008; Womersley et al. 
2011).  The aim of this study was to (1) use the WKY/NCrl and MS WKY/NCrl models 
of depression to measure changes in behaviour during antidepressant drug treatment in 
comparison with the Wistar that served as the control group and (2) to investigate 
molecular changes in dopamine and serotonin levels, opioid receptors and their signalling 
proteins (phospho (ser9)-GSK3β (p-GSK), phospho-ERK1/2 (p-ERK)) to provide further 
insight into the molecular pathways that are affected by antidepressant drug treatment and 
MS in the WKY model of depression..   
It was hypothesized that MS WKY rats would display exaggerated depression-/anxiety-
like behaviour and increased response to desipramine treatment compared to normally 
reared WKY rats.  Wistar rats were used as a reference strain for behaviour.  Furthermore, 
it was hypothesized that desipramine treatment would increase the number of high 
frequency USVs emitted by the rat remaining in the home cage after removal of the cage 
mate(s) (signalling communication and desire for social contact with the litter mates) and 
normalize serotonin and dopamine neurotransmitters, opioid receptors and their signalling 
proteins. 
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3.2 Materials and methods 
3.2.1 Animals 
This study was conducted in accordance with the guidelines of the South African National 
Standard: The care and use of animals for scientific purposes (1st edition, 2008) and 
approved by the University of Cape Town Faculty of Health Sciences Animal Ethics 
Committee (#010/036).  A total number of 76 animals were obtained from the University 
of Cape Town Animal Unit.  Housing conditions were similar as described in chapter 2.  
This study consisted of 3 rat groups: normally reared WKY/NCrl (WKY), maternally 
separated WKY/NCrl (MS WKY) and Wistar control rats.  The rat groups were randomly 
divided into treatment groups: (a) normally reared WKY/NCrl treated with Saline (WKY 
Sal, n =15), (b) normally reared WKY/NCrl treated with desipramine (WKY DMI, n =5-
6), (c) maternally separated WKY/NCrl treated with Saline (MS WKY Sal, n =17), (d) 
maternally separated WKY/NCrl treated with desipramine (MS WKY DMI, n = 9–10), (e) 
Wistar rats treated with Saline (Wistar Sal, n =15) and (f) Wistar rats treated with 
desipramine (Wistar DMI, n =13).  A total of 9 rats were lost to the study before the 
endpoint was reached (dying/euthanased) and this led to transferring 6 rats from the 
desipramine group to the saline group before treatment started. 
WKY/NCrl pups were separated from their dams for 3 h per day between 09h00 and 
13h00 from P2 to P14.  Some of the WKY/NCrl litters  were normally reared and left 
undisturbed in their home cage.  At P21, all pups were weaned and males were separated 
from the females.   Wistar rats were obtained from the Animal Unit at a minimum of 1 
week before the start of the experiment.  For 4 days prior to baseline USV recording (P52 
- P55), rats were transferred to the room in which the USVs were to be recorded, where 
they were handled briefly and then returned to the rat facility.  One day after the last day 
of brief handling, baseline USVs were recorded for 4 days (P56 – P59) prior to treatment.   
Desipramine treatment started at P60 for 15 days at a dose of 15 mg/kg during which time 
USV‟s were recorded daily in the dark phase (20h00–00h00) until the end of treatment 
(P74).  Recording started immediately after the cage mate(s) had been removed from the 
home cage and continued for 6 min. The USVs of the cage mate(s) were recorded on the 
same evening with a minimum interval of 1 h between recordings of the cage mates.  At 
P71 (17 h after desipramine/saline injection) each rat was allowed to swim for 15-min 
(pretest-swim).  After 24 h, the rats were exposed to a 5-min test swim session (17 h after 
desipramine/saline injection).  The EPM test was performed on rats at P74 (17 h after 
desipramine/saline injection) and immediately followed by the OFT.  On P74, rats were 
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decapitated and brain areas rapidly dissected, snap frozen and stored in liquid nitrogen 
until later biochemical analysis.  The rats with immobility data closest to the mean value 
for their group (12 WKY Sal, 6 WKY DMI, 13 MS WKY Sal and 9 MS WKY DMI) were 
selected for determination of serotonin and dopamine levels. Rats (9 WKY Sal, 6 WKY 
DMI, 9 MS WKY Sal and 8 MS WKY DMI) were similarly selected for western blot 
analysis. 
3.2.2 Maternal Separation 
Postnatal day 0 (P0) was designated as the date of birth. On P2, rats that were born in the 
Satellite Animal Facility were culled to 8 pups per litter to allow equal nourishment 
between litters.  MS was carried out for 3 h per day between 09h00 and 13h00 from P2 to 
P14 (Daniels et al. 2004).  Pups were transferred (together with some home cage bedding 
to avoid handling of the pups) to a clean cage and housed in a different room (31–33 °C, 
to prevent hypothermia) to prohibit communication between pups and dam by means of 
USVs.  After 3 h of separation, pups were returned to the home cage with the dam.  Care 
was taken to prevent handling of the pups. Non-maternally separated control rats were 
normally reared and left undisturbed during the MS procedure.  Cages of MS and non-
maternally separated rats were cleaned twice a week, half of the soiled bedding was 
replaced with fresh bedding to prevent disturbance of the pups.  At P21, all pups were 
weaned; males were separated from females and housed 2–3 in a cage. 
3.2.3 Behaviour 
Behavioural tests were conducted on adult male rats in the same conditions as in chapter 
2. 
3.2.3.1 Elevated plus maze 
The EPM were performed on rats at P74 (17 h after desipramine/saline injection) as 
described in chapter 2. 
3.2.3.2 Open field test 
The OFT was performed immediately after the EPM as described in chapter 2 
3.2.3.3 Forced swim test 
The FST was carried out as described in chapter 2 for experiment 1 and 3.  At P71 (17 h 
after desipramine/saline injection) the rats were placed in individual transparent cylinders 
(40×19 cm) containing 30 cm of water (23–25 °C).  Each rat was allowed to swim for 15 
min (habituation).  After 24 h, the rats were exposed to a 5-min test swim session (17 h 
Behavioural changes during antidepressant treatment in the maternally 





after desipramine/saline injection) during which FST behaviour was recorded for later 
analysis as described in chapter 2. 
3.2.3.4 Ultrasonic vocalizations 
The USV protocol was carried out according to Wohr et al. (2008) who showed that the 
rat remaining in the home cage after removal of its cage mates emits an increased number 
of 50-kHz USVs (Wohr et al. 2008).  Rats were housed 2–3 in their home cage (36×20×18 
cm).  USVs were measured in the dark phase (20h00–00h00).  For 4 days prior to baseline 
USV recording (P52 - P55), rats were transferred to the room in which the USVs were to 
be recorded, where they were handled briefly and then returned to the rat facility.  This 
was necessary in order for the rats to get accustomed to the handling procedure as well as 
the room conditions.  One day after the last day of brief handling, baseline USVs were 
recorded for 4 days (P56 – P59) prior to treatment.  Desipramine treatment started at P60 
during which USV‟s were recorded daily until the end of treatment (P74).  Rats were left 
for a minimum of 2 h to habituate to the room conditions before USV recording. No other 
rats were present in the USV room during a USV recording session. Recording started 
immediately after the cage mate(s) had been removed from the home cage and continued 
for 6 min. The USVs of the cage mate(s) were recorded on the same evening with a 
minimum interval of 1 h between recordings of the cage mates. No significant differences 
in baseline USVs were found between rats recorded first, second and third.  Rat calls were 
recorded with a P48 Electret ultrasound microphone (Avisoft Bioacoustics) positioned 30 
cm above the base of the cage. The microphone was sensitive to frequencies of 10–120 
kHz and connected with the E-MU 0404 Audio/midi interface (E-MU Systems, USA) to a 
computer with a sampling rate of 192 kHz and 16 bit resolution. Acoustic data were 
displayed in real-time on Sea Pro Ultra version 2.0 software and recorded for later 
analysis. Analysis of data was conducted with a Fast Fourier Transform (2048 FFT, 
Hanning window, 1024 window size and a 75 % time window overlap). Spectrograms 
were produced at a frequency resolution of 187.5 Hz and a time resolution of 0.667 ms. 
Calls were manually counted as total number of calls, number of FM calls and number of 
flat calls between 40 kHz and 96 kHz. Calls that were counted were based on the selection 
criteria described by Wright et al. (2010). Calls had to meet certain spectrographic 
criteria: they had to occur within a range of 40 kHz to 96 kHz, with maximum interruption 
of 20 ms and a sound intensity and structure that were clearly distinct from background 
under optimal viewing settings. A call that was classified as flat had minimum change in 
frequency with a mean slope between −0.2 and 0.2 kHz/ms. 
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3.2.4 Drug Treatment 
On P60, rats were either injected with 15 mg/kg desipramine hydrochloride (Sigma-
Aldrich, St Louis, MO) or an equivalent volume of 0.9 % sterile saline between 13h00 and 
14h00 for 15 days.  Desipramine and saline were administered intraperitoneally in a 
volume equivalent to 2.5 ml/kg.  Desipramine was freshly prepared each morning as 
described in chapter 2.  On P74, rats were decapitated and brain areas rapidly dissected, 
snap frozen and stored in liquid nitrogen until later biochemical analysis. 
3.2.5 Biochemistry 
3.2.5.1 Dopamine and Serotonin determination by Enzyme-linked 
immunosorbent assay (ELISA) 
The NAcS and PFC brain tissue samples of drug-treated WKY rat groups (WKY Sal, 
WKY DMI, MS WKY Sal and MS WKY DMI) were used to determine dopamine and 
serotonin levels respectively.  Brain samples were weighed and sonicated for 10 s in 1ml 
RIPA buffer/50mg tissue (150 mM NaCl, 1% Triton X-100, 0.1% SDS, 20 mM Tris base 
(pH 7.5), 1% deoxycholate, 1 mM EGTA and 2 µl/1ml protease inhibitor cocktail).  
Following sonication, samples were mixed on a vortex and centrifuged at 17200 x g at 4 
°C for 30 min.  A volume of 20 µl of each sample was used for ELISA and the rest stored 
in liquid nitrogen for western blotting.   The dopamine and serotonin concentration of the 
supernatant was determined according to the manufacturer‟s instructions (IBL 
international, Hamburg, Germany).  Determinations were in duplicate.  Results are 
expressed as ng/mg wet weight (ww).    
3.2.5.2 Western blotting with chemiluminescence detection 
The NAcC, NAcS and PFC brain tissue samples were prepared for western blotting as 
described above (section 3.2.5.1).  Twenty micrograms of total protein was loaded onto 
12% SDS-polyacrylamide gels and electrophoresed at 150 V for 2 h.  Electrophoresed 
proteins were transferred onto nitrocellulose membranes (Amersham Hybond-ECL, GE 
Healthcare, USA) at 100 V for 1 h.  The membranes were blocked for 1h with 5 % bovine 
serum albumin (BSA) in TBS-Tween for membranes with phospho- and total proteins, 5 
% BSA in PBS-Tween for membranes with MOR proteins and 5 % milk in PBS-Tween 
for membranes with KOR proteins.  Following blocking, membranes were immunolabeled 
with rabbit polyclonal primary antibody against MOR-1 (C-20, sc-7488-R, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) (1:12000), KOR-1 (H70, sc-9112; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) (1:14000) and phospho-p44/42 MAPK (p-ERK, 
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Thr202/Tyr204, #9101; Cell Signaling Technology, Beverly, MA, USA) (1:7000) and 
with rabbit monoclonal primary antibody against p-GSK3β (Ser9)(#9323S; Cell Signaling 
Technology, Beverly, MA, USA) (1:2000).  Membranes were incubated with their 
respective antibodies overnight at 4 °C.  Following incubation, membranes were 
incubated with the appropriate secondary HRP-conjugated antibodies for 2 h.  Blots were 
developed using Clarity Western ECL Substrate (Biorad laboratories Inc., USA).  Blots 
with p-GSK and p-ERK were stripped and reprobed with rabbit monoclonal primary 
antibody against total GSK-3β (GSK, #9315; Cell Signaling Technology, Beverly, MA, 
USA) (1:8000) and with rabbit polyclonal primary antibody against total p44/42 MAPK 
(ERK, #9102L; Cell Signaling Technology, Beverly, MA, USA) (1:8000) respectively.  
After detection of total proteins with SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Scientific, Rockford, USA), all membranes were stripped and reprobed with 
anti-p38 MAP kinase antibody (P38, Sigma, Missouri, USA) (1:9000) to confirm equal 
loading of proteins.  Densitometric analysis was performed using Un-Scan-It gel analysis 
software (Silk Scientific, Inc, USA).  The density of each band was determined and 
expressed as a percentage of the mean density of all the bands of that specific protein. 
3.2.6 Statistical Analysis 
Behavioural and biochemical data were normally distributed (Shapiro-Wilk test) and were 
analyzed by means of analysis of variance (ANOVA), followed by Tukey‟s post-hoc test 
with correction for multiple comparisons.  USV data were not normally distributed 
(Shapiro-Wilk test) and were analyzed with the Kruskal–Wallis ANOVA, followed by 
Dunn‟s post-hoc test with correction for multiple comparisons. The behavioural (EPM, 
OFT and FST) and biochemical data are presented as mean ± SEM and USV data are 
presented as median and interquartile range. 
3.3 Results 
3.3.1 Behaviour 
3.3.1.1 Elevated plus maze 
Time spent in open arms  
Two-way ANOVA (rat group and drug treatment as factors) showed a significant 
difference between rat groups (WKY, MS WKY and Wistar) (F(2, 69) = 6.51, p < 0.01) in 
time spent in the open arms in the EPM.  Post-hoc analysis indicated that the MS WKY 
DMI rats spent a greater amount of time in the open arms of the EPM than MS WKY Sal 
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rats (p < 0.05; Fig. 3.1a). The MS WKY DMI rats spent more time in the open arms than 
Wistar DMI rats (p < 0.01).  The WKY Sal rats similarly spent more time in the open 
arms than the Wistar Sal rats (p < 0.05).   
Time spent in closed arms 
Two-way ANOVA (rat group and drug treatment as factors) showed a significant 
difference between rat groups (F(2, 69) = 19.24, p < 0.001) in time spent in the closed arms 
of the EPM.  Post-hoc analysis indicated that the MS WKY Sal rats spent more time in the 
closed arms than WKY Sal (p < 0.05; Fig. 3.1b). The Wistar Sal spent more time in the 
closed arms than the WKY Sal (p < 0.001) and MS WKY Sal rats (p < 0.05). The Wistar 
DMI rats spent more time in closed arms than WKY DMI (p < 0.01) and MS WKY DMI 
rats (p < 0.05). 
Time spent in the center zone  
Two-way ANOVA (rat group and drug treatment as factors) showed a significant 
difference between rat groups (F(2, 69) = 14.52, p < 0.01) and a rat group × drug treatment 
interaction (F(2, 69) = 3.30, p < 0.05) in time spent in the center zone of the EPM.  Post-hoc 
analysis indicated that the MS WKY DMI rats spent less time in the center zone than 
WKY DMI rats (p < 0.01; Fig. 3.1c).  The WKY DMI rats spent more time in the center 
zone than Wistar DMI (p < 0.01) and MS WKY DMI rats (p < 0.01).  The Wistar Sal rats 
spent less time in the center zone than WKY Sal (p < 0.001) and MS WKY Sal rats (p < 
0.05).  The MS WKY DMI rats spent less time in the center zone than MS WKY Sal rats 
(p < 0.01). 
Behavioural changes during antidepressant treatment in the maternally 






Figure 3.1:  Time spent in the open arms, closed arms and center area by WKY, MS WKY and 
Wistar rats in the EPM following treatment with saline/desipramine.  Desipramine treatment 
decreased anxiety (a) and indecisiveness (c) in MS WKY rats in the EPM. The MS WKY spent more 
time in the closed arms than the WKY (b). * MS WKY DMI significantly different from MS WKY Sal, p 
< 0.05; ** Wistar Sal significantly different from WKY Sal, p < 0.05; *** Wistar DMI significantly 
different from MS WKY DMI, p < 0.01; ^ WKY DMI significantly different from MS WKY DMI and 
Wistar DMI, p < 0.05; ^^ WKY Sal and MS WKY Sal significantly different from Wistar Sal, p < 0.01; 
+ MS WKY Sal significantly different from WKY Sal, p < 0.05; ++ Wistar DMI significantly different 
from WKY DMI and MS WKY DMI; Tukey‟s post-hoc test (WKY sal: n = 15; WKY DMI: n = 6; MS 
WKY sal: n = 17; MS WKY DMI: n = 9; Wistar Sal: n = 15; Wistar DMI: n = 13).  Data presented as 
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3.3.1.2 Open field test 
Distance travelled  
Two-way ANOVA (rat group and drug treatment as factors) showed a significant 
difference between rat groups (F(2, 69) = 96.10, p < 0.001), a drug treatment effect (F(1, 69) = 
41.53, p < 0.001) and a rat group × drug treatment interaction (F(2, 69) = 9.92, p < 0.001) in 
total distance travelled in the open field.  Post-hoc analysis revealed that the WKY DMI 
rats travelled a shorter distance than the WKY Sal rats and MS WKY DMI travelled a 
shorter distance than MS WKY Sal rats (p < 0.001; Fig. 3.2). The Wistar Sal rats travelled 
a greater distance than WKY Sal (p < 0.001) and MS WKY Sal rats (p < 0.001).  The 
Wistar DMI rats travelled a greater distance than MS WKY DMI (p < 0.001) and WKY 
DMI rats (p < 0.001). 
3.3.1.3 Forced swim test 
Immobility  
Two-way ANOVA (rat group and drug treatment as factors) showed a significant 
difference between rat groups (F(2, 67) = 34.86, p < 0.001), a drug treatment effect (F(1, 67) = 
30.86, p < 0.001) and a rat group × drug treatment interaction (F(2, 67) = 9.88, p < 0.001) 
for time spent immobile in the FST.  Post-hoc analysis revealed that the WKY DMI rats 
spent less time immobile than WKY Sal rats (p < 0.01; Fig. 3.3a) and the MS WKY DMI 
rats spent less time immobile than MS WKY Sal rats (p < 0.001).  Wistar Sal rats spent 
less time immobile than WKY Sal and MS WKY Sal rats (p < 0.001) and the Wistar DMI 
rats spent less time immobile than the WKY DMI rats (p < 0.05). 
Swimming  
Two-way ANOVA (rat group and drug treatment as factors) showed a significant 
difference between rat groups (F(2, 67) = 21.84, p < 0.001), a drug treatment effect (F(1, 67) = 
23.47, p < 0.001) and a rat group × drug treatment interaction (F(2, 67) = 8.64, p < 0.001) in 
time spent swimming in the FST.  Post-hoc analysis revealed that WKY DMI rats spent 
more time swimming than WKY Sal rats (p < 0.01; Fig. 3.3b) and the MS WKY DMI rats 
spent more time swimming than MS WKY Sal rats (p < 0.001).  Wistar Sal rats spent 
more time swimming than WKY Sal and MS WKY Sal rats (p < 0.001).   
Struggling  
Two-way ANOVA (rat group and drug treatment as factors) showed a significant 
difference between rat groups (F(2, 67) = 35.36; p < 0.001), a drug treatment effect (F(1, 67) 
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= 23.09, p < 0.001) and a rat group × drug treatment interaction (F(2, 67) = 6.50, p < 0.01) in 
time spent struggling in the FST. Post-hoc analysis revealed that MS WKY DMI rats 
spent more time struggling than MS WKY Sal rats (p < 0.001; Fig. 3.3c).  Wistar Sal rats 
spent more time struggling than WKY Sal (p < 0.001) and MS WKY Sal rats (p < 0.001). 
The Wistar DMI rats spent more time struggling than WKY DMI rats (p < 0.001). 
 
 
Figure 3.2:  Distance travelled by WKY, MS WKY and Wistar rats in the OFT following treatment 
with saline/desipramine.  Desipramine treatment decreased distance travelled by the WKY rats in the 
OFT without effect on the Wistar rats. * WKY DMI and MS WKY DMI significantly different from 
WKY Sal and MS WKY Sal rats, p < 0.001; ** Wistar Sal significantly different from WKY Sal and MS 
WKY Sal, p < 0.001; *** Wistar DMI rats significantly different from WKY DMI and MS WKY DMI 
rats, p < 0.001; Tukey‟s post-hoc test (WKY sal: n = 15; WKY DMI: n = 6; MS WKY sal: n = 17; MS 
WKY DMI: n = 9; Wistar Sal: n = 15; Wistar DMI: n = 13)).  Data presented as mean ±SEM. 
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Figure 3.3:  Immobility, swimming and struggling behaviours of WKY, MS WKY and Wistar rats 
in the FST following treatment with saline/desipramine.  Desipramine treatment decreased immobility 
(a) and increased active swimming (b) and struggling (c) behaviours in the MS WKY and WKY rats 
without affecting the Wistar rats in the FST. * WKY DMI significantly different from WKY Sal, p < 
0.05; ** MS WKY DMI significantly different from MS WKY Sal, p < 0.001; *** Wistar Sal 
significantly different from WKY Sal and MS WKY Sal, p < 0.001; ^ Wistar DMI significantly different 
from WKY DMI, p < 0.05; Tukey‟s post-hoc test (WKY sal: n = 15; WKY DMI: n = 6; MS WKY sal: n 
= 17; MS WKY DMI: n = 10; Wistar Sal: n = 13; Wistar DMI: n = 13). Data presented as mean ± SEM. 
3.3.1.4 Ultrasonic vocalizations 
Frequency modulated calls 
The Kruskal–Wallis ANOVA showed a significant difference between drug/saline-treated 
rat groups (WKY Sal, WKY DMI, MS WKY Sal, MS WKY DMI, Wistar Sal and Wistar 
DMI rats) in FM calls on day 11 (H(5,N = 99) = 37.42, p < 0.001), day 13 (H(5,N = 76) = 27.12, 
p < 0.001) and day 15 (H(5,N = 75) = 33.11, p < 0.001) of drug treatment.  Post-hoc analysis 
revealed that WKY DMI rats vocalized less than WKY Sal rats (p < 0.05; Fig. 3.4b) on 
day 11 of treatment.  Wistar Sal rats vocalized less than MS WKY Sal (p < 0.001) and 
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WKY Sal rats (p < 0.01).  At day 13 of treatment, Wistar Sal rats vocalized less than MS 
WKY Sal (p < 0.01) and WKY Sal rats (p < 0.01; Fig. 3.4b).  At day 15 of treatment, MS 
WKY DMI vocalized less than MS WKY Sal rats (p < 0.05; Fig. 3.4b).  Wistar Sal 
vocalized less than MS WKY Sal rats (p < 0.05). 
Flat calls 
The Kruskal–Wallis ANOVA revealed a significant difference between drug-treated rat 
groups in flat calls on day 11 (H(5,N = 99) = 20.89, p < 0.001) and day 15 (H(5,N = 75) = 11.15, 
p < 0.05).  Post-hoc analysis showed that, Wistar Sal rats vocalized less than MS WKY 
Sal rats (p < 0.01; Fig. 3.5b) on day 11 of treatment. 
Total number of calls 
The Kruskal–Wallis ANOVA showed a significant difference between drug/saline-treated 
rat groups in the total number of calls on day 11 (H(5,N = 99) = 33.13, p < 0.001), day 13 
(H(5,N = 76) = 27.03, p < 0.001) and day 15 (H(5,N = 75) = 25.03, p < 0.001).  Post-hoc analysis 
revealed that Wistar Sal rats vocalized less than WKY Sal (p < 0.01) and MS WKY Sal (p 
< 0.001; Fig. 3.6b) on day 11 of treatment.  At day 13 of treatment, Wistar Sal rats 
vocalized less than WKY Sal (p < 0.05) and MS WKY Sal rats (p < 0.01; Fig. 3.6b). 
3.3.2 Biochemistry 
3.3.2.1 Serotonin and dopamine concentration in the prefrontal cortex and 
nucleus accumbens shell 
Two-way ANOVA (rat group and drug treatment) showed no effect of rat group or drug 
treatment on serotonin (Fig. 3.7) and dopamine (Fig. 3.8) concentration in the PFC and 
NAcS respectively. 
3.3.2.2 Density of opioid receptor proteins in the nucleus accumbens core and 
shell 
Two-way ANOVA (rat group and drug treatment) revealed no effect of rat group or drug 
treatment on MOR and KOR in the NAcC (Fig. 3.9) and NAcS (Fig. 3.10) 
3.3.2.3 Density of phospho-GSK3β and phospho-ERK1/2 in the prefrontal 
cortex 
Two-way ANOVA (rat group and drug treatment) showed a drug treatment effect (F(1.28) = 
4.74; p < 0.05) on the density of p-GSK3β in the PFC and no effect on p-ERK1/2 (Fig. 
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3.11b) in the PFC.  Post-hoc analysis showed higher phosphorylated GSK3β in WKY 
DMI than WKY Sal rats (p < 0.05; Fig. 3.11a). 
 
 
Figure 3.4:  Number of FM USVs of WKY, MS WKY and Wistar rats treated with 
saline/desipramine.  No significant difference found in the number of FM calls before treatment (a).  
Desipramine treatment (b) decreased FM calls in the WKY at day 11 of treatment and MS WKY rats at 
day 15 of treatment.  The MS WKY Sal and WKY Sal rats vocalized more than Wistar Sal rats at day 11, 
13 and 15 of treatment. * WKY DMI significantly different fromWKY Sal, p < 0.05; ** Wistar Sal 
significantly different from WKY Sal and MS WKY Sal, p < 0.01; *** Wistar Sal significantly different 
from MS WKY Sal, p < 0.05; Dunn‟s multiple comparisons post-hoc test (WKY sal: n = 12-18; WKY 
DMI: n = 8-10; MS WKY sal: n = 13-21; MS WKY DMI: n = 6-14; Wistar Sal: n = 12-19; Wistar DMI: 
n = 11-18).  Data presented as median and interquartile range. 
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Figure 3.5:  Number of flat USVs of WKY, MS WKY and Wistar rats treated with 
saline/desipramine. No significant difference found in the number of flat calls before treatment (a). 
Desipramine treatment (b) had no significant effect on the number of flat calls made by WKY, MS WKY 
and Wistar rats. * Wistar Sal significantly different from MS WKY Sal, p < 0.01; Dunn‟s multiple 
comparisons post-hoc test (WKY sal: n = 12-18; WKY DMI: n = 8-10; MS WKY sal: n = 13-21; MS 
WKY DMI: n = 6-14; Wistar Sal: n = 12-19; Wistar DMI: n = 11-18). Data presented as median and 
interquartile range. 
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Figure 3.6:  Total number of USVs of WKY, MS WKY and Wistar rats treated with 
saline/desipramine.  No significant difference found in the total number of calls before treatment (a). 
Desipramine treatment (b) had no significant effect on the total number of calls made by WKY, MS 
WKY and Wistar rats.  The MS WKY Sal and WKY Sal rats vocalized more than Wistar Sal rats at day 
11and 13 of treatment. * Wistar Sal significantly different from WKY Sal and MS WKY Sal, p < 0.05; 
Dunn‟s multiple comparisons post-hoc test (WKY sal: n = 12-18; WKY DMI: n = 8-10; MS WKY sal: n 
= 13-21; MS WKY DMI: n = 6-14; Wistar Sal: n = 12-19; Wistar DMI: n = 11-18).  Data presented as 
median and interquartile range. 
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Figure 3.7:  Serotonin levels in the PFC of WKY and MS WKY rats following treatment with 
saline/desipramine.  No significant difference found in serotonin levels in PFC between WKY Sal, 
WKY DMI, MS WKY Sal and MS WKY DMI rats (WKY sal: n = 12; WKY DMI: n = 6; MS WKY sal: 
n = 12; MS WKY DMI: n = 9).  Data presented as mean ± SEM. 
 
 
Figure 3.8:  Dopamine levels in the NAcS of WKY and MS WKY rats following treatment with 
saline/desipramine.  No significant difference found in dopamine levels in NAcS between WKY Sal, 
WKY DMI, MS WKY Sal and MS WKY DMI rats (WKY sal: n = 12; WKY DMI: n = 6; MS WKY sal: 
n = 13; MS WKY DMI: n = 9).  Data presented as mean ± SEM. 
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Figure 3.9:  Density of KOR and MOR in the NAcC of WKY and MS WKY rats following 
treatment with saline/desipramine.  No significant difference found in density of KOR (a) and MOR 
(b) in the NAcC between WKY Sal, WKY DMI, MS WKY Sal and MS WKY DMI rats. KOR and MOR 
normalized to P38 loading control (WKY sal: n = 9; WKY DMI: n = 6; MS WKY sal: n = 9; MS WKY 
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Figure 3.10:  Density of KOR and MOR in the NAcS of WKY and MS WKY rats following 
treatment with saline/desipramine.  No significant difference found in density of KOR (a) and MOR 
(b) in the NAcS between WKY Sal, WKY DMI, MS WKY Sal and MS WKY DMI rats. KOR and MOR 
normalized to P38 loading control (WKY sal: n = 9; WKY DMI: n = 6; MS WKY sal: n = 9; MS WKY 
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Figure 3.11:  Density of p-GSK3β and p-ERK in the PFC of WKY and MS WKY rats following 
treatment with saline/desipramine.  Desipramine treatment increased density of p-GSK3β in the PFC 
of WKY rats (a) and without effect on p-ERK/1/2 in the PFC (b) * WKY DMI significantly different 
from WKY Sal rats, p < 0.05; Tukey post-hoc test.  Phospho-GSK3β and p-ERK1/2 normalized to total 
GSK and total ERK1/2 respectively (WKY sal: n = 9; WKY DMI: n = 6; MS WKY sal: n = 9; MS WKY 
DMI: n = 8).  Data presented as mean ± SEM. 
 
3.4 Discussion 
The main findings of this study are consistent with the use of MS WKY/NCrl as a robust 
model of depression-/anxiety-like behaviour, (1) MS, a model of depression in itself, 
increased anxiety-like behaviour of WKY/NCrl, enhancing the potential of WKY/NCrl to 
serve as a model of anxiety (2) consistent with a model of depression, desipramine 
treatment decreased depression-like behaviour in MS WKY/NCrl and normally reared 
WKY/NCrl rats, (3) together with the decreased depression-like behaviour, desipramine 
treatment decreased the need of WKY/NCrl rats to reconnect with the cage mate after 
social isolation, evidenced by the decreased number of FM USVs in response to removal 
of the cage mate(s), and (4) desipramine increased p-GSK3β in the WKY/NCrl, an effect 
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Desipramine decreased immobility and increased active swimming and struggling 
behaviours of WKY/NCrl rats in the FST without affecting the Wistar rats. The results of 
the current study are therefore in agreement with previous studies (Lopez-Rubalcava and 
Lucki 2000; Tejani-Butt et al. 2003).  These previous studies also found that desipramine 
increased swimming behaviour in the WKY/NCrl.  This is contrary to findings with other 
rat strains (Detke and Lucki 1995; Lucki 1997).  Noradrenaline uptake inhibitors were 
shown to selectively increase climbing behaviour and serotonin uptake inhibitors 
selectively increased swimming behaviour in SD rats (Detke and Lucki 1995; Lucki 
1997).  Indeed, it was suggested that desipramine treatment rats may involve changes in 
the serotonergic system (Racagni and Brunello 1984) therefore also affecting swimming 
behaviour (Lopez-Rubalcava and Lucki 2000).  In agreement with previous studies, 
desipramine did not affect the performance of the control Wistar rats in the FST 
(Jeannotte et al. 2009; Tejani-Butt et al. 2003).  In the current study, both the normally 
reared WKY/NCrl and MS WKY/NCrl rats responded to the antidepressant effect of 
desipramine.  MS did not enhance the depression-like behaviour in the WKY/NCrl rats.   
MS WKY/NCrl displayed more anxiety-like behaviour than normally reared WKY/NCrl.  
They spent more time in the closed arms of the EPM than normally reared WKY/NCrl 
and also responded to desipramine treatment evidenced by the increased amount of time 
they spent in the open arms and decreased amount of time spent in the center zone of the 
EPM.  Similarly, prepubertal MS WKY rats spent more time in the closed arms of the 
EPM during the first minute of testing compared to non-separated WKY (Womersley et 
al. 2011).  However, the WKY/NCrl showed less anxiety in the open arms and closed 
arms of the EPM compared to the Wistar rats. WKY/NCrl rats spent more time in the 
open arms of the EPM and less time in the closed arms than the Wistar reference strain.  It 
appeared that the WKY/NCrl rats were less anxious, possibly as a result of additional 
handling during the daily injections and USV recordings.  Previous studies found that 
repeated handling can reduce anxiety-like behaviour in the EPM (Costa et al. 2012; 
Schmitt and Hiemke 1998).  The center zone of the EPM provides a decision point at 
which the rat chooses to enter either the open arms or closed arms of the EPM through 
risk assessment (Nosek et al. 2008).  Rats that are indecisive/ambivalent will spend more 
time in the center zone (Nosek et al. 2008; Rodgers and Johnson 1995).  Desipramine 
decreased the amount of time the MS WKY spent in the center zone of the EPM, 
apparently reducing indecisiveness which is one of the core symptoms of depression 
(American Psychiatric Association 2013). The present results therefore demonstrated the 
heightened anxiety of the MS WKY/NCrl compared to the normally reared WKY/NCrl, 
evidenced by the increased amount of time spent in the closed arms of the EPM.  They 
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also responded to the anxiolytic effects of desipramine in terms of increased time spent in 
the open arms and by spending less time in the center zone of the EPM.   
In the OFT, desipramine treatment reduced the locomotor activity of the WKY/NCrl 
without affecting Wistar rats. This is in agreement with some studies (Kulkarni and 
Dandiya 1973; Mitchell et al. 2006; Tucker and File 1986) and in contrast to others 
(Lahmame and Armario 1996; Tejani-Butt et al. 2003). The reasons for discrepancies 
between studies in locomotor activity following antidepressant treatment could be 
attributed to differences in experimental design, duration of treatment, time after last drug 
administration, as well as the rat strain being tested.  Several studies measured the acute 
effects of desipramine whereas desipramine administered chronically, as in the present 
study, involved a complex sequence of changes in affinity, function and number of α1-
,α2-, β1- and β2-adrenoceptors both pre- and postsynaptically (Deupree et al. 2007; 
Paetsch and Greenshaw 1993; Racagni and Brunello 1984; Subhash et al. 2003; Zhang et 
al. 2009).  Reduced noradrenergic firing rate, TH activity and cortical levels of 
normetanephrine all indicate reduced noradrenergic activity following chronic 
antidepressant treatment (Grant and Weiss 2001; Nestler et al. 1990; Racagni et al. 1983).  
In addition, WKY rats have a higher density of noradrenaline transporter binding sites 
than control rats that only decrease in the cortex, hippocampus, amygdala, hypothalamus 
and locus coeruleus after repeated stressors (Tejani-Butt et al. 1994; Zafar et al. 1997).  
Therefore, reduced noradrenaline transporter function resulting from exposure of WKY 
rats to repeated stressors (FST and OFT) may have further enhanced extracellular levels 
of noradrenaline and ultimately reduced locomotor activity.   
The USVs is indicative of communication of the animal‟s emotional state (Mällo et al. 
2007).  In the current study, it was found that the WKY/NCrl emitted more calls 
(predominantly FM calls) than the Wistar control rats and desipramine treatment 
decreased FM calls in the WKY/NCrl. The decreased number of USVs after 
antidepressant treatment is therefore not in line with the hypothesis that high frequency 
USVs are indicative of a positive emotional state.  However, some experimental situations 
that are not seen as rewarding are also known to induce high frequency vocalizations 
(Miczek et al. 1995; Tornatzky and Miczek 1995; Vivian and Miczek 1991; Wohr et al. 
2008).  For example, it was previously found that an intruder rat emitted high frequency 
(31–70 kHz) and low frequency calls when introduced to an environment of a resident rat 
or environment where it had been previously defeated by a resident rat (Miczek et al. 
1995; Takahashi et al. 1983; Tornatzky and Miczek 1995). Anxiolytic drugs were 
effective in reducing the high frequency calls in response to anticipation of a threat.  
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Similarly, high frequency USVs were recorded during morphine withdrawal (Vivian and 
Miczek 1991).  Apart from USVs having an emotional function (Burgdorf and Panksepp 
2006), it also provides a mechanism of communication of specific information between 
rats regarding their well-being as well as directing specific behaviours (Burman et al. 
2007; Portfors 2007).  Therefore, USVs in aversive situations could serve a social 
function and in the current study may play a role in trying to re-establish social contact 
with the cage mate (Brudzynski and Pniak 2002; Wohr et al. 2008).  In this study, FM 
calls were more affected than the flat calls which is in line with previous findings that FM 
calls play a role in emotion (Burgdorf et al. 2011). The social isolation resulting from 
removal of the cage mate may therefore have induced social signalling to the cage mate 
containing emotional information regarding the need to re-connect. The social signalling 
to re-establish contact with the cage-mate was found to be more evident in the WKY/NCrl 
compared to the Wistar rats. The WKY/NCrl therefore appeared to be more affected by 
separation from the cage mate, hence the need for more social signalling to be reunited 
with the cage mate. Treatment with desipramine reduced the number of FM USVs in the 
WKY/NCrl rat model of depression without affecting the control Wistar rats.  However, 
the number of USVs emitted by the Wistar rats was already low and could possibly not be 
further reduced by desipramine treatment.  The increased USVs in WKY/NCrl compared 
to Wistar rats and decreased FM USVs after desipramine treatment, suggest that USVs in 
this study occurred in response to an aversive situation that induced social signalling in an 
attempt to re-establish social contact with the cage mate(s). 
Serotonin and dopamine levels in the PFC and NAcS respectively and opioid receptor 
(MOR and KOR) densities in the NAcC and NAcS were unaffected by desipramine 
treatment and found to be similar in the different rat groups (WKY, MS WKY and 
Wistar).  It is therefore possible that these neurotransmitter systems in the NAc and PFC 
brain areas are unrelated to the response to desipramine treatment as well as the 
depression-/anxiety-like behaviour of normally reared WKY/NCrl and MS WKY/NCrl rat 
models (Berrocoso and Mico 2009; Page et al. 1999; Plaznik et al. 1985).   
Desipramine treatment increased p-GSK3β in the PFC of normally reared WKY/NCrl rats 
but had no effect on p-GSK3β in MS WKY/NCrl rats.  Furthermore, p-ERK was 
unaffected by desipramine treatment in WKY/NCrl rats.  Desipramine had no effect on 
these proteins in Wistar rats.  This is the first study to show an increase in p-GSK3β after 
chronic desipramine treatment.  Previous studies showed that antidepressant drugs that are 
more selective in blocking the reuptake of serotonin, increased p-GSK3β (Li et al. 2004; 
Liu et al. 2012; Okamoto et al. 2010; Sutton and Rushlow 2011).  Furthermore, 
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phosphorylation of GSK3β was found to be regulated by serotonin 5HT1A and 5HT2 
receptors (Li et al. 2004).  It is unlikely that increased p-GSK3β by desipramine was 
modulated by serotonin signalling mechanisms in the current study, since desipramine had 
no effect on serotonin levels in the PFC.  However, the exact mechanism by which 
antidepressants regulate phosphorylation of GSK3β remains unknown although it has 
been shown that the serotonin reuptake inhibitor, citalopram increased p-GSK3β through 
the Wnt signalling pathway (Liu et al. 2012) whereas other antidepressants were 
suggested to regulate GSK3β through phosphorylated protein kinase B (Akt) (Sutton and 
Rushlow 2011).  Previous studies have shown that antidepressant drugs also regulated 
signalling proteins in the MAPK/ERK pathway in the hippocampus and frontal cortex 
(Balu et al. 2008; Bravo et al. 2009; Fumagalli et al. 2005; Nibuya et al. 1995) while other 
studies failed to show this (Budziszewska et al. 2010; Dias et al. 2003).  In the current 
study, phosphorylated and total ERK1/2 were unaffected by desipramine treatment in 
WKY/NCrl rats.  These discrepancies in the results could be in fact ascribed to the 
different rat strains, experimental procedures, differential effects of antidepressant drugs, 
and treatment regimens.  Indeed, it has been shown that different classes of antidepressant 
drugs regulated ERK1/2 differently and which is specific to the brain region being 
measured (Fumagalli et al. 2005).  For example, chronic desipramine treatment decreased 
p-ERK in the hippocampus in a restraint stress rat model of depression (Bravo et al. 
2009).  Furthermore, fluoxetine treatment decreased p-ERK in the PFC but not in the 
striatum whereas imipramine did not reduce p-ERK in the hippocampus but increased p-
ERK1 in the PFC (Fumagalli et al. 2005).  On the other hand, acute desipramine treatment 
had no effect on p-ERK in the PFC, hippocampus and striatum of mice (Di Benedetto et 
al. 2013). However, further studies are necessary to determine the chronic effect of 
desipramine on p-ERK in a wider variety of limbic brain areas in the WKY rats.   
MS had no effect on p-GSK and p-ERK in in the PFC of WKY/NCrl rats.  Stress is 
known to activate the MAPK/ERK signalling pathway and thereby increasing p-ERK 
protein levels (Bhat et al. 1998; Meller et al. 2003; Musazzi et al. 2010).  However, the rat 
strain may be the determining factor in the signalling pathways being affected.  A 
previous study, using the MS FSL genetic model of depression, also found no effect of 
MS on p-ERK in the FSL rats but a higher levels of p-ERK compared to the control, FRL 
rat  (Musazzi et al. 2010).  The fact that MS had no effect on p-ERK in FSL rats was 
suggested to be the result of the already innate sustained increase in p-ERK.  It is 
therefore possible that p-ERK levels were already elevated in the normally reared WKY 
rats in this study and could therefore not be further elevated by MS. 
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In conclusion, the MS WKY/NCrl rats were found to be an animal model of depression-
/anxiety-like behaviour.  In addition to the depression-like behaviour and response to 
antidepressant treatment, MS WKY/NCrl rats displayed more anxiety-like behaviour than 
normally reared WKY/NCrl rats and responded to the anxiolytic effects of desipramine 
treatment.  Together with diminished depression-/anxiety-like behaviour, diminished 
USVs could signal reduced attempts to maintain social contact in response to isolation 
stress in the WKY/NCrl following chronic desipramine treatment.  Since GSK3β has been 
involved in neurogenesis (Lange et al. 2011) and changes in neurogenesis have been 
linked to depression (Banasr et al. 2011), it may be suggested that as least some of the 
antidepressant behavioural effects may be linked to enhanced neurogenesis in the PFC in 
WKY/NCrl rats; an effect that is blocked by MS.  Therefore, in addition to its depression-

















Chapter 4  
Behavioural and biochemical changes in 
maternally separated Sprague-Dawley rats 
exposed to restraint stress 
 
4.1 Introduction 
Chronic exposure to stressful life events is considered a major risk factor in developing 
various psychological conditions, including major depression (Kendler et al. 1998; 
Kendler et al. 1999).  Moreover, individuals with a history of childhood trauma are more 
vulnerable in developing depression compared to individuals with no childhood trauma 
(Harkness et al. 2006).  In addition, the type of childhood trauma or recent stressful event 
has differential effects on the symptomatology of depression (van Veen et al. 2013). 
Various animal models, including chronic restraint stress, have been developed to study 
the effects of chronic stress on the neurobiology of depression.  Restraint stress has 
proved to be a valid stress-inducing animal model of depression and anxiety (Bombi et al. 
2013; Chiba et al. 2012; Naert et al. 2011; Ulloa et al. 2010).  Furthermore, it was evident 
from previous studies that restraint stress induced depression-like behaviour in rats that 
were subjected to MS in early life (Marais et al. 2008; Uchida et al. 2010).   
It has been reported that chronic stress that results in depression-like behaviour in rodents, 
decreased BDNF levels in the hippocampus and PFC (Ray et al. 2011; Xu et al. 2004;Xu 
et al. 2006) although several inconsistencies have been reported with some studies 
showing an increase (Adlard et al. 2004; Larsen et al. 2010; Naert et al. 2011) or no effect 
on BDNF (Kuroda and McEwen 1998; Rosenbrock et al. 2005).    
However, depression is a multifaceted disorder with various causative factors present 
during childhood and adulthood involving multiple signalling pathways that regulate the 
release of many neurotransmitters and neurotrophins (Covington et al. 2010; Stepanichev 
et al. 2014).  It is therefore necessary to further investigate differently regulated proteins 
to provide further insight into the stress-induced pathology of depression-like behaviour in 
rats.  Proteomic analysis with iTRAQ labeling allows separation and 
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identification of many proteins and is proving to be an effective method to identify the 
molecular changes associated with depression. 
The aim of the current study was therefore to measure BDNF concentration in the ventral 
hippocampus with ELISA and further to follow with proteomic analysis of the PFC in rats 
exposed to early-life MS and restraint stress in adulthood.   This was achieved in order to 
identify differential protein expression, involved in the development of depression-like 
behaviour.  A mild stressor such as restraint stress was selected to minimize the stressful 
experience of the animal as much as possible. This was the first proteomic study to assess 
protein regulation in the PFC of the early life MS model of depression that was also 
subjected to stress in adulthood.   
4.2 Materials and Methods 
4.2.1 Animals 
A total of 50 SD rats that were bred in the Satellite Animal Facility at the University of 
Cape Town, were used for the study.  Rats were kept under the same conditions as 
described in chapter 2.  The study was conducted in accordance with the guidelines of the 
South African National Standard: The care and use of animals for scientific purposes 
(2008) and approved by the University of Cape Town Faculty of Health Sciences Animal 
Ethics Committee (#010/036).  This study consisted of 4 groups: control SD (Ctr, n =12), 
maternally separated SD (MS, n =12), restraint stressed SD (RS, n =13) and maternally 
separated SD rats that had been restraint stressed in adulthood (MS+RS, n = 13).  
SD pups were separated from their dams for 3 h per day between 09h00 and 13h00 from 
P2 to P14.  Some of the SD litters were normally reared and left undisturbed in their home 
cages.  At P21, all pups were weaned and males separated from the females.  Some of the 
MS rats were chronically restrained for 4 h on 5 consecutive days between 09h00 – 
13h00, starting at P61-P67.  Following 5 days of restraint, rats were left undisturbed for 7 
days before each rat was allowed to swim for 15 min (pretest-swim; P72-P78).  After 24 
h, the rats were exposed to a 5-min test swim session.  Four days after the FST, rats were 
tested in the EPM and the OFT.  On P79-P85, rats were killed and brain areas (ventral 
hippocampus and PFC) collected and stored in liquid nitrogen until analysis. A total of 10 
rats/group were selected for determination of BDNF levels and 6 rats/group selected for 
proteomic analysis, according to their immobility scores in the FST. The rats with scores 
closest to the mean value of their respective group (Ctr, MS, RS and MS+RS) were 
selected. 
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4.2.2 Maternal separation 
MS was performed according to the procedure and under similar conditions as described 
in chapter 3.   Pups were weaned at P21; males were separated from females and housed 
2–4 in a cage. 
4.2.3 Restraint Stress 
According to the procedure by Marais et al. (2008), some rats were chronically restrained 
in Plexiglas tubes for 4 h on 5 consecutive days between 09h00 – 13h00, starting at P61-
P67.  Following 5 days of restraint, rats were left undisturbed for 7 days to overcome the 
short-term effects of stress before depression-like behaviour was measured in the FST. 
  4.2.4 Behaviour 
Behavioural tests were conducted on adult male rats under the same conditions as 
decribed in chapter 2. 
4.2.4.1 Forced swim test 
Seven days after the last restraint stress (P72-P78), the FST was carried out as described 
in chapter 2 for experiment 1 and 3.  The FST behaviours were measured manually since 
external interferences during the process of placing rats in the cylinder affected automatic 
ethovision detection.  Ethovision identifies the subject as the pixel difference between the 
reference image and the image of interest.  However, any change in the image of interest 
due to any interference (e.g. light reflection), results in ethovision tracking the artifact as 
well as the rat.  The total time spent immobile, swimming and struggling was measured by 
an experienced observer blind to the experimental conditions. 
4.2.4.2 Elevated plus maze  
Four days after the FST, rats were tested in the EPM as described in chapter 2. 
4.2.4.3 Open field test 
The OFT was performed immediately after the EPM as described in chapter 2. 
4.2.5 Biochemistry 
4.2.5.1 BDNF determination with ELISA 
The ventral hippocampus brain tissue samples of the SD behavioural rat groups (Ctr (n = 
10), MS (n = 10), RS (n = 10) and MS+RS (n = 10)) were used to determine BDNF 
concentration.  Brain samples were weighed and sonicated for 15 s in 300 µl lysis buffer 
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(137 mM NaCl, 20 mM Tris-HCl (pH = 8), 1 % NP40, 10 % glycerol, 1 mM PMSF, 10 
µg/ml aprotinin, 1 µg/ml leupeptin and 0.5 mM sodium vanadate).  Following sonication, 
samples were mixed on a vortex mixer and centrifuged at 12 000 x g at 4 °C for 30 min.  
A volume of 40 µl of each sample was used for ELISA.   The BDNF concentration of the 
supernatant was determined according to the manufacturer‟s instructions (Promega 
Corporation, Madison, WI, USA).  Determinations were in duplicate.  Results are 
expressed as pg/mg wet weight (ww).    
4.2.5.2 Proteomics 
Samples of the PFC obtained from 3 SD rats were pooled (3 SD rats/digest), sonicated in 
1 M triethylammonium bicarbonate (TEAB) buffer and centrifuged at 17200 x g for 30 
min at 4°C.  Supernatants were collected and protein concentration, iTRAQ labeling and 
liquid chromatography mass spectrometry (LC-MS) were carried out by the Centre for 
Proteomic and Genomic Research (CPGR) at the University of Cape Town. 
Protein concentration of the supernatant was determined with a nanodrop at 280 nm.  The 
samples were adjusted to 10 µg/µl with 50 mM TEAB and incubated for 1 h at 60 °C with 
100 mM Tris (2-carboxyethyl) phosphine (TCEP) reducing agent.  Methyl 
methanethiosulfonate (MMTS) was added to the samples to block reduced cysteines 
followed by incubation for 15 min at room temperature.  Following incubation, samples 
were adjusted to 45 µl with 50 mM TEAB and 1 µg/µl trypsin added.  The reaction was 
allowed to proceed at 37 °C for 18 h whereafter the samples were suspended in 0.1 % 
trifluoroacetic acid (TFA).  The digested samples were reduced to a volume of 10 µl and 
made up to a final volume of 10 µl with 1 M TEAB to adjust the pH (> 7.5).  The iTRAQ 
labeling was carried out using an 8-plex labeling kit for Ctr, MS and RS rat groups (2 
pooled PFC digests for each group) and a 4-plex labeling kit for the Ctr and MS+RS rat 
groups (2 pooled PFC digests for each group).  Labeling was performed at room 
temperature for 2 h according to the manufacturer‟s instructions (Applied Biosystems).   
Label confirmation was performed by applying the sample mixture to a C-18 column 
conditioned with 20 µl of 100 % acetonitrile (ACN) and equilibrated with 20 µl of 0.1% 
TFA.  A volume of 1 µl of each sample were pooled and desalted using a C18 ZipTip, 
washed with 20 µl of 0.1 % TFA and eluted with 10 µl of 50 % ACN and 0.1% TFA.  The 
desalted sample was mixed with α-cyano-4-hydroxycinnamic acid (CHCA, Sigma 
Aldrich) solution and spotted on a MALDI target plate.  Labeling was confirmed using 
tandem mass spectroscopy (MS/MS).  After label confirmation, 100 µl of Milli Q water 
were added to each sample and incubated at room temperature for 30 min.  The samples 
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were pooled and the volume reduced to 100 µl.  The pooled sample was stored for further 
LC-MS analysis.   
The LC was performed using a Dionex Ultimate 3000 nano-HPLC system.  The HPLC 
fractionated peptides were dissolved in sample loading buffer (95% water, 5% 
Acetonitrile, 0.05% TFA) and loaded on a C18 trap column (100 µm×20 mm×5 µm). 
Chromatographic separation was performed with an Acclaim Pepmap (Thermo Fisher 
Scientific, USA) C18 column (75 µm×250 mm×3 µm).  The mobile phases consisted of 
solvent A (0.1% formic acid in water) and solvent B (80% ACN, 10% water, and 0.1% 
formic acid).  The gradient was delivered at 250 nl/min and consisted of a linear gradient 
of mobile phase B initiating with solvent B: 6–30% over 148 min. 
Mass spectroscopy was performed using an electron spray ion source coupled to a Q-
Exactive quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, USA).  The 
MS was operated in positive electron spray ionized mode with a capillary temperature of 
250 °C.  The applied electrospray voltage was set at 1.95 kV.  Data were collected in the 
full scan mode and data-dependent MS/MS modes with a maximum ion injection time of 
50 ms.  In full scan mode, ions were collected in the mass range of 350-2000 m/z and 
acquired at a resolution of 70,000 at m/z 200. 
Data analysis was performed using Scaffold software (Proteome software Inc., Portland, 
OR) using the Rattus sequence database (Source: UniprotKB-www.uniprot.org , filtered 
by “Organism – „Rattus‟”, dated 22/03/2014) with the MASCOT (Matrix Science, 
London, U.K.; version 2.1) search algorithm.  All identified peptides had an ion score 
above the Mascot peptide identity threshold (a high confidence score of 99% and a low 
false discovery rate (FDR) of 1%), and a target protein was considered identified if at least 
two such unique peptide matches were apparent for the protein.  Acquired intensities in the 
experiment were globally normalized across all acquisition runs. Individual quantitative 
samples were normalized within each acquisition run. Intensities for each peptide were 
normalized within the assigned protein. The reference channels were normalized to 
produce a 1:1 fold change. All normalization calculations were performed using medians 
to multiplicatively normalize data.  Values for duplicate rat groups were averaged and 
MS, RS and MS+RS rat groups expressed as fold difference relative to the Ctr group.  Rat 
groups were considered to be increased or decreased if they were ± 0.2 fold different from 
Ctr rats.  
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4.2.6 Statistical Analysis 
Behavioural and BDNF data were normally distributed (Shapiro-Wilk test).  The data 
were analyzed by means of analysis of variance (ANOVA), followed by Tukey‟s post-hoc 
test with correction for multiple comparisons.  Behavioural and BDNF data are presented 
as mean ± SEM.  
4.3 Results 
4.3.1 Behaviour 
4.3.1.1 Forced swim test 
One-way ANOVA revealed a significant effect of stress on immobility (F(3, 46) = 19.56, p 
< 0.001) and swimming (F(3, 46) = 32.03, p < 0.001) in the FST.  Post-hoc comparisons 
revealed that both MS (p < 0.01) and MS + RS rats (p < 0.05) spent significantly more 
time immobile than Ctr rats and the RS rats spent significantly less time immobile than 
Ctr (p < 0.05), MS (p < 0.001) and MS + RS rats (p < 0.001; Fig. 4.1a).  Both MS (p < 
0.001) and MS + RS rats (p < 0.05) spent significantly less time swimming than Ctr rats 
and RS rats spent significantly more time swimming than Ctr, MS and MS + RS rats (p < 
0.001; Fig. 4.1b). 
4.3.1.2 Elevated plus maze 
One-way ANOVA showed no effect of stress on the amount of time spent in the open 
arms (Fig. 4.2a), closed arms (Fig. 4.2b) or center area (Fig. 4.2c) of the EPM. 
4.3.1.3 Open field test 
One-way ANOVA revealed a significant effect of stress on distance travelled (F(3, 47) = 
8.03, p < 0.001) in the OFT.  Post-hoc comparisons revealed that both MS (p < 0.001) and 
MS + RS rats (p < 0.05) travelled a significantly longer distance than Ctr rats (Fig. 4.3). 
4.3.2 Biochemistry 
4.3.2.1 BDNF concentration in the ventral hippocampus 
One-way ANOVA showed no effect of stress on BDNF concentration (Fig. 4.4) in the 
ventral hippocampus. 
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Figure 4.1:  Immobility, swimming and climbing behaviours of control SD, MS SD, restraint 
stressed SD and MS SD rats subjected to restraint stress in the FST.  MS and MS+RS increased 
immobility (a) and decreased swimming (b) behaviours.  Restraint stress decreased immobility (a) and 
increased swimming (b) behaviours in the FST.  Restraint stress had no additional effect on MS. * MS 
and MS+RS rats significantly different from Ctr rats, p < 0.05; ** RS rats significantly different from 
Ctr, MS and MS+RS rats, p < 0.001; Tukey‟s post-hoc test (n = 12-13/group).  Data presented as mean ± 
SEM. 
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Figure 4.2:  Time spent in the open arms, closed arms and center area by control SD, MS SD, 
restraint stressed SD and MS SD rats subjected to restraint stress in the EPM.  The EPM revealed 
no difference between Ctr, MS, RS, and MS+RS rats in time spent in the open arms (a) and closed arms 
(b) and center area (c) (n = 12-13/group).  Data presented as mean ± SEM. 
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Figure 4.3:  Distance travelled by control SD, MS SD, restraint stressed SD and MS SD rats 
subjected to restraint stress in the OFT.  MS and MS+RS increased activity in the OFT and restraint 
stress had no effect on MS.  *MS and MS + RS rats significantly different from Ctr rats, p < 0.05; 
Tukey‟s post-hoc test (n = 12-13/group). Data presented as mean ± SEM. 
 
Figure 4.4:  BDNF levels in the ventral hippocampus of control SD, MS SD, restraint stressed SD 
and MS SD rats subjected to restraint stress.  No significant difference found in BDNF levels in the 
ventral hippocampus between Ctr, MS, RS and MS + RS rats (n = 10/group).  Data presented as mean ± 
SEM. 
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4.3.2.2 Proteomics  
Using the Rattus sequence database, 814 proteins were identified for the 8-plex (appendix 
A; table A1) and 869 proteins identified for the 4-plex (appendix A; table A2) with > 95 
% confidence.  In the 8-plex, 32 proteins were identified to be increased or decreased in 
the PFC of MS and RS relative to the Ctr rats (Table 4.1).  In the 4-plex, 29 proteins were 
identified to be increased or decreased in the PFC of MS+RS relative to the Ctr rats (Table 
4.2). 
The 8-plex (table 4.1) quantification revealed that MS and RS rats had decreased actin-
associated structural proteins (Actin related protein 2/3 complex, subunit 3, Alpha II 
spectrin or ARP10 actin-related protein 10 homolog) compared to Ctr rats.  The 8-plex 
and 4-plex (table 4.1 and 4.2) quantification revealed that MS, RS and MS+RS rats had 
decreased mitochondrial energy-related proteins (Trifunctional enzyme subunit alpha, 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, ATP synthase 
subunit O, Cytochrome b-c1 complex subunit 1, ATP synthase gamma chain, 
Mitochondrial 2-oxoglutarate/malate carrier protein) compared to Ctr rats.  
Neurotransmission/signalling proteins in MS, RS and MS+RS rats were increased or 
decreased compared to Ctr rats.  However, proteins involved in glutamate and opioid 
signalling (Opioid-binding protein/cell adhesion molecule, Glutamate receptor 2) were 
decreased in the MS+RS compared to Ctr rats.  Furthermore, the 4-plex revealed a 
decrease in proteins involved in protein synthesis (Protein Tardbp, 40S ribosomal protein 
S12, RCG45615, isoform CRA_a and Tyrosine--tRNA ligase) and increase in proteins 
involved in protein degradation (F-box only protein 2 and COP9 (Constitutive 
photomorphogenic) homolog, subunit 7a) in MS+RS compared to Ctr rats.  In further 
support of the disruption in protein synthesis/degradation in MS+RS rats, 
carboxypeptidase E was found to be decreased.






Protein / function Accession no Ctr 1 Ctr 2 Avg Ctr/ Ctr MS 1 MS 2 Avg 
MS/ 
Ctr RS 1 RS 2 Avg 
RS/ 
Ctr 
              
Cytoskeletal/Structural              
              
Actin related protein 2/3 complex, subunit 3  tr│B2GV73│ 1 1.20 1.10 1.00 0.80 0.80 0.80 0.73 1.20 1.20 1.20 1.09 
Alpha II spectrin  sp│P16086│ 1 1.10 1.05 1.00 0.80 0.70 0.75 0.71 0.90 1.30 1.10 1.05 
ARP10 actin-related protein 10 homolog (S. 
cerevisiae) tr│Q5M9F7│ 1 1.00 1.00 1.00 1.10 0.70 0.90 0.90 0.80 0.80 0.80 0.80 
Myosin regulatory light chain  tr│Q63781│ 1 1.00 1.00 1.00 1.20 1.20 1.20 1.20 1.00 1.10 1.05 1.05 
Myelin basic protein transcript variant 1  tr│I7FKL4│ 1 0.50 0.75 1.00 0.90 0.80 0.85 1.13 1.20 1.00 1.10 1.47 
              
Energy metabolism              
              
Trifunctional enzyme subunit alpha, 
mitochondrial  sp│Q64428│ 1 1.10 1.05 1.00 0.40 1.00 0.70 0.67 0.90 0.70 0.80 0.76 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 10, mitochondrial  sp│Q561S0│ 1 0.70 0.85 1.00 0.50 0.70 0.60 0.71 0.70 0.70 0.70 0.82 
ATP synthase subunit O, mitochondrial  sp│Q06647│ 1 0.90 0.95 1.00 0.80 0.80 0.80 0.84 0.80 0.70 0.75 0.79 
ADP/ATP translocase 1  sp│Q05962│ 1 0.70 0.85 1.00 0.60 0.70 0.65 0.76 0.80 0.70 0.75 0.88 
              
Neurotransmission/Signalling              
              
Adaptor protein complex AP-1, sigma 1 
(Predicted), isoform CRA_b  tr│B5DFI3│ 1 1.00 1.00 1.00 1.10 1.30 1.20 1.20 1.10 1.00 1.05 1.05 
SH3-containing GRB2-like protein 3-
interacting protein 1  sp│P0DJJ3│ 1 1.00 1.00 1.00 1.20 1.30 1.25 1.25 1.20 1.10 1.15 1.15 
Guanine nucleotide-binding protein G(k) 
subunit alpha  sp│P08753│ 1 0.70 0.85 1.00 1.10 1.10 1.10 1.29 0.80 0.90 0.85 1.00 
Serine/threonine-protein phosphatase 2A 55 
kDa regulatory subunit B alpha isoform  sp│P36876│ 1 1.10 1.05 1.00 1.80 1.00 1.40 1.33 1.00 1.10 1.05 1.00 
Diphosphoinositol polyphosphate sp│Q566C7│ 1 1.00 1.00 1.00 1.10 1.40 1.25 1.25 0.90 0.90 0.90 0.90 
Table 4.1:  Proteins that differed by more than 20% (1.2-fold change) from non-maternally separated, non-stressed rats (Ctr) in the proteomic 
profile of the PFC of MS and restraint stressed (RS) rats (in red).  Data presented as average fold difference relative to Ctr (in blue). 




phosphohydrolase 1  
MAP/microtubule affinity-regulating kinase 
3  sp│Q8VHF0│ 1 1.00 1.00 1.00 0.80 0.80 0.80 0.80 1.00 1.00 1.00 1.00 
Visinin-like protein 1  sp│P62762│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 1.20 1.20 1.20 1.20 
Annexin A3  sp│P14669│ 1 1.30 1.15 1.00 0.70 0.90 0.80 0.70 0.90 1.20 1.05 0.91 
Neuronal pentraxin receptor (Fragment)  sp│O35764│ 1 0.90 0.95 1.00 0.80 0.80 0.80 0.84 0.70 0.80 0.75 0.79 
              
Protein 
synthesis/neurotrophic              
              
RNA binding motif protein, X-linked-like-1  sp│D4AE41│ 1 0.80 0.90 1.00 0.80 0.70 0.75 0.83 0.70 0.70 0.70 0.78 
Scaffold attachment factor B1  sp│O88453│ 1 1.00 1.00 1.00 1.10 0.90 1.00 1.00 0.80 0.70 0.75 0.75 
Polyadenylate-binding protein 1  sp│Q9EPH8│ 1 0.90 0.95 1.00 1.10 1.00 1.05 1.11 0.80 0.70 0.75 0.79 
60S ribosomal protein L19  sp│P84100│ 1 1.00 1.00 1.00 1.20 1.20 1.20 1.20 0.90 0.90 0.90 0.90 
Peptidyl-prolyl cis-trans isomerase 
FKBP1A  sp│Q62658│ 1 1.00 1.00 1.00 1.20 1.20 1.20 1.20 1.00 1.00 1.00 1.00 
              
Other              
              
Ferritin  tr│F1M5T1│ 1 0.90 0.95 1.00 1.20 1.10 1.15 1.21 1.10 0.80 0.95 1.00 
Nitrilase 1, isoform CRA_a  tr│F7ESM5│ 1 0.90 0.95 1.00 1.10 1.20 1.15 1.21 1.10 1.00 1.05 1.11 
Adenine phosphoribosyltransferase  sp│P36972│ 1 1.10 1.05 1.00 1.40 1.20 1.30 1.24 1.20 1.20 1.20 1.14 
Cysteine and glycine-rich protein 1  sp│P47875│ 1 1.00 1.00 1.00 1.30 1.10 1.20 1.20 1.00 1.20 1.10 1.10 
Neuromodulin  sp│P07936│ 1 0.90 0.95 1.00 1.10 0.90 1.00 1.05 1.20 1.20 1.20 1.26 
Programmed cell death 6-interacting protein  sp│Q9QZA2│ 1 0.90 0.95 1.00 1.10 1.20 1.15 1.21 0.90 1.00 0.95 1.00 
Protein RGD1304884  tr│D4A3C2│ 1 1.00 1.00 1.00 1.30 1.10 1.20 1.20 1.10 1.10 1.10 1.10 
Protein RGD1309586  tr│D3ZN21│ 1 1.50 1.25 1.00 1.40 1.70 1.55 1.24 1.90 1.70 1.80 1.44 











Protein / function Accession No Ctr 1 Ctr 2 Avg Ctr/Ctr MS+RS 1 MS+RS 2 Avg 
MS+RS/ 
Ctr 
          
Cytoskeletal/Structural          
          
Tropomyosin alpha isoform tr│Q91XN7│ 1 1.00 1.00 1.00 1.20 1.30 1.25 1.25 
Protein Twf2 tr│B0BMY7│ 1 1.00 1.00 1.00 1.20 1.20 1.20 1.20 
Neuronal migration protein doublecortin sp│Q9ESI7│ 1 1.00 1.00 1.00 0.80 0.80 0.80 0.80 
Paralemmin-1 sp│Q920Q0│ 1 1.00 1.00 1.00 0.80 0.80 0.80 0.80 
          
Energy metabolism          
          
Cytochrome b-c1 complex subunit 1, 
mitochondrial sp│Q68FY0│ 1 0.80 0.90 1.00 0.80 0.60 0.70 0.78 
Cytochrome c oxidase subunit 6B1 tr│D3ZD09│ 1 0.70 0.85 1.00 0.70 0.60 0.65 0.76 
ATP synthase F(0) complex subunit B1, 
mitochondrial sp│P19511│ 1 0.70 0.85 1.00 0.80 0.50 0.65 0.76 
ATP synthase gamma chain tr│Q6QI09│ 1 0.80 0.90 1.00 0.80 0.60 0.70 0.78 
Mitochondrial 2-oxoglutarate/malate carrier 
protein tr│G3V6H5│ 1 0.90 0.95 1.00 0.80 0.70 0.75 0.79 
          
Neurotransmission/signalling          
          
Opioid-binding protein/cell adhesion molecule sp│P32736│ 1 1.00 1.00 1.00 0.80 0.70 0.75 0.75 
Glutamate receptor 2 tr│F1LNE4│ 1 1.00 1.00 1.00 0.80 0.80 0.80 0.80 
Voltage-dependent anion-selective channel 
protein 1 sp│Q9Z2L0│ 1 0.70 0.85 1.00 0.80 0.50 0.65 0.76 
Dynein light chain 2, cytoplasmic sp│Q78P75│ 1 1.00 1.00 1.00 0.70 0.80 0.75 0.75 
Table 4.2:  Proteins that differed by more than 20% (1.2-fold change) from non-maternally separated, non-stressed rats (Ctr) in the proteomic 
profile of the PFC of MS and restraint stressed (MS+RS) rats (in red).  Data presented as average fold difference relative to Ctr (in blue). 




Protein Ranbp1 tr│D4A2G9│ 1 1.00 1.00 1.00 1.30 1.20 1.25 1.25 
Mitochondrial 2-oxoglutarate/malate carrier 
protein tr│G3V6H5│ 1 0.90 0.95 1.00 0.80 0.70 0.75 0.79 
Rho guanine nucleotide exchange factor 2 sp│Q5FVC2│ 1 1.00 1.00 1.00 0.80 0.80 0.80 0.80 
Regulator of G-protein-signaling 6 tr│F1LS67│ 1 0.90 0.95 1.00 1.20 1.20 1.20 1.26 
Calcium/calmodulin-dependent 3',5'-cyclic 
nucleotide phosphodiesterase 1B sp│Q01066│ 1 0.90 0.95 1.00 0.70 0.80 0.75 0.79 
          
Protein synthesis/neurotrophic          
          
Protein Tardbp tr│I6L9G6│ 1 1.00 1.00 1.00 0.80 0.80 0.80 0.80 
40S ribosomal protein S12 tr│M0R9I8│ 1 1.00 1.00 1.00 0.70 0.80 0.75 0.75 
RCG45615, isoform CRA_a tr│B2RYU2│ 1 0.90 0.95 1.00 0.70 0.80 0.75 0.79 
Tyrosine--tRNA ligase, cytoplasmic sp│Q4KM49│ 1 1.00 1.00 1.00 0.80 0.80 0.80 0.80 
          
Protein degradation          
          
F-box only protein 2 tr│G3V774│ 1 0.90 0.95 1.00 1.40 1.10 1.25 1.32 
COP9 (Constitutive photomorphogenic) 
homolog, subunit 7a (Arabidopsis thaliana) 
(Predicted) 
tr│G3V8Z9│ 1 0.90 0.95 1.00 1.10 1.20 1.15 1.21 
Carboxypeptidase E sp│P15087│ 1 1.10 1.05 1.00 0.80 0.80 0.80 0.76 
          
Other          
          
Uncharacterized protein tr│M0R9D5│ 1 1.00 1.00 1.00 0.70 0.80 0.75 0.75 
Protein LOC679748 tr│D3ZE63│ 1 1.10 1.05 1.00 0.80 0.70 0.75 0.71 
Thiosulfate sulfurtransferase sp│P24329│ 1 1.00 1.00 1.00 1.10 1.60 1.35 1.35 
C-terminal-binding protein 1 sp│Q9Z2F5│ 1 1.00 1.00 1.00 0.80 0.80 0.80 0.80 
Ig kappa chain C region, A allele sp│P01836│ 1 1.00 1.00 1.00 1.10 1.30 1.20 1.20 
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The main findings of the current study showed that MS SD rats or MS SD rats subjected 
to restraint stress displayed depression-like behaviour without anxiety-like behaviour and 
that MS was not affected by chronic restraint stress in adulthood.  Biochemical studies of 
the ventral hippocampus revealed no effect of MS and restraint stress on BDNF levels.  
Proteomic analysis of the PFC revealed a decrease in actin-associated proteins in MS SD 
rats (Actin related protein 2/3 complex, subunit 3, Alpha II spectrin) and non-separated 
SD rats subjected to restraint stress (ARP10 actin-related protein 10 homolog) as well as a 
decrease in mitochondrial energy-related proteins in MS SD rats (Trifunctional enzyme, 
NADH dehydrogenase, ADP/ATP translocase 1), non-separated SD rats subjected to 
restraint stress (Trifunctional enzyme and ATP synthase) and MS SD rats subjected to 
restraint stress (cytochrome subunits, ATP synthase and malate carrier protein).  
Furthermore, a decrease in proteins involved in protein synthesis (Protein Tardbp, RCG, 
40s ribosomal protein and tyrosine-tRNA ligase) and an increase in proteins involved in 
protein degradation (F-box protein and COP9) were found in MS SD rats subjected to 
restraint stress.  
Rats subjected to MS or MS and restraint stress displayed depression-like behaviour as 
evidenced by increased immobility and decreased swimming behaviours in the FST.  
Restraint stress decreased immobility and increased swimming behaviours in the FST in 
SD rats.  Restraint stress had no effect on MS rats.  The depression-like behaviour of MS 
SD rats in the FST is in agreement with previous studies using the same MS protocol 
(Desbonnet et al. 2010; Dimatelis et al. 2012b; Lambás-Señas et al. 2009; Yoo et al. 
2013).  However, the current study showed that restraint stress decreased immobility in 
the FST.  This is in contrast to studies that showed a stress-induced increase in immobility 
(Bombi et al. 2013; Chiba et al. 2012; Ulloa et al. 2010).  This paradoxical effect of 
restraint stress on immobility in the FST has been reported previously (Platt and Stone 
1982; Swiergiel et al. 2007), an effect further supported by data demonstrating that 
chronically administered corticosterone decreased immobility in the FST (Brotto et al. 
2001).  There is no understandable explanation for the decreased immobility following 
restraint stress but has been previously suggested to be the result of adaptation to chronic 
stress and changes in the β-adrenergic receptor (Platt and Stone 1982; Swiergiel et al. 
2007).  The inconsistent effect of restraint stress on immobility could also probably be 
ascribed to the different restraint stress protocols since different durations and intensity of 
restraint stress have different effects on immobility in the FST (Cancela et al. 1991; 
Suvrathan et al. 2010). 
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To exclude the possibility that the depression-like behaviour observed in the MS rats may 
be due to a change in motor activity, the distance travelled by the rat was determined in 
the OFT.  Rats subjected to MS or MS and restraint stress displayed increased locomotor 
activity in the OFT compared to control rats.  This is in line with results obtained by 
Lambás-Señas et al. (2009) who showed that MS SD rats displayed increased motor 
activity in a novel environment, using a similar MS protocol.  Therefore, the results in the 
FST could not be related to a decrease in motor activity per se. 
Furthermore, MS and restraint stress did not induce anxiety-like behaviour as measured 
by time spent in the closed arms of the EPM.  This is consistent with various studies that 
found no anxiety-like behaviour in adult rats subjected to MS in early life (Dimatelis et al. 
2012b; Rüedi-Bettschen et al. 2005; van Heerden et al. 2010; Yoo et al. 2013).  
Differences in both MS and restraint stress procedures between studies may explain 
differences in reported results such as anxiety-like behaviour.  This is not only true for the 
duration of restraint stress or MS, but also for the method of restraint stress (restraint in 
tubes or with wire mesh as well as by taping the limbs to restrict movement) or MS 
(removing the pups or removing the dam from the home cage during MS as well as 
separation with a whole litter or separation in isolation) (Glavin et al. 1994; Vetulani 
2013).   
BDNF is highly expressed in the hippocampus (Yan et al. 1997) and the results of its 
action include neuronal sprouting, synaptic reorganization and neurogenesis (Lindvall et 
al. 1994; McAllister et al. 1999).  In the current study, MS and restraint stress had no 
effect on BDNF concentration in the ventral hippocampus.  The results are therefore in 
contrast with various studies that showed decreased BDNF expression in the hippocampus 
of MS or restraint stress rats (Roceri et al. 2002; Xu et al. 2006).  However, the neuronal 
mechanisms involved seem complex, since other studies found increased (Greisen et al. 
2005) or even no effect of MS or restraint stress on BDNF expression in the hippocampus 
(Kuroda and McEwen 1998; Reagan et al. 2007; Roceri et al. 2004; Rosenbrock et al. 
2005).  However, it is not surprising that BDNF results were inconsistant since the 
methodology such as time of stressor for both MS and restraint stress are quite variable 
between these studies.  For example, it has previously been shown that variations in the 
duration of restraint stress have different effects on BDNF.  This was evidenced by 
reduced BDNF concentration after 21 days compared to 7 days of restraint stress in mice 
(Capoccia et al. 2013).  It is also likely that the neurobiology of the depression-like 
behaviour in MS rats or MS rats subjected to restraint stress is related to diverse and 
regionally specific neurotrophin function (Berton et al. 2006).  This could be due to the 
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fact that BDNF is highly complex (eight exons, multiple splice variants and alternate 
polyadenylation sites), providing the potential for multiple BDNF transcripts that are 
differently regulated by stress and therefore resulting in contrasting functional effects 
(Groves 2007; Liu et al. 2006).          
To further evaluate the effect of restraint stress and MS on rats, a proteomic analysis of 
the PFC was performed.  Proteins that were differently regulated in the PFC of rats 
subjected to MS, restraint stress or MS and restraint stress, fall into five broadly defined 
functional categories:  (a) cytoskeletal, (b) energy metabolism, (c) neurotransmission, (d) 
protein synthesis and (e) protein degradation.  These functional categories will be further 
discussed according to current understanding of the neurobiology of animal models of 
stress-induced depression-like behaviour. 
Cytoskeletal proteins such as microfilaments, microtubules and intermediate filaments 
play a central role in neuronal function and the creation and maintenance of cell shape 
(Pigino et al. 2006).  In the current study, actin microfilament-associated proteins such as 
actin related protein 2/3, alpha II spectrin and actin-related protein 10 were reduced in rats 
subjected to MS or restraint stress.  On the other hand, actin binding proteins, such as the 
myosin regulatory light chain and tropomyosin alpha isoform were increased in rats 
subjected to MS or MS and restraint stress.  It has previously been shown that MS reduced 
actin microfilament-associated proteins in the NAc and ventral hippocampus suggesting 
altered neurotransmission and synaptic function (Daniels et al. 2012; Dimatelis et al. 
2012a). Furthermore, it has also been shown that a combination of various stressors 
(restraint stress, forced swim stress and ether vapor) decreased structural proteins in the 
ventral hippocampus (Uys et al. 2008).  In line with the current study, Daniels et al. (2012) 
found that MS increased the expression of tropomyosin-5 in the ventral hippocampus.  
Tropomyosin and myosin regulatory light chain not only bind to actin, but also increase 
axoplasmic transport, synaptic rearrangement, vesicle transport or neurotransmitter release 
(Lees-Miller et al. 1990; Mochida 1995).  It therefore appeared that the stress of MS 
increased the expression of myosin regulatory light chain and tropomyosin alpha isoform 
in the rats subjected to MS or MS and restraint stress, to compensate for the loss of 
structural proteins.    Therefore, the stress of MS and restraint stress mostly decreased 
actin-associated proteins, which function to maintain the cytoskeletal network and 
therefore may have altered neuronal function in the PFC.   
The current study demonstrated a decrease in proteins involved in mitochondrial energy 
metabolism in the PFC of rats subjected to MS, restraint stress or MS and restraint stress.  
These proteins included trifunctional enzyme subunit alpha, ATP synthase subunit O, 
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ATP synthase gamma chain, cytochrome b-c1 complex subunit 1 and mitochondrial 2-
oxoglutarate/malate carrier protein.  Most of these proteins are involved in oxidative 
phosphorylation of ADP to produce ATP (ATP synthase subunit O, ATP synthase gamma 
chain, cytochrome b-c1 complex subunit 1 and mitochondrial 2-oxoglutarate/malate 
carrier protein).  Dysfunction of the mitochondrial electron transport chain has been 
suggested to be an important factor in the pathogenesis of neuropsychiatric disorders such 
as depression (Tobe 2013) as well as being associated with cellular degeneration 
(Calabrese et al. 2001).  The findings of the current study are in line with previous studies 
that showed decreased energy-related proteins in the hippocampus in response to chronic 
unpredictable stress (21 days) and MS stress (Dimatelis et al. 2012a; Mu et al. 2007).  
Furthermore, chronic mild stress (40 days) or restraint stress (7 - 21 days) in Wistar rats 
has been previously shown to decrease energy-related proteins in the PFC associated with 
oxidative phosphorylation (Madrigal et al. 2001; Réus et al. 2014).  Therefore, 
dysfunction of mitochondrial energy metabolism may compromise neuronal function as a 
possible consequence of mitochondrial damage and degeneration in rats subjected to MS, 
restraint stress or MS and restraint stress.     
Proteins in the 8-plex and 4-plex, especially the energy-related proteins, were found to be 
variable in most of the control duplicates.  Both biological and technical variability have 
been previously reported (Gan et al. 2007) and may have contributed to the variation of 
duplicates in the current study.  The technical variability is often introduced in the 
multiple steps of sample preparation, efficiency of enzymatic digestion, efficiency of 
chemical labeling, performance of instrumentation and overlapping of mass of reporter 
ions which have an impact on yield of fragmentation (Pottiez et al. 2012).  Nonetheless, 
iTRAQ proteomic quantification is widely used in all fields of research and proved to be 
highly sensitive (Wu et al. 2006).  Biological variability is introduced as variability that 
exists from animal-to-animal within experimental groups.  Outbred rat strains are 
genetically undefined and show greater inherent biological variation than inbred strains 
(Zakharkin et al. 2005) which may be the cause of biological variability in the current 
study, since two samples of pooled tissue from 3 rats per group were analyzed separately.  
In the current study, most of the proteins in the 8-plex and 4-plex control duplicates that 
varied more than 20 %, showed similar fold differences in both analysis.  The differences 
between control duplicate analyses may therefore be attributed to the biological 
variability.  However, since some of the proteins in the control duplicates were also 
variable in the 4-plex and 8-plex, technical variability may also be a factor.       
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A number of proteins involved in neurotransmission/signalling were differentially 
expressed in the MS rats and non-maternally separated rats and MS rats subjected to 
restraint stress.  The AMPA glutamate receptor 2 (GluR2) was decreased in the rats 
subjected to MS and restraint stress.  The involvement of AMPA receptors in animal 
models of depression and mechanism of antidepressant action have been well documented 
(Chourbaji et al. 2008; Li et al. 2001; Martinez-Turrillas et al. 2002; Martínez-Turrillas et 
al. 2007).  AMPA receptor knockout mice displayed increased learned helplessness, 
decreased serotonin and noradrenaline levels and increased NMDA receptor expression in 
the hippocampus (Chourbaji et al. 2008).  Furthermore, the social defeat model of 
depression in mice showed decreased GluR2 in the NAc as measured by 
immunohistochemistry (Vialou et al. 2010).  This was further supported by evidence 
showing decreased GluR2 mRNA expression in the hippocampus of Wistar rats 
previously exposed to MS (3 h daily for 21 days) (Pickering et al. 2006).  Furthermore, 
AMPA receptor channel impermeability to calcium is dependent on the GluR2 subunit 
and cells that contain AMPA receptors lacking the GluR2 subunit show high calcium 
permeability and therefore vulnerability to excitotoxicity (Liu and Zukin 2007).  AMPA 
receptors are also known to play an important role in neurotrophic/neuroprotective effects 
(Zarate, Jr. and Manji 2008).  For example, in vivo and in vitro studies showed that 
treatment with kainic acid or ampakines (AMPA receptor modulator) increased BDNF 
and nerve growth factor mRNA and protein levels in the cerebral cortex and hippocampus 
of rats (Lauterborn et al. 2000; Lauterborn et al. 2003; Zafra et al. 1990).  It is therefore 
evident that modifications of AMPA receptors alter synaptic function through various 
signalling proteins that underlie the neuropathology of psychiatric disorders such as 
depression. 
The neuroprotective effects of GluR2 were further supported by evidence indicating an 
interaction between AMPA and opioid receptors (Fundytus 2001).   The acute and chronic 
function of opioid receptors is regulated by the opioid-binding protein/cell adhesion 
molecule (OBCAM) (Loh and Smith 1996) and was found to be decreased in the present 
study.  OBCAM is a glycosylphosphatidylinositol (GPI)-anchored protein with selectivity 
for the MOR ligands (Brown et al. 2012) and has been shown to regulate DOR function 
(Lane et al. 1992).  Furthermore, OBCAM has been shown to be associated with 
individuals with depression in a genome-wide linkage analysis in a family-based study 
(Schol-Gelok et al. 2010).  The DOR and MOR are also involved in the 
neurotrophic/neuroprotective effects of opioids as evidenced by increased BDNF mRNA 
expression in the frontal cortex, hippocampus and amygdala following administration of 
an opioid agonist or endogenous ligand (Torregrossa et al. 2004; Zhang et al. 2006).   
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Proteins involved in protein synthesis were decreased (Protein Tardbp, 40S ribosomal 
protein S12, RCG45615/ 60S ribosomal protein L12 and Tyrosine tRNA ligase) and 
proteins involved in protein degradation (F-box only protein 2 and COP9 homolog, 
subunit 7a) were increased in the PFC of rats subjected to both MS and restraint stress.  
Inhibition of protein synthesis is a common response of cells to severe forms of stress 
such as thermal, physical and metabolic stress and viral infection (Clemens et al. 2000; 
Clemens et al. 1998; Gale, Jr. et al. 2000; Sheikh and Fornace 1999).  For instance, animal 
models of transient cerebral ischemia have shown reduced protein synthesis (Hu and 
Wieloch 1993; Mengesdorf et al. 2002).  The involvement of protein synthesis in 
depression was evidenced by the antidepressant drug, ketamine that triggered protein 
synthesis by dephosphorylating and activating eukaryotic elongation factor 2 in the 
hippocampus of mice (Autry et al. 2011; Flight 2011).  On the other hand, restraint stress 
for 1 h daily for 4 weeks showed increased protein degradation in the brain of SD rats as 
measured by the H2O2 degradation assay (Hong et al. 2014).  The decreased protein 
synthesis and increased protein degradation in the current study may possibly result in 
atrophy and reduced function of PFC neurons in rats subjected to MS and restraint stress.  
In further support of disruptions in protein synthesis and degradation, carboxypeptidase E 
was found to be increased in the PFC of rats subjected to MS and RS.  Carboxypeptidase 
E is the enzyme responsible for cleaving the C-terminally extended residues of peptide 
intermediates to produce bioactive peptides (Cawley et al. 2012).  Additionally, this 
protein is also involved in depressive-like behaviour since a previous study in mice with a 
mutation in carboxypeptidase E that renders the protein inactive and unstable, displayed 
increased immobility in the FST and tail suspension test (Rodriguiz et al. 2013).  
In conclusion, rats exposed to early life MS without or with additional restraint stress, 
displayed depression-like behaviour in the FST.  Furthermore, reduced mitochondrial 
energy-related, structural actin-associated proteins as well as disruption in proteins 
associated with protein synthesis and degradation, may be the result of the stress of MS 





Chapter 5  
Effect of ketamine in Wistar-Kyoto and Sprague-
Dawley rat models of depression 
 
5.1 Introduction 
The NMDA receptor antagonist, ketamine at subanaesthetic doses, has recently been used 
to treat depression.  On the other hand, a subanaesthetic dose of ketamine has also been 
shown to produce symptoms of schizophrenia in healthy individuals and to exacerbate 
symptoms in patients with schizophrenia due to its psychotomimetic effects (Lahti et al. 
1995; Lahti et al. 2001; Malhotra et al. 1997).  Unfortunately, the adverse 
psychotomimetic effects and abuse potential of ketamine have limited its use as an 
antidepressant.  
In rodents, antagonists of the NMDA receptor such as phencyclidine have been used in 
naïve rodents to produce a model of schizophrenia to gain insight into the mechanisms 
underlying some of the positive (hyperactivity, heightened stimulant sensitivity), negative 
(reduced social behaviour), affective (depression-like behaviour in the FST) and cognitive 
symptoms (impairment of executive function and reduced memory in object recognition 
tasks) and disruption of sensory motor gating (latent inhibition and prepulse inhibition) 
characteristic of schizophrenia (Egerton et al. 2005; Grayson et al. 2007; Kalinichev et al. 
2008; Martinez et al. 1999; Noda et al. 1995; Sams-Dodd 1995).  Similarly, ketamine, an 
NMDA receptor antagonist, has also recently been used to study schizophrenia-like 
behaviour in rodents (Becker et al. 2003; Becker and Grecksch 2004; Chatterjee et al. 
2011; Chindo et al. 2012; Hou et al. 2013; Imre et al. 2006).  At a dose of 30 – 50 mg/kg, 
ketamine decreased social behaviour in rats and increased immobility in the FST (Becker 
et al. 2003; Becker and Grecksch 2004; Chindo et al. 2012).  However, acute and chronic 
treatment with ketamine produced differential effects.  For example, acute treatment of 
mice with various doses (12 - 100 mg/kg) of ketamine induced hyperactivity in the OFT, 
impaired memory in the passive avoidance task and disrupted prepulse inhibition 
(Chatterjee et al. 2011; Hou et al. 2013; Imre et al. 2006) whereas chronic treatment of 
rodents with ketamine at a dose of 30 – 100 mg/kg for 5 days or longer increased 
immobility in the FST (Chatterjee et al. 2011; Chindo et al. 2012; Hou et al. 2013).  In 
further support of the ketamine model of schizophrenia, behaviours such as reduced social 






behaviour, increased activity in the OFT, reduced learning and memory in the passive 
avoidance task and increased immobility in the FST were reversed by antipsychotic drugs 
(risperidone and clozapine) (Becker and Grecksch 2004; Chatterjee et al. 2011; Chindo et 
al. 2012). 
At lower doses, in various rodent models of depression, ketamine showed rapid 
antidepressant-like effects in the FST, learned helplessness paradigm and tail suspension 
test (Garcia et al. 2008; Koike et al. 2011; Li et al. 2010; Maeng et al. 2008; Tizabi et al. 
2012).  Ketamine treatment of rats at a dose of 10 mg/kg and 15 mg/kg has been shown to 
reduce the duration of immobility in the FST induced by the 15-min pretest-swim, at 60 
min after treatment (Garcia et al. 2008).  Furthermore, ketamine treatment at a dose of 10 
mg/kg has been shown to reduce the number of escape failures in the learned helplessness 
paradigm, increased sucrose consumption and reduced latency to feed (measure of 
anxiety) in rats that had been exposed to chronic unpredictable stressors (Koike et al. 
2011; Li et al. 2011).  However, ketamine, at higher doses (80 mg/kg or 160 mg/kg), had 
no sustained antidepressant effect in the FST in rats at 24 h or 1 week after acute 
treatment (Li et al. 2010; Popik et al. 2008).  Furthermore, repeated treatment (3 days, 7 
days or 3 injections at 24, 5 and 1 h before test swim) of ketamine at a dose of 25 mg/kg 
had no immediate effect on immobility in the FST at 1 h after treatment in rats (Fraga et 
al. 2013; Gigliucci et al. 2013).  Therefore, treatment of rodent models of depression with 
a lower dose of ketamine was required to produce rapid antidepressant effects.      
Similarly, it has recently been shown that acute ketamine treatment of female WKY rats at 
low doses (2.5 mg/kg and 5 mg/kg) reversed their depressive-like behaviour as evidenced 
by reduced duration of immobility in the FST more than 20 min after treatment (Tizabi et 
al. 2012).  Furthermore, reduced immobility induced by ketamine treatment at a dose of 5 
mg/kg was still evident 1 week after treatment (Tizabi et al. 2012).  The exact mechanism 
of ketamine‟s rapid and sustained antidepressant effect is still unknown.  However, a 
direct role for the AMPA and NMDA receptor in the antidepressant effects of ketamine 
has been suggested (Koike et al. 2011; Maeng et al. 2008; Tizabi et al. 2012).  Previous 
studies showed that ketamine treatment increased the AMPA/NMDA ratio in WKY rats 
and the antidepressant effect was enhanced by an AMPA receptor agonist (Akinfiresoye 
and Tizabi 2013; Tizabi et al. 2012) or blocked by an antagonist (Koike et al. 2011; 
Maeng et al. 2008).  Furthermore, WKY rats have a unique neurochemical profile.  
Previous studies showed that the NMDA receptor density was reduced in several brain 
areas of WKY rats.  NMDA receptor density was reduced in the cerebral cortex, striatum, 
NAc, hippocampus and substantia nigra of WKY compared to Wistar rats (Lei and Tejani-






Butt 2010; Lei et al. 2009).  In addition, noradrenaline and dopamine uptake blockers such 
as desipramine and nomifensine have been shown to reduce depressive-like behaviour in 
the FST in WKY rats while selective serotonin uptake blockers (paroxetine and 
fluoxetine) were without effect (Lopez-Rubalcava and Lucki 2000; Paré 1992; Tejani-Butt 
et al. 2003).  It was therefore suggested that the WKY may be a suitable model to study 
depression with resistance to specific antidepressant drugs (Lahmame et al. 1997; Lopez-
Rubalcava and Lucki 2000; Tejani-Butt et al. 2003) similar to patients who show a 
differential response to antidepressant drugs (Labermaier et al. 2013).                 
The aim of the current study was therefore to measure the antidepressant-like effects of 
ketamine in the WKY rat model of depression at low subanaesthetic doses (5-15 mg/kg) 
previously shown to induce antidepressant-like effects in animal models of depression 
(Garcia et al. 2008; Tizabi et al. 2012).  The FST was used to measure antidepressant-like 
effects at different times (2 h, 48 h and 72 h) after a single injection of ketamine in order 
to determine both the rapid and sustained effects of ketamine.  Since high frequency 
USVs have previously been shown to be associated with appetitive behaviour and 
communication of emotional information (Knutson et al. 2002), the effect of ketamine on 
isolation-induced social signalling was measured in WKY rats.  MS of SD rats has been 
shown to produce a model of depression that is sensitive to a variety of antidepressant 
drugs (El Khoury et al. 2006; Huang and Lin 2010).  Consequently, the effect of ketamine 
on the MS SD model of depression was also investigated. 
5.2 Materials and Methods 
5.2.1 Animals 
A total of 75 male WKY/NCrl, 51 male Wistar and 123 male SD rats were used for 
experiment 1, 2 and 3.  Wistar rats were used as the control for the WKY rats.  All 
animals were obtained from the University of Cape Town Animal Unit except for SD rats 
that were bred in the Satellite Animal Facility in the Anatomy Building of the University 
of Cape Town for experiment 3.  Rats were kept under the same conditions as described in 
section 2.2.1.  The study was conducted in accordance with the guidelines of the South 
African National Standard: The care and use of animals for scientific purposes (2008) and 
approved by the University of Cape Town Faculty of Health Sciences Animal Ethics 
Committee (#012/045 for WKY and Wistar rats and #012/046 for SD rats).   
Experiments 1-3 consisted of the following rat groups:  WKY/NCrl (WKY) and Wistar 
rats for experiment 1, WKY/NCrl (WKY) rats for experiment 2 and non-maternally 






separated SD (nMS SD) and maternally separated SD rats (MS SD) for experiment 3.  The 
groups were randomly divided into drug treatment groups and further randomly divided 
into behavioural groups for experiment 1 and 3 according to treatment at different times 
before OFT and FST behavioural analysis (see behavioural group A and B in figure 5.1).   
Experiment 1 consisted of 8 treatment groups:  (a) WKY/NCrl tested 46 h and 72 h 
(Group A, n = 9) and 22 h and 48 h (Group B, n = 8) after intraperitoneal injection of 
saline (WKY Sal), (b) WKY/NCrl tested 46 h and 72 h (Group A, n = 5) and 22 h and 48 
h (Group B, n = 5) after injection of 5 mg/kg ketamine (WKY Ket-5), (c) WKY/NCrl 
tested 46 h and 72 h (Group A, n = 6) and 22 h and 48 h (Group B, n = 5) after injection of 
10 mg/kg ketamine (WKY Ket-10), (d) WKY/NCrl tested 46 h and 72 h (Group A, n = 5) 
and 22 h and 48 h (Group B, n = 5) after injection of 15 mg/kg ketamine (WKY Ket-15), 
(e) Wistar tested 46 h and 72 h (Group A, n = 9) and 22 h and 48 h (Group B, n = 8) after 
injection of saline (Wistar Sal), (f) Wistar tested 46 h and 72 h (Group A, n = 7) and 22 h 
and 48 h (Group B, n = 5) after injection of 5 mg/kg ketamine (Wistar Ket-5), (g) Wistar 
tested 46 h and 72 h (Group A, n = 6) and 22 h and 48 h (Group B, n = 6) after injection of 
10 mg/kg ketamine (Wistar Ket-10) and (h) Wistar tested 46 h and 72 h (Group A, n = 5) 
and 22 h and 48 h (Group B, n = 5) after injection of 15 mg/kg ketamine (Wistar Ket-15).   
Experiment 2 consisted of 2 treatment groups:  WKY/NCrl treated with saline (WKY Sal, 
n = 13) and WKY/NCrl treated with 10 mg/kg ketamine (WKY Ket-10, n = 11). 
Experiment 3 consisted of 4 treatment groups:  (a) non-maternally separated SD (nMS 
SD) tested 46 h and 72 h (Group A, n = 15) and 22 h and 48 h (Group B, n = 17) after 
injection of saline (nMS SD Sal), (b) non-maternally separated SD (nMS SD) tested 46 h 
and 72 h (Group A, n = 16) and 22 h and 48 h (Group B, n = 16) after injection of 15 
mg/kg ketamine (nMS SD Ket-15), (c) maternally separated SD (MS SD) tested 46 h and 
72 h (Group A, n = 16) and 22 h and 48 h (Group B, n = 15) after injection of saline (MS 
SD Sal) and (d) maternally separated SD (MS SD) tested 46 h and 72 h (Group A, n = 15) 
and 22 h and 48 h (Group B, n = 15) after injection of 15 mg/kg ketamine (MS SD Ket-
15).  
In experiment 1 (WKY/NCrl and Wistar rats) and experiment 3 (MS SD and non-
maternally SD rats), for 2 days prior to baseline USV recording (P60 – P61), rats were 
transferred to the room in which the USVs were to be recorded, where they were handled 
briefly and then returned to the rat facility.  One day after the last day of brief handling, 
baseline USVs were recorded for 8 days (P62 – P69) prior to treatment.  The USVs of the 
cage mate (Group B; figure 5.1) were recorded the next evening so that  USVs were 






recorded every alternate day for each rat. Each rat received a single ketamine injection at 
P70 - P71 and USV‟s were recorded after 5 h and 29 h.  At P72 (22 h and 46 h after 
ketamine/saline injection), the OFT was carried out and 2 h thereafter each rat was 
allowed to swim for 15 min in the FST (pretest-swim).  After 24 h, the rats were exposed 
to a second 5-min test swim session (48 h and 72 h after ketamine/saline injection). 
In experiment 2 (WKY/NCrl rats), each rat (P60) was allowed to swim for 15 min 
(pretest-swim) and 2 h before the test swim session, injected with 10 mg/kg 
ketamine/saline.  At 24 h after the pretest-swim, the rats were exposed to a second 5-min 
swim session (2 h after ketamine/saline injection). 
5.2.2 Drug treatment 
At P70 (between 13h00-14h00), rats in experiment 1 were either injected with a single 
subanesthetic dose of ketamine hydrochloride (Anaket ®, Bayer Healthcare, Isando, RSA) 
(5, 10 or 15 mg/kg) or an equivalent volume of 0.9 % sterile saline (on day 1 and day 2 in 
figure 5.1).  Ketamine and saline were administered intraperitoneally in a volume 
equivalent to 1 ml/kg as a single dose.  Acute administration of 2.5 - 15 mg/kg ketamine 
have been shown previously to induce antidepressant-like effects in the FST (Garcia et al. 
2008; Tizabi et al. 2012).  It was therefore decided to use doses 5 mg/kg, 10 mg/kg or 15 
mg/kg in the current study.  Rats in experiment 2 and 3 were either injected with a single 
subanesthetic dose of 10 mg/kg or 15 mg/kg of ketamine, respectively, or an equivalent 
volume of sterile saline. 
5.2.3 Maternal separation 
MS was performed on SD rats according to the procedure and under similar conditions as 
described in chapter 3.  Pups were weaned at P21; males were separated from females and 
housed 2–4 in a cage. 
5.2.4 Behaviour 
USVs were measured in the rats‟ dark phase (18h00-23h00) and OFT and FST tests were 
conducted in the light phase (06h00-13h00).  Adult male rats were transferred to a room 
adjacent to the behavioural room on the morning of behavioural testing and allowed to 
habituate for 1 h before behavioural testing. 
 
 
























Figure 5.1:  An illustration of the experimental protocol (a) (Experiment 1 and 3):  Rats in 
behavioural groups A and B were tested on alternate days for USV, injected on different days (day 1 and 
day 2) and tested in the OFT and FST on the same day. The OFT and FST were therefore carried out at 
different time points after ketamine injection for group A (46 h for OFT and 72 h for test swim) and 
group B (22 h for OFT and 48 h for test swim). (b) (Experiment 1-3):  Rats in experiment 1 (WKY/NCrl 
and Wistar) and 3 (MS SD and non-maternally separated SD) were treated with 5, 10 or 15 mg/kg 
ketamine/saline at 72 h/48 h before the 5-min test swim.  WKY/NCrl rats in experiment 2 were treated 
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5.2.4.1 Open field test (experiments 1 and 3) 
At P72 (22 h and 46 h after ketamine/saline injection), the OFT was carried out as 
described in section 2.2.2.2 
 5.2.4.2 Forced swim test (experiments 1-3) 
At P72, 2 h after the OFT, the rats were placed in individual transparent cylinders (40×19 
cm) containing 30 cm of water (23–25 °C).  Each rat was allowed to swim for 15 min 
(habituation).  After 24 h, the rats were exposed to a second 5-min swim session (48 h and 
72 h after ketamine/saline injection for experiments 1 and 3 and 2 h after ketamine/saline 
injection for experiment 2) during which FST behaviour was recorded for later analysis as 
described in chapter 2.  The total time spent immobile, swimming and struggling was 
tracked by Ethovision (automated scoring) and also measured manually for experiment 3.  
This was necessary to confirm that the FST results that were tracked by Ethovision were 
not influenced by the method of analysis (automated and manual scoring) since 
immobility for SD rats were previously manually scored (section 4.2.4.1). 
5.2.4.3 Ultrasonic vocalizations (experiments 1 and 3) 
Rats were housed 2–3 in their home cage (36×20×18 cm) in which USV‟s were recorded.  
For 2 days prior to baseline USV recording (P60 – P61), rats were transferred to the room 
in which the USVs were to be recorded, where they were handled briefly and then 
returned to the rat facility in order to habituate rats to the testing environment.  One day 
after the last day of brief handling, baseline USVs were recorded for 8 days (P62 – P69) 
prior to treatment.  Each rat received a single ketamine injection at P70 - P71 and USV‟s 
were recorded after 5 h and 29 h.  Rats were left for a minimum of 1 h to habituate to the 
room conditions before USV recording.  No other rats were present in the USV room 
during a USV recording session.  Recording started immediately after the cage mate(s) 
had been removed from the home cage and continued for 6 min. The USVs of the cage 
mate (Group B; figure 5.1) were recorded the next evening so that USVs were recorded 
every alternate day for each rat.  In cages with 3 rats, only 2 rats were used for USV 
recordings.  The same recording equipment and analyses were used as described in section 
3.2.3.4. 
5.2.5 Statistical Analysis 
The OFT and FST data were normally distributed (Shapiro-Wilk test) and were analyzed 
by means of analysis of variance (ANOVA), followed by Tukey‟s post-hoc test with 






correction for multiple comparisons.  A t-test was used to compare the behaviour of two 
groups of rats (group A and Group B) studied.  USV data were not normally distributed 
and were analyzed with the Kruskal–Wallis ANOVA, followed by Dunn‟s post-hoc test 
with correction for multiple comparisons. The Friedman test for repeated measures was 
used to test for differences between USVs at different time points before and after 
treatment..  The OFT and FST data are presented as mean ± SEM and USV data are 
presented as median and interquartile range. 
5.3 Results 
5.3.1 Experiment 1:  Sustained effects of acute ketamine on Wistar-Kyoto 
and Wistar rats 
5.3.1.1 Open field test 
Distance travelled 
Two-way ANOVA (rat strain and drug as factors) showed a significant rat strain effect on 
total distance travelled in the open field at 22 h (F(1, 39) = 84.12, p < 0.001) and 46 h (F(1, 47) 
= 40.64, p < 0.001) after the ketamine/saline injection and no significant drug effect at 22 
h and 46 h after ketamine/saline injection.  Post-hoc analysis revealed that the WKY Sal 
rats travelled a shorter distance than Wistar Sal rats at 22 h (Fig. 5.2a) and 46 h (Fig. 5.2b) 
after the saline injection (p < 0.001). 
Since there was no difference between treated rat groups at 22 h and 46 h, the distance 
travelled data for the two ketamine/saline-treated rat groups studied at 22 h (group B) and 
46 h (group A) after ketamine/saline injection were combined (22 h + 46 h).  Furthermore, 
these were different groups of rats at 22 h and 46 h and a t-test showed no significant 
difference in distance travelled by the two ketamine/saline-treated rat groups at these time 
points.  Two-way ANOVA revealed a significant rat strain effect (F(1, 94) = 113.8, p < 
0.001) and no significant drug effect on distance travelled.  Post-hoc analysis showed that 
the WKY Sal rats travelled a shorter distance than Wistar Sal rats (Fig. 5.2c, p < 0.001). 







Figure 5.2:  Distance travelled by WKY and Wistar rats in the OFT following treatment with 
saline/ketamine. Treatment with 5, 10 and 15 mg/kg ketamine had no effect on distance travelled by 
WKY and Wistar rats in the OFT at (a) 22 h (n = 5 – 9/group), (b) 46 h (n = 5 – 8/group) and (c) 22 h + 
46 h (n = 10 – 17/group) after saline/ketamine injection.  * WKY Sal significantly different from Wistar 
Sal, p < 0.001; Tukey‟s post-hoc test.  Data presented as mean ± SEM. 
 
5.3.1.2 Forced swim test 
Immobility 
Two-way ANOVA (rat strain and drug as factors) showed a significant rat strain effect on 
immobility in the FST at 48 h (F(1,47) = 239.7, p < 0.001) and 72 h (F(1,39) = 122.60, p < 
0.001) after the ketamine/saline injection and no significant drug effect at 48 h and 72 h 
after the ketamine/saline injection.  Post-hoc analysis showed that the WKY Sal rats spent 






more time immobile than Wistar Sal rats at 48 h (Fig. 5.3a) and 72 h (Fig. 5.3b) after the 
saline injection (p < 0.001).  WKY Ket-10 rats tended to spend more time immobile than 
WKY Sal rats at 48 h after the ketamine/saline injection (p = 0.05, Fig. 5.3a) 
Since there was no difference between treated rat groups at 48 h and 72 h, the immobility 
data for ketamine/saline-treated rat groups at 48 h and 72 h after ketamine/saline injection 
were combined (48 h + 72 h).  Furthermore, these were different groups of rats at 48 h 
(group B) and 72 h (groups A) and a t-test showed no significant difference in immobility 
by the two ketamine/saline-treated rat groups measured at these time points.  Two-way 
ANOVA showed a significant rat strain effect (F(1,94) = 352.10, p < 0.001) and drug effect 
(F(3,94) = 2.80, p < 0.05) on immobility in the FST.  Post-hoc analysis revealed that the 
WKY Sal rats spent more time immobile than Wistar Sal rats (Fig. 5.3c, p < 0.001). 
One-way ANOVA of the combined 48 h and 72 h (Group A + Group B) data revealed a 
significant drug effect (F(3,47) = 3.28, p < 0.05) on immobility in the FST.  Post-hoc 
analysis revealed that the WKY Sal rats spent less time immobile than WKY Ket-10 rats 
(p < 0.05, Fig 5.3c). 
Swimming 
Two-way ANOVA (rat strain and drug as factors) revealed a significant rat strain effect 
on swimming behavior in the FST at 48 h (F(1,47) = 155.00, p < 0.001) and 72 h (F(1,39) = 
128.80, p < 0.001) after the ketamine/saline injection, a rat strain × drug interaction (F(3,47) 
= 2.83, p < 0.05) at 48 h after the ketamine/saline injection and no significant drug 
treatment effect at 48 h and 72 h after the ketamine/saline injection.  Post-hoc analysis 
showed that the WKY Sal rats spent less time swimming than Wistar Sal rats at 48 h (Fig. 
5.4a) and 72 h (Fig. 5.4b) after the saline injection (p < 0.001). 
One-way ANOVA revealed a significant drug treatment effect (F(3,24) = 4.16, p < 0.05) on 
swimming in the FST at 48 h after the ketamine/saline injection.  Post-hoc analysis 
showed that the WKY Ket-10 rats spent less time swimming than WKY Sal rats at 48 h 
after the ketamine/saline injection (p < 0.05, Fig 5.4c). 
Since there was no difference between treated rat groups at 48 h and 72 h, the swimming 
for ketamine/saline-treated rat groups at 48 h and 72 h after ketamine/saline injection were 
combined (48 h + 72 h).  Furthermore, these were different groups of rats (Group A and 
Group B) and a t-test showed no significant difference in swimming behaviour at these 
two time points.  Two-way ANOVA showed a significant rat strain effect (F(1,94) = 290.80, 






p < 0.001) and no significant drug effect.  Post-hoc analysis revealed that the WKY Sal 
rats spent more time immobile than Wistar Sal rats (Fig. 5.4c, p < 0.001). 
 
Figure 5.3:  Immobility of WKY and Wistar rats in the FST following treatment with 
saline/ketamine.  Treatment with 10 mg/kg ketamine increased immobility of the combined WKY 
groups at (c) 48 h + 72 h (n = 10 – 17/group) in WKY rats with no effect on Wistar rats.  Treatment with 
5, 10 and 15 mg/kg ketamine had no effect on immobility of WKY and Wistar rats in the FST at (a) 48 h 
(n = 5 – 9/group) and (b) 72 h (n = 5 – 8/group) after saline/ketamine injection.    * WKY Sal 
significantly different from Wistar Sal, p < 0.001; ** WKY Sal significantly different from WKY Ket-












Figure 5.4:  Swimming behaviour of WKY and Wistar rats in the FST following treatment with 
saline/ketamine. Treatment with 10 mg/kg ketamine decreased swimming after (a) 48 h (n = 5 – 
9/group) in WKY rats without any drug effect in Wistar rats.  Treatment with 5, 10 and 15 mg/kg 
ketamine had no effect on swimming after (b) 72h (n = 5 – 8/group) and (c) at the combined time points 
(48 h + 72 h) (n = 10 – 17/group) in WKY and Wistar rats.  * WKY Sal significantly different from 
Wistar Sal, p < 0.001; ** WKY Sal significantly different from WKY Ket-10, p < 0.05; Tukey‟s post-hoc 













Two-way ANOVA (rat strain and drug as factors) revealed a significant rat strain effect on 
struggling behaviour in the FST at 48 h (F(1,47) = 204.30, p < 0.001) and 72 h (F(1,39) = 
61.53, p < 0.001) after the ketamine/saline injection and no significant drug treatment 
effect at 48 h and 72 h after the ketamine/saline injection.  Post-hoc analysis showed that 
the WKY Sal rats spent less time struggling than Wistar Sal rats at 48 h (Fig. 5.5a) and 72 
h (Fig. 5.5b) after the saline injection (p < 0.001). 
Since there was no difference between treated rat groups at 48 h and 72 h, the struggling 
for ketamine/saline-treated rat groups at 48 h and 72 h after ketamine/saline injection were 
combined (48 h + 72 h).  Furthermore, these were different groups of rats (Group A and 
Group B) and a t-test showed no significant difference in struggling behaviour of the two 
groups of rats at these two time points.  Two-way ANOVA showed a significant rat strain 
effect (F(1,94) = 290.80, p < 0.001) and no significant drug effect.  Post-hoc analysis 
revealed that the WKY Sal rats spent less time struggling than Wistar Sal rats (Fig. 5.5c, p 
< 0.001). 







Figure 5.5:  Struggling behaviour of WKY and Wistar rats in the FST following treatment with 
saline/ketamine. Treatment with 5, 10 and 15 mg/kg ketamine had no effect on struggling behaviour at 
(a) 48 h (n = 5 – 9/group), (b) 72 h (n = 5 – 8/group) and (c) at the combined time points (48 h + 72 h) (n 
= 10 – 17/group) in WKY and Wistar rats. * WKY Sal significantly different from Wistar Sal, p < 0.001; 
Tukey‟s post-hoc test.   Data presented as mean ± SEM. 
 
5.3.1.3 Ultrasonic vocalizations 
Frequency modulated calls 
The Kruskal-Wallis ANOVA revealed a significant difference between rat groups in FM 
calls on day -4 (H(7,N = 94) = 23.11, p < 0.01) before the ketamine/saline injection. Post-hoc 
analysis showed that WKY Sal rats vocalized less than Wistar Sal rats on day -4 before 
treatment (p < 0.05, Fig. 5.6a).  






Furthermore, the Friedman test for repeated measures revealed a significant difference in 
FM calls at different time points before and after treatment (Q = 17.86, p < 0.01).  Post-
hoc analysis showed that WKY rats on day -4 and day -3 before treatment vocalized less 
than at 29 h after ketamine/saline treatment (p < 0.01 and p < 0.05 respectively, Fig. 5.6).  
Flat calls 
The Kruskal-Wallis ANOVA showed a significant difference between rat groups in flat 
calls on day -4 (H(7,N = 94) = 22.43, p < 0.01) before ketamine/saline injection. Post-hoc 
analysis showed that WKY Sal rats vocalized less than Wistar Sal rats (p < 0.05, Fig. 
5.7a).   
The Friedman test for repeated measures revealed a significant difference in flat calls at 
different time points and after treatment (Q = 17.71, p < 0.01).  Post-hoc analysis showed 
that WKY rats on day -4 and day -3 before treatment vocalized less than at 29 h after 
ketamine/saline treatment (p < 0.01 and p < 0.05 respectively, Fig. 5.7). 
Total number of calls 
The Kruskal-Wallis ANOVA revealed a significant difference between rat groups in total 
number of calls (FM + flat calls) on day -4 (H(7,N = 94) = 24.03, p < 0.01) before 
ketamine/saline injection.  Post-hoc analysis showed that WKY Sal rats vocalized less 
than Wistar Sal rats (p < 0.05, Fig. 5.8a).  
The Friedman test for repeated measures revealed a significant difference in total number 
of calls at different time points before and after treatment (Q = 18.14, p < 0.01).  Post-hoc 
analysis revealed that WKY rats on day -4 and day -3 before treatment vocalized less than 
at 29 h after ketamine/saline treatment (p < 0.01 and p < 0.05 respectively, Fig. 5.8). 








Figure 5.6:  Number of FM USVs of WKY and Wistar rats treated with saline/ketamine. (a) WKY 
Sal vocalized less than Wistar Sal rats on day -4 and WKY rats before treatment on day -4 and day -3 
vocalized significantly less than (b) WKY at 29 h after ketamine/saline injection.  Ketamine treatment 
had no significant effect on the number of FM calls made by WKY and Wistar rats. * WKY Sal 
significantly different from Wistar Sal on day -4 before treatment, p < 0.05, ** WKY at 29 h after 
treatment significantly different from WKY on day -4 and day -3 before treatment; Dunn‟s multiple 
comparisons post-hoc test (n = 10 – 16/group). Data presented as median and interquartile range. 








Figure 5.7:  Number of flat USVs of WKY and Wistar rats treated with saline/ketamine. (a) WKY 
Sal vocalized less than Wistar Sal rats on day -4 and WKY rats before treatment on day -4 and day -3 
vocalized less than (b) WKY at 29 h after ketamine/saline injection. Ketamine treatment had no 
significant effect on the number of flat calls made by WKY and Wistar rats. * WKY Sal significantly 
different from Wistar Sal on day -4 before treatment, p < 0.05, ** WKY at 29 h after treatment 
significantly different from WKY on day -4 and day -3 before treatment; Dunn‟s multiple comparisons 
post-hoc test (n = 10 – 16/group). Data presented as median and interquartile range. 








Figure 5.8:  Total number of USVs of WKY and Wistar rats treated with saline/ketamine. (a) WKY 
Sal vocalized significantly less than Wistar Sal rats on day -4 and WKY rats before treatment on day -4 
and day -3 vocalized significantly less than (b) WKY at 29 h after ketamine/saline injection.  Ketamine 
treatment had no significant effect on the total number of calls made by WKY and Wistar rats. * WKY 
Sal significantly different from Wistar Sal on day -4 before treatment, p < 0.05, ** WKY at 29 h after 
treatment significantly different from WKY on day -4 and day -3 before treatment; Dunn‟s multiple 
comparisons post-hoc test (n = 10 – 16/group).  Data presented as median and interquartile range. 






5.3.2 Experiment 2:  Rapid effect of acute ketamine in Wistar-Kyoto rats 
5.3.2.1 Forced swim test 
Immobility 
Unpaired t-test showed no significant difference between WKY Sal and WKY Ket-10 rats 
in immobility in the FST (Fig. 5.9) 2 h after the ketamine/saline injection. 
 
 
Figure 5.9:  Immobility of WKY rats in the FST following treatment with saline/ketamine. 
Treatment with 10 mg/kg ketamine had no effect on immobility of WKY in the FST at 2 h after the 
ketamine/saline injection (WKY Sal, n = 13 and WKY Ket-10, n = 11).  Data presented as mean ± SEM. 
 
5.3.3 Experiment 3:  Sustained effects of acute ketamine in non-
maternally separated and maternally separated Sprague-Dawley rats 
5.3.3.1 Open field test 
Distance travelled 
Two-way ANOVA (MS and drug as factors) showed no significant effect of MS or drug 
on the total distance travelled by nMS SD and MS SD rats in the open field at 22 h (Fig. 
5.10a) and 46 h (Fig. 5.10b) after the ketamine/saline injection.  
Since there was no difference between treated rat groups at 22 h and 46 h, the distance 
travelled data for ketamine/saline-treated rat groups at 22 h and 46 h after ketamine/saline 






injection were combined (22 h + 46 h).  Furthermore, a t-test showed no significant 
difference in distance travelled by these two groups of rats at the time points tested (22 h 
and 46 h) after the ketamine/saline injection.  Two-way ANOVA revealed no significant 
MS or drug effect on distance travelled in the OFT (Fig. 5.10c). 
 
Figure 5.10:  Distance travelled by non-maternally separated and MS SD rats in the FST following 
treatment with saline/ketamine. Treatment with 15 mg/kg ketamine had no effect on distance travelled 
at (a) 22 h (n = 15 – 16/group), (b) 46 h (n = 15 - 17/group) and (c) at the combined time points (22 h + 
46 h) (n = 30 – 32/group) in nMS SD and MS SD rats.  Data presented as mean ± SEM. 
 
5.3.3.2 Forced swim test 
Immobility 
Two-way ANOVA (MS and drug as factors) showed no significant MS or drug effect on 
immobility in the FST at 48 h (analyzed by automated scoring, Fig. 5.11a and manual 






scoring, Fig. 5.12a) and 72 h (analyzed by automated scoring, Fig. 5.11b and manual 
scoring, Fig. 5.12b) after the ketamine/saline injection.   
Since there was no difference between treated rat groups at 48 h and 72 h, the immobility 
data for ketamine/saline-treated rat groups were also combined (48 h + 72 h).  
Furthermore a t-test showed no significant difference in immobility by the two treated rat 
groups at 48 h and 72 h after the ketamine/saline injection.  Two-way ANOVA showed no 
significant MS or drug treatment effect in the combined data obtained at 48 h + 72 h after 
ketamine/saline injection for automated scoring (Fig. 5.11c) and manual scoring (Fig. 
5.12c). 
 
Figure 5.11:  Immobility (automated scoring) of non-maternally separated and MS SD rats in the 
FST following treatment with saline/ketamine. Immobility in the FST obtained with ethovision 
(automated scoring).  Treatment with 15 mg/kg ketamine showed no effect on immobility after (a) 48 h (n 
= 15 – 16/group) and (b) 72 h (n = 15 – 17/group) and (c) at the combined time points (48 h + 72 h) (n = 
30 – 32/group) in nMS SD and MS SD rats.  Data presented as mean ± SEM. 







Figure 5.12:  Immobility (manual scoring) of non-maternally separated and MS SD rats in the FST 
following treatment with saline/ketamine. Immobility in the FST obtained with manual scoring.  
Treatment with 15 mg/kg ketamine showed no effect on immobility after (a) 48 h (n = 15 – 16/group) 
and (b) 72 h (n = 15 – 17/group) and (c) at the combined time points (48 h + 72 h) (n = 30 – 32/group) in 
nMS SD and MS SD rats.  Data presented as mean ± SEM. 
5.3.3.3 Ultrasonic vocalizations 
The Kruskal–Wallis ANOVA revealed no significant difference between ketamine/saline-
treated rat groups in isolation-induced FM calls (Fig. 5.13), flat calls (Fig. 5.14) and total 
number of calls (Fig. 5.15) at any of the times before or after the ketamine/saline 
injection.   
The Friedman test for repeated measures revealed no significant difference in FM calls, 
flat calls and total number of calls between nMS SD or MS SD rat groups at different time 
points before and after ketamine/saline injection. 








Figure 5.13:  Number of FM USVs of non-maternally separated and MS SD rats treated with 
saline/ketamine. (a) No significant difference between ketamine/saline-treated rat groups with FM calls 
found before treatment.  (b) Ketamine treatment had no significant effect on FM calls compared to saline 
treated nMS SD and MS SD rats (n = 10 – 14/group).  Data presented as median and interquartile range. 








Figure 5.14:  Number of flat USVs of non-maternally separated and MS SD rats treated with 
saline/ketamine. (a) No significant difference between ketamine/saline-treated rat groups with flat calls 
found before treatment.  (b) Ketamine treatment had no significant effect on flat calls compared to saline 
treated nMS SD and MS SD rats (n = 10 – 14/group).  Data presented as median and interquartile range. 
 









Figure 5.15:  Total number of USVs of non-maternally separated and MS SD rats treated with 
saline/ketamine. (a) No significant differences between ketamine/saline-treated rat groups found with 
total number of calls (FM + flat calls) before treatment.  (b) Ketamine treatment had no significant effect 
on total number of calls compared to saline treated nMS SD and MS SD rats (n = 10 – 14/group).  Data 
presented as median and interquartile range. 







The primary findings on the effects of ketamine in the WKY and MS SD rat models of 
depression showed (1) enhanced depression-like behaviour in WKY at 48 h and 72 h after 
ketamine injection and no effect on Wistar or MS SD rats and (2) no change in isolation-
induced USVs in WKY and MS SD rats.  
The WKY rats travelled a shorter distance than Wistar rats in the OFT thereby confirming 
previous results in chapter 2 and 3 showing reduced activity of WKY rats in the OFT.  
However, the rats remained unaffected by acute treatment of ketamine.  It was previously 
shown that ketamine produced hyperactivity immediately following acute treatment in 
rodents (Chatterjee et al. 2011; Hou et al. 2013; Imre et al. 2006).  When rats were tested 
in the light phase, acute treatment with ketamine (16 mg/kg) significantly increased 
locomotor activity that lasted for 20 min and returned to baseline after 40 min (Imre et al. 
2006).  Also in mice, acute treatment with ketamine increased locomotor activity after 10 
min at low subanaesthetic doses (5 – 25 mg/kg) (da Silva et al. 2010; Hou et al. 2013).  
However, most studies have reported no long-term effect of acute ketamine treatment on 
locomotor activity.  These studies showed that a single injection of ketamine (0.25 – 15 
mg/kg) had no effect on locomotor activity beyond 30 min after injection in rats 
(Akinfiresoye and Tizabi 2013; Garcia et al. 2008; Réus et al. 2011; Tizabi et al. 2012) or 
mice (Koike et al. 2011).  The current study is therefore in agreement with most studies 
showing that a low subanaesthetic dose of ketamine had no effect on activity in the OFT 
in rats.  However, taken together, these data highlight the importance of measuring the 
activity of rats following ketamine treatment in order to eliminate any possible false-
positives in the behavioural response to ketamine.  The effect of ketamine on immobility 
in the FST in WKY rats was therefore not a result of altered locomotor function.    
The present study confirmed the depression-like behaviour of WKY rats in the FST as 
described in chapter 2 and 3.  This was evidenced by increased immobility and decreased 
active swimming and struggling behaviours in the FST of WKY compared to Wistar rats. 
Furthermore, ketamine increased immobility and decreased active swimming behaviour of 
WKY rats in the FST without affecting Wistar rats.  The results with ketamine treatment 
are in contrast to numerous studies which showed that acute treatment with ketamine at 
doses similar to those used in the present study produced rapid and sustained 
antidepressant-like effects in rodents (Autry et al. 2011; Carrier and Kabbaj 2013; Garcia 
et al. 2008; Li et al. 2010; Maeng et al. 2008; Tizabi et al. 2012).  This was evidenced by 
decreased immobility in the FST at doses of 10 mg/kg and 15 mg/kg of ketamine at 1 h or 
24 h after injection in Wistar and SD rats (Garcia et al. 2008; Li et al. 2010).  The timing 






between the drug administration and test swim may be important for the response of 
ketamine in the FST as previously suggested (Gigliucci et al. 2013).  In these previous 
studies of SD and Wistar rats, ketamine was injected 1 h or 24 h before the test swim 
whereas in the current study ketamine was administered 48 h and 72 h before the 15-min 
pretest-swim.  However, acute treatment with ketamine 2 h before the test swim in 
experiment 2 was also unable to reduce the immobility in the WKY rats although the rats 
used in these previous studies (Garcia et al. 2008; Li et al. 2010) were different from the 
current study.  Indeed, the rat strain and dose of ketamine may also be an important 
consideration in the behavioural response to ketamine.  At a lower dose of 5 mg/kg, a 
previous study by Tizabi et al. (2012) showed an immediate and sustained antidepressant 
effect of ketamine in female WKY rats as evidenced by decreased immobility in the FST 
at a dose that had no effect in Wistar rats.  The decreased duration of immobility in the 
FST at a dose of 5 mg/kg lasted up to 1 week after injection of ketamine in female WKY 
rats (Tizabi et al. 2012).  However, the current study was unable to show sustained 
antidepressant effects with a low dose of 5 mg/kg ketamine in male WKY rats in the FST.  
However, in male WKY rats, chronic treatment with ketamine for 10 days at a lower dose 
of 0.5 mg/kg reduced the immobility at 20 - 22 h after treatment (Akinfiresoye and Tizabi 
2013).  Therefore, the higher doses in the current study compared to the study by 
Akinfiresoye and Tizabi (2013) could have contributed in the lack of an antidepressant 
effect in the FST.   Furthermore, the study by Tizabi et al. (2012) and Akinfiresoye and 
Tizabi (2013) followed a different methodology.  For example, the behavioural 
experiments were performed in the rats‟ dark phase when they were more active.  It was 
previously shown that rats displayed higher levels of immobility in the FST during their 
dark phase (Kelliher et al. 2000) which would allow for easier determination of reduction 
in immobility.  Furthermore, the FST was performed without a pretest-swim session 
which could account for differences in antidepressant response (Borsini et al. 1989).  
Also, the acute ketamine study by Tizabi et al. (2012) was performed in female WKY rats.  
It has been previously shown that female rats were more sensitive to acute treatment with 
ketamine than male rats (Carrier and Kabbaj 2013).  They showed that acute ketamine 
treatment at a low dose of 2.5 mg/kg reduced the duration of immobility in the FST in 
female SD rats but was found to be ineffective in male SD rats (Carrier and Kabbaj 2013).  
Therefore, the lack of ketamine response in male WKY rats in the current study may be 
further explained by the difference in the acute antidepressant-like response in the FST 
between male and female rats. 
At high doses of 30 mg/kg – 100 mg/kg, sub-chronic treatment with ketamine for 5 days 
or more, increased duration of immobility in the FST in naïve rodents (Chatterjee et al. 






2011; Chindo et al. 2012).  In Wistar rats, sub-chronic treatment with ketamine for 5 days 
at a dose of 30 mg/kg or 50 mg/kg enhanced duration of immobility in the FST at 24 h 
after treatment (Chindo et al. 2012).  In agreement with Chindo et al. (2012), acute 
treatment with ketamine in the current study had no effect on immobility in the FST in 
Wistar rats.  However, the WKY rats in the current study appeared to be more sensitive to 
higher doses of ketamine-induced immobility in the FST.  The enhanced immobility 
induced by ketamine may possibly be related to the neurochemical disturbances in the 
WKY rats.  Previous studies showed that male WKY rats have reduced NMDA receptor 
function as measured by lower density of NMDA receptors in the substantia nigra, 
striatum, NAc, hippocampus, anterior cingulate cortex and PFC compared to Wistar rats 
(Lei and Tejani-Butt 2010; Lei et al. 2009).  However, no difference in NMDA receptor 
density in the hippocampus was found in female WKY compared to Wistar rats (Tizabi et 
al. 2012).  Furthermore, ketamine is a non-competitive antagonist of the NMDA receptor 
(Harrison and Simmonds 1985) and has been shown to regulate glutamate, dopamine and 
serotonin release as measured by microdialysis (Lindefors et al. 1997; Moghaddam et al. 
1997; Westerink et al. 1998).  Therefore, dysfunction of this receptor may further alter 
neurotransmission.  It is possible that together with the reduced NMDA receptor function 
in the various brain areas in WKY rats, ketamine may have further blocked NMDA 
receptor function and therefore enhanced the duration of immobility as previously found 
with a chronic high dose of ketamine in naïve rats. 
High frequency USVs have been postulated as an index of the rat‟s positive emotional 
state (reviewed in Burgdorf et al. 2011; Knutson et al. 2002) as well as providing a way of 
communication during social interaction or anticipation of interaction (Brudzynski and 
Pniak 2002; Willey et al. 2009).  However, these two functions are not necessarily 
unrelated since USVs can also convey specific information associated with the emotional 
state of the rat (Brudzynski and Pniak 2002; Wohr et al. 2008).  In the current study, the 
isolation-induced USVs in WKY rats were lower at -4 days and -3 days before treatment 
compared to 29 h after treatment.  However, the number of USVs in Wistar rats remained 
unaffected before and after treatment.  Previous studies showed that rats required 
habituation to the experimental conditions before emitting stable levels of USVs (Knutson 
et al. 1998; Mällo et al. 2007).  It therefore appeared that the WKY rats became more 
gradually accustomed to the USV procedure than Wistar rats before treatment so that 
differences in USVs between WKY and Wistar rats were shown on the first day of USV 
testing.  Another possibility may originate from the fact that rats were immediately 
rejoined with the cage mate(s) following isolation-induced USV testing.  It is therefore 
plausible that WKY rats might have learned over time to anticipate reconnection with the 






cage mate(s) after USV testing.  A recent study showed that rats emitted 50-kHz USVs 
(FM and flat calls) during food cue presentation and that the number of USVs increased 
across days in response to the food cues (Buck et al. 2014).  Similarly, other studies also 
reported increased number of 50-kHz USVs across days in response to rewarding cues 
such as olfaction from other rats (Bialy et al. 2000; Brudzynski and Pniak 2002; Burgdorf 
et al. 2000).  Therefore, the increased number of isolation-induced USVs (FM, flat and 
total number of calls) from baseline (-4 and -3 days before treatment) to treatment (at 29 h 
after treatment) in WKY rats may have resulted from cues of olfaction from the home 
cage to anticipate reconnection with the cage mate(s).  
Ketamine treatment had no effect on the FM calls, flat calls and total number of calls in 
WKY and Wistar rats.  Previous studies showed that NMDA antagonists such as ketamine 
and MK-801 decreased 50-kHz USVs therefore suggesting a role of glutamate in the 
production of USVs during social signalling (Bialy et al. 2000; Brudzynski and Pniak 
2002; Nikiforuk et al. 2013).  This was evidenced by a study showing that acute treatment 
with ketamine at a dose of 20 mg/kg decreased 50-kHz USVs during social interaction 30 
min after treatment (Nikiforuk et al. 2013).  Furthermore, the NMDA antagonist, MK-801 
(0.1 mg/kg intraperitoneal or 0.6 µg intracerebral), reduced 50-kHz USVs that were 
emitted by a rat during repeated exposure to a cage that was previously visited by other 
rats or before introduction of a female rat (Bialy et al. 2000; Brudzynski and Pniak 2002).  
However, USVs in the current study were measured long after treatment (5 h and 29 h) at 
lower doses (5 mg/kg – 15 mg/kg) compared to the previous study by Nikiforuk et al. 
(2013).  Also, the context in which USVs were recorded was different, since the USVs 
recorded from their study were measured during social interaction whereas USVs in the 
current study were measured during social isolation, which could account for the 
difference in findings between the studies.   
The aim of experiment 3 was to further investigate the effects of ketamine in the MS rat 
model of depression.  MS showed no effect on immobility in the FST in SD rats.  
Previous studies reported that MS in early life produced depression-like behaviour in adult 
rats as evidenced by increased immobility in the FST (Dimatelis et al. 2012b; Lambás-
Señas et al. 2009; Lee et al. 2007; Ryu et al. 2009).  The results of the current study are 
therefore in contrast to these studies.  However, some studies also reported no effect of 
MS during early life on immobility in the FST (Marais et al. 2008; Nam et al. 2014; 
Piubelli et al. 2011) or a decreased duration of immobility in the FST (Kwak et al. 2009).  
These inconsistencies reported may be related to methodological differences between 
studies.   Indeed, there is an ongoing discussion on the various factors leading to the 






inconsistencies of data reported between previous studies (Lehmann and Feldon 2000; 
Vetulani 2013).  For example, the most common differences between studies are the 
duration of MS procedure, frequency of separations, time point of MS exposure during 
development and choice of control group.  However, a previous study using the exact 
same MS procedure, showed that MS on P2 until P14 for 3 h daily, increased the duration 
of immobility in the FST at P67 (Dimatelis et al. 2012b).  In the current study, rats were 
handled from P60 - P73 during USV testing and injections that may have reduced their 
depression-like behaviour.  Repeated handling has previously been shown to result in rats 
being less susceptible to stress-induced depression-like behaviour in later life (Hsu et al. 
2003; Silveira et al. 2011) as well as reducing their anxiety (Costa et al. 2012; Schmitt and 
Hiemke 1998).          
Furthermore, ketamine showed no effect on immobility in the FST of MS rats.  These 
results are in contrast to a previous study showing that the immobility of MS Wistar rats 
in the FST was reversed by chronic treatment with a subanaesthetic dose of ketamine (15 
mg/kg) at 1 h after treatment (Réus et al. 2013).  Although ketamine was administered at a 
similar dose, rats in the current study were treated acutely and the FST was conducted 
much later (48 h and 72 h) which might explain the differences in behavioural findings.  
Also, the study by Réus et al. (2013) showed that ketamine did not affect immobility of 
control rats in the FST.  Since the immobility of the MS rats was similar to the control 
rats, it is therefore possible that ketamine treatment was unable to further reduce the 
immobility in SD rats. 
Similar to WKY and Wistar rats, ketamine had no effect on the number of USVs (FM, flat 
and total number of calls) in SD rats. However, the results in this study are in contrast to 
the previous study that measured USVs at 30 min after ketamine treatment during social 
interaction in SD rats (Nikiforuk et al. 2013).  Although the dose of 15 mg/kg ketamine 
used in the current study (experiment 3) was very similar to the study by Nikiforuk et al. 
(2013), USV testing was performed at 5 h and 29 h after ketamine treatment.  Therefore, 
similar to experiment 1, USV testing in SD rats in the current study was measured at a 
longer time after treatment as well as during social isolation opposed to social interaction 
which may explain the different results obtained in the studies. 
In conclusion, WKY rats were unresponsive to the rapid and sustained antidepressant 
effects of an acute subanaesthetic dose of ketamine but instead more sensitive to the 
ketamine-induced immobility at a higher dose possibly because the NMDA receptor 
function was already reduced.  Therefore, the WKY rat may be a useful model to study 
treatment-resistant depression.  Furthermore, ketamine had no antidepressant-like effect in 






MS SD and Wistar rats since these strains did not represent a model for depression.  
Therefore, the rat strain or model as well as the dose and duration of ketamine treatment 





Chapter 6  
General discussion 
 
In this chapter, the key findings of the study will be summarized and novel findings 
further discussed. 
6.1 Summary of results 
Since the results of the current study are presented in different chapters, a summary of the 
main findings will be provided and their implications discussed.  This study successfully 
achieved all the aims through multiple objectives in order to establish a more robust WKY 
and MS model of depression as outlined in Chapter 1, section 1.6, as follows: 
▪ Chapter 2:   When comparing depression-/anxiety-like behaviour in WKY 
substrains, the WKY/NCrl rats displayed higher immobility levels in the FST and 
less activity in the OFT compared to the WKY/NHsd substrain and Wistar control 
strain, which is consistant with its use as a model of depression.  Furthermore, 
chronic desipramine treatment (15 mg/kg) of WKY/NCrl rats attenuated the 
depression-like behaviour as evidenced by decreased immobility and increased 
active struggling behaviour in the FST.  However, desipramine had no effect on 
opioid receptors (MOR and KOR) and TH in the NAc or PFC in WKY/NCrl rats.     
▪ Chapter 3:  Similar to normally reared WKY/NCrl rats, MS WKY/NCrl rats 
displayed reduced activity in the FST and OFT and spent more time in the center 
zone of the EPM.  Furthermore, MS WKY/NCrl rats subjected to early-life MS, 
displayed anxiety-like behaviour as presented by increased time spent in the closed 
arms of the EPM compared to normally reared WKY/NCrl rats.  Moreover, both 
MS WKY/NCrl and WKY/NCrl rats emitted more USVs than Wistar rats following 
separation from the cage mate(s).  Chronic desipramine treatment not only 
decreased depression-like behaviour of WKY rats, but also increased the time spent 
in the open arms of the EPM by MS WKY/NCrl, indicative of an anxiolytic effect.  
Furthermore, desipramine treatment decreased FM USVs in both MS WKY/NCrl 
and WKY/NCrl rats.  Biochemical studies showed no effect of desipramine on 
serotonin levels and p-ERK in the PFC or dopamine concentration and opioid 
receptors in the NAc of normally reared WKY/NCrl and MS WKY/NCrl rats.  
However, desipramine treatment increased p-GSK3β in the PFC of  




WKY/NCrl rats but not in MS WKY/NCrl rats, therefore indicating that this effect 
of desipramine was blocked by MS.    
▪ Chapter 4:  The stress of MS increased depression-like behaviour in SD rats as 
evidenced by increased immobility and decreased active swimming behaviour in 
the FST.  Restraint stress did not exaggerate the effect of MS on depression-
/anxiety-like behavior of MS rats in the FST.  Further biochemical studies to 
determine changes in the brain associated with the depression-like behaviour of MS 
SD rats subjected to restraint stress, revealed no effect of MS, restraint stress, or 
MS together with restraint stress, on levels of BDNF in the ventral hippocampus.  
However, proteomic analysis of the PFC revealed a decrease in structural proteins 
(actin-related) in MS rats and non-separated rats subjected to restraint stress as well 
as a decrease in mitochondrial energy-related proteins in MS rats with or without 
subsequent exposure to restraint stress and non-separated rats subjected to restraint 
stress.  Furthermore, rats subjected to both MS and restraint stress displayed a 
decrease in proteins involved in protein synthesis and an increase in proteins 
involved in protein degradation   
▪ The study in Chapter 5 provides novel evidence in that it shows that 10 mg/kg of 
ketamine increased immobility of WKY/NCrl rats in the FST at 48 h and 72 h after 
treatment which may be indicative of a disturbance in glutamate function.  
Ketamine had no effect on the MS SD rats and Wistar control rats.   
6.2 Novel findings and conclusion 
The novel key findings related to the rat models of depression (normally reared 
WKY/NCrl, MS WKY/NCrl, MS SD rats and MS SD rats subjected to restraint stress) 
will be further discussed. 
6.2.1 Comparison of WKY/ NCrl and maternally separated WKY/NCrl as 
rat models of depression/anxiety 
WKY/NCrl 
This is the first study that measured depression- and anxiety-like behaviour in WKY 
substrains in order to characterize the WKY as a rat model of depression/anxiety (Chapter 
2).  The WKY/NCrl substrain was selected as the most suitable model of depression-like 
behaviour according to its high levels of immobility in the FST and reduced activity in the 
OFT.  WKY/NCrl rats displayed increased immobility in the FST and reduced activity in 
the OFT compared to Wistar rats, similar to results reported in Chapter 3 and Chapter 5.   




However, neither of the WKY substrains displayed anxiety-like behaviour in the EPM.  A 
previous study comparing WKY substrains as suitable controls for the spontaneously 
hyperactive rat (SHR) model of attention-deficit/hyperactivity disorder (ADHD), showed 
that WKY/NCrl displayed no overactivity, compared to WKY/NHsd in a visual 
discrimination task, which suggested that WKY/NCrl  may model an inattentive subtype 
of ADHD (Sagvolden et al. 2008).  In addition, most of the studies that specified the 
substrain of WKY, showed depression-like behaviour in the FST and OFT in WKY 
obtained from Charles River Laboratories (Rubalcava and Lucki 2000; Tejani-Butt et al. 
2003; Nam et al. 2014; Lahmame and Armario 1996).  Therefore, this study provides 
novel evidence for the WKY/NCrl as a more appropriate substrain than the WKY/NHsd 
to model the depression-like behaviour.     
In further characterization of the WKY/NCrl as a model of depression, its response to 
desipramine treatment in terms of immobility in the FST was determined (Chapter 2).  
This study provides novel evidence to show that a 15-min pretest-swim is necessary for 
desipramine (15 mg/kg) to reverse the depression-like behaviour of  WKY/NCrl  in the 
FST.  Since WKY rats exhibit spontaneous immobility in the FST, it was previously 
considered that no pretest-swim is necessary to induce such behaviour (Tizabi et al. 2012).  
However, the dose of antidepressant drug, duration of treatment (sub-chronic or chronic) 
and protocol of FST (inclusion of a pretest-swim or single swim session) are all important 
factors to consider when determining the response of WKY/NCrl rats to desipramine in 
the FST.  Previous studies that measured the antidepressant effect of desipramine in 
WKY/NCrl rats, showed that desipramine had no effect on immobility in a single FST 
session at a sub-chronic dose (5 mg/kg – 15 mg/kg) but decreased immobility in the FST 
at a higher dose of 25 mg/kg (Lahmame and Armario 1996).  However, when WKY/NCrl 
rats were habituated to a pretest-swim in the FST, sub-chronic or chronic treatment with 
desipramine (5 mg/kg – 20 mg/kg) was effective in reversing the immobility (Lopez-
Rubalcava and Lucki 2000; Tejani-Butt et al. 2003).  Since learning and memory 
consolidation has been suggested to be required for immobility during the 5-min test swim 
(Campus et al. 2015), it may be speculated that the WKY/NCrl rats have impaired 
memory consolidation because of their reduced NMDA receptor density in the striatum, 
substantia nigra, NAc, hippocampus (CA1 region) and cingulate cortex (Lei and Tejani-
Butt 2010; Lei et al. 2009).  The immobility in the WKY rats may also reflect an 
increased stress response as evidenced by a previous study showing that increased 
immobility of WKY rats in the FST was accompanied by increased ACTH and 
corticosterone secretion (Rittenhouse et al. 2002).     




Chronic desipramine treatment had no effect on TH, dopamine and serotonin levels, 
opioid receptors (KOR and MOR) or p-ERK in the NAc or PFC of WKY/NCrl rats 
(Chapter 2 and 3).  However, desipramine treatment increased p-GSK3β in the PFC of 
WKY/NCrl rats (Chapter 3).  The latter provides novel evidence for the mechanism of 
action of desipramine and the role of p-GSK3β (inactive form of GSK3β) in possibly 
mediating the decrease in depression-like behaviour in WKY/NCrl rats.  GSK3β play a 
key role as regulator of cell survival and apoptosis and over-expression of GSK3β has 
been linked to apoptotic cell death in neuronal cell cultures (Beurel and Jope 2006; 
Crowder and Freeman 2000; Liu 2014).  The mechanism by which desipramine may 
affect p-GSK3β is still unknown and needs to be further explored.  GSK3β is regulated by 
several mehanisms that include direct or indirect modulation by the serotonergic, 
dopaminergic neuropsychiatric drugs and lithium, the Wingless (Wnt) signalling pathway, 
protein kinase A, protein kinase C and Akt (Crowder and Freeman 2000; Polter and Li 
2011; Sutton and Rushlow 2011).  Neuropsychiatric classes of drugs such as 
antipsychotics (haloperidol and clozapine), mood stabilizers (lithium and valproic acid) 
and antidepressant drugs (imipramine and fluoxetine) regulate GSK3β activity by 
increasing Akt signalling (increased phosphorylated Akt and p-GSK3) in the PFC and 
striatum (Sutton and Rushlow 2011).  However, regulation of the Wnt pathway is specific 
to antipsychotics (Sutton and Rushlow 2011).  It is well recognized that chronic 
antidepressant drug treatment, including desipramine treatment, enhance BDNF 
neurotransmission (Castrén et al. 2007; Nibuya et al. 1995) and consequently may 
increase phosphorylation of GSK3β through increasing activity in the 
phosphatidylinositol-3 kinase (PI3K)/Akt pathway (Johnson-Farley et al. 2006; Smillie et 
al. 2013).  However, further studies are needed to determine the involvement of the 
PI3K/Akt pathway and other components such as the mammalian target of rapamycin 
(mTOR), in order to study the role of GSK3β in the depression phenotype of WKY/NCrl 
rats and antidepressant mechanism of action of desipramine treatment.  Studies to show 
the involvement of p-GSK3β may include using GSK3 knock-in mice where 
phosphorylatioin of GSK3β is blocked,  This is achieved by altering the phosphorylation 
site (Ser9 replaced by mutant protein) on GSK3β.  GSK3 knock-in may diminish the 
reduced immobility in the FST following desipramine treatment as previously shown with 
other antidepressant drugs (Polter et al. 2012).  This may reveal whether p-GSK3β plays a 
role in the mechanism of action of desipramine.    
Maternally separated WKY/NCrl 
In addition to the depression-like behaviour, WKY/NCrl rats subjected to MS enhanced 
the potential of WKY rats to serve as a model of anxiety-like behaviour (Chapter 3).    




Previous studies showed that WKY rats displayed anxiety-like behaviour only in some of 
the behavioural tests such as a longer latency to feed in the novelty-supressed feeding test 
and increased freezing in the OFT (Braw et al. 2006; Malkesman et al. 2005; Yamada et 
al. 2013).  However, they did not exhibit any anxiety-like behaviour in the EPM (Braw et 
al. 2006; Getachew et al. 2008; Nam et al. 2014; Pardon et al. 2002).  Therefore, this 
study provides novel evidence in showing that the WKY/NCrl rats subjected to MS may 
be useful as a model for depression- and anxiety-like behaviour. 
In line with the efficacy of desipramine to treat symptoms of depression and anxiety, MS 
WKY/NCrl rats responded to the antidepressant-like effects and anxiolytic effect of 
desipramine in the FST and EPM (Chapter 3).  Furthermore, desipramine treatment 
decreased the duration that MS WKY/NCrl rats spent in the center area of the EPM, 
indicative of reduced indecisiveness; an effect that was not observed in WKY/NCrl rats.  
Therefore, WKY/NCrl rats subjected to MS and treated with desipramine provide more 
evidence for WKY/NCrl rats subjected to MS to model depression/anxiety.  Desipramine 
had no effect on dopamine and serotonin concentration, opioid receptors (KOR and 
MOR), p-ERK or p-GSK3β in the NAc or PFC of MS WKY/NCrl rats (Chapter 3).  Since 
desipramine treatment increased p-GSK3β in normally reared WKY/NCrl rats and not in 
MS WKY/NCrl rats, it may be suggested that MS blocked this effect and therefore 
suggests that other pathways or brain areas may be involved in the depression-/anxiety-
like phenotype of MS WKY/NCrl rats.     
Ultrasonic vocalizations 
High frequency USVs in adult rats may indicate a positive affective state and/or may 
function as a social signal (Brudzynski and Pniak 2002; Mällo et al. 2007).  In chapter 3, 
rats emitted high frequency USVs during a situation considered stressful (social isolation).  
Furthermore, the number of USVs was greater in both WKY/NCrl and MS WKY/NCrl 
rats compared to Wistar rats.   Therefore, the 50-kHz USVs emitted in response to 
removal of the cage mate(s) in the present study, are in contrast to the positive emotion 
frequently associated with 50-kHz USVs (Burgdorf et al. 2007; Burgdorf et al. 2008; 
Panksepp and Burgdorf 2000).  However, high frequency USVs have also been found in 
situations generally not seen as appetitive such when rats were singly tested in a test arena 
previously visited by other rats, when rats were reunited following separation or when 
isolated from the cage mate(s), indicative of a communicational function (Brudzynski and 
Pniak 2002; Wohr et al. 2008).  Therefore, it may be suggested that the USVs in this study 
function to serve a communicational role in signalling the need to re-connect with the 
cage mate(s).  Since FM calls play a role in emotion (Burgdorf et al. 2008) whereas flat 




calls have a communicational function in rats (Wohr et al. 2008), the FM calls that were 
affected by the social isolation in the present study may also convey information 
regarding the emotional state of the rats.  Furthermore, desipramine treatment decreased 
FM calls in WKY rats which further supports an emotional function.  In the current 
context of the study, USVs may therefore function to signal emotional information to the 
cage mate(s) during social isolation regarding the need to re-connect.  Furthermore, the 
high number of USVs in WKY rats may be an additional marker for their depression 
phenotype although further USV studies are needed in different experimental conditions 
(e.g. other stressors) to provide further support.   
It should be noted that the strain differences (WKY and Wistar rats) in USVs in Chapter 3 
were only evident while they were being treated with desipramine (after 18 days of 
habituation).  It could be that the WKY and Wistar rats needed time to habituate to the 
handling and testing conditions before differences between WKY and Wistar rats became 
apparent.  However, no significant difference in the number of USVs was found between 
WKY and Wistar rats when they were habituated and baseline USVs were measured at an 
older age (P60-P69 in Chapter 5, compared to rats at P52-P59 in Chapter 3).  Also, rats in 
Chapter 5 were handled for a shorter period before USVs were measured during treatment 
(from 10 days after habituation started).  Therefore, the USVs may be influenced by the 
experimental procedure.  
6.2.2 Maternally separated Sprague-Dawley rats subjected to restraint 
stress as a model of depression  
It is well recognized that early life trauma results in hyperactivity of the HPA axis and 
symptoms of depression when individuals are confronted with stressful life events 
(Juruena 2014; Shapero et al. 2014; Slavich et al. 2011).  Similarly, animal studies have 
shown that the stress of MS in early life potentiates the HPA axis response to various 
types of stressors and is associated with the development of depression-/anxiety-like 
behaviour in adulthood (Eiland and McEwen 2012; Marais et al. 2008; Uchida et al. 
2010).  MS SD rats were chosen for BDNF and proteomic analysis (Chapter 4) since they 
represent a more general widely accepted rat model of depression and it was important to 
gain further insight into the molecular changes in this model.  Consistent with its use as a 
model of depression, SD rats subjected to MS displayed depression-like behaviour in the 
FST.  However, in agreement with the previously reported variability of the effects of MS, 
the study in Chapter 5 did not reveal any effect of MS on depression-like behaviour in the 
FST.  The variability of this model has been extensively reviewed with difference in 
frequency and timing of separation, gender differences and choice of control that all 




contribute in the variability of results between studies (Vetulani 2013).  Although a 
similar MS protocol was followed in the studies in Chapter 4 and 5, rats were handled 
significantly more in the study in Chapter 5 due to USV testing.  This may have had an 
effect on their emotionality which may have attenuated difference between the MS and 
non-maternally separated rats. 
Restraint stress did not alter depression-like behaviour of MS rats in the FST, nor did it 
induce anxiety-like behaviour in the EPM (Chapter 4).  This is in contrast to previous 
studies that showed that additional stress in adulthood in MS rats potentiated their 
depression-/anxiety-like behaviour (Eiland and McEwen 2012; Marais et al. 2008; Uchida 
et al. 2010).  However, these studies showed that MS on its own did not evoke depression-
/anxiety-like behaviour but MS rats were more susceptible to developing depression-
/anxiety-like behaviour when subjected to chronic stress in adulthood (Marais et al. 2008).  
Since MS on its own produced depression-like behaviour in the current study (Chapter 4), 
it may be suggested that restraint stress, that has similar effects on the HPA axis and acts 
on the same signalling pathways involving BDNF, was prevented from exerting its 
depression-like effects.     
A proteomic analysis of the PFC (Chapter 4) revealed that MS and restraint stress affected 
a number of proteins from various functional groups.  The proteins affected were related 
to structure, energy metabolism, neurotransmission, protein synthesis and degradation.  
Rats subjected to MS or restraint stress had decreased structural proteins associated with 
actin (actin related protein 2/3 complex, alpha II spectrin, ARP10 actin-related protein).  
Furthermore, a decrease in energy-related proteins was found in MS rats, restraint stressed 
rats and MS rats subjected to restraint stress.  This is in line with a previous study that 
found reduced structure- and energy-related proteins in the PFC in response to MS stress 
(Dimatelis et al. 2013).  The reduced energy-related proteins in the PFC found in this 
study and increased energy-related proteins in the ventral hippocampus (Marais et al. 
2009) may possibly be related to clinical studies of depression that showed 
hypometabolism in the PFC and hypermetabolism in limbic brain areas (Salerian and 
Altar 2012).  In addition, the current study showed that MS rats subjected to restraint 
stress had a decrease in proteins involved in protein synthesis (Protein Tardbp, 40S 
ribosomal protein S12, RCG45615 and Tyrosine--tRNA ligase) and an increase in 
proteins involved in protein degradation (F-box only protein 2 and COP9).  However, the 
current study did not reveal similarity in the protein profile between MS and MS rats 
subjected to restraint stress as well as differences between MS rats with or without stress 
and non-maternally separated rats subjected to restraint stress.  Therefore, the changes in 
proteins that were identified in the PFC of MS rats with or without stress may not be 




related to their depression-like behaviour.  For example, the structural proteins affected in 
MS rats were not affected in MS rats subjected to restraint stress.  However, the energy-
related proteins were similarly reduced in MS rats with or without restraint stress but were 
also in non-maternally separated rats subjected to restraint stress and therefore may rather 
indicate an effect of stress on the PFC.  The lack of similarity in the protein profile 
between MS rats and MS rats subjected to restraint stress may be due to the fact that they 
were analysed separately (8-plex vs 4-plex) which accounted for different proteins being 
identified. 
In conclusion, the effect of MS on depression-like behaviour was found to be inconsistent 
between studies in Chapter 4 and 5, possibly due to increased handling of the rats in 
Chapter 5, highlighting the need for the MS protocol to be standardized across studies.  
However, proteomic results in the MS rats with or without restraint stress revealed 
important proteins affected that are related to structure, energy metabolism and proteins 
involved in protein synthesis and degradation, which may be the effect of stress on the 
PFC and not related to their depression-like behaviour.   
6.2.3 The effect of ketamine in WKY/NCrl and maternally separated 
Sprague-Dawley models of depression 
Ketamine at subanaesthetic doses has shown rapid and sustained antidepressant effects in 
patients with depression (Larkin and Beautrais 2011; Zarate et al. 2006) as well as in 
animal models of depression at doses of 5 mg/kg - 15 mg/kg (Koike et al. 2011; Tizabi et 
al. 2012).  However, chronic ketamine treatment for 5 days at higher doses (30 mg/kg – 
100 mg/kg) induces depression-like behaviour in naïve rats in the FST (Chatterjee et al. 
2011; Chindo et al. 2012; Hou et al. 2013).  In the current study (Chapter 5), acute 
ketamine increased immobility in the FST at 48 h and 72 h after treatment at a dose (10 
mg/kg) that normally showed antidepressant effects in other rat models of depression 
(Garcia et al. 2008; Koike et al. 2011; Li et al. 2011).  Therefore, this study provides novel 
evidence showing that ketamine treatment in WKY rats at a dose of 10 mg/kg potentiates 
their depression-like behaviour in the FST.  This is the first study that measured the effect 
of acute treatment of male WKY rats with ketamine.   A previous study in female WKY 
rats showed that acute ketamine treatment had a rapid and sustained antidepressant effect 
at a lower dose of 5 mg/kg, measured as reduced immobility in the FST.  However, 5 
mg/kg of ketamine in the current study had no effect on male WKY rats in the FST at 48 h 
or 72 h after injection.  Therefore, the current study provides evidence of ketamine-
induced immobility in male WKY rats which may possibly be related to their disrupted 
glutamate neurochemistry.  This is supported by studies showing reduced NMDA receptor 




density in male WKY rats at basal levels in various brain areas such as the substantia 
nigra, striatum, NAc, hippocampus, anterior cingulate cortex and PFC compared to Wistar 
rats (Lei and Tejani-Butt 2010; Lei et al. 2009).  However, no difference in NMDA 
receptor density was reported in female WKY rats in the hippocampus (Tizabi et al. 
2012).  It may therefore be concluded that by further blocking the NMDA receptor in 
WKY rats, with reduced NMDA receptor density, ketamine treatment may ultimately lead 
to effects that are similar to the effects exhibited by naïve rats treated with high doses of 
ketamine.   
This study further supports suggestions that WKY rats are selective in their response to 
antidepressant drug treatment and only responsive to the antidepressant effects of 
desipramine in the current study (Chapter 2 and 3).  The response to the antidepressant 
effects of desipramine would suggest that a noradrenergic mechanism is involved in the 
depression-like behaviour of WKY rats.  Indeed, consistent with the monoamine 
hypothesis, previous studies showed reduced noradrenaline levels in several brain areas of 
WKY rats (ventral hippocampus, NAc, dorsal raphe nuclei, lateral hypothalamus and 
locus coeruleus) compared to Wistar or SD rats (Scholl et al. 2010) that may be implicated 
in their depression phenotype.     
6.2.4 Conclusion     
In summary, this study provides novel evidence showing that WKY/NCrl is a more 
appropriate WKY substrain to model depression and when subjected to MS provides a 
more robust model of depression/anxiety that responds to the antidepressant and 
anxiolytic effects of desipramine in the FST and EPM.  Furthermore, desipramine 
treatment increased p-GSK3β in the PFC of normally reared WKY/NCrl rats, an effect 
blocked by MS which provides novel evidence for the mechanism of action of 
desipramine and role of p-GSK3 β in possibly mediating the decrease in depression-
/anxiety-like behaviour of WKY/NCrl rats.   The USVs in WKY rats appeared to reflect 
signalling to establish social contact with the cage mate(s) and the high number of 
isolation-induced USVs in WKY compared to Wistar rats may reflect a marker for their 
depression phenotype that was attenuated by desipramine treatment.  The MS SD as a 
comparator model provides evidence for depression-like behaviour in the FST, but 
findings were inconsistent between experiments, possibly due to increased handling of the 
rats during repeated recording of isolation-induced vocalizations.  In addition, restraint 
stress showed no effect on the depression-like behaviour of MS rats in the FST but 
revealed important proteins related to energy metabolism and protein synthesis and 
degradation that were affected.  The WKY rats were selective in their response to 




antidepressant drug treatment, since ketamine showed no antidepressant effects in the FST 
but increased their immobility which may be related to a dysfunction of NMDA receptors.     
The above findings could be extended into further experiments of in vivo 
chronoamperometric measurements of drug-induced changes of glutamate, noradrenaline 
and dopamine in the NAc, PFC or hippocampus in order to further elucidate the 
mechanisms underlying the depression-like behaviour.  Furthermore, electrochemical 
measurements of these neurotransmitters in different subareas of the PFC, that suggest 
disparate functionality, may provide more insight in the neuropathology of depression.    
For example, the ventromedial PFC has been associated with cognitive or executive 
functions whereas the dorsolateral PFC with emotional functions (Koenigs and Grafman 
2009).  Proteomic analysis could also be followed up with a more targeted analysis of 
specific molecules of interest in different brain regions such as the hippocampus and 
nucleus accumbens.  Future behavioural and neurochemical studies could also compare 
male and female rats.   Ketamine showed no antidepressant effect in the FST of male 
WKY rats.  It may therefore be useful to replicate the antidepressant effect of ketamine in 
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Additional proteomic results 
 
Table A1 (8-plex) and A2 (4-plex) contains all the proteins identified in Ctr, RS, MS and 
MS+RS rat groups in Chapter 4.  Proteins are divided in different functional groups 
(cytoskeletal, energy metabolism, neurotransmission, proteins synthesis, proteins 
degradation and other) and further subdivided according to their specific function in that 
group.  Values for duplicate rat groups were averaged and MS, RS and MS+RS rat groups 
expressed as fold difference relative to the Ctr group.  Data of proteins highlighted in 
turquoise were considered to be increased or decreased when they were ± 0.2 fold 
different from Ctr rats (reported and discussed in Chapter 4).  
 





Protein / function Accession no Ctr 1 Ctr 2 Avg Ctr/ Ctr MS 1 MS 2 Avg 
MS/ 
Ctr RS 1 RS 2 Avg 
RS/ 
Ctr 
              
Cytoskeletal/Structural              
              
Actin-binding              
Actin related protein 2/3 complex, subunit 3 tr│B2GV73│ 1 1.20 1.10 1.0 0.80 0.80 0.80 0.73 1.20 1.20 1.20 1.09 
Actin related protein 2/3 complex, subunit 4 
(Predicted), isoform CRA_a tr│B2RZ72│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 0.90 1.00 0.95 0.95 
Actin, alpha cardiac muscle 1 sp│P68035│ 1 1.20 1.10 1.0 1.00 1.00 1.00 0.91 1.20 1.20 1.20 1.09 
Actin-related protein 2 sp│Q5M7U6│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Actin-related protein 2/3 complex subunit 1A sp│Q99PD4│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 0.90 0.90 0.90 0.90 
Actin-related protein 2/3 complex subunit 2 sp│P85970│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Actin-related protein 2/3 complex subunit 5 sp│Q4KLF8│ 1 1.00 1.00 1.0 1.20 1.00 1.10 1.10 1.00 1.00 1.00 1.00 
Actin-related protein 2/3 complex subunit 5-
like protein sp│A1L108│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Actin-related protein 3 sp│Q4V7C7│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 0.90 1.00 0.95 0.90 
Actin, cytoplasmic 1 sp│P60711│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Actn1 protein tr│Q6GMN8│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 1.00 0.90 0.95 1.00 
Spectrin alpha chain, non-erythrocytic 1 sp│P16086│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.10 1.05 1.00 
Alpha II spectrin tr│C9EH87│ 1 1.10 1.05 1.0 0.80 0.70 0.75 0.71 0.90 1.30 1.10 1.05 
Spectrin beta 3 tr│F1MA36│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.00 1.00 1.00 
F-actin-capping protein subunit alpha-1 sp│B2GUZ5│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.00 1.00 0.95 
F-actin-capping protein subunit alpha-2 sp│Q3T1K5│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
F-actin-capping protein subunit beta sp│Q5XI32│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.10 1.05 1.00 
Vinculin tr│R9PXU6│ 1 1.70 1.35 1.0 1.80 1.30 1.55 1.15 1.40 1.50 1.45 1.07 
ARP10 actin-related protein 10 homolog (S. 
cerevisiae) tr│Q5M9F7│ 1 1.00 1.00 1.0 1.10 0.70 0.90 0.90 0.80 0.80 0.80 0.80 
Dynactin 1, isoform CRA_a tr│D4A8U7│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.10 1.05 1.00 
Dynactin subunit 2 sp│Q6AYH5│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Alpha-actinin-4 sp│Q9QXQ0│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
 Table A 1:  Proteomic (8-plex) profile of the PFC of Ctr, MS and restraint stressed (RS) rats.  Data presented as a ratio to Ctr 1.  The average Ctr 
ratio (Avg) was calculated and normalized to 1.0 (blue).  Data in red differed from the normalized Ctr/Ctr by more than 20% (1.2-fold increase or 
decrease). 




Tropomodulin-2 sp│P70566│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 1.00 1.00 1.00 1.00 
Tropomyosin 5 tr│P97726│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.00 1.00 1.00 
Tropomyosin alpha isoform tr│Q91XN7│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Myl6 protein tr│B2GV99│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.00 1.00 1.00 
Myosin regulatory light chain tr│Q63781│ 1 1.00 1.00 1.0 1.20 1.20 1.20 1.20 1.00 1.10 1.05 1.05 
Myosin, heavy polypeptide 10, non-muscle, 
isoform CRA_b tr│G3V9Y1│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.00 1.00 1.00 
Myosin, heavy polypeptide 9, non-muscle tr│G3V6P7│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.10 1.10 1.10 1.05 
Protein Twf2 tr│B0BMY7│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.10 1.05 1.05 
Plectin 7 tr│Q6S399│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Fascin sp│P85845│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.00 1.00 1.00 
Destrin sp│Q7M0E3│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 0.90 0.90 0.90 0.95 
Drebrin E tr│C6L8E0│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Drebrin-like protein sp│Q9JHL4│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.10 1.05 1.05 
Adducin 3 (Gamma), isoform CRA_b tr│D3ZCH7│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.00 1.00 1.00 
Alpha-adducin sp│Q63028│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Beta-adducin tr│F8WFS9│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Band 4.1-like protein 1 tr│D3ZMI4│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Calponin-3 sp│P37397│ 1 1.00 1.00 1.0 1.10 0.90 1.00 1.00 0.80 0.90 0.85 0.85 
Cofilin-1 sp│P45592│ 1 1.20 1.10 1.0 1.00 1.00 1.00 0.91 1.10 1.20 1.15 1.05 
Coronin (Fragment) tr│F1LMV9│ 1 0.90 0.95 1.0 0.90 1.10 1.00 1.05 1.10 0.90 1.00 1.05 
Coronin tr│G3V940│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 0.90 0.80 0.85 0.89 
Coronin-1A sp│Q91ZN1│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Cytoplasmic FMR1 interacting protein 1 
(Predicted) tr│D4A8H8│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Cytoplasmic FMR1 interacting protein 2 
(Predicted) tr│D3ZX82│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Erythrocyte protein band 4.1-like 3, isoform 
CRA_d tr│Q9JMB3│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 1.00 1.00 1.00 1.05 
Profilin tr│D3ZDU5│ 1 0.90 0.95 1.0 1.10 1.10 1.10 1.16 0.90 0.90 0.90 0.95 
Profilin-1 sp│P62963│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein Ank2 (Fragment) tr│F1M9N9│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Synaptopodin tr│B1VKB4│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Ezrin sp│P31977│ 1 1.00 1.00 1.0 0.80 0.90 0.85 0.85 1.10 1.00 1.05 1.05 




NCK interacting protein with SH3 domain 
(Predicted), isoform CRA_a tr│D3ZWX4│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.20 1.10 1.15 1.10 
Nck-associated protein 1 sp│P55161│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein Actbl2 tr│D3ZRN3│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 1.00 1.00 1.00 
Protein Sptbn1 tr│G3V6S0│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Twinfilin-1 sp│Q5RJR2│ 1 1.00 1.00 1.0 0.90 1.10 1.00 1.00 0.90 0.90 0.90 0.90 
Alpha-centractin sp│P85515│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Adenylyl cyclase-associated protein 1 sp│Q08163│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Adenylyl cyclase-associated protein 2 sp│P52481│ 1 1.10 1.05 1.0 1.20 1.00 1.10 1.05 1.00 1.00 1.00 0.95 
Myristoylated alanine-rich C-kinase substrate sp│P30009│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
  Tubulin-binding 
             
Tubulin alpha-1A chain sp│P68370│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Tubulin alpha-4A chain sp│Q5XIF6│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Tubulin beta-2A chain sp│P85108│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.10 1.10 1.10 1.05 
Tubulin beta-3 chain sp│Q4QRB4│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Tubulin beta-5 chain sp│P69897│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.10 1.10 1.05 
Microtubule-actin cross-linking factor 1 tr│M9MMM9│ 1 1.30 1.15 1.0 1.10 1.00 1.05 0.91 1.10 1.20 1.15 1.00 
Microtubule-associated protein 1 A, isoform 
CRA_c tr│G3V7U2│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.00 1.00 1.00 0.95 
Microtubule-associated protein 1B tr│F1LRL9│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.10 1.10 1.05 
Microtubule-associated protein 4 sp│Q5M7W5│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 0.90 0.95 0.95 
Microtubule-associated protein 6 sp│Q63560│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.00 1.00 1.00 
Microtubule-associated protein tr│F1MAQ5│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.10 1.10 1.05 
Microtubule-associated protein RP/EB family 
member 3 sp│Q5XIT1│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.10 1.10 1.05 
Microtubule-associated proteins 1A/1B light 
chain 3A sp│Q6XVN8│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 1.00 1.00 1.00 
Protein Tppp tr  D3ZQL7│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Protein Tubb4a tr│B4F7C2│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein Tubb6 tr│Q4QQV0│ 1 0.80 0.90 1.0 0.90 0.90 0.90 1.00 0.90 0.90 0.90 1.00 
Protein Tubal3 tr│F1LUM5│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.00 1.00 1.00 
HMW-MAP2 (Fragment) tr│P70652│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 0.90 1.10 1.00 0.95 
CAP-Gly domain-containing linker protein 2 tr│G3V949│ 1 1.20 1.10 1.0 1.30 0.90 1.10 1.00 1.10 1.00 1.05 0.95 
2',3'-cyclic-nucleotide 3'-phosphodiesterase sp│P13233│ 1 0.70 0.85 1.0 0.90 0.80 0.85 1.00 1.00 0.80 0.90 1.06 




Gephyrin sp│Q03555│ 1 1.10 1.05 1.0 1.20 1.00 1.10 1.05 0.90 1.00 0.95 0.90 
Echinoderm microtubule associated protein like 
4 (Predicted), isoform CRA_a tr│F1LT71│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 1.00 0.90 0.95 0.95 
  Intermediated filament binding 
             
Vimentin sp│P31000│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Lamin A, isoform CRA_b tr│G3V8L3│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Alpha-internexin sp│P23565│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 1.00 1.00 1.00 1.05 
Neurofilament heavy polypeptide tr│F1LRZ7│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.10 1.10 1.10 1.10 
Neurofilament light polypeptide sp│P19527│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 1.10 1.10 1.10 1.10 
Neurofilament medium polypeptide sp│P12839│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Glial fibrillary acidic protein sp│P47819│ 1 0.90 0.95 1.0 1.10 1.00 1.05 1.11 0.90 0.90 0.90 0.95 
sp|P30427|PLEC_RAT-DECOY Plectin sp│P30427│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Protein Synm tr│G3V9G5│ 1 1.20 1.10 1.0 1.20 1.00 1.10 1.00 1.00 1.10 1.05 0.95 
  Other 
             
Paralemmin-1 sp│Q920Q0│ 1 1.20 1.10 1.0 1.30 1.00 1.15 1.05 1.10 1.00 1.05 0.95 
Brevican, isoform CRA_a tr│G3V8G4│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 0.90 1.00 0.95 0.90 
Hyaluronan and proteoglycan link protein 1 sp│P03994│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.10 1.10 1.05 
Myelin basic protein transcript variant 1 tr│I7FKL4│ 1 0.50 0.75 1.0 0.90 0.80 0.85 1.13 1.20 1.00 1.10 1.47 
Myelin proteolipid protein sp│P60203│ 1 0.70 0.85 1.0 0.70 0.70 0.70 0.82 0.90 0.70 0.80 0.94 
Catenin beta-1 sp│Q9WU82│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.20 1.10 1.15 1.10 
Laminin, alpha 5, isoform CRA_a tr│F1MAN8│ 1 1.20 1.10 1.0 1.00 1.10 1.05 0.95 1.00 0.90 0.95 0.86 
Keratin, type I cytoskeletal 10 sp│Q6IFW6│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.10 0.90 1.00 1.00 
Keratin, type II cytoskeletal 1 sp│Q6IMF3│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 1.00 0.90 0.95 1.00 
Dihydropyrimidinase-related protein 1 sp│Q62950│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Dihydropyrimidinase-related protein 2 sp│P47942│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Dihydropyrimidinase-related protein 3 sp│Q62952│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 0.90 0.90 0.90 0.95 
Dihydropyrimidinase-related protein 4 
(Fragment) sp│Q62951│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Dihydropyrimidinase-related protein 5 sp│Q9JHU0│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.00 1.00 1.00 
              
              
              




Energy metabolism                            
  Glycolysis 
             
Pyruvate dehydrogenase E1 component subunit 
alpha, somatic form, mitochondrial tr│F7FKI5│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 0.90 0.90 0.90 0.90 
Pyruvate dehydrogenase E1 component subunit 
beta, mitochondrial sp│P49432│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 1.00 1.00 1.00 
Pyruvate carboxylase, mitochondrial sp│P52873│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 1.00 0.90 0.95 1.00 
Pyruvate kinase tr│Q6P7S0│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.20 1.15 1.10 
Pyruvate kinase PKM sp│P11980│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Gamma-enolase sp│P07323│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.10 1.10 1.05 
  Citric Acid Cycle 
             
2-oxoglutarate dehydrogenase, mitochondrial sp│Q5XI78│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 0.90 0.90 0.90 0.90 
Fumarate hydratase, mitochondrial sp│P14408│ 1 1.00 1.00 1.0 0.90 0.90 0.90 0.90 1.00 1.00 1.00 1.00 
Aconitate hydratase, mitochondrial sp│Q9ER34│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 1.00 1.00 1.00 
ATP-citrate synthase sp│P16638│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.10 1.05 1.00 
Citrate synthase tr│G3V936│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 0.90 0.90 0.90 0.95 
Dihydrolipoamide S-succinyltransferase (E2 
component of 2-oxo-glutarate complex), 
isoform CRA_a 
tr│G3V6P2│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 0.80 0.80 0.80 0.84 
Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase 
complex, mitochondrial 
sp│P08461│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 0.90 0.95 0.95 
Glutamate dehydrogenase 1, mitochondrial sp│P10860│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Malate dehydrogenase, cytoplasmic sp│O88989│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.00 1.00 0.95 
Malate dehydrogenase, mitochondrial sp│P04636│ 1 1.00 1.00 1.0 0.90 0.90 0.90 0.90 1.00 1.00 1.00 1.00 
Malic enzyme (Fragment) tr│F1LQQ1│ 1 1.20 1.10 1.0 1.10 1.10 1.10 1.00 1.10 1.10 1.10 1.00 
Malic enzyme tr│F1M5N4│ 1 1.20 1.10 1.0 1.30 1.10 1.20 1.09 0.90 0.90 0.90 0.82 
Succinyl-CoA ligase [ADP/GDP-forming] 
subunit alpha, mitochondrial sp│P13086│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Trifunctional enzyme subunit alpha, 
mitochondrial sp│Q64428│ 1 1.10 1.05 1.0 0.40 1.00 0.70 0.67 0.90 0.70 0.80 0.76 
Protein Sucla2 tr│F1LM47│ 1 1.00 1.00 1.0 0.90 0.90 0.90 0.90 1.00 1.00 1.00 1.00 
  Oxidative phosphorylation 
             
Cytochrome b-c1 complex subunit 2, 
mitochondrial sp│P32551│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 0.80 0.90 0.85 0.89 




Cytochrome c oxidase subunit 2 sp│P00406│ 1 0.60 0.80 1.0 0.60 0.70 0.65 0.81 0.70 0.70 0.70 0.88 
Cytochrome c oxidase subunit 4 isoform 1, 
mitochondrial sp│P10888│ 1 0.70 0.85 1.0 0.80 0.80 0.80 0.94 0.80 0.70 0.75 0.88 
Cytochrome c oxidase subunit 5B, 
mitochondrial sp│P12075│ 1 0.80 0.90 1.0 0.70 0.80 0.75 0.83 0.90 0.70 0.80 0.89 
Cytochrome c, somatic sp│P62898│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.20 1.15 1.10 
Cox7a2 protein tr│B2RYS0│ 1 0.80 0.90 1.0 0.80 0.80 0.80 0.89 0.90 0.80 0.85 0.94 
Ndufa4 protein tr│B2RZD6│ 1 0.70 0.85 1.0 0.70 0.80 0.75 0.88 0.80 0.70 0.75 0.88 
Isocitrate dehydrogenase [NAD] subunit alpha, 
mitochondrial tr│F1LNF7│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 0.90 0.90 0.90 0.95 
Isocitrate dehydrogenase [NAD] subunit beta, 
mitochondrial sp│Q68FX0│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 0.90 0.90 0.90 0.95 
Isocitrate dehydrogenase [NAD] subunit 
gamma 1, mitochondrial sp│P41565│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.00 1.00 1.00 
Isocitrate dehydrogenase [NADP] cytoplasmic sp│P41562│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 1.00 0.90 0.95 1.00 
Isocitrate dehydrogenase [NADP], 
mitochondrial sp│P56574│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 10, mitochondrial sp│Q561S0│ 1 0.70 0.85 1.0 0.50 0.70 0.60 0.71 0.70 0.70 0.70 0.82 
NADH-ubiquinone oxidoreductase 75 kDa 
subunit, mitochondrial sp│Q66HF1│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 1.00 1.00 1.00 1.00 
Succinate dehydrogenase complex subunit A 
(Fragment) tr│Q0QF18│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 1.00 0.80 0.90 0.95 
ATP synthase F(0) complex subunit B1, 
mitochondrial sp│P19511│ 1 0.70 0.85 1.0 0.80 0.80 0.80 0.94 0.80 0.70 0.75 0.88 
ATP synthase subunit alpha, mitochondrial sp│P15999│ 1 0.70 0.85 1.0 0.70 0.80 0.75 0.88 0.80 0.70 0.75 0.88 
ATP synthase subunit beta, mitochondrial sp│P10719│ 1 0.70 0.85 1.0 0.70 0.90 0.80 0.94 0.80 0.70 0.75 0.88 
ATP synthase subunit delta, mitochondrial sp│P35434│ 1 0.80 0.90 1.0 0.80 0.90 0.85 0.94 0.80 0.80 0.80 0.89 
ATP synthase subunit gamma, mitochondrial sp│P35435│ 1 0.70 0.85 1.0 0.80 0.80 0.80 0.94 0.80 0.70 0.75 0.88 
ATP synthase subunit O, mitochondrial sp│Q06647│ 1 0.90 0.95 1.0 0.80 0.80 0.80 0.84 0.80 0.70 0.75 0.79 
ADP/ATP translocase 1 sp│Q05962│ 1 0.70 0.85 1.0 0.60 0.70 0.65 0.76 0.80 0.70 0.75 0.88 
ADP/ATP translocase 2 sp│Q09073│ 1 0.70 0.85 1.0 0.60 0.80 0.70 0.82 0.80 0.70 0.75 0.88 
Phosphate carrier protein, mitochondrial tr│G3V741│ 1 0.60 0.80 1.0 0.60 0.80 0.70 0.88 0.70 0.60 0.65 0.81 
  Phosphagen System 
             
Creatine kinase B-type sp│P07335│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.10 1.05 1.00 
Creatine kinase, mitochondrial 1, ubiquitous tr│Q5BJT9│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 0.90 0.80 0.85 0.89 
              




  Other 
             
3'(2'),5'-bisphosphate nucleotidase 1 sp│Q9Z1N4│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 0.90 0.90 0.90 0.95 
 
              
Neurotransmission/signalling                            
  Cell Adhesion 
             
Neural cell adhesion molecule 1 (Fragment) tr│F1LNY3│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 1.00 0.90 0.95 1.00 
Limbic system-associated membrane protein sp│Q62813│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 0.90 0.80 0.85 0.89 
Neurocan core protein tr│G3V8R2│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.00 1.00 1.00 
Neurofascin sp│P97685│ 1 1.10 1.05 1.0 0.90 1.10 1.00 0.95 1.10 1.10 1.10 1.05 
Neuronal growth regulator 1 sp│Q9Z0J8│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 1.10 1.00 1.05 1.11 
Neurotrimin tr│G3V964│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
Obg-like ATPase 1 sp│A0JPJ7│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Opioid-binding protein/cell adhesion molecule sp│P32736│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 1.00 0.90 0.95 1.00 
Peripheral plasma membrane protein CASK sp│Q62915│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 0.80 0.85 0.85 
Protein Cdh13 (Fragment) tr│F1M7X3│ 1 1.00 1.00 1.0 0.90 0.90 0.90 0.90 0.90 0.80 0.85 0.85 
Protein Cttn tr│D3ZGE6│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.00 0.90 0.95 0.90 
Synaptosomal-associated protein 25 sp│P60881│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Tenascin-R sp│Q05546│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Versican core protein (Fragments) sp│Q9ERB4│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Thy-1 membrane glycoprotein sp│P01830│ 1 0.80 0.90 1.0 0.90 0.90 0.90 1.00 0.90 0.80 0.85 0.94 
Neuroplastin tr│D3ZDF0│ 1 0.80 0.90 1.0 0.90 1.00 0.95 1.06 0.80 0.80 0.80 0.89 
Protein Omg tr│F7EYB9│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 0.90 0.95 0.95 
Protein Icam5 tr│D4A435│ 1 1.10 1.05 1.0 1.10 1.20 1.15 1.10 1.00 1.00 1.00 0.95 
  Vesicle Regulation 
             
Vesicle-associated membrane protein 1 
(Fragment) tr│F1M9V2│ 1 0.70 0.85 1.0 0.80 0.80 0.80 0.94 0.80 0.70 0.75 0.88 
Vesicle associated membrane protein 2B tr│Q9WUW2│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
Vesicle-associated membrane protein-
associated protein A sp│Q9Z270│ 1 1.00 1.00 1.0 0.90 0.90 0.90 0.90 0.90 1.00 0.95 0.95 
Vesicle-fusing ATPase sp│Q9QUL6│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 1.00 1.00 1.00 1.05 
Vesicle-trafficking protein SEC22b sp│Q4KM74│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 1.00 0.95 1.00 




Vesicular glutamate transporter 1 sp│Q62634│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Adaptin ear-binding coat-associated protein 1 sp│P69682│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
Adaptor protein complex AP-1, sigma 1 
(Predicted), isoform CRA_b tr│B5DFI3│ 1 1.00 1.00 1.0 1.10 1.30 1.20 1.20 1.10 1.00 1.05 1.05 
Adaptor protein complex AP-2, alpha 1 subunit 
(Predicted) tr│D3ZUY8│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Adaptor-related protein complex 1, gamma 1 
subunit, isoform CRA_b tr│B2RYN6│ 1 1.00 1.00 1.0 0.90 0.90 0.90 0.90 1.00 0.90 0.95 0.95 
Adaptor-related protein complex 3, delta 1 
subunit, isoform CRA_b tr│B5DFK6│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
AP-1 complex subunit beta-1 tr│G3V9N8│ 1 1.20 1.10 1.0 1.10 1.00 1.05 0.95 1.10 1.20 1.15 1.05 
AP-2 complex subunit alpha-2 sp│P18484│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 1.00 1.00 1.00 
AP-2 complex subunit beta sp│P62944│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
AP-2 complex subunit mu sp│P84092│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
AP-2 complex subunit sigma sp│P62744│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
AP2-associated protein kinase 1 sp│P0C1X8│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
AP-3 complex subunit mu-2 sp│P53678│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 0.90 0.95 0.95 
Alpha-soluble NSF attachment protein sp│P54921│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 1.00 0.95 1.00 
Beta-soluble NSF attachment protein tr│F8WFM2│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Calnexin sp│P35565│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 0.90 0.90 0.90 0.95 
Clathrin coat assembly protein AP180 tr│F1LRK0│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 1.00 1.00 1.00 1.00 
Clathrin heavy chain tr│F1M779│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Clathrin light chain A sp│P08081│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Clathrin light chain B sp│P08082│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.10 1.10 1.05 
Coatomer subunit delta sp│Q66H80│ 1 1.10 1.05 1.0 1.20 0.90 1.05 1.00 1.10 1.00 1.05 1.00 
Complexin-2 sp│P84087│ 1 1.10 1.05 1.0 1.20 1.00 1.10 1.05 1.10 1.10 1.10 1.05 
Copa protein tr│B5DFK1│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
EH domain-containing protein 1 sp│Q641Z6│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 1.10 0.90 1.00 1.05 
EH domain-containing protein 3 sp│Q8R491│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.10 1.05 1.00 
Endophilin-A1 (Fragment) tr│F1LQ05│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Endophilin-A2 sp│O35964│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.20 1.15 1.10 
Endophilin-B2 tr│D4A7V1│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.10 1.05 1.05 
Myc box-dependent-interacting protein 1 sp│O08839│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Protein Psd3 tr│D3ZUW0│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 




Protein Snx2 tr│B2RYP4│ 1 0.90 0.95 1.0 1.00 1.10 1.05 1.11 0.80 0.90 0.85 0.89 
Reticulon tr│F1LQN3│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.00 1.00 1.00 
Reticulon-1 sp│Q64548│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Reticulon-3 sp│Q6RJR6│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Secernin-1 sp│Q6AY84│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Secretory carrier-associated membrane protein 
5 (Fragment) tr│F1M882│ 1 0.80 0.90 1.0 0.90 0.90 0.90 1.00 0.80 0.80 0.80 0.89 
SH3 domain-binding glutamic acid-rich-like 
protein tr│B5DFD8│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 0.90 0.90 0.90 0.90 
SH3-containing GRB2-like protein 3-
interacting protein 1 sp│P0DJJ3│ 1 1.00 1.00 1.0 1.20 1.30 1.25 1.25 1.20 1.10 1.15 1.15 
SRC kinase signaling inhibitor 1 sp│Q9QXY2│ 1 1.00 1.00 1.0 1.10 0.90 1.00 1.00 1.00 1.10 1.05 1.05 
Synapsin-1 sp│P09951│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Synapsin-2 sp│Q63537│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Synaptogyrin-1 sp│Q62876│ 1 0.90 0.95 1.0 1.00 1.10 1.05 1.11 0.90 0.90 0.90 0.95 
Synaptic vesicle glycoprotein 2A sp│Q02563│ 1 0.80 0.90 1.0 1.00 0.90 0.95 1.06 0.90 0.90 0.90 1.00 
Synaptic vesicle glycoprotein 2B sp│Q63564│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 0.90 0.90 0.90 0.95 
Synaptobrevin homolog YKT6 sp│Q5EGY4│ 1 1.20 1.10 1.0 1.10 1.20 1.15 1.05 1.00 1.00 1.00 0.91 
Synaptojanin-1 sp│Q62910│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.00 1.00 1.00 
Synaptophysin sp│P07825│ 1 0.90 0.95 1.0 0.80 0.90 0.85 0.89 0.90 1.00 0.95 1.00 
Syntaxin 1A tr│Q9QXG3│ 1 0.80 0.90 1.0 0.90 0.90 0.90 1.00 0.90 0.90 0.90 1.00 
Syntaxin-1B sp│P61265│ 1 0.80 0.90 1.0 0.90 0.90 0.90 1.00 0.90 0.90 0.90 1.00 
Syntaxin-binding protein 1 sp│P61765│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Unconventional myosin-Va sp│Q9QYF3│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Amphiphysin sp│O08838│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein kinase C and casein kinase substrate in 
neurons protein 1 tr│F1LPP3│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.10 1.10 1.05 
Dynamin-1 sp│P21575│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Dynamin-1-like protein sp│O35303│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.00 1.00 1.00 
Dynamin-3 sp│Q08877│ 1 1.50 1.25 1.0 1.20 1.30 1.25 1.00 1.20 1.70 1.45 1.16 
Protein Syngr3 tr│D4ABK1│ 1 0.90 0.95 1.0 0.80 1.00 0.90 0.95 0.80 0.80 0.80 0.84 
Synaptotagmin-1 sp│P21707│ 1 0.80 0.90 1.0 0.90 0.90 0.90 1.00 0.90 0.90 0.90 1.00 
Calcium-dependent secretion activator 1 sp│Q62717│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
              




  Transport 
             
Excitatory amino acid transporter 1 sp│P24942│ 1 0.70 0.85 1.0 1.00 0.90 0.95 1.12 0.80 0.70 0.75 0.88 
Excitatory amino acid transporter 2 sp│P31596│ 1 0.70 0.85 1.0 0.80 0.70 0.75 0.88 0.80 0.70 0.75 0.88 
Acyl-CoA-binding protein tr│Q6TXF3│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.10 1.10 1.05 
Disks large homolog 3 sp│Q62936│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 0.90 1.00 0.95 1.00 
ATPase, H+ transporting, lysosomal 38kDa, V0 
subunit d1 tr│Q5M7T6│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 0.90 1.00 0.95 1.00 
ATPase, H+ transporting, V1 subunit D, 
isoform CRA_c tr│Q6P503│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.10 1.10 1.10 1.05 
ATPase, H+ transporting, V1 subunit E isoform 
1, isoform CRA_a tr│G3V7L8│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
ATPase, H+ transporting, V1 subunit G isoform 
2 tr│Q8R2H0│ 1 0.90 0.95 1.0 1.20 1.00 1.10 1.16 0.90 1.10 1.00 1.05 
V-H+ATPase subunit a1-III tr│Q2I6B2│ 1 0.80 0.90 1.0 0.90 1.00 0.95 1.06 0.90 0.90 0.90 1.00 
V-type proton ATPase subunit B, brain isoform sp│P62815│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.00 1.00 1.00 
V-type proton ATPase subunit C 1 sp│Q5FVI6│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
V-type proton ATPase subunit F sp│P50408│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
Protein Atp6v1a tr│D4A133│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 1.00 1.00 1.00 1.05 
Protein Atp6v1h tr│E9PTI1│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Voltage-dependent anion-selective channel 
protein 1 sp│Q9Z2L0│ 1 0.80 0.90 1.0 0.70 0.90 0.80 0.89 0.80 0.80 0.80 0.89 
Voltage-dependent anion-selective channel 
protein 2 sp│P81155│ 1 0.80 0.90 1.0 0.70 0.90 0.80 0.89 0.80 0.80 0.80 0.89 
Voltage-dependent calcium channel subunit 
alpha-2/delta-1 tr│D3ZKP9│ 1 1.20 1.10 1.0 1.00 1.10 1.05 0.95 1.30 1.20 1.25 1.14 
Sarcoplasmic/endoplasmic reticulum calcium 
ATPase 2 sp│P11507│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 0.90 1.00 0.95 1.00 
Plasma membrane calcium-transporting 
ATPase 1 sp│P11505│ 1 0.80 0.90 1.0 0.90 0.90 0.90 1.00 0.90 0.90 0.90 1.00 
Plasma membrane calcium-transporting 
ATPase 2 tr│D3ZCE9│ 1 0.80 0.90 1.0 0.90 0.90 0.90 1.00 0.90 0.90 0.90 1.00 
Plasma membrane calcium-transporting 
ATPase 4 tr│D3ZH00│ 1 0.80 0.90 1.0 0.90 0.90 0.90 1.00 0.90 0.80 0.85 0.94 
Sodium/potassium-transporting ATPase subunit 
alpha-1 sp│P06685│ 1 0.70 0.85 1.0 0.80 0.80 0.80 0.94 0.90 0.80 0.85 1.00 
Sodium/potassium-transporting ATPase subunit 
alpha-2 sp│P06686│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 0.90 0.80 0.85 0.89 
Sodium/potassium-transporting ATPase subunit 
alpha-3 sp│P06687│ 1 0.70 0.85 1.0 0.80 0.80 0.80 0.94 0.90 0.80 0.85 1.00 




Sodium/potassium-transporting ATPase subunit 
beta-1 sp│P07340│ 1 0.70 0.85 1.0 0.80 0.80 0.80 0.94 0.90 0.90 0.90 1.06 
Sodium-dependent neutral amino acid 
transporter SLC6A17 sp│P31662│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Alpha-endosulfine sp│P60841│ 1 1.00 1.00 1.0 1.20 1.10 1.15 1.15 1.00 1.00 1.00 1.00 
Solute carrier family 12 member 5 sp│Q63633│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 1.00 1.00 1.00 1.05 
Astrocytic phosphoprotein PEA-15 sp│Q5U318│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Cytoplasmic dynein 1 heavy chain 1 tr│M0R9X8│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Cytoplasmic dynein 1 light intermediate chain 1 sp│Q9QXU8 │ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Cytoplasmic dynein 1 light intermediate chain 2 sp│Q62698│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 0.90 0.90 0.90 0.90 
Dynein light chain 2, cytoplasmic sp│Q78P75│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 1.00 1.00 1.00 1.00 
Dynein light chain roadblock-type 1 sp│P62628│ 1 1.20 1.10 1.0 1.30 1.10 1.20 1.09 1.20 1.10 1.15 1.05 
Fatty acid-binding protein, epidermal sp│P55053│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.00 1.10 1.05 1.00 
Fatty acid-binding protein sp│P07483│ 1 1.20 1.10 1.0 1.20 1.20 1.20 1.09 1.10 1.20 1.15 1.05 
Importin 7 (Predicted), isoform CRA_c tr│D4AE96│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.10 1.05 1.05 
Importin subunit beta-1 tr│F2Z3Q8│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 1.00 0.95 1.00 
LIM and SH3 domain protein 1 sp│Q99MZ8│ 1 0.90 0.95 1.0 1.10 1.10 1.10 1.16 1.00 1.00 1.00 1.05 
Mitochondrial import receptor subunit TOM34 sp│Q3KRD5│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 1.00 1.00 1.00 1.00 
Phosphofurin acidic cluster sorting protein 1 tr│F1LPG3│ 1 1.10 1.05 1.0 1.30 1.10 1.20 1.14 1.00 1.00 1.00 0.95 
Protein Napg tr│D4A0E2│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Protein Ranbp1 tr│D4A2G9│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.10 1.10 1.05 
Protein Tom1l2 tr  D4A6C9│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Rabphilin-3A tr│F1LPB9│ 1 1.00 1.00 1.0 1.20 1.00 1.10 1.10 0.90 1.00 0.95 0.95 
Vacuolar protein sorting-associated protein 29 sp│B2RZ78│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 0.90 0.80 0.85 0.89 
Vacuolar protein sorting-associated protein 35 tr│G3V8A5│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein Vps53 tr│D3ZPE5│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 0.90 1.10 1.00 0.95 
Protein Ipo5 tr│D4A781│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 1.10 0.80 0.95 1.00 
  GTPase Signalling 
             
CB1 cannabinoid receptor-interacting protein 1 sp│Q5M7A7│ 1 1.30 1.15 1.0 1.20 1.10 1.15 1.00 1.10 1.10 1.10 0.96 
GTP-binding nuclear protein Ran sp│P62828│ 1 1.10 1.05 1.0 1.10 0.90 1.00 0.95 1.00 1.10 1.05 1.00 
Septin 5, isoform CRA_d tr│D3ZDH8│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 1.00 1.00 1.00 1.00 
Septin 7 tr│A2VCW8│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Septin 8 (Predicted) tr│G3V9Z6│ 1 0.90 0.95 1.0 0.90 1.10 1.00 1.05 1.00 0.90 0.95 1.00 




Septin-11 sp│B3GNI6│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Septin-2 sp│Q91Y81│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.10 1.05 1.05 
Septin-9 sp│Q9QZR6│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Neuronal-specific septin-3 tr│D3ZPP8│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.10 1.10 1.05 
Protein Diras2 tr│D3ZHX3│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.10 1.05 1.00 
ADP-ribosylation factor 3 sp│P61206│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.20 1.15 1.10 
ADP-ribosylation factor 5 sp│P84083│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
ADP-ribosylation factor-like protein 3 sp│P37996│ 1 1.10 1.05 1.0 1.20 1.00 1.10 1.05 1.10 1.10 1.10 1.05 
Cell division control protein 42 homolog sp│Q8CFN2│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 1.00 1.00 1.00 1.00 
Guanine nucleotide binding protein, alpha q 
polypeptide, isoform CRA_a tr│D4AE68│ 1 0.80 0.90 1.0 1.00 1.00 1.00 1.11 0.90 1.00 0.95 1.06 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 sp│P54311│ 1 0.80 0.90 1.0 1.00 1.00 1.00 1.11 1.00 0.90 0.95 1.06 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2 sp│P54313│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Guanine nucleotide-binding protein G(k) 
subunit alpha sp│P08753│ 1 0.70 0.85 1.0 1.10 1.10 1.10 1.29 0.80 0.90 0.85 1.00 
Guanine nucleotide-binding protein G(o) 
subunit alpha sp│P59215│ 1 0.70 0.85 1.0 0.90 0.80 0.85 1.00 0.90 0.90 0.90 1.06 
Guanine nucleotide-binding protein subunit 
beta-2-like 1 sp│P63245│ 1 1.20 1.10 1.0 1.00 1.10 1.05 0.95 1.00 1.10 1.05 0.95 
Guanine nucleotide-binding protein subunit 
beta-5 sp│P62882│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
Guanine nucleotide-binding protein subunit 
gamma tr│G3V8K2│ 1 0.60 0.80 1.0 0.80 1.00 0.90 1.13 0.80 0.80 0.80 1.00 
Neuronal guanine nucleotide exchange factor 
(Predicted) tr│G3V856│ 1 1.10 1.05 1.0 1.00 0.90 0.95 0.90 0.90 0.90 0.90 0.86 
Cytohesin-2 sp│P63035│ 1 1.10 1.05 1.0 0.90 1.30 1.10 1.05 1.00 1.00 1.00 0.95 
Ras-related C3 botulinum toxin substrate 1 sp│Q6RUV5│ 1 0.80 0.90 1.0 0.90 0.90 0.90 1.00 0.90 0.90 0.90 1.00 
Ras-related protein Rab-11B sp│O35509│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Ras-related protein Rab-18 sp│Q5EB77│ 1 1.00 1.00 1.0 0.90 1.10 1.00 1.00 1.10 0.90 1.00 1.00 
Ras-related protein Rab-1A sp│Q6NYB7│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Ras-related protein Rab-2A sp│P05712│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 0.90 0.90 0.90 0.90 
Ras-related protein Rab-3A sp│P63012│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 1.00 1.00 1.00 1.05 
Ras-related protein Rab-3C sp│P62824│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Ras-related protein Rab-6A sp│Q9WVB1│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 0.90 1.00 0.95 1.00 




Ras-related protein Rab-7a sp│P09527│ 1 1.00 1.00 1.0 0.90 0.90 0.90 0.90 1.00 1.00 1.00 1.00 
Ras-related protein Ral-A sp│P63322│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 0.80 0.90 0.85 0.89 
Ras-related protein Rap-1A sp│P62836│ 1 0.80 0.90 1.0 1.00 0.90 0.95 1.06 0.90 1.00 0.95 1.06 
Protein Rab5c tr│B0BNK1│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Protein Rab6b tr│F1LVC3│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Protein Rab5b tr│A1L1J8│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
GTPase NRas sp│Q04970│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Rho GDP-dissociation inhibitor 1 sp│Q5XI73│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Transforming protein RhoA sp│P61589│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
SLIT-ROBO Rho GTPase-activating protein 2 tr│B5DEJ1│ 1 0.80 0.90 1.0 1.00 0.90 0.95 1.06 0.90 1.00 0.95 1.06 
Protein Rap1gds1 tr│F1M7Y3│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Rab GDP dissociation inhibitor alpha sp│P50398│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Rab GDP dissociation inhibitor beta sp│P50399│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.10 1.05 1.00 
RAB14, member RAS oncogene family tr│B0BMW0│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
RAB10, member RAS oncogene family tr│Q5RKJ9│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 0.90 0.90 0.90 0.95 
RAB5A, member RAS oncogene family tr│O88565│ 1 1.10 1.05 1.0 1.20 1.00 1.10 1.05 1.10 1.00 1.05 1.00 
Protein Sbf1 tr│D3ZNN0│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 0.90 0.95 0.95 
Protein Abi2 tr│F1LYA6│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein Arhgap1 tr│D4A6C5│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.00 1.10 1.05 1.00 
Regulator of G-protein signaling 7 sp│P49803│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Protein Pkn3 tr│D3ZC07│ 1 1.00 1.00 1.0 1.20 1.00 1.10 1.10 1.00 1.00 1.00 1.00 
Serine/threonine-protein kinase BRSK1 sp│B2DD29│ 1 1.30 1.15 1.0 1.20 1.00 1.10 0.96 1.20 1.30 1.25 1.09 
Serine/threonine-protein kinase DCLK1 sp│O08875│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 1.00 1.00 1.00 
Serine/threonine-protein kinase PAK 1 sp│P35465│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Serine/threonine-protein phosphatase 2A 55 
kDa regulatory subunit B alpha isoform sp│P36876│ 1 1.10 1.05 1.0 1.80 1.00 1.40 1.33 1.00 1.10 1.05 1.00 
Serine/threonine-protein phosphatase 2A 
catalytic subunit alpha isoform sp│P63331│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Serine/threonine-protein phosphatase 2B 
catalytic subunit alpha isoform sp│P63329│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Serine/threonine-protein phosphatase 2B 
catalytic subunit beta isoform sp│P20651│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 0.90 1.00 0.95 0.95 
Serine/threonine-protein phosphatase 5 sp│P53042│ 1 1.10 1.05 1.0 1.00 0.90 0.95 0.90 1.00 0.90 0.95 0.90 
Serine/threonine-protein phosphatase PP1-alpha sp│P62138│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.10 1.05 1.05 





Serine/threonine-protein phosphatase PP1-beta 
catalytic subunit sp│P62142│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Protein Ppp2r1a tr│Q5XI34│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein Ppp2r4 tr│B2RYQ2│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.00 1.00 1.00 
Nucleoside diphosphate kinase A sp│Q05982│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.10 1.05 1.00 
Adenylate kinase isoenzyme 1 sp│P39069│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Phosphatidylethanolamine-binding protein 1 sp│P31044│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.10 1.05 1.00 
Phosphatidylinositol 4-phosphate 5-kinase type-
1 gamma sp│Q5I6B8│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 0.90 0.90 0.90 0.90 
Phosphatidylinositol 5-phosphate 4-kinase type-
2 beta sp│O88377│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Phosphatidylinositol transfer protein alpha 
isoform sp│P16446│ 1 1.20 1.10 1.0 1.10 1.10 1.10 1.00 1.10 1.10 1.10 1.00 
1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase beta-1 sp│P10687│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Diphosphoinositol polyphosphate 
phosphohydrolase 1 sp│Q566C7│ 1 1.00 1.00 1.0 1.10 1.40 1.25 1.25 0.90 0.90 0.90 0.90 
Inositol monophosphatase 1 tr│F1M978│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Inositol-trisphosphate 3-kinase A sp│P17105│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 0.90 0.90 0.90 0.90 
Phosphatidate cytidylyltransferase 2 sp│Q91XU8│ 1 0.90 0.95 1.0 0.90 1.10 1.00 1.05 0.80 1.00 0.90 0.95 
ArfGAP with dual PH domains 1 tr│O88768│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 0.90 1.00 0.95 0.95 
Calcium/calmodulin-dependent 3',5'-cyclic 
nucleotide phosphodiesterase 1B sp│Q01066│ 1 0.90 0.95 1.0 1.00 1.10 1.05 1.11 1.00 0.90 0.95 1.00 
cGMP-dependent 3',5'-cyclic phosphodiesterase tr│F8WFW5│ 1 1.30 1.15 1.0 1.10 1.20 1.15 1.00 1.20 1.10 1.15 1.00 
cAMP-dependent protein kinase type II-alpha 
regulatory subunit sp│P12368│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.10 1.00 1.05 1.00 
cAMP-dependent protein kinase type II-beta 
regulatory subunit sp│P12369│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Protein kinase, cAMP-dependent, catalytic, 
alpha tr│A1L1M0│ 1 1.00 1.00 1.0 0.80 0.90 0.85 0.85 1.00 1.00 1.00 1.00 
A-kinase anchor protein 5 tr│F1LPP6│ 1 1.20 1.10 1.0 1.40 1.00 1.20 1.09 1.00 1.00 1.00 0.91 
Tyrosine-protein phosphatase non-receptor type 
11 sp│P41499│ 1 1.00 1.00 1.0 0.80 0.90 0.85 0.85 1.10 0.90 1.00 1.00 
Protein kinase C beta type (Fragment) tr│F1LS42│ 1 0.80 0.90 1.0 0.90 1.00 0.95 1.06 1.00 1.00 1.00 1.11 
Protein kinase C gamma type sp│P63319│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 1.00 1.00 1.00 
Protein kinase C tr│F1LMV8│ 1 1.20 1.10 1.0 1.10 1.10 1.10 1.00 1.00 1.10 1.05 0.95 




Dual specificity mitogen-activated protein 
kinase kinase 1 sp│Q01986│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.10 1.05 1.00 
MAP/microtubule affinity-regulating kinase 3 tr│F1M836│ 1 1.00 1.00 1.0 0.80 0.80 0.80 0.80 1.00 1.00 1.00 1.00 
Mitogen-activated protein kinase 1 sp│P63086│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Mitogen-activated protein kinase 9 tr│D4A5V8│ 1 1.10 1.05 1.0 0.90 0.90 0.90 0.86 1.10 1.20 1.15 1.10 
Protein Map2k4 (Fragment) tr│F1LP57│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.20 1.10 1.15 1.15 
Dusp3 protein tr│B5DFF7│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Connector enhancer of kinase suppressor of ras 
3 sp│Q5SGD7│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 0.90 0.95 0.95 
  Calcium Signalling 
             
Calcium/calmodulin-dependent protein kinase 
II, beta, isoform CRA_a tr│G3V9G3│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 1.00 1.00 1.00 
Calcium/calmodulin-dependent protein kinase 
type II subunit alpha sp│P11275│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 1.00 1.00 1.00 1.05 
Calcium/calmodulin-dependent protein kinase 
type II subunit delta tr│F1LWF6│ 1 0.90 0.95 1.0 1.10 1.10 1.10 1.16 1.00 1.10 1.05 1.11 
Calcium/calmodulin-dependent protein kinase 
type II subunit gamma sp│P11730│ 1 0.90 0.95 1.0 0.80 0.90 0.85 0.89 1.00 1.00 1.00 1.05 
Calcium/calmodulin-dependent protein kinase 
type IV sp│P13234│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 0.90 0.95 0.95 
Calmodulin sp│P62161│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 1.10 1.20 1.15 1.15 
Neurogranin sp│Q04940│ 1 1.10 1.05 1.0 1.20 1.10 1.15 1.10 1.00 1.10 1.05 1.00 
Purkinje cell protein 4 sp│P63055│ 1 1.00 1.00 1.0 1.20 1.10 1.15 1.15 1.00 1.00 1.00 1.00 
Neurochondrin sp│O35095│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.00 1.00 0.95 
Calbindin sp│P07171│ 1 1.10 1.05 1.0 1.10 0.90 1.00 0.95 1.00 1.10 1.05 1.00 
Calcineurin subunit B type 1 sp│P63100│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.10 1.10 1.05 
Calretinin sp│P47728│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 1.10 1.00 1.00 
CaM kinase-like vesicle-associated protein sp│Q63092│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 1.00 0.95 1.00 
Hippocalcin-like protein 1 sp│P62749│ 1 0.80 0.90 1.0 0.90 1.00 0.95 1.06 0.80 0.90 0.85 0.94 
Hippocalcin-like protein 4 sp│P35332│ 1 1.20 1.10 1.0 1.10 1.00 1.05 0.95 1.30 1.20 1.25 1.14 
Neurocalcin-delta sp│Q5PQN0│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Visinin-like protein 1 sp│P62762│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.20 1.20 1.20 1.20 
Annexin A3 sp│P14669│ 1 1.30 1.15 1.0 0.70 0.90 0.80 0.70 0.90 1.20 1.05 0.91 
Annexin A5 sp│P14668│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Reticulocalbin-2 sp│Q62703│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 1.00 0.90 0.95 0.95 




Calcium binding protein 39 (Predicted), 
isoform CRA_a tr│D3ZJ77│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 1.00 1.00 1.00 1.05 
Neuron-specific calcium-binding protein 
hippocalcin sp│P84076│ 1 0.80 0.90 1.0 1.00 0.90 0.95 1.06 0.90 0.90 0.90 1.00 
Protein S100-B sp│P04631│ 1 1.20 1.10 1.0 1.10 1.30 1.20 1.09 1.00 1.10 1.05 0.95 
Neuronal membrane glycoprotein M6-a sp│Q812E9│ 1 0.60 0.80 1.0 0.70 0.80 0.75 0.94 0.80 0.80 0.80 1.00 
  Other 
             
4-nitrophenylphosphatase domain and non-
neuronal SNAP25-like protein homolog 1 (C. 
elegans), isoform CRA_b 
tr│G3V728│ 1 0.90 0.95 1.0 1.00 1.20 1.10 1.16 1.00 0.90 0.95 1.00 
14-3-3 protein beta/alpha sp│P35213│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.20 1.15 1.10 
14-3-3 protein epsilon sp│P62260│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 1.00 1.00 1.00 
14-3-3 protein eta sp│P68511│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.10 1.10 1.05 
14-3-3 protein gamma sp│P61983│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.10 1.05 1.00 
14-3-3 protein theta sp│P68255│ 1 1.10 1.05 1.0 0.90 1.00 0.95 0.90 1.00 1.10 1.05 1.00 
14-3-3 protein zeta/delta sp│P63102│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.10 1.10 1.05 
ERC protein 2 sp│Q8K3M6│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 1.00 1.00 1.00 
Homer protein homolog 1 sp│Q9Z214│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 1.10 0.90 1.00 1.05 
Kinesin heavy chain isoform 5C (Fragment) tr│G3V6L4│ 1 1.10 1.05 1.0 0.90 1.10 1.00 0.95 1.20 1.10 1.15 1.10 
LanC-like protein 1 sp│Q9QX69│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Platelet-activating factor acetylhydrolase IB 
subunit alpha sp│P63004│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Platelet-activating factor acetylhydrolase IB 
subunit beta sp│O35264│ 1.1 1.00 1.05 1.0 1.20 1.20 1.20 1.14 1.00 1.00 1.00 0.95 
Protein bassoon tr│G3V984│ 1 0.90 0.95 1.0 1.00 1.10 1.05 1.11 0.90 0.90 0.90 0.95 
Protein Dmxl2 (Fragment) tr│F1M164│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein phosphatase 1 regulatory subunit 1B sp│Q6J4I0│ 1 0.90 0.95 1.0 0.80 0.90 0.85 0.89 1.10 1.00 1.05 1.11 
Protein phosphatase 1 regulatory subunit 7 sp│Q5HZV9│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 0.90 1.00 0.95 0.95 
Protein phosphatase 1, regulatory subunit 9B tr│B1H262│ 1 1.00 1.00 1.0 0.90 0.90 0.90 0.90 1.00 1.00 1.00 1.00 
Protein phosphatase 1E sp│Q80Z30│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.10 1.05 1.05 
Protein phosphatase methylesterase 1 sp│Q4FZT2│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.00 1.00 0.95 
Protein Srgap3 tr│F1M5M9│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.10 1.10 1.10 1.05 
Stathmin sp│P13668│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.10 1.10 1.05 
Wiskott-Aldrich syndrome protein family 
member 1 sp│Q5BJU7│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 1.00 0.95 1.00 




Alpha-synuclein sp│P37377│ 1 1.20 1.10 1.0 1.20 1.10 1.15 1.05 1.20 1.30 1.25 1.14 
Beta-synuclein sp│Q63754│ 1 1.20 1.10 1.0 1.30 1.10 1.20 1.09 1.10 1.20 1.15 1.05 
Glutamate decarboxylase 2 sp│Q05683│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 0.90 0.90 0.90 0.90 
Glutamine synthetase sp│P09606│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein NDRG2 sp│Q8VBU2│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Receptor expression-enhancing protein 5 sp│B2RZ37│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 0.90 0.95 0.95 
Tumor protein D54 sp│Q6PCT3│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.00 1.00 1.00 
Neuronal pentraxin receptor (Fragment) tr│F1LSY2│ 1 0.90 0.95 1.0 0.80 0.80 0.80 0.84 0.70 0.80 0.75 0.79 
Phytanoyl-CoA hydroxylase-interacting protein sp│Q568Z9│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Phytanoyl-CoA hydroxylase-interacting 
protein-like sp│Q6AYN4│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 0.90 0.90 0.90 0.90 
Receptor-type tyrosine-protein phosphatase zeta sp│Q62656│ 1 1.20 1.10 1.0 1.00 1.10 1.05 0.95 1.00 1.10 1.05 0.95 
 
             
Redox regulation                            
6-phosphogluconate dehydrogenase, 
decarboxylating sp│P85968│ 1 1.20 1.10 1.0 1.10 1.20 1.15 1.05 1.20 1.00 1.10 1.00 
Glyceraldehyde-3-phosphate dehydrogenase sp│P04797│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.10 1.05 1.00 
Glycerol-3-phosphate dehydrogenase 
[NAD(+)], cytoplasmic sp│O35077│ 1 1.10 1.05 1.0 0.90 1.00 0.95 0.90 1.10 1.20 1.15 1.10 
Alcohol dehydrogenase [NADP(+)] sp│P51635│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Aldehyde dehydrogenase family 6, subfamily 
A1, isoform CRA_b tr│G3V7J0│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Aldehyde dehydrogenase, mitochondrial tr│F1LN88│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Dihydrolipoyl dehydrogenase, mitochondrial sp│Q6P6R2│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
L-lactate dehydrogenase B chain sp│P42123│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.10 1.10 1.05 
L-lactate dehydrogenase tr│B5DEN4│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.10 1.10 1.05 
Cytosolic 10-formyltetrahydrofolate 
dehydrogenase sp│P28037│ 1 0.80 0.90 1.0 1.00 0.90 0.95 1.06 0.80 1.00 0.90 1.00 
3-hydroxyacyl-CoA dehydrogenase type-2 tr│B0BMW2│ 1 1.20 1.10 1.0 1.10 1.00 1.05 0.95 1.10 1.20 1.15 1.05 
D-3-phosphoglycerate dehydrogenase sp│O08651│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 0.90 0.95 0.95 
Succinate-semialdehyde dehydrogenase, 
mitochondrial tr│D3ZWV7│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Peroxiredoxin 3 tr│G3V7I0│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 0.90 0.95 0.95 
Peroxiredoxin-1 sp│Q63716│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 




Peroxiredoxin-2 sp│P35704│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.10 1.05 1.00 
Peroxiredoxin-5, mitochondrial (Fragment) tr│D3ZEN5│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.10 1.10 1.10 1.10 
Peroxiredoxin-6 sp│O35244│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Thioredoxin sp│P11232│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.10 1.10 1.05 
Thioredoxin reductase 1, cytoplasmic tr│R9PXU4│ 1 0.80 0.90 1.0 1.00 1.00 1.00 1.11 0.80 1.00 0.90 1.00 
Thioredoxin-like protein 1 sp│Q920J4│ 1 1.00 1.00 1.0 0.90 0.80 0.85 0.85 1.00 1.00 1.00 1.00 
Aldose reductase sp│P07943│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.00 0.90 0.95 0.90 
Biliverdin reductase A sp│P46844│ 1 1.20 1.10 1.0 1.00 1.10 1.05 0.95 1.00 1.20 1.10 1.00 
Biliverdin reductase B (Flavin reductase 
(NADPH)) tr│B5DF65│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 0.90 0.95 0.95 
Carbonyl reductase [NADPH] 1 sp│P47727│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.00 1.00 1.00 
Dihydropteridine reductase sp│P11348│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.10 1.10 1.05 
Electron transfer flavoprotein subunit alpha, 
mitochondrial sp│P13803│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 1.10 1.05 1.05 
Ketimine reductase mu-crystallin sp│Q9QYU4│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.00 1.00 0.95 
Oxidation resistance protein 1 sp│Q4V8B0│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Prenylcysteine oxidase sp│Q99ML5│ 1 1.10 1.05 1.0 1.10 0.90 1.00 0.95 1.00 1.00 1.00 0.95 
Protein Sh3bgrl3 tr│B2RZ27│ 1 1.00 1.00 1.0 1.20 1.10 1.15 1.15 1.00 0.90 0.95 0.95 
Redox-regulatory protein FAM213A sp│Q6AXX6│ 1 0.80 0.90 1.0 0.70 0.90 0.80 0.89 0.80 0.90 0.85 0.94 
 
             
Protein synthesis/neurotrophic                            
  Transcription 
             
Transcription elongation factor B polypeptide 1 sp│P83941│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.10 1.05 1.05 
Transcription elongation factor B polypeptide 2 sp│P62870│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 0.90 0.95 0.95 
Transcriptional activator protein Pur-alpha tr│F1LPS8│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.00 1.00 0.95 
Transcriptional activator protein Pur-beta sp│Q68A21│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 0.90 1.00 0.95 0.95 
Transgelin-3 sp│P37805│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.00 1.00 0.95 
Histone H1.4 sp│P15865│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Histone H2A type 1-C sp│P0C169│ 1 1.10 1.05 1.0 1.00 0.90 0.95 0.90 1.10 1.20 1.15 1.10 
Histone H2A.Z sp│P0C0S7│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.10 1.10 1.10 1.10 
Histone H2B tr│D3ZNH4│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 




Histone H3 tr│B0BMY8│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
Histone H4 sp│P62804│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Brain acid soluble protein 1 sp│Q05175│ 1 0.70 0.85 1.0 1.00 0.80 0.90 1.06 0.90 1.00 0.95 1.12 
Nucleolin sp│P13383│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Nucleosome assembly protein 1-like 1 tr│G3V6H9│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 1.00 1.00 1.00 1.00 
Nucleosome assembly protein 1-like 4 sp│Q5U2Z3│ 1 1.10 1.05 1.0 1.20 1.10 1.15 1.10 1.10 1.10 1.10 1.05 
Heterogeneous nuclear ribonucleoprotein A1 tr│F7FEZ6│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Heterogeneous nuclear ribonucleoprotein A3 sp│Q6URK4│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
Heterogeneous nuclear ribonucleoprotein C 
(C1/C2) tr│G3V9R8│ 1 1.10 1.05 1.0 0.90 1.00 0.95 0.90 1.10 1.20 1.15 1.10 
Heterogeneous nuclear ribonucleoprotein D, 
isoform CRA_b tr│G3V6A4│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Heterogeneous nuclear ribonucleoprotein F sp│Q794E4│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Heterogeneous nuclear ribonucleoprotein H2 sp│Q6AY09│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 0.90 0.95 0.95 
Heterogeneous nuclear ribonucleoprotein M sp│Q62826│ 1 1.20 1.10 1.0 0.90 1.10 1.00 0.91 1.00 0.80 0.90 0.82 
Heterogeneous nuclear ribonucleoproteins 
A2/B1 (Fragment) tr│F1LNF1│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
Protein Hnrnpl tr│F1LQ48│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 0.90 0.95 0.95 
Hnrpk protein tr│Q5D059│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
Small nuclear ribonucleoprotein-associated 
protein tr│Q63747│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 1.00 0.80 0.90 0.90 
Nucleophosmin sp│P13084│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
LRRGT00192 tr│Q6QI16│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 0.90 0.90 0.90 0.95 
Leucine-rich PPR motif-containing protein, 
mitochondrial tr│F1LM33│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 1.00 1.10 1.05 1.11 
Leucine-rich repeat-containing protein 57 tr│F1LN70│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 0.90 0.90 0.90 0.95 
Activated RNA polymerase II transcriptional 
coactivator p15 sp│Q63396│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 0.90 0.90 0.90 0.90 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 
(Fragment) tr│B6DTP5│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 0.90 0.90 0.90 0.90 
DEAH (Asp-Glu-Ala-His) box polypeptide 9 
(Predicted) tr│D4A9D6│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.00 1.00 0.95 
ELAV (Embryonic lethal, abnormal vision, 
Drosophila)-like 1 (Hu antigen R) tr│B5DF91│ 1 1.10 1.05 1.0 1.20 1.10 1.15 1.10 1.00 0.90 0.95 0.90 
ELAV (Embryonic lethal, abnormal vision, 
Drosophila)-like 4 (Hu antigen D) tr│B0BMT8│ 1 1.20 1.10 1.0 1.00 1.20 1.10 1.00 1.10 1.00 1.05 0.95 
Protein Tardbp tr│I6L9G6│ 1 1.00 1.00 1.0 0.90 0.90 0.90 0.90 0.90 1.00 0.95 0.95 




Spliceosome RNA helicase Ddx39b sp│Q63413│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.20 1.15 1.10 
Plasminogen activator inhibitor 1 RNA-binding 
protein sp│Q6AXS5│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Matrin-3 sp│P43244│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
RNA binding motif protein, X-linked-like-1 sp│D4AE41│ 1 0.80 0.90 1.0 0.80 0.70 0.75 0.83 0.70 0.70 0.70 0.78 
O-linked N-acetylglucosamine (GlcNAc) 
transferase (UDP-N-
acetylglucosamine:polypeptide-N-
acetylglucosaminyl transferase), isoform 
CRA_b 
tr│G3V6F4│ 1 1.00 1.00 1.0 1.20 1.00 1.10 1.10 1.00 1.00 1.00 1.00 
Scaffold attachment factor B1 sp│O88453│ 1 1.00 1.00 1.0 1.10 0.90 1.00 1.00 0.80 0.70 0.75 0.75 
Non-POU domain-containing octamer-binding 
protein sp│Q5FVM4│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Protein Btaf1 tr│F1LW16│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.10 1.10 1.10 1.05 
KH domain-containing, RNA-binding, signal 
transduction-associated protein 1 sp│Q91V33│ 1 1.10 1.05 1.0 0.90 0.90 0.90 0.86 1.00 1.10 1.05 1.00 
Protein Rnf14 tr│Q3ZAU6│ 1 1.20 1.10 1.0 0.90 1.20 1.05 0.95 1.10 1.00 1.05 0.95 
  Translation 
             
Elongation factor 1-alpha 1 sp│P62630│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Elongation factor 1-alpha 2 sp│P62632│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.00 1.00 0.95 
Elongation factor 1-delta sp│Q68FR9│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 0.80 0.85 0.85 
Elongation factor 1-gamma sp│Q68FR6│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.00 1.00 0.95 
Elongation factor 2 sp│P05197│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Elongation factor Tu, mitochondrial sp│P85834│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
Eukaryotic initiation factor 4A-II sp│Q5RKI1│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Eukaryotic translation initiation factor 2 subunit 
1 sp│P68101│ 1 1.20 1.10 1.0 1.20 1.10 1.15 1.05 1.20 1.30 1.25 1.14 
Eukaryotic translation initiation factor 5 sp│Q07205│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 1.10 1.00 1.05 1.11 
Eukaryotic translation initiation factor 5A-1 sp│Q3T1J1│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Eukaryotic translation elongation factor 1 beta 
2 tr│B5DEN5│ 1 1.40 1.20 1.0 1.50 1.00 1.25 1.04 1.00 1.20 1.10 0.92 
Poly(A) binding protein, cytoplasmic 3 tr│B5DF80│ 1 1.10 1.05 1.0 1.20 1.00 1.10 1.05 1.00 1.30 1.15 1.10 
Polyadenylate-binding protein 1 sp│Q9EPH8│ 1 0.90 0.95 1.0 1.10 1.00 1.05 1.11 0.80 0.70 0.75 0.79 
40S ribosomal protein S14 tr│Q6PDV6│ 1 1.00 1.00 1.0 0.90 1.10 1.00 1.00 0.90 0.90 0.90 0.90 
40S ribosomal protein S17 sp│P04644│ 1 1.20 1.10 1.0 1.10 1.10 1.10 1.00 1.10 1.20 1.15 1.05 




40S ribosomal protein S28 sp│P62859│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
40S ribosomal protein S3 sp│P62909│ 1 0.90 0.95 1.0 1.00 1.10 1.05 1.11 0.90 1.00 0.95 1.00 
40S ribosomal protein S3a tr│M0R6L4│ 1 1.10 1.05 1.0 1.30 1.10 1.20 1.14 1.10 1.00 1.05 1.00 
40S ribosomal protein S4, X isoform sp│P62703│ 1 1.20 1.10 1.0 1.20 0.90 1.05 0.95 1.00 1.20 1.10 1.00 
40S ribosomal protein S6 (Fragment) tr│M0RD75│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.10 1.20 1.15 1.15 
40S ribosomal protein S8 tr│B2RYR8│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
40S ribosomal protein S9 sp│P29314│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 0.90 0.90 0.90 0.95 
40S ribosomal protein SA sp│P38983│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 0.90 1.00 0.95 0.95 
60S acidic ribosomal protein P0 sp│P19945│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 0.90 0.90 0.90 0.90 
60S acidic ribosomal protein P1 sp│P19944│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 0.90 0.95 0.90 
60S ribosomal protein L11 sp│P62914│ 1 1.20 1.10 1.0 1.00 1.00 1.00 0.91 1.00 1.00 1.00 0.91 
60S ribosomal protein L13 tr│D3ZRM9│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.10 1.05 1.05 
60S ribosomal protein L13a tr│Q5RK10│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
60S ribosomal protein L17 sp│P24049│ 1 0.80 0.90 1.0 0.90 0.90 0.90 1.00 0.70 0.90 0.80 0.89 
60S ribosomal protein L18 (Fragment) tr│Q0QEW8│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 0.90 0.90 0.90 0.95 
60S ribosomal protein L19 sp│P84100│ 1 1.00 1.00 1.0 1.20 1.20 1.20 1.20 0.90 0.90 0.90 0.90 
60S ribosomal protein L23 sp│P62832│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
60S ribosomal protein L24 sp│P83732│ 1 1.10 1.05 1.0 1.10 0.90 1.00 0.95 1.00 1.10 1.05 1.00 
60S ribosomal protein L27 sp│P61354│ 1 1.00 1.00 1.0 1.20 1.10 1.15 1.15 1.00 1.00 1.00 1.00 
60S ribosomal protein L27a sp│P18445│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 0.90 0.90 0.90 0.95 
60S ribosomal protein L3 sp│P21531│ 1 1.10 1.05 1.0 1.10 0.90 1.00 0.95 1.00 1.00 1.00 0.95 
60S ribosomal protein L31 sp│P62902│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.00 1.00 1.00 
60S ribosomal protein L32 sp│P62912│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 0.90 0.90 0.90 0.90 
60S ribosomal protein L4 tr│Q6P3V9│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 1.00 1.00 1.00 1.05 
60S ribosomal protein L6 tr│F1LQS3│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.00 1.00 1.00 
60S ribosomal protein L7 tr│B0K031│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
RCG25732, isoform CRA_b tr│B5DEM5│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
RCG45400 tr│G3V7C6│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
RCG45476, isoform CRA_d tr│B0K021│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
RCG45615, isoform CRA_a tr│B2RYU2│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 0.90 1.00 0.95 0.95 
RCG62292, isoform CRA_a tr│B5DEL9│ 1 1.00 1.00 1.0 1.30 1.00 1.15 1.15 1.00 1.00 1.00 1.00 




Ribosomal protein (Fragment) tr│Q4KM60│ 1 1.20 1.10 1.0 1.00 1.10 1.05 0.95 1.10 1.20 1.15 1.05 
Ribosomal protein L9 tr│Q6P9U5│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 1.10 1.10 1.10 1.16 
Ribonuclease UK114 sp│P52759│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 0.90 0.95 0.90 
Rps16 protein (Fragment) tr│B0K038│ 1 1.00 1.00 1.0 0.90 0.90 0.90 0.90 1.00 1.00 1.00 1.00 
Protein LOC100909878 tr│D3ZLL8│ 1 1.10 1.05 1.0 1.00 0.90 0.95 0.90 0.90 0.90 0.90 0.86 
Protein LOC100911774 tr│Q1RP74│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 0.90 1.00 0.95 0.95 
Protein LOC100911918 (Fragment) tr│M0R7M8│ 1 1.30 1.15 1.0 1.10 1.10 1.10 0.96 1.10 1.20 1.15 1.00 
Protein LOC100912210 (Fragment) tr│F1M6F4│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.10 1.05 1.00 
Protein Nars tr│F1LPV0│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.10 1.05 1.05 
Pcbp2 protein tr│Q6AYU2│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.00 1.00 1.00 
Protein IMPACT sp│Q5GFD9│ 1 1.10 1.05 1.0 0.90 0.90 0.90 0.86 1.00 1.00 1.00 0.95 
  Post-translational modification 
             
Peptidylprolyl cis/trans isomerase, NIMA-
interacting 1 tr│B0BNL2│ 1 1.10 1.05 1.0 0.90 0.90 0.90 0.86 1.10 1.10 1.10 1.05 
Peptidyl-prolyl cis-trans isomerase A sp│P10111│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Peptidyl-prolyl cis-trans isomerase B sp│P24368│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Peptidyl-prolyl cis-trans isomerase FKBP1A sp│Q62658│ 1 1.00 1.00 1.0 1.20 1.20 1.20 1.20 1.00 1.00 1.00 1.00 
Protein disulfide-isomerase A3 sp│P11598│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
Protein disulfide-isomerase A6 sp│Q63081│ 1 1.00 1.00 1.0 1.00 1.20 1.10 1.10 1.00 0.90 0.95 0.95 
Protein disulfide-isomerase sp│P04785│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 0.90 0.90 0.90 0.95 
Endoplasmin sp│Q66HD0│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Protein Ppidl1 tr│M0RB67│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.00 1.00 0.95 
  Biosynthesis 
             
Acyl carrier protein tr│D3ZF13│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 1.00 0.90 0.95 1.00 
Fatty acid synthase sp│P12785│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.10 1.00 1.05 1.00 
Cytosolic acyl coenzyme A thioester hydrolase sp│Q64559│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Adenosylhomocysteinase (Fragment) tr│B5DFN2│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
Adenosylhomocysteinase sp│P10760│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Bifunctional purine biosynthesis protein PURH sp│O35567│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.10 1.05 1.00 
N-acetylneuraminic acid synthase tr│B1WC26│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
NSFL1 cofactor p47 sp│O35987│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.00 1.00 0.95 
Alanine--tRNA ligase, cytoplasmic sp│P50475│ 1 1.20 1.10 1.0 1.20 1.10 1.15 1.05 1.10 1.10 1.10 1.00 




Glycine--tRNA ligase tr│G3V7G8│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Serine--tRNA ligase, cytoplasmic OS=Rattus 
norvegicus GN=Sars PE=1 SV=3 sp│Q6P799│ 1 1.10 1.05 1.0 1.10 1.20 1.15 1.10 1.10 1.10 1.10 1.05 
Aspartyl-tRNA synthetase tr│A9CMB7│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.00 1.00 0.95 
              
Protein degradation                            
Ubiquitin carboxyl-terminal hydrolase isozyme 
L1 sp│Q00981│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.00 1.00 0.95 
Ubiquitin carboxyl-terminal hydrolase tr│D3ZVQ0│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Ubiquitin carboxyl-terminal hydrolase tr│D3ZC84│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 1.00 1.10 1.05 1.05 
Ubiquitin carboxyl-terminal hydrolase tr│G4XKZ2│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.00 1.00 0.95 
Ubiquitin thioesterase OTUB1 sp│B2RYG6│ 1 0.90 0.95 1.0 1.00 1.10 1.05 1.11 0.90 0.90 0.90 0.95 
Ubiquitin-conjugating enzyme E2 N sp│Q9EQX9│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Ubiquitin-like modifier-activating enzyme 1 sp│Q5U300│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.00 1.00 1.00 
Toll-interacting protein sp│A2RUW1│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 0.90 1.00 0.95 0.95 
Protein Ubqln2 tr│D4AA63│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.00 1.00 1.00 
Protein Ube2o (Fragment) tr│F1M403│ 1 1.00 1.00 1.0 1.10 1.20 1.15 1.15 0.90 0.90 0.90 0.90 
Protein Ube2m tr  D3ZNQ6│ 1 1.00 1.00 1.0 1.10 0.90 1.00 1.00 1.00 1.10 1.05 1.05 
Polyubiquitin-C tr│F1LML2│ 1 1.10 1.05 1.0 1.30 1.10 1.20 1.14 1.00 1.10 1.05 1.00 
Huntingtin interacting protein 2 (Predicted), 
isoform CRA_a tr│D3ZXS8│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 0.90 1.00 0.95 0.95 
Ubiquilin-1 sp│Q9JJP9│ 1 0.90 0.95 1.0 1.00 0.80 0.90 0.95 1.10 1.00 1.05 1.11 
UV excision repair protein RAD23 homolog B sp│Q4KMA2│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Transitional endoplasmic reticulum ATPase sp│P46462│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.00 1.05 1.00 
S-phase kinase-associated protein 1 sp│Q6PEC4│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
F-box/LRR-repeat protein 16 sp│Q5MJ12│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 0.90 0.90 0.90 0.95 
COP9 signalosome complex subunit 2 sp│P61203│ 1 1.20 1.10 1.0 1.00 1.00 1.00 0.91 1.00 1.10 1.05 0.95 
COP9 signalosome complex subunit 4 sp│Q68FS2│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.00 1.10 1.05 1.00 
COP9 signalosome complex subunit 8 sp│Q6P4Z9│ 1 1.30 1.15 1.0 1.30 1.30 1.30 1.13 1.10 1.10 1.10 0.96 
26S protease regulatory subunit 4 sp│P62193│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.10 0.90 1.00 0.95 
26S protease regulatory subunit 6A sp│Q63569│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.00 0.90 0.95 0.90 
26S protease regulatory subunit 7 tr│G3V7L6│ 1 0.90 0.95 1.0 1.10 1.10 1.10 1.16 1.00 1.00 1.00 1.05 




26S protease regulatory subunit 8 sp│P62198│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 1.00 1.00 1.00 1.05 
Protein Psmc6 tr│G3V6W6│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 0.90 0.95 0.95 
Xaa-Pro aminopeptidase 1 sp│O54975│ 1 1.00 1.00 1.0 1.20 1.00 1.10 1.10 0.90 0.90 0.90 0.90 
Aspartyl aminopeptidase tr│Q4V8H5│ 1 1.00 1.00 1.0 1.20 1.10 1.15 1.15 0.90 1.00 0.95 0.95 
Cytosolic non-specific dipeptidase sp│Q6Q0N1│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.10 1.00 1.05 1.05 
Tripeptidyl-peptidase 2 sp│Q64560│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.10 1.05 1.00 
Dipeptidyl peptidase 3 sp│O55096│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 0.80 0.90 0.85 0.89 
Thimet oligopeptidase sp│P24155│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.10 1.05 1.05 
Anionic trypsin-1 sp│P00762│ 1 1.40 1.20 1.0 1.30 1.10 1.20 1.00 1.20 1.50 1.35 1.13 
Acylamino-acid-releasing enzyme sp│P13676│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 0.90 0.80 0.85 0.85 
Cathepsin D tr│Q6P6T6│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.00 1.00 0.95 
Isoaspartyl peptidase/L-asparaginase sp│Q8VI04│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.00 1.00 1.00 
Proprotein convertase subtilisin/kexin type 1 
inhibitor tr│G3V6X7│ 1 1.10 1.05 1.0 1.20 1.10 1.15 1.10 1.00 0.90 0.95 0.90 
Protein Npepps tr│F1M9V7│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.00 1.00 1.00 0.95 
SP120 tr│Q63555│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
26S proteasome non-ATPase regulatory subunit 
13 sp│B0BN93│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
26S proteasome non-ATPase regulatory subunit 
2 sp│Q4FZT9│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.10 1.00 1.05 1.00 
Proteasome (Prosome, macropain) 26S subunit, 
non-ATPase, 6 tr│Q6PCT9│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Proteasome subunit alpha type tr│Q6P9V6│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.10 1.20 1.15 1.10 
Proteasome subunit alpha type tr│F1LSQ6│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.00 1.00 1.00 
Proteasome subunit alpha type-1 sp│P18420│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 1.00 0.90 0.95 0.95 
Proteasome subunit alpha type-3 sp│P18422│ 1 1.10 1.05 1.0 0.90 1.10 1.00 0.95 1.00 1.10 1.05 1.00 
Proteasome subunit alpha type-4 sp│P21670│ 1 1.10 1.05 1.0 0.90 0.90 0.90 0.86 1.10 1.10 1.10 1.05 
Proteasome subunit alpha type-6 sp│P60901│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 0.90 1.00 0.95 0.95 
Proteasome subunit beta type tr│F1LNN1│ 1 1.10 1.05 1.0 0.90 1.00 0.95 0.90 1.00 0.90 0.95 0.90 
Proteasome subunit beta type tr│G3V8U9│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Proteasome subunit beta type-1 sp│P18421│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.00 1.00 1.00 0.95 
Protein Pithd1 tr│D4ABS5│ 1 1.10 1.05 1.0 1.00 1.20 1.10 1.05 1.10 1.00 1.05 1.00 
Protein Cops7a tr│F1MAA2│ 1 1.20 1.10 1.0 1.00 1.10 1.05 0.95 1.00 1.00 1.00 0.91 
4-aminobutyrate aminotransferase, sp│P50554│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 1.00 1.00 1.00 






             
Other                            
Hemoglobin alpha, adult chain 2 tr│B1H216│ 1 1.30 1.15 1.0 1.10 1.10 1.10 0.96 1.10 1.10 1.10 0.96 
Hemoglobin subunit beta-1 sp│P02091│ 1 1.30 1.15 1.0 1.10 1.10 1.10 0.96 1.10 1.20 1.15 1.00 
Hemoglobin subunit beta-2 sp│P11517│ 1 1.30 1.15 1.0 1.10 1.10 1.10 0.96 1.10 1.10 1.10 0.96 
Ferritin tr│F1M5T1│ 1 0.90 0.95 1.0 1.20 1.10 1.15 1.21 1.10 0.80 0.95 1.00 
Heat shock 70 kDa protein 4 tr│F1LRV4│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.10 1.05 1.05 
Heat shock 70 kDa protein 4L tr│B4F772│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 1.00 0.95 1.00 
Heat shock 70kDa protein 12A (Predicted), 
isoform CRA_a tr│D3ZC55│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.00 1.05 1.00 
Heat shock cognate 71 kDa protein sp│P63018│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Heat shock protein 105 kDa sp│Q66HA8│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Heat shock protein HSP 90-alpha sp│P82995│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Heat shock protein HSP 90-beta sp│P34058│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.00 1.00 0.95 
28 kDa heat- and acid-stable phosphoprotein sp│Q62785│ 1 1.20 1.10 1.0 1.40 1.20 1.30 1.18 1.00 1.10 1.05 0.95 
10 kDa heat shock protein, mitochondrial sp│P26772│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
60 kDa heat shock protein, mitochondrial sp│P63039│ 1 1.00 1.00 1.0 0.90 0.90 0.90 0.90 1.00 1.00 1.00 1.00 
Chaperonin containing Tcp1, subunit 6A (Zeta 
1) tr│Q3MHS9│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Chaperonin subunit 8 (Theta) (Predicted), 
isoform CRA_a tr│D4ACB8│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
DnaJ (Hsp40) homolog, subfamily A, member 
2 tr│Q5M9H7│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
DnaJ (Hsp40) homolog, subfamily C, member 
6 (Predicted) tr│D4A0I5│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.00 1.00 1.00 
Hsp90 co-chaperone Cdc37 sp│Q63692│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.00 1.20 1.10 1.05 
Hsc70-interacting protein sp│P50503│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
Stress-induced-phosphoprotein 1 sp│O35814│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.00 1.00 0.95 
Stress-70 protein, mitochondrial tr│F1M953│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
T-complex protein 1 subunit alpha sp│P28480│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.10 1.10 1.05 
T-complex protein 1 subunit beta sp│Q5XIM9│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
T-complex protein 1 subunit delta sp│Q7TPB1│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 




T-complex protein 1 subunit epsilon sp│Q68FQ0│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.10 1.10 1.05 
T-complex protein 1 subunit gamma sp│Q6P502│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.00 1.00 1.00 
6-phosphofructokinase tr│Q52KS1│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
6-phosphofructokinase, liver type sp│P30835│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.10 1.05 1.05 
Glucose-6-phosphate isomerase sp│Q6P6V0│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.10 1.05 1.00 
Glycogen phosphorylase, brain form 
(Fragment) sp│P53534│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Alpha glucosidase 2 alpha neutral subunit 
(Predicted) tr│D3ZAN3│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.80 0.80 0.80 0.84 
78 kDa glucose-regulated protein sp│P06761│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Fructosamine-3-kinase-related protein tr│B2RYN1│ 1 0.70 0.85 1.0 0.80 0.70 0.75 0.88 0.70 0.70 0.70 0.82 
Fructose-bisphosphate aldolase A sp│P05065│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Fructose-bisphosphate aldolase C sp│P09117│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Ab2-076 tr│Q7TP61│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.00 1.10 1.05 1.00 
Ab2-417 tr│Q7TMC7│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 1.00 1.00 1.00 
Ac1002 tr│Q7TQ90│ 1 1.20 1.10 1.0 1.00 0.90 0.95 0.86 1.00 1.10 1.05 0.95 
Active BCR-related gene (Predicted) tr│D4A6K9│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Alpha-enolase sp│P04764│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.10 1.10 1.05 
C-1-tetrahydrofolate synthase, cytoplasmic tr│G3V6S5│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 1.00 0.80 0.90 0.95 
C38 protein tr│B7X6I3│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 1.00 0.90 0.95 1.00 
Uncharacterized protein (Fragment) tr│B5DEP6│ 1 1.20 1.10 1.0 1.00 1.10 1.05 0.95 1.10 1.10 1.10 1.00 
Uncharacterized protein (Fragment) tr│M0RAR9│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.10 0.80 0.95 0.95 
Uncharacterized protein (Fragment) tr│F1M8C9│ 1 1.40 1.20 1.0 1.00 1.20 1.10 0.92 1.20 1.40 1.30 1.08 
Uncharacterized protein tr│D3ZIY7│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.10 1.10 1.10 1.10 
Uncharacterized protein tr│D4A269│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.10 1.10 1.05 
tr|D3ZAP7|D3ZAP7_RAT-DECOY Protein 
Chd7 tr│D3ZAP7│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.20 1.10 1.10 
tr|D3ZV60|D3ZV60_RAT-DECOY Protein 
Cenpe tr│D3ZV60│ 1 0.80 0.90 1.0 1.00 1.00 1.00 1.11 0.90 0.90 0.90 1.00 
tr|F1LNQ8|F1LNQ8_RAT-DECOY 
Uncharacterized protein (Fragment) tr│F1LNQ8│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.00 1.10 1.05 1.00 
tr|F1LPM1|F1LPM1_RAT-DECOY 
Protocadherin Fat 2 tr│F1LPM1│ 1 1.30 1.15 1.0 1.20 1.30 1.25 1.09 1.30 1.50 1.40 1.22 
tr|F1LY70|F1LY70_RAT-DECOY Protein 
Birc6 (Fragment) tr│F1LY70│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 1.00 0.90 0.95 1.00 




Protein LOC100361103 tr│D3Z9G3│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 0.90 0.90 0.90 0.90 
Protein LOC100362298 (Fragment) tr│D3ZM33│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Protein LOC100362339 tr│D4A6G6│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein LOC100362751 tr│D4A4D5│ 1 1.10 1.05 1.0 1.20 1.20 1.20 1.14 1.10 1.20 1.15 1.10 
Protein LOC100365676 tr│D4ABI7│ 1 0.80 0.90 1.0 0.80 0.80 0.80 0.89 0.80 0.80 0.80 0.89 
Protein LOC683961 tr│M0RCY2│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.10 1.00 1.05 1.00 
Prostaglandin reductase 2 sp│Q5BK81│ 1 0.90 0.95 1.0 0.90 1.20 1.05 1.11 0.80 0.90 0.85 0.89 
Nitrilase 1, isoform CRA_a tr│F7ESM5│ 1 0.90 0.95 1.0 1.10 1.20 1.15 1.21 1.10 1.00 1.05 1.11 
D-dopachrome decarboxylase sp│P80254│ 1 1.20 1.10 1.0 1.20 1.30 1.25 1.14 1.10 1.20 1.15 1.05 
Glutathione S-transferase Mu 1 tr│G3V983│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Glutathione S-transferase Mu 5 sp│Q9Z1B2│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Glutathione S-transferase omega 1 tr│B6DYQ5│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Glutathione S-transferase tr│B6DYP8│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Glutathione S-transferase pi tr│B6DYQ7│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Glutathione S-transferase Yb-3 sp│P08009│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.10 1.10 1.05 
Aspartate aminotransferase, cytoplasmic sp│P13221│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 1.00 1.00 1.00 1.00 
Aspartate aminotransferase, mitochondrial sp│P00507│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 1.00 1.00 1.00 
Branched-chain-amino-acid aminotransferase, 
cytosolic sp│P54690│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 0.90 0.95 0.95 
Hypoxanthine-guanine 
phosphoribosyltransferase sp│P27605│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.10 1.05 1.00 
CDP-diacylglycerol--inositol 3-
phosphatidyltransferase sp│P70500│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 0.90 0.90 0.90 0.90 
Phosphoserine aminotransferase tr│Q68FU2│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Protein-L-isoaspartate(D-aspartate) O-
methyltransferase sp│P22062│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.10 1.05 1.00 
Succinyl-CoA:3-ketoacid coenzyme A 
transferase 1, mitochondrial sp│B2GV06│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.00 1.00 1.00 1.00 
Thiosulfate sulfurtransferase sp│P24329│ 1 1.00 1.00 1.0 1.20 1.10 1.15 1.15 1.00 0.90 0.95 0.95 
Ornithine aminotransferase, mitochondrial sp│P04182│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
Adenine phosphoribosyltransferase sp│P36972│ 1 1.10 1.05 1.0 1.40 1.20 1.30 1.24 1.20 1.20 1.20 1.14 
Geranylgeranyl transferase type-2 subunit alpha sp│Q08602│ 1 0.90 0.95 1.0 1.00 0.70 0.85 0.89 0.80 0.80 0.80 0.84 
Acetyl-CoA acetyltransferase, mitochondrial sp│P17764│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Acyl-CoA synthetase isoform 6 variant2 tr│Q6IU14│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 




Pyridoxal kinase tr│G3V647│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 0.90 0.90 0.90 0.90 
UMP-CMP kinase sp│Q4KM73│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 0.90 1.10 1.00 0.95 
Phosphoglycerate kinase 1 sp│P16617│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.10 1.10 1.05 
Ribose-phosphate pyrophosphokinase 1 sp│P60892│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Hexokinase-1 sp│P05708│ 1 0.90 0.95 1.0 0.90 1.00 0.95 1.00 0.90 0.90 0.90 0.95 
Aminopeptidase B sp│O09175│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.10 1.05 1.00 
Atlastin-1 sp│Q6PST4│ 1 0.90 0.95 1.0 1.10 1.00 1.05 1.11 1.00 0.90 0.95 1.00 
Calreticulin sp│P18418│ 1 1.00 1.00 1.0 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 
Carbonic anhydrase 1 sp│B0BNN3│ 1 1.30 1.15 1.0 0.90 1.00 0.95 0.83 1.30 1.00 1.15 1.00 
Carbonic anhydrase 2 sp│P27139│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.20 1.10 1.15 1.10 
Clusterin sp│P05371│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 0.90 0.90 0.90 0.90 
Contactin-1 sp│Q63198│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Cullin-3 sp│B5DF89│ 1 1.20 1.10 1.0 1.10 1.10 1.10 1.00 1.10 1.20 1.15 1.05 
Cullin-associated NEDD8-dissociated protein 1 sp│P97536│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.00 1.00 0.95 
Cysteine and glycine-rich protein 1 sp│P47875│ 1 1.00 1.00 1.0 1.30 1.10 1.20 1.20 1.00 1.20 1.10 1.10 
DnaJ homolog subfamily C member 5 sp│P60905│ 1 1.00 1.00 1.0 0.90 1.00 0.95 0.95 1.10 1.00 1.05 1.05 
EF-hand domain-containing protein D2 sp│Q4FZY0│ 1 1.20 1.10 1.0 1.20 1.10 1.15 1.05 1.10 1.10 1.10 1.00 
Fam49b protein tr│B2GUZ9│ 1 1.10 1.05 1.0 1.00 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Family with sequence similarity 49, member A tr│B0BN65│ 1 1.00 1.00 1.0 1.10 1.00 1.05 1.05 0.90 1.20 1.05 1.05 
Fumarylacetoacetase tr│F1M6W1│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
Fumarylacetoacetate hydrolase domain-
containing protein 2 sp│B2RYW9│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
S-formylglutathione hydrolase sp│B0BNE5│ 1 1.00 1.00 1.0 1.10 0.90 1.00 1.00 1.10 1.00 1.05 1.05 
Galectin tr│B4F7A3│ 1 1.00 1.00 1.0 1.00 1.10 1.05 1.05 1.00 0.90 0.95 0.95 
Glia maturation factor beta sp│Q63228│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.10 1.10 1.10 1.05 
Glyoxalase domain-containing protein 4 tr│GLOD4│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Inosine triphosphate pyrophosphatase sp│D3ZW55│ 1 0.90 0.95 1.0 0.90 0.90 0.90 0.95 1.00 1.10 1.05 1.11 
Lactoylglutathione lyase sp│Q6P7Q4│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 1.00 1.00 1.00 1.00 
Low molecular weight phosphotyrosine protein 
phosphatase sp│P41498│ 1 1.20 1.10 1.0 1.10 1.10 1.10 1.00 1.10 1.10 1.10 1.00 
N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 1 sp│O08557│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.00 1.10 1.05 1.00 
Neuromodulin sp│P07936│ 1 0.90 0.95 1.0 1.10 0.90 1.00 1.05 1.20 1.20 1.20 1.26 




Parathymosin tr│B3DM95│ 1 1.10 1.05 1.0 1.10 1.10 1.10 1.05 1.00 1.10 1.05 1.00 
Pdxp protein tr│B2GV79│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Pgm1 protein (Fragment) tr│A1A5L2│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.00 1.00 0.95 
Phosphoglycerate mutase 1 sp│P25113│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.00 1.05 1.00 
Phosphorylase tr│B1WBU9│ 1 0.90 0.95 1.0 1.00 1.00 1.00 1.05 0.90 0.90 0.90 0.95 
Programmed cell death 6-interacting protein sp│Q9QZA2│ 1 0.90 0.95 1.0 1.10 1.20 1.15 1.21 0.90 1.00 0.95 1.00 
Protein Ak5 tr│M0R7U1│ 1 1.10 1.05 1.0 0.90 1.00 0.95 0.90 1.00 1.00 1.00 0.95 
Protein Cct7 tr│D4AC23│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein DJ-1 sp│O88767│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.00 1.00 0.95 
Protein Irgq tr│M0R686│ 1 1.00 1.00 1.0 1.00 0.90 0.95 0.95 0.90 1.10 1.00 1.00 
Protein Ppa1 tr│F7EPH4│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.00 1.00 1.00 0.95 
Protein RGD1304884 tr│D4A3C2│ 1 1.00 1.00 1.0 1.30 1.10 1.20 1.20 1.10 1.10 1.10 1.10 
Protein RGD1309586 tr│D3ZN21│ 1 1.50 1.25 1.0 1.40 1.70 1.55 1.24 1.90 1.70 1.80 1.44 
Protein RGD1559864 tr│D3ZBS6│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Protein RGD1564698 tr│F1LT36│ 1 1.00 1.00 1.0 0.80 1.00 0.90 0.90 1.20 1.00 1.10 1.10 
Protein RUFY3 sp│Q5FVJ0│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Protein Sept6 tr│B5DFG5│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.00 1.10 1.05 1.00 
Protein Ugp2 tr│Q4V8I9│ 1 1.20 1.10 1.0 0.90 1.10 1.00 0.91 0.90 0.90 0.90 0.82 
Protein unc-45 homolog A tr│M0RC57│ 1 1.00 1.00 1.0 1.10 0.90 1.00 1.00 0.90 0.90 0.90 0.90 
Protein Nbeal2 tr│D3ZUA5│ 1 0.70 0.85 1.0 0.90 1.10 1.00 1.18 0.80 0.70 0.75 0.88 
Protein Cisd2 tr│D4AAE9│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.00 1.00 1.00 
Protein Tsnaxip1 tr  D3ZU07│ 1 1.00 1.00 1.0 0.90 0.90 0.90 0.90 1.00 1.00 1.00 1.00 
Ptges3 protein tr│B2GV92│ 1 1.00 1.00 1.0 1.10 0.90 1.00 1.00 1.00 1.00 1.00 1.00 
Purine nucleoside phosphorylase (Fragment) tr│D3ZXK9│ 1 1.10 1.05 1.0 1.10 1.20 1.15 1.10 1.00 1.00 1.00 0.95 
Serum albumin sp│P02770│ 1 1.10 1.00 1.0 0.90 1.00 0.95 0.95 1.00 1.10 1.05 1.05 
Sulfated glycoprotein 1 tr│F7EPE0│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Superoxide dismutase [Cu-Zn] tr│Q6LDS4│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.10 1.10 1.10 1.10 
Superoxide dismutase [Mn], mitochondrial sp│P07895│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Transaldolase sp│Q9EQS0│ 1 1.10 1.05 1.0 1.00 0.90 0.95 0.90 1.00 1.00 1.00 0.95 
Transketolase sp│P50137│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.00 1.05 1.00 
Triosephosphate isomerase sp│P48500│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.10 1.10 1.05 




Tripartite motif-containing protein 2 
(Fragment) tr│D3ZM62│ 1 1.10 1.05 1.0 1.20 1.10 1.15 1.10 1.00 1.10 1.05 1.00 
WD repeat-containing protein 1 sp│Q5RKI0│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
WD repeat-containing protein 7 sp│Q9ERH3│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Guanine deaminase tr│Q9JKB7│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Casein kinase II subunit alpha sp│P19139│ 1 1.10 1.05 1.0 1.00 1.00 1.00 0.95 1.10 1.00 1.05 1.00 
NAD-dependent protein deacylase sirtuin-5, 
mitochondrial sp│Q68FX9│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 0.80 0.80 0.80 0.84 
NAD(P)H-hydrate epimerase sp│B0BNM1│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Zero beta-globin (Fragment) tr│Q63011│ 1 1.30 1.15 1.0 1.00 1.00 1.00 0.87 1.10 1.20 1.15 1.00 
Monoglyceride lipase sp│Q8R431│ 1 1.00 1.00 1.0 0.80 1.00 0.90 0.90 1.10 1.10 1.10 1.10 
Cystatin-B sp│P01041│ 1 1.20 1.10 1.0 1.10 1.10 1.10 1.00 1.10 1.20 1.15 1.05 
Cystatin-C sp│P14841│ 1 1.00 1.00 1.0 1.10 1.10 1.10 1.10 1.00 1.00 1.00 1.00 
Complement component 1 Q subcomponent-
binding protein, mitochondrial sp│O35796│ 1 1.10 1.05 1.0 1.10 0.80 0.95 0.90 1.20 0.90 1.05 1.00 
Translationally-controlled tumor protein sp│P63029│ 1 1.10 1.05 1.0 1.10 1.00 1.05 1.00 1.10 1.10 1.10 1.05 
Acidic leucine-rich nuclear phosphoprotein 32 
family member A sp│P49911│ 1 0.90 0.95 1.0 1.10 1.00 1.05 1.11 1.00 1.00 1.00 1.05 
C-terminal-binding protein 1 sp│Q9Z2F5│ 1 1.00 1.00 1.0 0.90 1.10 1.00 1.00 1.00 0.90 0.95 0.95 
Ganglioside-induced differentiation-associated 
protein 1-like 1 (Predicted) tr│B4F774│ 1 1.00 1.00 1.0 0.90 1.10 1.00 1.00 1.00 1.00 1.00 1.00 
LanC lantibiotic synthetase component C-like 2 
(Bacterial) tr│Q68FQ9│ 1 1.00 1.00 1.0 0.90 1.10 1.00 1.00 1.00 1.00 1.00 1.00 
Latexin sp│Q64361│ 1 0.90 0.95 1.0 1.00 0.90 0.95 1.00 1.00 1.10 1.05 1.11 
Macrophage migration inhibitory factor sp│P30904│ 1 0.90 0.95 1.0 1.10 1.00 1.05 1.11 0.90 0.90 0.90 0.95 
ES1 protein homolog, mitochondrial sp│P56571│ 1 1.00 1.00 1.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
6-phosphogluconolactonase sp│P85971│ 1 0.90 0.95 1.0 1.00 1.10 1.05 1.11 1.10 1.20 1.15 1.21 
Myotrophin sp│P62775│ 1 1.20 1.10 1.0 1.10 1.10 1.10 1.00 1.10 1.20 1.15 1.05 
Asparagine-linked glycosylation 2 homolog, 
isoform CRA_a tr│G3V6U3│ 1 1.00 1.00 1.0 0.80 1.10 0.95 0.95 0.90 1.00 0.95 0.95 







             




          
          
Protein / function Accession No Ctr 1 Ctr 2 Avg Ctr/Ctr MS+RS 1 MS+RS 2 Avg MS+RS/ Ctr 
          
Cytoskeletal/Structural          
          
  Actin-binding          
Actin related protein 2/3 complex, subunit 3  tr│B2GV73│ 1 1.30 1.15 1.00 1.10 1.30 1.20 1.04 
Actin related protein 2/3 complex, subunit 4 
(Predicted), isoform CRA_a  tr│B2RZ72│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Actin, alpha cardiac muscle 1 sp│P68035│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Actin-related protein 2  sp│Q5M7U6│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Actin-related protein 2/3 complex subunit 1A  sp│Q99PD4│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Actin-related protein 2/3 complex subunit 2  sp│P85970│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Actin-related protein 2/3 complex subunit 5  sp│Q4KLF8│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Actin-related protein 2/3 complex subunit 5-like 
protein  sp│A1L108│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Actin-related protein 3  sp│Q4V7C7│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Actin, cytoplasmic 1  sp│P60711│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Actn1 protein  tr│Q6GMN8│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Alpha II spectrin  tr│C9EH87│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Spectrin beta 3  tr│F1MA36│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Non-erythroid spectrin beta  tr│Q6XD99│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
F-actin-capping protein subunit alpha-1  sp│B2GUZ5│ 1 1.10 1.05 1.00 0.90 1.20 1.05 1.00 
F-actin-capping protein subunit alpha-2  sp│Q3T1K5│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
F-actin-capping protein subunit beta  sp│Q5XI32│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Neurabin-1  sp│O35867│ 1 0.90 0.95 1.00 1.10 1.10 1.10 1.16 
ARP1 actin-related protein 1 homolog B tr│B2RYJ7│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Dynactin 1, isoform CRA_a  tr│D4A8U7│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Dynactin subunit 2  sp│Q6AYH5│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
 Table A 2:  Proteomic (4-plex) profile of the PFC of Ctr and MS+RS rats.  Data presented as ratio to Ctr 1.  The average Ctr ratio (Avg) was 
calculated and normalized to 1.0 (blue).  Data in red differed from the normalized Ctr/Ctr by more than 20% (1.2-fold increase or decrease). 




Protein Dctn3  tr│D4A1B8│ 1 1.00 1.00 1.00 0.90 0.80 0.85 0.85 
Alpha-actinin-4  sp│Q9QXQ0│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Tropomodulin-1  sp│P70567│ 1 0.80 0.90 1.00 1.00 1.00 1.00 1.11 
Tropomodulin-2  sp│P70566│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Tropomyosin 5  tr│P97726│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Tropomyosin alpha isoform  tr│Q91XN7│ 1 1.00 1.00 1.00 1.20 1.30 1.25 1.25 
Tropomyosin alpha-4 chain  sp│P09495│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Myl6 protein  tr│B2GV99│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Myosin, heavy polypeptide 10, non-muscle, isoform 
CRA_b  tr│G3V9Y1│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Myosin, heavy polypeptide 9, non-muscle  tr│G3V6P7│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Protein Twf2  tr│B0BMY7│ 1 1.00 1.00 1.00 1.20 1.20 1.20 1.20 
Plectin 6  tr│Q6S3A0│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Fascin  sp│P85845│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Coactosin-like protein  sp│B0BNA5│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Destrin  sp│Q7M0E3│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Drebrin E  tr│C6L8E0│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Drebrin-like protein  sp│Q9JHL4│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Adducin 3 (Gamma), isoform CRA_b  tr│D3ZCH7│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Alpha-adducin  sp│Q63028│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Beta-adducin  tr│F8WFS9│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Adenylyl cyclase-associated protein 1  sp│Q08163│ 1 1.10 1.05 1.00 1.10 1.00 1.05 1.00 
Adenylyl cyclase-associated protein 2  sp│P52481│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Band 4.1-like protein 1  tr│D3ZMI4│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Calponin-3  sp│P37397│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
Cofilin-1  sp│P45592│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Coronin (Fragment)  tr│F1LMV9│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Coronin  tr│G3V940│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
Coronin-1A  sp│Q91ZN1│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Coronin-1B  sp│O89046 │ 1 1.20 1.10 1.00 1.00 0.90 0.95 0.86 
Cytoplasmic FMR1 interacting protein 1 (Predicted)  tr│D4A8H8│ 1 1.10 1.05 1.00 1.20 1.10 1.15 1.10 
Cytoplasmic FMR1 interacting protein 2 (Predicted)  tr│D3ZX82│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 




Epb4.9 protein  tr│B2GUY4│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Erythrocyte protein band 4.1-like 3, isoform CRA_d  tr│Q9JMB3│ 1 1.10 1.05 1.00 1.10 1.20 1.15 1.10 
Gelsolin  sp|Q68FP1│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Profilin  tr│D3ZDU5│ 1 1.10 1.05 1.00 1.00 0.90 0.95 0.90 
Profilin-1  sp│P62963│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Protein Ank2 (Fragment)  tr│F1M9N9│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Synaptopodin  tr│B1VKB4│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Ezrin  sp│P31977│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Nck-associated protein 1  sp│P55161│ 1 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Myristoylated alanine-rich C-kinase substrate  sp│P30009│ 1 0.80 0.90 1.00 1.00 0.90 0.95 1.06 
Plastin 3 (T-isoform), isoform CRA_a  tr│F1LPK7│ 1 1.10 1.05 1.00 1.00 0.90 0.95 0.90 
Protein Nrap  tr│D3Z802│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Protein Tln2  tr│D3ZA84│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Sorbin and SH3 domain-containing protein 2  tr│F1LPM3│ 1 0.90 0.95 1.00 0.80 1.00 0.90 0.95 
  Tubulin-binding 
         
Tubulin beta-5 chain  sp│P69897│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Tubulin alpha-1A chain  sp│P68370│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Tubulin alpha-4A chain  sp│Q5XIF6│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Tubulin beta-2A chain  sp│P85108│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
Tubulin beta-3 chain  sp│Q4QRB4│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Tubulin-specific chaperone A (Fragment)  tr│M0RE00│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Microtubule-actin cross-linking factor 1  tr│M9MMM9│ 1 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Microtubule-associated protein 1 A, isoform CRA_c  tr│G3V7U2│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Microtubule-associated protein 1B  tr│F1LRL9│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Microtubule-associated protein 4  sp│Q5M7W5│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Microtubule-associated protein 6  sp│Q63560│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Microtubule-associated protein  tr│F1MAQ5│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Microtubule-associated protein RP/EB family 
member 3  sp│Q5XIT1│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Microtubule-associated proteins 1A/1B light chain 
3A  sp│Q6XVN8│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Protein Tppp  tr  D3ZQL7│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Protein Tubb4a  tr│B4F7C2│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 




HMW-MAP2 (Fragment)  tr│P70652│ 1 0.90 0.95 1.00 0.80 1.00 0.90 0.95 
CAP-Gly domain-containing linker protein 2  tr│G3V949│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
2',3'-cyclic-nucleotide 3'-phosphodiesterase  sp│P13233│ 1 0.80 0.90 1.00 0.90 0.80 0.85 0.94 
Neuronal migration protein doublecortin  sp│Q9ESI7│ 1 1.00 1.00 1.00 0.80 0.80 0.80 0.80 
  Intermediated filament binding 
         
Vimentin  sp│P31000│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Lamin A, isoform CRA_b  tr│G3V8L3│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Alpha-internexin  sp│P23565│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Neurofilament heavy polypeptide  tr│F1LRZ7│ 1 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Neurofilament light polypeptide  sp│P19527│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Neurofilament medium polypeptide  sp│P12839│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Glial fibrillary acidic protein  sp│P47819│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
  Other 
         
Paralemmin-1  sp│Q920Q0│ 1 1.00 1.00 1.00 0.80 0.80 0.80 0.80 
Brevican, isoform CRA_a  tr│G3V8G4│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Hyaluronan and proteoglycan link protein 1  sp│P03994│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
Myelin basic protein transcript variant 1  tr│I7FKL4│ 1 0.60 0.80 1.00 1.00 0.80 0.90 1.13 
Myelin proteolipid protein  sp│P60203│ 1 0.70 0.85 1.00 0.80 0.60 0.70 0.82 
Dihydropyrimidinase-related protein 1  sp│Q62950│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Dihydropyrimidinase-related protein 2  sp│P47942│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Dihydropyrimidinase-related protein 3  sp│Q62952│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Dihydropyrimidinase-related protein 4 (Fragment)  sp│Q62951│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Dihydropyrimidinase-related protein 5  sp│Q9JHU0│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
 
         
Energy metabolism                    
  Glycolysis 
         
Pyruvate dehydrogenase E1 component subunit 
alpha, somatic form, mitochondrial  tr│F7FKI5│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Pyruvate dehydrogenase E1 component subunit beta, 
mitochondrial  sp│P49432│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Pyruvate kinase PKM  sp│P11980│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 




Pyruvate carboxylase, mitochondrial  sp│P52873│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Gamma-enolase  sp│P07323│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
  Citric Acid Cycle 
         
2-oxoglutarate dehydrogenase, mitochondrial  sp│Q5XI78│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Fumarate hydratase, mitochondrial  sp│P14408│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Aconitate hydratase, mitochondrial  sp│Q9ER34│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Cytoplasmic aconitate hydratase  sp│Q63270│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
ATP-citrate synthase  sp│P16638│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Citrate synthase, mitochondrial  sp│Q8VHF5│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Dihydrolipoamide S-succinyltransferase (E2 
component of 2-oxo-glutarate complex), isoform 
CRA_a  
tr│G3V6P2│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase complex, 
mitochondrial  
sp│P08461│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Glutamate dehydrogenase 1, mitochondrial  sp│P10860│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Malate dehydrogenase, cytoplasmic  sp│O88989│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Malate dehydrogenase, mitochondrial  sp│P04636│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Malic enzyme (Fragment)  tr│F1LQQ1│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Malic enzyme  tr│F1M5N4│ 1 0.90 0.95 1.00 0.90 1.00 0.95 1.00 
Succinyl-CoA ligase [ADP/GDP-forming] subunit 
alpha, mitochondrial  sp│P13086│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Trifunctional enzyme subunit alpha, mitochondrial  sp│Q64428│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
Sucla2 protein (Fragment)  tr│B2RZ24│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  Oxidative phosphorylation 
         
Cytochrome b-c1 complex subunit 1, mitochondrial  sp│Q68FY0│ 1 0.80 0.90 1.00 0.80 0.60 0.70 0.78 
Cytochrome b-c1 complex subunit 2, mitochondrial  sp│P32551│ 1 0.80 0.90 1.00 0.90 0.70 0.80 0.89 
Cytochrome c oxidase subunit 4 isoform 1, 
mitochondrial  sp│P10888│ 1 0.80 0.90 1.00 0.90 0.70 0.80 0.89 
Cytochrome c oxidase subunit 5B, mitochondrial  sp│P12075│ 1 0.70 0.85 1.00 0.90 0.60 0.75 0.88 
Cytochrome c oxidase subunit 6B1  tr│D3ZD09│ 1 0.70 0.85 1.00 0.70 0.60 0.65 0.76 
Cytochrome c, somatic  sp│P62898│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Isocitrate dehydrogenase [NAD] subunit alpha, 
mitochondrial  tr│F1LNF7│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Isocitrate dehydrogenase [NAD] subunit beta, sp│Q68FX0│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 





Isocitrate dehydrogenase [NADP] cytoplasmic  sp│P41562│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Isocitrate dehydrogenase [NADP], mitochondrial  sp│P56574│ 1 1.10 1.05 1.00 0.90 0.90 0.90 0.86 
Isocitrate dehydrogenase 3 (NAD), gamma  tr│Q5XIJ3│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
NADH dehydrogenase (Ubiquinone) Fe-S protein 7  tr│Q5RJN0│ 1 0.80 0.90 1.00 0.90 0.80 0.85 0.94 
NADH dehydrogenase (Ubiquinone) flavoprotein 1  tr│Q5XIH3│ 1 0.80 0.90 1.00 0.80 0.80 0.80 0.89 
Succinate dehydrogenase complex subunit A 
(Fragment)  tr│Q0QF18│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
ATP synthase F(0) complex subunit B1, 
mitochondrial  sp│P19511│ 1 0.70 0.85 1.00 0.80 0.50 0.65 0.76 
ATP synthase gamma chain  tr│Q6QI09│ 1 0.80 0.90 1.00 0.80 0.60 0.70 0.78 
ATP synthase subunit alpha, mitochondrial  sp│P15999│ 1 0.80 0.90 1.00 0.90 0.70 0.80 0.89 
ATP synthase subunit beta, mitochondrial  sp│P10719│ 1 0.70 0.85 1.00 0.90 0.70 0.80 0.94 
ATP synthase subunit O, mitochondrial  sp│Q06647│ 1 0.80 0.90 1.00 1.00 0.80 0.90 1.00 
ADP/ATP translocase 1  sp│Q05962│ 1 0.70 0.85 1.00 0.80 0.60 0.70 0.82 
ADP/ATP translocase 2  sp│Q09073│ 1 0.80 0.90 1.00 0.80 0.70 0.75 0.83 
Mitochondrial 2-oxoglutarate/malate carrier protein  tr│G3V6H5│ 1 0.90 0.95 1.00 0.80 0.70 0.75 0.79 
Phosphate carrier protein, mitochondrial  tr│G3V741│ 1 0.70 0.85 1.00 0.90 0.60 0.75 0.88 
  Phosphagen System 
         
Creatine kinase B-type  sp│P07335│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Creatine kinase M-type  sp│P00564│ 1 1.50 1.25 1.00 1.00 1.90 1.45 1.16 
Creatine kinase, mitochondrial 1, ubiquitous  tr│Q5BJT9│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
  Other 
         
3'(2'),5'-bisphosphate nucleotidase 1  sp│Q9Z1N4│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
 
         
Neurotransmission/signalling          
          
  Cell Adhesion 
         
Cell adhesion molecule 2  sp│Q1WIM2│ 1 0.90 0.95 1.00 0.90 0.80 0.85 0.89 
Limbic system-associated membrane protein  sp│Q62813│ 1 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Neural cell adhesion molecule 1 (Fragment)  tr│F1LNY3│ 1 0.90 0.95 1.00 1.00 0.80 0.90 0.95 
Neurocan core protein  tr│G3V8R2│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 




Neurofascin  sp│P97685│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Neuronal growth regulator 1  sp│Q9Z0J8│ 1 1.00 1.00 1.00 0.90 0.80 0.85 0.85 
Neurotrimin  tr│G3V964│ 1 1.00 1.00 1.00 1.10 0.80 0.95 0.95 
Obg-like ATPase 1  sp│A0JPJ7│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Opioid-binding protein/cell adhesion molecule  sp│P32736│ 1 1.00 1.00 1.00 0.80 0.70 0.75 0.75 
Peripheral plasma membrane protein CASK  sp│Q62915│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Protein Cdh13 (Fragment)  tr│F1M7X3│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
Protein Cttn  tr│D3ZGE6│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Synaptosomal-associated protein 25  sp│P60881│ 1 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Tenascin-R  sp│Q05546│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Versican core protein (Fragments)  sp│Q9ERB4│ 1 1.10 1.05 1.00 1.10 1.00 1.05 1.00 
Thy-1 membrane glycoprotein  sp│P01830│ 1 0.90 0.95 1.00 0.80 0.90 0.85 0.89 
Neuroplastin  tr│D3ZDF0│ 1 0.80 0.90 1.00 1.00 0.80 0.90 1.00 
Protein Omg  tr│F7EYB9│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Liprin-alpha-3  tr│F1LSE6│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Neurexin-3  sp│Q07310│ 1 0.90 0.95 1.00 0.90 0.80 0.85 0.89 
Neuronal cell adhesion molecule  sp│P97686│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Protein Ncam2 (Fragment)  tr│F1M8G9│ 1 0.80 0.90 1.00 0.80 0.80 0.80 0.89 
  Vesicle Regulation 
         
Vesicle associated membrane protein 2B  tr│Q9WUW2│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Vesicle-associated membrane protein-associated 
protein A  sp│Q9Z270│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Vesicle-fusing ATPase (Fragment)  tr│F1LQ81│ 1 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Vesicle-trafficking protein SEC22b  sp│Q4KM74│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Vesicular glutamate transporter 1  sp│Q62634│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Vesicular inhibitory amino acid transporter  sp│O35458│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
AP-1 complex subunit beta-1  tr│G3V9N8│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
AP-1 complex subunit mu-1  sp│Q32Q06│ 1 1.00 1.00 1.00 0.80 1.00 0.90 0.90 
AP-2 complex subunit alpha-2  sp│P18484│ 1 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
AP-2 complex subunit beta  sp│P62944│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
AP-2 complex subunit mu  sp│P84092│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
AP-2 complex subunit sigma  sp│P62744│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 




AP2-associated protein kinase 1  sp│P0C1X8│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
AP-3 complex subunit mu-2  sp│P53678│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Adaptin ear-binding coat-associated protein 1  sp│P69682│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
Adaptor protein complex AP-2, alpha 1 subunit 
(Predicted)  tr│D3ZUY8│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Adaptor-related protein complex 1, gamma 1 
subunit, isoform CRA_b  tr│B2RYN6│ 1 1.00 1.00 1.00 0.90 0.80 0.85 0.85 
Adaptor-related protein complex 3, delta 1 subunit, 
isoform CRA_b  tr│B5DFK6│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Alpha-soluble NSF attachment protein  sp│P54921│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Beta-soluble NSF attachment protein  tr│F8WFM2│ 1 0.90 0.95 1.00 1.10 1.00 1.05 1.11 
Calnexin  sp│P35565│ 1 0.90 0.95 1.00 0.90 0.80 0.85 0.89 
Clathrin coat assembly protein AP180  tr│F1LRK0│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Clathrin heavy chain 1  sp│P11442│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Clathrin light chain A  sp│P08081│ 1 0.90 0.95 1.00 0.90 0.80 0.85 0.89 
Clathrin light chain B  sp│P08082│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Coatomer protein complex, subunit zeta 1 
(Predicted)  tr│D4A8T3│ 1 1.20 1.10 1.00 1.00 1.00 1.00 0.91 
Complexin-2  sp│P84087│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
EH domain-containing protein 3  sp│Q8R491│ 1 1.10 1.05 1.00 1.10 1.00 1.05 1.00 
Endophilin-A1  tr│F1LQ05│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Endophilin-A2  sp│O35964│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Endophilin-B2  tr│D4A7V1│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Epsin-1  sp│O88339│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
General vesicular transport factor p115  sp|P41542│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Myc box-dependent-interacting protein 1  sp│O08839│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Protein Psd3  tr│D3ZUW0│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Protein Snx2  tr│B2RYP4│ 1 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Reticulon  tr│F1LQN3│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Reticulon-1  sp│Q64548│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Reticulon-3  sp│Q6RJR6│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Secernin-1  sp│Q6AY84│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Secretory carrier-associated membrane protein 1  sp│P56603│ 1 0.90 0.95 1.00 0.90 0.80 0.85 0.89 
Secretory carrier-associated membrane protein 5 tr│F1M882│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 





SH3-containing GRB2-like protein 3-interacting 
protein 1  sp│P0DJJ3│ 1 1.00 1.00 1.00 1.10 1.20 1.15 1.15 
SRC kinase signaling inhibitor 1  sp│Q9QXY2│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Synapsin-1  sp│P09951│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Synapsin-2  sp│Q63537│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Synaptic vesicle glycoprotein 2A  sp│Q02563│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Synaptic vesicle glycoprotein 2B  sp│Q63564│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Synaptobrevin homolog YKT6  sp│Q5EGY4│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Synaptogyrin-1  sp│Q62876│ 1 0.80 0.90 1.00 0.90 0.90 0.90 1.00 
Synaptojanin-1  sp│Q62910│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Synaptophysin  sp│P07825│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Synaptotagmin-1  sp│P21707│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Syntaxin 1A  tr│Q9QXG3│ 1 0.80 0.90 1.00 1.10 0.90 1.00 1.11 
Syntaxin-1B  sp│P61265│ 1 0.80 0.90 1.00 1.00 0.90 0.95 1.06 
Syntaxin-binding protein 1  sp│P61765│ 1 0.90 0.95 1.00 1.10 1.00 1.05 1.11 
Unconventional myosin-Va  sp│Q9QYF3│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Amphiphysin  sp│O08838│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein kinase C and casein kinase substrate in 
neurons protein 1  tr│F1LPP3│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Protein Eea1 (Fragment)  tr│F1LUA1│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Protein piccolo  sp│Q9JKS6│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Dynamin-1  sp│P21575│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Dynamin-1-like protein  sp│O35303│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Dynamin-like 120 kDa protein, mitochondrial  tr│D4A8U5│ 1 0.70 0.85 1.00 1.10 0.90 1.00 1.18 
Calcium-dependent secretion activator 1  sp│Q62717│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  Transport 
         
Excitatory amino acid transporter 1  sp│P24942│ 1 0.70 0.85 1.00 1.00 0.90 0.95 1.12 
Excitatory amino acid transporter 2  sp│P31596│ 1 0.70 0.85 1.00 1.00 0.70 0.85 1.00 
Glutamate receptor 2  tr|F1LNE4│ 1 1.00 1.00 1.00 0.80 0.80 0.80 0.80 
Gamma-aminobutyric acid receptor subunit alpha-1  tr│U6DDM1│ 1 0.80 0.90 1.00 0.90 0.60 0.75 0.83 
Gamma-aminobutyric acid receptor-associated 
protein-like 2  sp│P60522│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 




Acyl-CoA-binding protein  sp│P11030│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Disks large homolog 1  sp│Q62696│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Disks large homolog 3  sp│Q62936│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
ATPase, H+ transporting, lysosomal 38kDa, V0 
subunit d1  tr│Q5M7T6│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
ATPase, H+ transporting, V1 subunit D, isoform 
CRA_c  tr│Q6P503│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
ATPase, H+ transporting, V1 subunit E isoform 1, 
isoform CRA_a  tr│G3V7L8│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
ATPase, H+ transporting, V1 subunit G isoform 2  tr│Q8R2H0│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
V-H+ATPase subunit a1-III  tr│Q2I6B2│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
V-type proton ATPase subunit B, brain isoform  sp│P62815│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
V-type proton ATPase subunit C 1  sp│Q5FVI6│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
V-type proton ATPase subunit F  sp│P50408│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Protein Atp8a1 (Fragment)  tr│F1M585│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Protein Atp6v1a  tr│D4A133│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein Atp6v1h  tr│E9PTI1│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Voltage-dependent anion-selective channel protein 1  sp│Q9Z2L0│ 1 0.70 0.85 1.00 0.80 0.50 0.65 0.76 
Voltage-dependent anion-selective channel protein 3  sp│Q9R1Z0│ 1 0.80 0.90 1.00 0.90 0.70 0.80 0.89 
Voltage-dependent calcium channel subunit alpha-
2/delta-1  sp│P54290│ 1 0.90 0.95 1.00 0.80 0.80 0.80 0.84 
Voltage-gated potassium channel subunit beta-2 sp│P62483│ 1 1.10 1.05 1.00 0.90 0.80 0.85 0.81 
Sodium/calcium exchanger 2  tr│F1M9A2│ 1 0.80 0.90 1.00 0.90 0.90 0.90 1.00 
Sarcoplasmic/endoplasmic reticulum calcium 
ATPase 2  sp│P11507│ 1 0.90 0.95 1.00 0.90 0.80 0.85 0.89 
Plasma membrane calcium-transporting ATPase 1  sp│P11505│ 1 0.90 0.95 1.00 1.00 0.80 0.90 0.95 
Plasma membrane calcium-transporting ATPase 2  tr│D3ZCE9│ 1 0.90 0.95 1.00 1.10 0.90 1.00 1.05 
Plasma membrane calcium-transporting ATPase 4  tr│D3ZH00│ 1 0.70 0.85 1.00 1.00 0.70 0.85 1.00 
Sodium/potassium-transporting ATPase subunit 
alpha-1  sp│P06685│ 1 0.80 0.90 1.00 1.00 0.80 0.90 1.00 
Sodium/potassium-transporting ATPase subunit 
alpha-2  sp│P06686│ 1 0.70 0.85 1.00 0.90 0.70 0.80 0.94 
Sodium/potassium-transporting ATPase subunit 
alpha-3  sp│P06687│ 1 0.70 0.85 1.00 1.00 0.70 0.85 1.00 
Sodium/potassium-transporting ATPase subunit 
beta-1  sp│P07340│ 1 0.80 0.90 1.00 0.90 0.80 0.85 0.94 




Sodium-dependent neutral amino acid transporter 
SLC6A17  sp│P31662│ 1 1.10 1.05 1.00 1.10 1.00 1.05 1.00 
Solute carrier family 12 member 5  sp│Q63633│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
ATPase Asna1  tr│G3V9T7│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Astrocytic phosphoprotein PEA-15  sp│Q5U318│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Cytoplasmic dynein 1 heavy chain 1  tr│M0R9X8│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Cytoplasmic dynein 1 light intermediate chain 1  sp│Q9QXU8│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
sp|Q9JJ79|DYHC2_RAT-DECOY Cytoplasmic 
dynein 2 heavy chain 1  sp│Q9JJ79│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Dynein light chain 1, cytoplasmic  sp│P63170│ 1 1.10 1.05 1.00 1.20 1.30 1.25 1.19 
Dynein light chain 2, cytoplasmic  sp│Q78P75│ 1 1.00 1.00 1.00 0.70 0.80 0.75 0.75 
Exportin-1  sp│Q80U96│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Protein Tnpo2  tr│D3ZER6│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
Fatty acid-binding protein, brain  sp│P55051│ 1 1.20 1.10 1.00 1.00 1.00 1.00 0.91 
Fatty acid-binding protein, epidermal  sp│P55053│ 1 1.10 1.05 1.00 0.90 0.90 0.90 0.86 
Importin 7 (Predicted), isoform CRA_c  tr│D4AE96│ 1 0.90 0.95 1.00 1.00 1.10 1.05 1.11 
Importin subunit beta-1  tr│F2Z3Q8│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
LIM and SH3 domain protein 1  sp│Q99MZ8│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Mitochondrial import inner membrane translocase 
subunit Tim13  sp│P62076│ 1 1.10 1.05 1.00 1.10 1.20 1.15 1.10 
Mitochondrial import receptor subunit TOM70  tr│R9PXR4│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Phosphofurin acidic cluster sorting protein 1  tr│F1LPG3│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Protein Napg  tr│D4A0E2│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein Ranbp1  tr│D4A2G9│ 1 1.00 1.00 1.00 1.30 1.20 1.25 1.25 
Protein Tom1l2  tr  D4A6C9│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Protein Vps26b  tr│B1WBS4│ 1 1.20 1.10 1.00 1.00 1.30 1.15 1.05 
Rabphilin-3A  tr│F1LPB9│ 1 1.00 1.00 1.00 1.10 1.20 1.15 1.15 
Vacuolar protein sorting-associated protein 29  sp│B2RZ78│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Vacuolar protein sorting-associated protein 35  tr│G3V8A5│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Hepatocyte growth factor-regulated tyrosine kinase 
substrate  sp│Q9JJ50│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Oxysterol-binding protein  tr│M0R916│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Protein Ap3b2  tr│D4AE00│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Protein Chmp4bl1  tr│D4A9Z8│ 1 1.00 1.00 1.00 0.90 0.80 0.85 0.85 




Protein Kif21a (Fragment)  tr│D3ZCG2│ 1 0.90 0.95 1.00 0.80 0.90 0.85 0.89 
Protein lin-7 homolog A  tr│M0R7K1│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Protein transport protein Sec31A  tr│G3V699│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
SEC14-like 2 (S. cerevisiae)  tr│Q5EBD0│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Transmembrane emp24 domain-containing protein 
10  sp│Q63584│ 1 0.80 0.90 1.00 0.90 0.70 0.80 0.89 
  GTPase Signalling 
         
CB1 cannabinoid receptor-interacting protein 1  sp│Q5M7A7│ 1 1.20 1.10 1.00 1.10 1.10 1.10 1.00 
GTP-binding nuclear protein Ran  sp│P62828│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein Sar1a  tr│Q6AY18│ 1 1.10 1.05 1.00 1.10 1.00 1.05 1.00 
Sept9 protein (Fragment)  tr│B2GVB4│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Septin 5, isoform CRA_d  tr│D3ZDH8│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Septin 7  tr│A2VCW8│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Septin 8 (Predicted)  tr│G3V9Z6│ 1 0.90 0.95 1.00 0.90 1.00 0.95 1.00 
Septin-11  sp│B3GNI6│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Septin-2  sp│Q91Y81│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Neuronal-specific septin-3  tr│D3ZPP8│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Protein Diras2  tr│D3ZHX3│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Arf-GAP with SH3 domain, ANK repeat and PH 
domain-containing protein 1  sp│Q1AAU6│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
ADP-ribosylation factor 1  sp│P84079│ 1 1.00 1.00 1.00 1.10 1.20 1.15 1.15 
ADP-ribosylation factor 5  sp│P84083│ 1 1.20 1.10 1.00 1.20 1.20 1.20 1.09 
ADP-ribosylation factor-like protein 3  sp│P37996│ 1 1.10 1.05 1.00 1.00 1.20 1.10 1.05 
Centaurin alpha  tr│Q63629│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Cell division control protein 42 homolog  sp│Q8CFN2│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Guanine nucleotide binding protein, alpha q 
polypeptide, isoform CRA_a  tr│D4AE68│ 1 0.80 0.90 1.00 0.80 0.70 0.75 0.83 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-1 sp│P54311│ 1 0.70 0.85 1.00 1.00 0.90 0.95 1.12 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-2  sp│P54313│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Guanine nucleotide-binding protein G(o) subunit 
alpha  sp│P59215│ 1 0.70 0.85 1.00 1.00 0.80 0.90 1.06 
Guanine nucleotide-binding protein subunit beta-2-
like 1  sp│P63245│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 




Guanine nucleotide-binding protein subunit beta-5  sp│P62882│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Protein Gng13  tr│G3V8Y0│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Ras-related C3 botulinum toxin substrate 1  sp│Q6RUV5│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Ras-related protein Rab-10  sp│P35281│ 1 0.90 0.95 1.00 0.90 0.80 0.85 0.89 
Ras-related protein Rab-11A  sp│P62494│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Ras-related protein Rab-18  sp│Q5EB77│ 1 0.80 0.90 1.00 0.90 0.90 0.90 1.00 
Ras-related protein Rab-1A  tr│E9PU16│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Ras-related protein Rab-2A  sp│P05712│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Ras-related protein Rab-3A  sp│P63012│ 1 0.90 0.95 1.00 1.10 1.10 1.10 1.16 
Ras-related protein Rab-3C  sp│P62824│ 1 0.90 0.95 1.00 1.10 1.00 1.05 1.11 
Ras-related protein Rab-4B  sp│P51146│ 1 1.10 1.05 1.00 1.00 0.90 0.95 0.90 
Ras-related protein Rab-6A  sp│Q9WVB1│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Ras-related protein Rab-7a  sp│P09527│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Ras-related protein Ral-A  sp│P63322│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Ras-related protein Rap-1b  sp│Q62636│ 1 0.80 0.90 1.00 0.90 0.90 0.90 1.00 
Protein Rab5b  tr│A1L1J8│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Protein Rab5c  tr│B0BNK1│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
GTP-binding protein Rheb  tr│M0R3K1│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Rho GDP-dissociation inhibitor 1  sp│Q5XI73│ 1 1.10 1.05 1.00 1.10 1.20 1.15 1.10 
Rho guanine nucleotide exchange factor 2  sp│Q5FVC2│ 1 1.00 1.00 1.00 0.80 0.80 0.80 0.80 
Rho-associated protein kinase 2  sp│Q62868│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Transforming protein RhoA  sp│P61589│ 1 1.00 1.00 1.00 0.90 1.10 1.00 1.00 
Protein Rap1gds1  tr│F1M7Y3│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Rab GDP dissociation inhibitor alpha  sp│P50398│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Rab GDP dissociation inhibitor beta  sp│P50399│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
RAB14, member RAS oncogene family  tr│B0BMW0│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein Sbf1  tr│D3ZNN0│ 1 0.90 0.95 1.00 0.90 1.00 0.95 1.00 
MAP kinase-activating death domain protein  sp│O08873│ 1 1.10 1.05 1.00 0.90 1.10 1.00 0.95 
Regulator of G-protein-signaling 6  tr│F1LS67│ 1 0.90 0.95 1.00 1.20 1.20 1.20 1.26 
Serine/threonine-protein kinase DCLK1  sp│O08875│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Serine/threonine-protein kinase MARK1 (Fragment)  tr│F1LNE7│ 1 1.00 1.00 1.00 1.10 0.90 1.00 1.00 




Serine/threonine-protein kinase PAK 1  sp│P35465│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Serine/threonine-protein phosphatase 2A 55 kDa 
regulatory subunit B alpha isoform  sp│P36876│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Serine/threonine-protein phosphatase 2A catalytic 
subunit alpha isoform  sp│P63331│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Serine/threonine-protein phosphatase 2B catalytic 
subunit alpha isoform  sp│P63329│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Serine/threonine-protein phosphatase 2B catalytic 
subunit beta isoform  sp│P20651│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Serine/threonine-protein phosphatase 5  sp│P53042│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Serine/threonine-protein phosphatase PP1-beta 
catalytic subunit  sp│P62142│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Protein Ppp2r1a  tr│Q5XI34│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Protein Ppp2r4  tr│B2RYQ2│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Protein Ppp2r5e  tr│D3ZHI9│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Nucleoside diphosphate kinase A  sp│Q05982│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Nucleoside diphosphate kinase B  sp│P19804│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
Phosphatidylethanolamine-binding protein 1  sp│P31044│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Phosphatidylinositol 4-phosphate 5-kinase type-1 
gamma  tr│F1M8H6│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Phosphatidylinositol 5-phosphate 4-kinase type-2 
alpha  sp│Q9R0I8│ 1 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Phosphatidylinositol 5-phosphate 4-kinase type-2 
beta  sp│O88377│ 1 1.10 1.05 1.00 1.10 1.20 1.15 1.10 
Phosphatidylinositol transfer protein alpha isoform  sp│P16446│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Phosphatidylinositol-binding clathrin assembly 
protein  tr│E9PTD2│ 1 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase beta-1  sp│P10687│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Type I inositol 3,4-bisphosphate 4-phosphatase  tr│D3ZAN1│ 1 0.90 0.95 1.00 0.80 0.80 0.80 0.84 
Inositol monophosphatase 1  tr│F1M978│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Inositol-trisphosphate 3-kinase A  sp│P17105│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Membrane-associated phosphatidylinositol transfer 
protein 1  sp│Q5U2N3│ 1 1.20 1.10 1.00 1.10 1.10 1.10 1.00 
Calcium/calmodulin-dependent 3',5'-cyclic 
nucleotide phosphodiesterase 1B  sp│Q01066│ 1 0.90 0.95 1.00 0.70 0.80 0.75 0.79 
cGMP-dependent 3',5'-cyclic phosphodiesterase  tr│F8WFW5│ 1 0.80 0.90 1.00 1.00 0.90 0.95 1.06 
cAMP-dependent protein kinase catalytic subunit sp│P68182│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 





cAMP-dependent protein kinase type II-beta 
regulatory subunit  sp│P12369│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
cAMP-regulated phosphoprotein 19  sp│Q712U5│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Protein kinase, cAMP-dependent, regulatory, type 2, 
alpha, isoform CRA_a  tr│G3V8Q6│ 1 0.90 0.95 1.00 1.10 0.90 1.00 1.05 
Protein Pde1a  tr│F1LMC0│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
A-kinase anchor protein 5  tr│F1LPP6│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Tyrosine-protein phosphatase non-receptor type 11  sp│P41499│ 1 1.10 1.05 1.00 0.90 1.10 1.00 0.95 
Protein kinase C beta type  tr│F1LS42│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Protein kinase C gamma type  sp│P63319│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Protein kinase C  tr│F1LMV8│ 1 1.10 1.05 1.00 0.90 0.90 0.90 0.86 
Dual specificity mitogen-activated protein kinase 
kinase 1  sp│Q01986│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Mitogen-activated protein kinase 1  sp│P63086│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Mitogen-activated protein kinase 3  sp│P21708│ 1 0.80 0.90 1.00 0.90 0.80 0.85 0.94 
Protein Map2k4 (Fragment)  tr│F1LP57│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
JNK3 protein  tr│B0VXR6│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Calcium Signalling 
         
Calcium/calmodulin-dependent protein kinase II, 
beta, isoform CRA_a  tr│G3V9G3│ 1 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Calcium/calmodulin-dependent protein kinase type II 
subunit alpha  sp│P11275│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Calcium/calmodulin-dependent protein kinase type II 
subunit delta  tr│F1LWF6│ 1 1.00 1.00 1.00 1.00 1.20 1.10 1.10 
Calcium/calmodulin-dependent protein kinase type II 
subunit gamma (Fragment)  tr│F1LMC3│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Calcium/calmodulin-dependent protein kinase type 
IV  sp│P13234│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
Calmodulin  sp│P62161│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Neurogranin  sp│Q04940│ 1 1.20 1.10 1.00 1.00 1.10 1.05 0.95 
Purkinje cell protein 4  sp│P63055│ 1 1.10 1.05 1.00 1.10 1.20 1.15 1.10 
Neurochondrin  sp│O35095│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Calbindin  sp│P07171│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Calcineurin subunit B type 1  sp│P63100│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Calpain-2 catalytic subunit  sp│Q07009│ 1 1.10 1.05 1.00 0.90 0.90 0.90 0.86 




Calretinin  sp│P47728│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
CaM kinase-like vesicle-associated protein  sp│Q63092│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Hippocalcin-like protein 4  sp│P35332│ 1 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Neurocalcin-delta  sp│Q5PQN0│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Neuronal membrane glycoprotein M6-a  sp│Q812E9│ 1 0.70 0.85 1.00 0.90 0.80 0.85 1.00 
Neuron-specific calcium-binding protein hippocalcin  sp│P84076│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Protein S100-B  sp│P04631│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Visinin-like protein 1  sp│P62762│ 1 0.90 0.95 1.00 1.10 1.10 1.10 1.16 
Annexin A3  sp│P14669│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Annexin A5  sp│P14668│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Other 
         
Brain-specific angiogenesis inhibitor 1-associated 
protein 2  sp│Q6GMN2│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Amyloid beta A4 protein  sp│P08592│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
4-nitrophenylphosphatase domain and non-neuronal 
SNAP25-like protein homolog 1 (C. elegans), 
isoform CRA_b  
tr│G3V728│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
14-3-3 protein epsilon  sp│P62260│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
14-3-3 protein eta  sp│P68511│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
14-3-3 protein theta  sp│P68255│ 1 1.00 1.00 1.00 1.10 1.20 1.15 1.15 
14-3-3 protein zeta/delta  sp│P63102│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
CDGSH iron-sulfur domain-containing protein 1  sp│B0K020│ 1 0.80 0.90 1.00 0.80 0.80 0.80 0.89 
ERC protein 2  sp│Q8K3M6│ 1 1.10 1.05 1.00 1.10 1.00 1.05 1.00 
Gephyrin isoform  tr|B3GS92│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Growth factor receptor-bound protein 2  sp|P62994│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Homer protein homolog 1  sp│Q9Z214│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Kinesin heavy chain isoform 5C (Fragment)  tr│G3V6L4│ 1 1.20 1.10 1.00 1.10 1.20 1.15 1.05 
Kinesin-like protein KIF2A  tr│F1M745│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
LanC-like protein 1  sp│Q9QX69│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Platelet-activating factor acetylhydrolase IB subunit 
alpha  sp│P63004│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein bassoon  tr│G3V984│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Protein Dmxl2 (Fragment)  tr│F1M164│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 




Protein phosphatase 1 regulatory subunit 7  sp│Q5HZV9│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Protein phosphatase 1, regulatory subunit 9B  tr│B1H262│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Protein phosphatase 1A  sp│P20650│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
Protein phosphatase 1E  sp│Q80Z30│ 1 1.10 1.05 1.00 1.00 1.20 1.10 1.05 
Protein phosphatase methylesterase 1  sp│Q4FZT2│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Stathmin  sp│P13668│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Wiskott-Aldrich syndrome protein family member 1  sp│Q5BJU7│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Alpha-synuclein  sp│P37377│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Beta-synuclein  sp│Q63754│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Glutamate decarboxylase 2  sp│Q05683│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Glutamine synthetase  sp│P09606│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein NDRG2  sp│Q8VBU2│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein NDRG3  sp│Q6AYR2│ 1 1.10 1.05 1.00 0.80 0.90 0.85 0.81 
Protein NDRG4  tr│D3Z831│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
Receptor expression-enhancing protein 5  sp│B2RZ37│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Membrane protein, palmitoylated 2 (MAGUK p55 
subfamily member 2), isoform CRA_a  tr│D3ZAA9│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Phytanoyl-CoA hydroxylase-interacting protein  sp│Q568Z9│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Phytanoyl-CoA hydroxylase-interacting protein-like  sp│Q6AYN4│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Receptor-type tyrosine-protein phosphatase zeta  sp│Q62656│ 1 1.20 1.10 1.00 1.00 1.10 1.05 0.95 
 
         
Redox regulation                    
6-phosphogluconate dehydrogenase, decarboxylating  sp│P85968│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Glyceraldehyde-3-phosphate dehydrogenase  sp│P04797│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Glycerol-3-phosphate dehydrogenase [NAD(+)], 
cytoplasmic  sp│O35077│ 1 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Alcohol dehydrogenase [NADP(+)]  sp│P51635│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Aldehyde dehydrogenase family 5, subfamily A1  tr│G3V945│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Aldehyde dehydrogenase family 6, subfamily A1, 
isoform CRA_b  tr│G3V7J0│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Aldehyde dehydrogenase, mitochondrial  tr│F1LN88│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Dihydrolipoyl dehydrogenase, mitochondrial  sp│Q6P6R2│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 




Isovaleryl-CoA dehydrogenase, mitochondrial  sp│P12007│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
L-lactate dehydrogenase B chain  sp│P42123│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
L-lactate dehydrogenase  tr│B5DEN4│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
D-3-phosphoglycerate dehydrogenase  sp│O08651│ 1 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Protein Gpd1l  tr│D3ZAP9│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Peroxiredoxin 3  tr│G3V7I0│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Peroxiredoxin-1  sp│Q63716│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Peroxiredoxin-2  sp│P35704│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Peroxiredoxin-5, mitochondrial (Fragment)  tr│D3ZEN5│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Peroxiredoxin-6  sp│O35244│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Acad9 protein  tr│B1WC61│ 1 1.10 1.05 1.00 0.90 0.90 0.90 0.86 
Thioredoxin  sp│P11232│ 1 1.10 1.05 1.00 1.00 0.90 0.95 0.90 
Thioredoxin reductase 1, cytoplasmic  tr│R9PXU4│ 1 1.20 1.10 1.00 1.00 1.20 1.10 1.00 
Thioredoxin-like protein 1  sp│Q920J4│ 1 0.90 0.95 1.00 0.90 0.80 0.85 0.89 
Aldose reductase  sp│P07943│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
Biliverdin reductase A  sp│P46844│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Biliverdin reductase B (Flavin reductase (NADPH))  tr│B5DF65│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Carbonyl reductase [NADPH] 1  sp│P47727│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Dihydropteridine reductase  sp│P11348│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Electron transfer flavoprotein subunit alpha, 
mitochondrial  sp│P13803│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Electron transfer flavoprotein subunit beta  sp│Q68FU3│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Ketimine reductase mu-crystallin  sp│Q9QYU4│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Oxidation resistance protein 1  sp│Q4V8B0│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Prenylcysteine oxidase  sp│Q99ML5│ 1 0.80 0.90 1.00 0.90 0.80 0.85 0.94 
Protein Sh3bgrl3  tr│B2RZ27│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Redox-regulatory protein FAM213A  sp│Q6AXX6│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Protein Vat1l  tr│D3ZE32│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
          
          
          
 
         




Protein synthesis/neurotrophic                    
Transcription 
         
Transcription elongation factor B polypeptide 2  sp│P62870│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Protein Tceal5  tr│M0RDJ7│ 1 0.90 0.95 1.00 0.80 1.00 0.90 0.95 
Transcription factor Pur-beta  tr│F1LSL1│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Transcription intermediary factor 1-beta  sp│O08629│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Transcriptional activator protein Pur-alpha  tr│F1LPS8│ 1 1.10 1.05 1.00 1.10 1.00 1.05 1.00 
Transgelin-3  sp│P37805│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein Btf3l4  tr│D4A3I4│ 1 0.90 0.95 1.00 0.90 0.80 0.85 0.89 
Core histone macro-H2A.1  sp│Q02874│ 1 1.10 1.05 1.00 0.90 0.90 0.90 0.86 
Histone H1.0  sp│P43278│ 1 1.10 1.05 1.00 0.90 0.90 0.90 0.86 
Histone H1.4  sp│P15865│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Histone H1.5  sp│D3ZBN0│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Histone H2A tr│D3ZVK7│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Histone H2B  tr│D3ZNH4│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Histone H3  tr│B0BMY8│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
Histone H4  sp│P62804│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Heterochromatin protein 1-binding protein 3  sp│Q6P747│ 1 1.10 1.05 1.00 1.00 0.90 0.95 0.90 
Brain acid soluble protein 1  sp│Q05175│ 1 0.60 0.80 1.00 1.00 0.80 0.90 1.13 
Nucleolin  sp│P13383│ 1 1.10 1.05 1.00 0.90 0.90 0.90 0.86 
Nucleosome assembly protein 1-like 1  tr│G3V6H9│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Heterogeneous nuclear ribonucleoprotein A1  tr│F7FEZ6│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Heterogeneous nuclear ribonucleoprotein A3  sp│Q6URK4│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Heterogeneous nuclear ribonucleoprotein C (C1/C2)  tr│G3V9R8│ 1 1.10 1.05 1.00 1.00 0.90 0.95 0.90 
Heterogeneous nuclear ribonucleoprotein D, isoform 
CRA_b  tr│G3V6A4│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Heterogeneous nuclear ribonucleoprotein H  tr│D3ZYW2│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Heterogeneous nuclear ribonucleoprotein K  sp│P61980│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Heterogeneous nuclear ribonucleoprotein M  tr│F1LV13│ 1 0.90 0.95 1.00 1.10 0.90 1.00 1.05 
Heterogeneous nuclear ribonucleoprotein Q  sp│Q7TP47│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Heterogeneous nuclear ribonucleoproteins A2/B1  tr│F1LM82│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 




Hnrnpl protein (Fragment)  tr│B5DFG2│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Protein Hnrnpul2  tr│D4ABT8│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Far upstream element-binding protein 2  sp│Q99PF5│ 1 1.20 1.10 1.00 1.00 1.00 1.00 0.91 
Matrin-3  sp│P43244│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Nucleophosmin  sp│P13084│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
LRRGT00192  tr│Q6QI16│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Leucine-rich PPR motif-containing protein, 
mitochondrial  tr│F1LM33│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
ATP-dependent RNA helicase DDX1  sp│Q641Y8│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Activated RNA polymerase II transcriptional 
coactivator p15  sp│Q63396│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
CUGBP Elav-like family member 2  sp│Q792H5│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
AU RNA binding protein/enoyl-coenzyme A 
hydratase (Predicted), isoform CRA_a  tr│F1LU71│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 
(Fragment)  tr│B6DTP5│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
ELAV (Embryonic lethal, abnormal vision, 
Drosophila)-like 1 (Hu antigen R)  tr│B5DF91│ 1 1.00 1.00 1.00 0.90 0.80 0.85 0.85 
Protein Tardbp  tr│I6L9G6│ 1 1.00 1.00 1.00 0.80 0.80 0.80 0.80 
Spliceosome RNA helicase Ddx39b  sp│Q63413│ 1 1.10 1.05 1.00 1.10 1.00 1.05 1.00 
O-linked N-acetylglucosamine (GlcNAc) transferase 
(UDP-N-acetylglucosamine:polypeptide-N-
acetylglucosaminyl transferase), isoform CRA_b  
tr│G3V6F4│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Serine-threonine kinase receptor-associated protein  sp│Q5XIG8│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Splicing factor proline/glutamine rich 
(Polypyrimidine tract binding protein associated)  tr│Q4KM71│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Histidine triad nucleotide-binding protein 1  sp│P62959│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Ilf2 protein  tr│B2RZC6│ 1 1.10 1.05 1.00 1.10 1.00 1.05 1.00 
Paraspeckle component 1  sp│Q4KLH4│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Proliferation-associated 2G4  tr│Q6AYD3│ 1 1.00 1.00 1.00 0.90 1.10 1.00 1.00 
Protein Alyref  tr│D3ZXH7│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Translation 
         
Elongation factor 1-alpha 1  sp│P62630│ 1 1.00 1.00 1.00 1.00 1.20 1.10 1.10 
Elongation factor 1-alpha 2  sp│P62632│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Elongation factor 1-gamma  sp│Q68FR6│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 




Elongation factor 2  sp│P05197│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Elongation factor Tu, mitochondrial  sp│P85834│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Eukaryotic initiation factor 4A-II  sp│Q5RKI1│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Eukaryotic translation elongation factor 1 beta 2  tr│B5DEN5│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
Eukaryotic translation initiation factor 2 subunit 1  sp│P68101│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Eukaryotic translation initiation factor 4H  sp│Q5XI72│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Eukaryotic translation initiation factor 5  sp│Q07205│ 1 1.20 1.10 1.00 1.00 1.10 1.05 0.95 
Eukaryotic translation initiation factor 5A-1  sp│Q3T1J1│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
40S ribosomal protein S10  sp│P63326│ 1 1.10 1.05 1.00 0.90 0.90 0.90 0.86 
40S ribosomal protein S12  tr│M0R9I8│ 1 1.00 1.00 1.00 0.70 0.80 0.75 0.75 
40S ribosomal protein S13  sp│P62278│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
40S ribosomal protein S14  tr│Q6PDV6│ 1 1.10 1.05 1.00 0.90 1.10 1.00 0.95 
40S ribosomal protein S18  sp│P62271│ 1 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
40S ribosomal protein S23  sp│P62268│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
40S ribosomal protein S24  tr│D4ACJ1│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
40S ribosomal protein S3  sp│P62909│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
40S ribosomal protein S3a  sp│P49242│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
40S ribosomal protein S4, X isoform  sp│P62703│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
40S ribosomal protein S6 (Fragment)  tr│M0RD75│ 1 1.10 1.05 1.00 0.90 0.90 0.90 0.86 
40S ribosomal protein S8  tr│B2RYR8│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
40S ribosomal protein S9  sp│P29314│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
40S ribosomal protein SA  sp│P38983│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
60S acidic ribosomal protein P0  sp│P19945│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
60S ribosomal protein L11  sp│P62914│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
60S ribosomal protein L13  tr│D3ZRM9│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
60S ribosomal protein L13a  tr│Q5RK10│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
60S ribosomal protein L18  sp│P12001│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
60S ribosomal protein L18a  sp│P62718│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
60S ribosomal protein L23  sp│P62832│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
60S ribosomal protein L24  sp│P83732│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
60S ribosomal protein L3  sp│P21531│ 1 1.10 1.05 1.00 1.00 0.90 0.95 0.90 




60S ribosomal protein L30  sp│P62890│ 1 1.00 1.00 1.00 0.90 0.80 0.85 0.85 
60S ribosomal protein L34  tr│B2RZD4│ 1 1.00 1.00 1.00 0.90 0.80 0.85 0.85 
60S ribosomal protein L36  tr│D3ZZ95│ 1 0.90 0.95 1.00 0.80 0.80 0.80 0.84 
60S ribosomal protein L4  tr│Q6P3V9│ 1 1.10 1.05 1.00 1.00 0.90 0.95 0.90 
60S ribosomal protein L5  sp│P09895│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
60S ribosomal protein L6  tr│F1LQS3│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
60S ribosomal protein L7  tr│B0K031│ 1 1.00 1.00 1.00 0.90 0.80 0.85 0.85 
60S ribosomal protein L8  sp│P62919│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
RCG25732, isoform CRA_b  tr│B5DEM5│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
RCG45400  tr│G3V7C6│ 1 1.10 1.05 1.00 1.20 1.20 1.20 1.14 
RCG45476, isoform CRA_d  tr│B0K021│ 1 1.10 1.05 1.00 0.90 0.90 0.90 0.86 
RCG45615, isoform CRA_a  tr│B2RYU2│ 1 0.90 0.95 1.00 0.70 0.80 0.75 0.79 
RCG55853, isoform CRA_b  tr│F1LVX3│ 1 1.00 1.00 1.00 0.90 1.10 1.00 1.00 
RCG62292, isoform CRA_a  tr│B5DEL9│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
Ribosomal protein (Fragment)  tr│Q4KM60│ 1 1.00 1.00 1.00 1.00 0.80 0.90 0.90 
Ribosomal protein S11  tr│Q6PDV9│ 1 1.10 1.05 1.00 1.00 0.90 0.95 0.90 
Ribonuclease UK114  sp│P52759│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Rps16 protein (Fragment)  tr│B0K038│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Protein LOC100359563  tr│D3ZZK1│ 1 1.10 1.05 1.00 1.00 0.90 0.95 0.90 
Protein LOC100360057 (Fragment)  tr│F7FLF2│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Protein LOC100360604  tr│D3ZPN7│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Protein LOC100360791  tr│M0R8Q2│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Protein LOC100362339  tr│D4A6G6│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Protein LOC100909464  tr│F1MAA3│ 1 1.10 1.05 1.00 1.10 1.20 1.15 1.10 
Protein LOC100909878  tr│D3ZLL8│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Protein LOC100910017  tr│D3ZX87│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
Protein LOC100911422 (Fragment)  tr│M0R9U5│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein LOC100911472  tr│M0RBD4│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Protein LOC100911774  tr│Q1RP74│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Protein LOC100912618  tr│D3ZFY8│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Protein LOC689899  tr│D3ZTH8│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 




Protein Nars  tr│F1LPV0│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
Pcbp2 protein  tr│Q6AYU2│ 1 1.20 1.10 1.00 1.10 1.10 1.10 1.00 
Protein IMPACT  sp│Q5GFD9│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Posttranslational modification 
         
Peptidylprolyl cis/trans isomerase, NIMA-interacting 
1  tr│B0BNL2│ 1 1.00 1.00 1.00 0.90 0.80 0.85 0.85 
Peptidyl-prolyl cis-trans isomerase A  sp│P10111│ 1 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Peptidyl-prolyl cis-trans isomerase B  sp│P24368│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Peptidyl-prolyl cis-trans isomerase D  sp│Q6DGG0│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Peptidyl-prolyl cis-trans isomerase FKBP1A  sp│Q62658│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Peptidyl-prolyl cis-trans isomerase FKBP4 sp│Q9QVC8│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Protein disulfide-isomerase A3  sp│P11598│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Protein disulfide-isomerase A6  sp│Q63081│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
Protein disulfide-isomerase  sp│P04785│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Endoplasmic reticulum resident protein 29  sp│P52555│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Endoplasmin  sp│Q66HD0│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Biosynthesis 
         
Acyl carrier protein  tr│D3ZF13│ 1 0.90 0.95 1.00 0.90 0.80 0.85 0.89 
Fatty acid synthase  sp│P12785│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Cytosolic acyl coenzyme A thioester hydrolase  sp│Q64559│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Adenosylhomocysteinase (Fragment)  tr│B5DFN2│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Adenosylhomocysteinase  sp│P10760│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Bifunctional purine biosynthesis protein PURH  sp│O35567│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
N-acetylneuraminic acid synthase  tr│B1WC26│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
Alanine--tRNA ligase, cytoplasmic  sp│P50475│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Glycine--tRNA ligase  tr│G3V7G8│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Serine--tRNA ligase, cytoplasmic  sp│Q6P799│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Tryptophan--tRNA ligase, cytoplasmic  tr│F8WFH8│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Tyrosine--tRNA ligase, cytoplasmic  sp│Q4KM49│ 1 1.00 1.00 1.00 0.80 0.80 0.80 0.80 
Aspartyl-tRNA synthetase  tr│A9CMB7│ 1 1.10 1.05 1.00 1.00 0.90 0.95 0.90 
Methionine adenosyltransferase 2 subunit beta  sp│Q5U2R0│ 1 1.20 1.10 1.00 1.00 0.90 0.95 0.86 
Phosphoribosyl pyrophosphate synthase-associated 
protein 2  sp│O08618│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 




Phosphoribosyl pyrophosphate synthetase 1-like 1 
(Predicted)  tr│M0RBK1│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
S-adenosylmethionine synthase  tr│F1LRB8│ 1 1.10 1.05 1.00 0.80 0.90 0.85 0.81 
 
         
Protein degradation                    
Ubiquitin carboxyl-terminal hydrolase isozyme L1  sp│Q00981│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Ubiquitin carboxyl-terminal hydrolase  tr│D3ZVQ0│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Ubiquitin carboxyl-terminal hydrolase  tr│Q5U2N2│ 1 1.20 1.10 1.00 1.00 1.00 1.00 0.91 
Ubiquitin carboxyl-terminal hydrolase  tr│D3ZC84│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Ubiquitin thioesterase OTUB1  sp│B2RYG6│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Ubiquitin-conjugating enzyme E2 D2 (Fragment)  tr│F1M5C9│ 1 1.20 1.10 1.00 1.10 1.10 1.10 1.00 
Ubiquitin-conjugating enzyme E2 N  sp│Q9EQX9│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Ubiquitin-like modifier-activating enzyme 1  sp│Q5U300│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Protein Ube2l3  tr│B2RZA9│ 1 1.10 1.05 1.00 1.10 1.20 1.15 1.10 
Protein Ube2m  tr  D3ZNQ6│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Protein Ube2o (Fragment)  tr│F1M403│ 1 1.20 1.10 1.00 1.10 1.20 1.15 1.05 
Protein Ubqln2  tr│D4AA63│ 1 0.90 0.95 1.00 1.00 1.00 1.00 1.05 
Polyubiquitin-C  tr│F1LML2│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
SUMO-activating enzyme subunit 1  sp│Q6AXQ0│ 1 1.20 1.10 1.00 0.80 1.00 0.90 0.82 
UV excision repair protein RAD23 homolog B sp│Q4KMA2│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Transitional endoplasmic reticulum ATPase sp│P46462│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
S-phase kinase-associated protein 1  sp│Q6PEC4│ 1 1.00 1.00 1.00 1.10 1.20 1.15 1.15 
DNA damage-binding protein 1  sp│Q9ESW0│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
F-box only protein 2  tr│G3V774│ 1 0.90 0.95 1.00 1.40 1.10 1.25 1.32 
COP9 (Constitutive photomorphogenic) homolog, 
subunit 5 (Arabidopsis thaliana)  tr│Q4KM69│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
COP9 (Constitutive photomorphogenic) homolog, 
subunit 7a (Arabidopsis thaliana) (Predicted)  tr│G3V8Z9│ 1 0.90 0.95 1.00 1.10 1.20 1.15 1.21 
COP9 signalosome complex subunit 2  sp│P61203│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
COP9 signalosome complex subunit 3  sp│Q68FW9│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
COP9 signalosome complex subunit 4  sp│Q68FS2│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
26S protease regulatory subunit 4  sp│P62193│ 1 1.10 1.05 1.00 0.90 0.90 0.90 0.86 




26S protease regulatory subunit 6A  sp│Q63569│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
26S protease regulatory subunit 6B  sp│Q63570│ 1 1.10 1.05 1.00 0.80 0.90 0.85 0.81 
26S protease regulatory subunit 7  sp│Q63570│ 1 1.10 1.05 1.00 1.00 0.90 0.95 0.90 
26S protease regulatory subunit 8  sp│P62198│ 1 1.10 1.05 1.00 1.00 1.20 1.10 1.05 
Lon protease homolog, mitochondrial  sp│Q924S5│ 1 0.90 0.95 1.00 0.90 1.00 0.95 1.00 
Protein Psmc6  tr│G3V6W6│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Xaa-Pro aminopeptidase 1  sp│O54975│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Xaa-Pro dipeptidase  sp│Q5I0D7│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Carboxypeptidase E  sp│P15087│ 1 1.10 1.05 1.00 0.80 0.80 0.80 0.76 
Cytosolic non-specific dipeptidase  sp│Q6Q0N1│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Tripeptidyl-peptidase 2  sp│Q64560│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Dipeptidyl peptidase 3  sp│O55096│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Prolyl endopeptidase-like  tr│D3ZZ32│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Cathepsin D  tr│Q6P6T6│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Isoaspartyl peptidase/L-asparaginase  sp│Q8VI04│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Proprotein convertase subtilisin/kexin type 1 
inhibitor  tr│G3V6X7│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
Protein Npepps  tr│F1M9V7│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
SP120  tr│Q63555│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
26S proteasome non-ATPase regulatory subunit 1  tr│G3V8B6│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
26S proteasome non-ATPase regulatory subunit 13  sp│B0BN93│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
26S proteasome non-ATPase regulatory subunit 9  tr│G3V9P0│ 1 0.90 0.95 1.00 0.80 0.90 0.85 0.89 
Proteasome (Prosome, macropain) 26S subunit, non-
ATPase, 3  tr│Q5U2S7│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Proteasome (Prosome, macropain) 26S subunit, non-
ATPase, 6  tr│Q6PCT9│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Proteasome subunit alpha type  tr│F1LSQ6│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Proteasome subunit alpha type-1  sp│P18420│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Proteasome subunit alpha type-2  sp│P17220│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Proteasome subunit alpha type-3  sp│P18422│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Proteasome subunit alpha type-4  sp│P21670│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Proteasome subunit alpha type-5  sp│P34064│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Proteasome subunit alpha type-6  sp│P60901│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 




Proteasome subunit beta type  tr│Q6PDW4│ 1 1.10 1.05 1.00 0.80 1.10 0.95 0.90 
Proteasome subunit beta type  tr│F1LNN1│ 1 1.00 1.00 1.00 0.90 1.10 1.00 1.00 
Proteasome subunit beta type  tr│G3V7Q6│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Proteasome subunit beta type-2  sp│P40307│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Proteasome subunit beta type-6  sp│P28073│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Alpha-1-inhibitor 3  sp│P14046│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Alpha-1-antiproteinase  sp│P17475│ 1 1.20 1.10 1.00 0.90 0.90 0.90 0.82 
4-aminobutyrate aminotransferase, mitochondrial  sp│P50554│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
 
         
Other                    
Hemoglobin alpha, adult chain 2  tr│B1H216│ 1 1.30 1.15 1.00 1.00 1.10 1.05 0.91 
Hemoglobin subunit beta-1  sp│P02091│ 1 1.20 1.10 1.00 1.00 1.00 1.00 0.91 
Hemoglobin subunit beta-2 sp│P11517│ 1 1.40 1.20 1.00 1.00 1.00 1.00 0.83 
Hemopexin  sp│P20059│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
0 beta-2 globin  tr│Q62670│ 1 1.20 1.10 1.00 1.10 1.10 1.10 1.00 
Heat shock 70 kDa protein 4  tr│F1LRV4│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Heat shock 70 kDa protein 4L  tr│B4F772│ 1 0.90 0.95 1.00 1.10 1.10 1.10 1.16 
Heat shock 70kDa protein 12A (Predicted), isoform 
CRA_a  tr│D3ZC55│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Hypoxia up-regulated protein 1  tr│F1LN18│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Heat shock cognate 71 kDa protein  sp│P63018│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Heat shock factor-binding protein 1  sp│Q8K3X8│ 1 1.10 1.05 1.00 0.90 1.10 1.00 0.95 
Heat shock protein 105 kDa  sp│Q66HA8│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Heat shock protein HSP 90-alpha  sp│P82995│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Heat shock protein HSP 90-beta  sp│P34058│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
10 kDa heat shock protein, mitochondrial  sp│P26772│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
60 kDa heat shock protein, mitochondrial  sp│P63039│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Chaperonin containing Tcp1, subunit 6A (Zeta 1)  tr│Q3MHS9│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Chaperonin subunit 8 (Theta) (Predicted), isoform 
CRA_a  tr│D4ACB8│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Hsc70-interacting protein  sp│P50503│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 




Small glutamine-rich tetratricopeptide repeat-
containing protein alpha  sp│O70593│ 1 1.10 1.05 1.00 1.10 1.30 1.20 1.14 
DnaJ (Hsp40) homolog, subfamily C, member 6 
(Predicted)  tr│D4A0I5│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
DnaJ homolog subfamily C member 5  sp│P60905│ 1 0.80 0.90 1.00 0.90 0.80 0.85 0.94 
Hsp90 co-chaperone Cdc37  sp│Q63692│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Stress-70 protein, mitochondrial  tr│F1M953│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Stress-induced-phosphoprotein 1  sp│O35814│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
T-complex protein 1 subunit alpha  sp│P28480│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
T-complex protein 1 subunit beta  sp│Q5XIM9│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
T-complex protein 1 subunit delta  sp│Q7TPB1│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
T-complex protein 1 subunit epsilon  sp│Q68FQ0│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
T-complex protein 1 subunit gamma  sp│Q6P502│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
6-phosphofructokinase  tr│Q52KS1│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
6-phosphofructokinase, liver type  sp│P30835│ 1 1.00 1.00 1.00 0.90 1.10 1.00 1.00 
Fructose-bisphosphate aldolase A  sp│P05065│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Fructose-bisphosphate aldolase C  sp│P09117│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Glucose-6-phosphate isomerase  sp│Q6P6V0│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
78 kDa glucose-regulated protein  sp│P06761│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Ab2-076  tr│Q7TP61│ 1 1.10 1.05 1.00 1.00 0.90 0.95 0.90 
Ab2-417  tr│Q7TMC7│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Abi1 protein  tr│A2VD09│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Ac1002  tr│Q7TQ90│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
Active BCR-related gene (Predicted)  tr│D4A6K9│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Acyl-CoA synthetase family member 2, 
mitochondrial  sp│Q499N5│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Acyl-CoA synthetase isoform 6 variant2  tr│Q6IU14│ 1 0.80 0.90 1.00 0.90 0.80 0.85 0.94 
Acyl-CoA thioesterase 9  tr│Q5U2X8│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
Acetyl-CoA acetyltransferase, mitochondrial  sp│P17764│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Alpha-enolase  sp│P04764│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
C-1-tetrahydrofolate synthase, cytoplasmic  tr│G3V6S5│ 1 0.80 0.90 1.00 0.90 1.10 1.00 1.11 
C38 protein  tr│B7X6I3│ 1 0.80 0.90 1.00 1.00 0.80 0.90 1.00 
Uncharacterized protein (Fragment)  tr│B5DEP6│ 1 1.00 1.00 1.00 0.90 1.10 1.00 1.00 




Uncharacterized protein (Fragment)  tr│M0R5N3│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Uncharacterized protein  tr│M0R9D5│ 1 1.00 1.00 1.00 0.70 0.80 0.75 0.75 
Uncharacterized protein  tr│D3ZFD0│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Uncharacterized protein  tr│E9PT76│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
LOC681996 protein  tr│B0BN63│ 1 0.90 0.95 1.00 1.00 1.10 1.05 1.11 
LOC684097 protein  tr│B0BMY2│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Protein LOC679748  tr│D3ZE63│ 1 1.10 1.05 1.00 0.80 0.70 0.75 0.71 
Glutathione S-transferase Mu 1  tr│G3V983│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Glutathione S-transferase Mu 5  sp│Q9Z1B2│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Glutathione S-transferase omega 1  tr│B6DYQ5│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Glutathione S-transferase  tr│B6DYP8│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Glutathione S-transferase pi  tr│B6DYQ7│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Glutathione S-transferase Yb-3  sp│P08009│ 1 1.20 1.10 1.00 1.00 1.10 1.05 0.95 
Aspartate aminotransferase, cytoplasmic  sp│P13221│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Aspartate aminotransferase, mitochondrial  sp│P00507│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Glycylpeptide N-tetradecanoyltransferase 1  sp|Q8K1Q0│ 1 0.90 0.95 1.00 0.80 0.80 0.80 0.84 
Branched-chain-amino-acid aminotransferase, 
cytosolic  sp│P54690│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Hypoxanthine-guanine phosphoribosyltransferase  sp│P27605│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
CDP-diacylglycerol--inositol 3-
phosphatidyltransferase  sp│P70500│ 1 0.90 0.95 1.00 0.80 0.90 0.85 0.89 
Phosphoserine aminotransferase  tr│Q68FU2│ 1 1.10 1.05 1.00 1.10 1.20 1.15 1.10 
Protein-L-isoaspartate(D-aspartate) O-
methyltransferase  sp│P22062│ 1 1.10 1.05 1.00 1.00 0.90 0.95 0.90 
Succinyl-CoA:3-ketoacid coenzyme A transferase 1, 
mitochondrial  sp│B2GV06│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Thiosulfate sulfurtransferase  sp│P24329│ 1 1.00 1.00 1.00 1.10 1.60 1.35 1.35 
Protein arginine N-methyltransferase 1  sp│Q63009│ 1 1.10 1.05 1.00 1.00 0.90 0.95 0.90 
GTP:AMP phosphotransferase AK3, mitochondrial  sp|P29411│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Hydroxymethylglutaryl-CoA synthase, cytoplasmic  sp│P17425│ 1 1.00 1.00 1.00 0.90 0.80 0.85 0.85 
Maleylacetoacetate isomerase  sp│P57113│ 1 1.20 1.10 1.00 1.10 1.10 1.10 1.00 
Pdhx protein (Fragment)  tr│Q5BJX2│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Protein Pgm2l1  tr│D3Z955│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Adenosine kinase  sp│Q64640│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 




Adenylate kinase isoenzyme 1  sp│P39069│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Pyridoxal kinase  tr│G3V647│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
UMP-CMP kinase  sp│Q4KM73│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
3-hydroxyacyl-CoA dehydrogenase type-2  tr│B0BMW2│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
4-trimethylaminobutyraldehyde dehydrogenase  sp│Q9JLJ3│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Aminopeptidase B  sp│O09175│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Apolipoprotein E  
 sp│P02650│ 1 0.90 0.95 1.00 1.10 1.00 1.05 1.11 
Atlastin-1  sp│Q6PST4│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Calreticulin  sp│P18418│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Carbonic anhydrase 2  sp│P27139│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Clusterin  sp│P05371│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Contactin-1  sp│Q63198│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
C-terminal-binding protein 1  sp│Q9Z2F5│ 1 1.00 1.00 1.00 0.80 0.80 0.80 0.80 
Cullin-3  sp│B5DF89│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Cullin-associated NEDD8-dissociated protein 1  sp│P97536│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Cystathionine beta-synthase  sp│P32232│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Cystatin-C  sp│P14841│ 1 1.00 1.00 1.00 1.10 1.20 1.15 1.15 
Cysteine and glycine-rich protein 1  sp│P47875│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Cysteine-rich protein 2  sp│P36201│ 1 1.20 1.10 1.00 1.10 1.00 1.05 0.95 
D-tyrosyl-tRNA(Tyr) deacylase  tr│B0K014│ 1 1.20 1.10 1.00 0.90 0.90 0.90 0.82 
EF-hand domain-containing protein D2  sp│Q4FZY0│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Enoyl-CoA hydratase, mitochondrial  sp│P14604│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
ES1 protein homolog, mitochondrial  sp│P56571│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Fam49b protein  tr│B2GUZ9│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Fibroblast growth factor  tr│Q794I6│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
Four and a half LIM domains protein 1  sp│Q9WUH4│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
Fumarylacetoacetate hydrolase domain-containing 
protein 2  sp│B2RYW9│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Galectin  tr│B4F7A3│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 
Glia maturation factor beta  sp│Q63228│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Glutamic acid decarboxylase 1, isoform CRA_a  tr│C9E895│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Glyoxalase domain-containing protein 4  tr│GLOD4│ 1 1.00 1.00 1.00 1.00 0.90 0.95 0.95 




Growth arrest-specific protein 7  sp|O55148│ 1 1.20 1.10 1.00 1.00 1.30 1.15 1.05 
Hexokinase-1  sp│P05708│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
Inosine triphosphate pyrophosphatase  sp│D3ZW55│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
Lactoylglutathione lyase  sp│Q6P7Q4│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Low molecular weight phosphotyrosine protein 
phosphatase  sp│P41498│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 1  sp│O08557│ 1 1.00 1.00 1.00 1.10 1.00 1.05 1.05 
Neuromodulin  sp│P07936│ 1 0.80 0.90 1.00 1.00 0.80 0.90 1.00 
Parathymosin  tr│B3DM95│ 1 1.20 1.10 1.00 1.10 1.10 1.10 1.00 
Pdxp protein  tr│B2GV79│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Pgm1 protein (Fragment)  tr│A1A5L2│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Phosphoglycerate kinase 1  sp│P16617│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Phosphoglycerate mutase 1  sp│P25113│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Phosphorylase  tr│B1WBU9│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Programmed cell death 6-interacting protein  sp│Q9QZA2│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Protein Ak5  tr│M0R7U1│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
Protein Cct7  tr│D4AC23│ 1 1.10 1.05 1.00 0.90 1.00 0.95 0.90 
Protein DJ-1  sp│O88767│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Protein Irgq  tr│M0R686│ 1 1.10 1.05 1.00 1.10 1.30 1.20 1.14 
Protein Ppa1  tr│F7EPH4│ 1 1.20 1.10 1.00 1.00 1.00 1.00 0.91 
Protein RGD1304884  tr│D4A3C2│ 1 1.00 1.00 1.00 1.10 1.20 1.15 1.15 
Protein RGD1309586  tr│D3ZN21│ 1 0.90 0.95 1.00 1.00 0.90 0.95 1.00 
Protein RGD1559864  tr│D3ZBS6│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Protein RUFY3  sp│Q5FVJ0│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Protein Sept6  tr│B5DFG5│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Protein Ugp2  tr│Q4V8I9│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Protein unc-45 homolog A  tr│M0RC57│ 1 1.10 1.05 1.00 1.10 1.00 1.05 1.00 
Purine nucleoside phosphorylase (Fragment)  tr│D3ZXK9│ 1 1.00 1.00 1.00 1.20 1.10 1.15 1.15 
Serum albumin  sp│P02770│ 1 1.20 1.10 1.00 1.10 1.10 1.10 1.00 
Sulfated glycoprotein 1  tr│F7EPE0│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Superoxide dismutase [Cu-Zn]  tr│Q6LDS4│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Superoxide dismutase [Mn], mitochondrial  sp│P07895│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 




Transaldolase  sp│Q9EQS0│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Transketolase  sp│P50137│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Triosephosphate isomerase  sp│P48500│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Tripartite motif-containing protein 2 (Fragment)  tr│D3ZM62│ 1 1.00 1.00 1.00 1.00 1.10 1.05 1.05 
WD repeat-containing protein 1  sp│Q5RKI0│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
WD repeat-containing protein 7  sp│Q9ERH3│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Guanine deaminase  tr│Q9JKB7│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Alpha-endosulfine  sp│P60841│ 1 0.90 0.95 1.00 1.00 0.70 0.85 0.89 
NSFL1 cofactor p47  sp│O35987│ 1 1.10 1.05 1.00 1.10 1.10 1.10 1.05 
Haloacid dehalogenase-like hydrolase domain-
containing protein 2  tr│Q6QI86│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Hepatoma-derived growth factor  tr│F1LPC7│ 1 1.10 1.05 1.00 0.90 1.10 1.00 0.95 
Ig kappa chain C region, A allele  sp│P01836│ 1 1.00 1.00 1.00 1.10 1.30 1.20 1.20 
Long-chain-fatty-acid--CoA ligase ACSBG1  sp│Q924N5│ 1 1.00 1.00 1.00 1.10 1.10 1.10 1.10 
Non-specific lipid-transfer protein  tr│F1LQ55│ 1 0.90 0.95 1.00 0.90 0.90 0.90 0.95 
Omega-amidase NIT2  sp│Q497B0│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Protein Aimp1  tr│Q4G079│ 1 1.10 1.05 1.00 1.10 1.20 1.15 1.10 
Protein Appl1 (Fragment)  tr│D3ZWA8│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Protein Nova2 (Fragment)  tr│F1M4H5│ 1 0.90 0.95 1.00 0.80 0.80 0.80 0.84 
Protein Wdr37  tr│D3ZQ02│ 1 1.00 1.00 1.00 0.90 1.00 0.95 0.95 
Protein Wdr47  tr│G3V9M3│ 1 1.10 1.05 1.00 1.00 1.10 1.05 1.00 
Set protein  tr│B0BMV1│ 1 1.10 1.05 1.00 1.20 1.10 1.15 1.10 
Myotrophin  sp│P62775│ 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
tRNA-splicing ligase RtcB homolog  sp│Q6AYT3│ 1 1.10 1.05 1.00 1.00 1.00 1.00 0.95 
Casein kinase II subunit alpha  sp│P19139│ 1 1.00 1.00 1.00 0.80 0.90 0.85 0.85 
Casein kinase II subunit beta  sp│P67874│ 1 1.00 1.00 1.00 0.90 0.90 0.90 0.90 
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